{"id":1612,"date":"2026-11-04T11:44:09","date_gmt":"2026-11-04T11:44:09","guid":{"rendered":"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/full\/"},"modified":"2026-11-04T18:24:56","modified_gmt":"2026-11-04T18:24:56","slug":"full","status":"publish","type":"page","link":"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/full\/","title":{"rendered":"Synthetic Biology and Bioengineering 2026: complete edition"},"content":{"rendered":"\n<!-- Nexus Reports \u00b7 GCRI \u00b7 https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/full\/ \u00b7 source sha256:2b627115084422b8664d9cc32f3508aeeaee4deda7618fe99ea45b9df8cfcd76 \u00b7 generated by integrations\/wordpress\/nexus-reports\/build.mjs, never edit this file --><script>window.nexusLiveStrings={\"label\":\"Load the live map\",\"note\":\"Imagery and feeds come from other services (NASA, USGS, OpenStreetMap) and load only when you ask.\"};<\/script><script>(function(){\"use strict\";var n=window,l=document,A=\"nexus.live-map\",K=\"nexus.live-map.reload\";if(n.NXLive){return}var B=[{\"id\":\"gibs\",\"host\":\"gibs.earthdata.nasa.gov\",\"path\":\"^\/(wmts|wms|legends|colormaps)\/\",\"to\":\"\/nx-data\/gibs\",\"credit\":\"NASA GIBS\",\"test\":[\"\/wmts\/epsg3857\/best\/BlueMarble_ShadedRelief_Bathymetry\/default\/GoogleMapsCompatible_Level8\/2\/1\/1.jpeg\",\"\/wmts\/epsg3857\/best\/OPERA_L3_Dynamic_Surface_Water_Extent-HLS\/default\/2026-10-30\/GoogleMapsCompatible_Level12\/3\/2\/4.png\",\"\/wmts\/epsg4326\/best\/ASTER_GDEM_Greyscale_Shaded_Relief\/default\/250m\/0\/0\/0.jpg\",\"\/wmts\/epsg3857\/best\/GOES-East_ABI_GeoColor\/default\/2026-10-31T12:00:00Z\/GoogleMapsCompatible_Level7\/1\/0\/0.png\",\"\/wmts\/epsg4326\/best\/1.0.0\/WMTSCapabilities.xml\",\"\/wms\/epsg4326\/best\/wms.cgi?SERVICE=WMS\\u0026REQUEST=GetMap\\u0026LAYERS=ASTER_GDEM_Color_Index\",\"\/legends\/GPM_Precipitation_Rate_H.svg\"]},{\"id\":\"eonet\",\"host\":\"eonet.gsfc.nasa.gov\",\"path\":\"^\/api\/v3\/\",\"to\":\"\/nx-data\/eonet\",\"credit\":\"NASA EONET\",\"test\":[\"\/api\/v3\/events?status=open\\u0026days=20\",\"\/api\/v3\/events\/geojson?status=open\\u0026days=7\"]},{\"id\":\"usgs\",\"host\":\"earthquake.usgs.gov\",\"path\":\"^\/earthquakes\/feed\/v1\\\\.0\/summary\/\",\"to\":\"\/nx-data\/usgs\",\"credit\":\"U.S. Geological Survey\",\"test\":[\"\/earthquakes\/feed\/v1.0\/summary\/4.5_week.geojson\"]},{\"id\":\"power\",\"host\":\"power.larc.nasa.gov\",\"path\":\"^\/api\/temporal\/\",\"to\":\"\/nx-data\/power\",\"credit\":\"NASA POWER\",\"test\":[\"\/api\/temporal\/daily\/point?parameters=T2M\\u0026community=RE\\u0026longitude=13.4\\u0026latitude=52.5\\u0026start=20261001\\u0026end=20261010\\u0026format=JSON\"]},{\"id\":\"open-meteo\",\"host\":\"open-meteo.com\",\"subs\":[\"api\",\"flood-api\",\"ensemble-api\",\"air-quality-api\",\"marine-api\",\"archive-api\",\"historical-forecast-api\"],\"path\":\"^\/v1\/\",\"to\":\"\/nx-data\/open-meteo\",\"credit\":\"Open-Meteo.com\",\"test\":[\"\/flood-api\/v1\/flood?latitude=52.5\\u0026longitude=13.4\\u0026daily=river_discharge\",\"\/api\/v1\/forecast?latitude=1\\u0026longitude=2\\u0026hourly=temperature_2m\"]},{\"id\":\"metno\",\"host\":\"api.met.no\",\"path\":\"^\/weatherapi\/locationforecast\/2\\\\.0\/(compact|complete)$\",\"to\":\"\/nx-data\/metno\",\"credit\":\"MET Norway\",\"test\":[\"\/weatherapi\/locationforecast\/2.0\/compact?lat=45.2\\u0026lon=8.45\"]},{\"id\":\"oisst\",\"host\":\"coastwatch.pfeg.noaa.gov\",\"path\":\"^\/erddap\/griddap\/ncdcOisst21Agg_LonPM180\\\\.json$\",\"to\":\"\/nx-data\/oisst\",\"credit\":\"NOAA OISST v2.1 (CoastWatch ERDDAP)\",\"test\":[\"\/erddap\/griddap\/ncdcOisst21Agg_LonPM180.json?sst%5B(last)%5D%5B(0.0)%5D%5B(43.5)%5D%5B(7.5)%5D\"]},{\"id\":\"terrain\",\"host\":\"elevation-tiles-prod.s3.amazonaws.com\",\"path\":\"^\/terrarium\/\",\"to\":\"\/nx-data\/terrain\",\"credit\":\"Terrain Tiles (Mapzen, AWS Open Data)\",\"test\":[\"\/terrarium\/3\/4\/2.png\"]},{\"id\":\"ofm\",\"host\":\"tiles.openfreemap.org\",\"path\":\"^\/(styles|planet|fonts|sprites|natural_earth)(\/|$)\",\"to\":\"\/nx-data\/ofm\",\"credit\":\"OpenFreeMap, OpenMapTiles, OpenStreetMap contributors\",\"test\":[\"\/styles\/dark\",\"\/planet\",\"\/planet\/20261029_001001_pt\/3\/4\/2.pbf\",\"\/fonts\/Noto%20Sans%20Regular\/0-255.pbf\",\"\/sprites\/ofm_f384\/ofm@2x.json\"]},{\"id\":\"geoboundaries\",\"host\":\"www.geoboundaries.org\",\"path\":\"^\/api\/current\/\",\"to\":\"\/nx-data\/geoboundaries\",\"credit\":\"geoBoundaries\",\"test\":[\"\/api\/current\/gbOpen\/KEN\/ADM1\/\"]},{\"id\":\"gh-raw\",\"host\":\"raw.githubusercontent.com\",\"path\":\"^\/wmgeolab\/geoBoundaries\/\",\"to\":\"\/nx-data\/gh-raw\",\"credit\":\"geoBoundaries\",\"test\":[\"\/wmgeolab\/geoBoundaries\/9469f09\/releaseData\/gbOpen\/KEN\/ADM1\/geoBoundaries-KEN-ADM1_simplified.geojson\"]},{\"id\":\"gh-media\",\"host\":\"media.githubusercontent.com\",\"path\":\"^\/media\/wmgeolab\/geoBoundaries\/\",\"to\":\"\/nx-data\/gh-media\",\"credit\":\"geoBoundaries\",\"test\":[\"\/media\/wmgeolab\/geoBoundaries\/9469f09\/releaseData\/gbOpen\/KEN\/ADM1\/geoBoundaries-KEN-ADM1_simplified.geojson\"]},{\"id\":\"jsdelivr\",\"host\":\"cdn.jsdelivr.net\",\"path\":\"^\/npm\/(maplibre-gl|h3-js|pmtiles)@[0-9]+\\\\.[0-9]+\\\\.[0-9]+\/dist\/\",\"to\":\"\/nx-data\/jsdelivr\",\"credit\":\"\",\"test\":[\"\/npm\/maplibre-gl@6.9.1\/dist\/maplibre-gl.mjs\",\"\/npm\/h3-js@4.5.0\/dist\/h3-js.umd.js\"]}];var T=[\/(^|\\.)gibs\\.earthdata\\.nasa\\.gov$\/i,\/(^|\\.)eonet\\.gsfc\\.nasa\\.gov$\/i,\/(^|\\.)power\\.larc\\.nasa\\.gov$\/i,\/(^|\\.)earthquake\\.usgs\\.gov$\/i,\/(^|\\.)open-meteo\\.com$\/i,\/(^|\\.)openfreemap\\.org$\/i,\/(^|\\.)openstreetmap\\.org$\/i,\/(^|\\.)cartocdn\\.com$\/i,\/(^|\\.)arcgisonline\\.com$\/i,\/(^|\\.)maplibre\\.org$\/i,\/(^|\\.)protomaps\\.com$\/i,\/(^|\\.)versatiles\\.org$\/i,\/(^|\\.)amazonaws\\.com$\/i,\/(^|\\.)raw\\.githubusercontent\\.com$\/i,\/(^|\\.)media\\.githubusercontent\\.com$\/i,\/(^|\\.)geoboundaries\\.org$\/i,\/(^|\\.)jsdelivr\\.net$\/i,\/(^|\\.)unpkg\\.com$\/i,\/(^|\\.)cdn[j]s\\.cloudflare\\.com$\/i,\/(^|\\.)googleapis\\.com$\/i,\/(^|\\.)gstatic\\.com$\/i];var W=n.nexusLiveStrings?n.nexusLiveStrings:{};var H={label:W.label?W.label:\"Load the live map\",note:\"Some layers of this map come from another service. They load only when you ask.\"};var J=[\"experience\",\"external\",\"optional-content\",\"embeds\",\"media\"];var v=[],f=[],C=0;function z(e,t,r,a){if(typeof e!==\"string\"){return\"\"}if(e.slice(0,8).toLowerCase()!==\"https:\/\/\"){return\"\"}var i=\/^https:\\\/\\\/([A-Za-z0-9.-]+)(?::443)?(\\\/[^?#]*)?(\\?[^#]*)?\/.exec(e);if(!i){return\"\"}var o=i[1].toLowerCase(),s=i[2]?i[2]:\"\/\",R=i[3]?i[3]:\"\";for(var m=0;m<t.length;m++){var h=t[m],L=\"\";if(h.subs){var M=\".\"+h.host;if(o.length<=M.length){continue}if(o.slice(o.length-M.length)!==M){continue}L=o.slice(0,o.length-M.length);if(h.subs.indexOf(L)<0){continue}}else if(o!==h.host){continue}if(!new RegExp(h.path).test(s)){continue}return r+a+h.to.slice(9)+(L?\"\/\"+L:\"\")+s+R}return\"\"}var O=n.location.protocol===\"https:\"?n.location.origin:n.location.protocol===\"http:\"?n.location.origin:\"\";var u=typeof n.NX_DATA_BASE===\"string\"?n.NX_DATA_BASE:\"\/nx-data\/\";if(u.charAt(u.length-1)!==\"\/\"){u+=\"\/\"}var D=O!==\"\"?n.NX_DATA!==false:false;function F(e){if(!e){return\"\"}if(typeof e===\"string\"){return e}if(e.url){return String(e.url)}if(e.href){return String(e.href)}return String(e)}function p(e){return D?z(F(e),B,O,u):\"\"}var k={};function oe(e){var t=e.slice(O.length+u.length);return t.slice(0,t.indexOf(\"\/\"))}function j(e,t){var r=oe(e),a=k[r]=k[r]||{req:0,ok:0,fail:0};a[t]++}function se(){try{if(n.localStorage.getItem(A)===\"1\"){return true}}catch(e){}try{return n.sessionStorage.getItem(A)===\"1\"}catch(e){return false}}function $(){var e=n.nexusConsent;if(!e){return null}return typeof e.allows===\"function\"?e:null}function le(){var e=n.nexusConsent;if(!e){return false}if(typeof e.granted!==\"function\"){return false}for(var t=0;t<J.length;t++){try{if(e.granted(J[t])){return true}}catch(r){}}return false}function I(e,t){if(typeof e.features!==\"function\"){return false}try{return e.features().indexOf(t)>=0}catch(r){return false}}function Y(e){var t=n.nexusConsent;if(!t){return false}if(typeof t.switchedOff!==\"function\"){return false}try{return t.switchedOff(e)===true}catch(r){return false}}function b(){var e=$();if(e){var t=I(e,\"map-embeds\")?\"map-embeds\":\"maps\";try{if(e.allows(t)===true){return true}}catch(r){}}return se()?true:le()}function d(e){var t=e?e:\"maps\";if(t===\"map-embeds\"){return b()}return!Y(t===\"globe\"?\"globe\":\"maps\")?!Y(\"maps\"):false}function ce(e){try{var t=new URL(F(e),l.baseURI);if(t.protocol!==\"http:\"){if(t.protocol!==\"https:\"){return\"\"}}return t.origin===n.location.origin?\"\":t.hostname}catch(r){return\"\"}}var Z=0;function g(e){var t=ce(e);if(!t){return false}var r=false;for(var a=0;a<T.length;a++){if(T[a].test(t)){r=true;break}}if(!r){return false}if(p(e)){return!d(\"maps\")}if(b()){return false}C++;Z++;return true}var q=0;function c(){if(q){return}q=setTimeout(function(){q=0;U()},250)}function y(e){setTimeout(function(){try{e.dispatchEvent(new Event(\"error\"))}catch(t){}},0)}var N=n.fetch;if(N){n.fetch=function(e,t){var r=p(e);if(r){if(!d(\"maps\")){C++;c();return Promise.reject(new TypeError(\"Maps are switched off in your privacy choices\"))}var a=e;if(typeof e===\"string\"){a=r}else if(n.Request?e instanceof n.Request:false){a=new n.Request(r,e)}else{a=r}j(r,\"req\");var i=arguments.length>1?N.call(n,a,t):N.call(n,a);i.then(function(o){j(r,o.ok?\"ok\":\"fail\")},function(o){if(o?o.name!==\"AbortError\":true){j(r,\"fail\")}});return i}if(g(e)){c();return Promise.reject(new TypeError(\"Blocked until the live map is loaded\"))}return N.apply(this,arguments)}}var x=n.XMLHttpRequest?n.XMLHttpRequest.prototype:null;if(x){var fe=x.open,ue=x.send;x.open=function(e,t){var r=p(t);if(r){arguments[1]=r}this.__nxLiveUrl=r?r:t;return fe.apply(this,arguments)};x.send=function(){if(g(this.__nxLiveUrl)){c();y(this);return}return ue.apply(this,arguments)}}var w=n.HTMLImageElement?Object.getOwnPropertyDescriptor(n.HTMLImageElement.prototype,\"src\"):null;if(w){if(w.set){Object.defineProperty(n.HTMLImageElement.prototype,\"src\",{configurable:true,enumerable:w.enumerable,get:w.get,set:function(e){var t=p(e);if(g(e)){c();y(this);return}w.set.call(this,t?t:e)}})}}var _=n.Element?n.Element.prototype.setAttribute:null;if(_){n.Element.prototype.setAttribute=function(e,t){if(e===\"src\"){if(this.tagName===\"IMG\"){if(g(t)){c();y(this);return}var r=p(t);if(r){return _.call(this,e,r)}}}return _.apply(this,arguments)}}function Q(e){if(!e){return false}var t=e.tagName===\"SCRIPT\"?\"src\":e.tagName===\"LINK\"?\"href\":\"\";if(!t){return false}var r=e.getAttribute?e.getAttribute(t):\"\";var a=r?p(r):\"\";if(a){_.call(e,t,a);return false}return g(e[t])}if(n.Node){var pe=n.Node.prototype.appendChild,de=n.Node.prototype.insertBefore;n.Node.prototype.appendChild=function(e){if(Q(e)){c();y(e);return e}return pe.apply(this,arguments)};n.Node.prototype.insertBefore=function(e){if(Q(e)){c();y(e);return e}return de.apply(this,arguments)}}var S=n.Worker;if(S?D:false){var ge=\"(function(){var T=\"+JSON.stringify(B)+\",O=\"+JSON.stringify(O)+\",B=\"+JSON.stringify(u)+\",R=\"+z.toString()+',f=self.fetch;if(!f){return;}self.fetch=function(i,o){var u=typeof i===\"string\"?i:(i?(i.url?i.url:String(i)):\"\"),r=R(u,T,O,B);if(r){i=(typeof i===\"string\"?r:(typeof Request!==\"undefined\"?(i instanceof Request?new Request(r,i):r):r));}return arguments.length>1?f.call(self,i,o):f.call(self,i);};})();\\n';var P=function(e,t){if(!(this instanceof P)){return new S(e,t)}try{var r=new URL(String(e),l.baseURI);if(r.protocol===\"blob:\"?true:r.origin===n.location.origin){var a=t?t.type===\"module\":false;var i=ge+(a?\"import \"+JSON.stringify(r.href)+\";\\n\":\"importScripts(\"+JSON.stringify(r.href)+\");\\n\");return new S(URL.createObjectURL(new Blob([i],{type:\"text\/javascript\"})),t)}}catch(o){}return new S(e,t)};P.prototype=S.prototype;try{n.Worker=P}catch(e){}}var V='[data-nx-map=\"ctx-field\"],[data-nx-le],[data-nx-eo],[data-grx-globe],[data-grx-obs],.nx-sb[data-nx-sb]';function ee(){var e=[l];var t=l.querySelectorAll(\"*\");for(var r=0;r<t.length;r++){if(t[r].shadowRoot){e.push(t[r].shadowRoot)}}return e}function G(){return d(\"maps\")?Z>0?!b():false:true}function te(){var e=$();if(e){if(typeof e.enable===\"function\"){if(!d(\"maps\")){try{e.enable(\"maps\",\"site\")}catch(t){}try{e.enable(\"globe\",\"site\")}catch(t){}}if(I(e,\"map-embeds\")){try{e.enable(\"map-embeds\",\"site\")}catch(t){}}else{try{e.enable(\"maps\",\"site\")}catch(t){}}E();return}}try{n.localStorage.setItem(A,\"1\")}catch(t){try{n.sessionStorage.setItem(A,\"1\")}catch(r){}}E()}function me(e,t){var r=e.createElement(\"button\");r.type=\"button\";r.textContent=H.label;r.setAttribute(\"style\",\"pointer-events:auto;min-height:44px;min-width:44px;padding:0 18px;cursor:pointer;font:inherit;font-weight:600;font-size:14px;line-height:1.2;border-radius:2px;border:1px solid var(--nx-border-strong,#8a8a8a);background:var(--nx-text-primary,#111);color:var(--nx-bg-canvas,#fff)\");var a=\"nx-live-note-\"+Math.floor(Math.random()*1e9);r.setAttribute(\"aria-describedby\",a);r.addEventListener(\"click\",te);r.addEventListener(\"focus\",function(){r.style.outline=\"2px solid var(--nx-focus,#4c9aff)\";r.style.outlineOffset=\"2px\"});r.addEventListener(\"blur\",function(){r.style.outline=\"\"});var i=e.createElement(\"span\");i.id=a;i.textContent=H.note;i.setAttribute(\"style\",\"pointer-events:none;font-size:12px;line-height:1.4;padding:3px 7px;border-radius:2px;background:var(--nx-bg-canvas,#fff);color:var(--nx-text-secondary,#333);border:1px solid var(--nx-border-hairline,#bbb);max-width:34em\");t.appendChild(r);t.appendChild(i)}function he(e){var t=e.ownerDocument;var r=t.createElement(\"div\");r.className=\"nx-live-gate\";r.setAttribute(\"style\",\"position:absolute;inset-block-start:10px;inset-inline-start:10px;z-index:6;display:flex;flex-direction:column;align-items:flex-start;gap:6px;max-width:calc(100% - 20px);pointer-events:none;font:inherit\");var a=$();var i=false;if(a){if(typeof a.placeholder===\"function\"){try{var o=t.createElement(\"div\");o.setAttribute(\"style\",\"pointer-events:auto\");r.appendChild(o);a.placeholder(o,d(\"maps\")?I(a,\"map-embeds\")?\"map-embeds\":\"maps\":\"maps\");i=o.childNodes.length>0;if(!i){r.removeChild(o)}}catch(s){i=false}}}if(!i){me(t,r)}return r}function U(){if(!G()){return}var e=ee();for(var t=0;t<e.length;t++){var r=e[t].querySelectorAll(V);for(var a=0;a<r.length;a++){var i=r[a];if(i.getAttribute(\"data-nx-live-gate\")){continue}if(i.closest(\".nx-live-gate\")){continue}var o=i.getBoundingClientRect();if(o.width<120){continue}var s=i.querySelector(\".le-stage,.eo-stage\");if(!s){if(i.hasAttribute(\"data-nx-le\")?true:i.hasAttribute(\"data-nx-eo\")){continue}s=i}i.setAttribute(\"data-nx-live-gate\",\"1\");var R=n.getComputedStyle(s);if(R.position===\"static\"){s.style.position=\"relative\"}var m=he(s);s.appendChild(m);f.push({host:i,wrap:m,stage:s})}}ve()}function ve(){for(var e=0;e<f.length;e++){var t=f[e].stage,r=t?t.querySelector(\".nx-wm-presets\"):null;var a=r?r.getBoundingClientRect():null;if(a?a.height>0:false){var i=Math.round(a.bottom-t.getBoundingClientRect().top+8)+\"px\";if(f[e].wrap.style.insetBlockStart!==i){f[e].wrap.style.insetBlockStart=i}}}}function be(){for(var e=0;e<f.length;e++){try{f[e].wrap.remove()}catch(t){}try{f[e].host.removeAttribute(\"data-nx-live-gate\")}catch(t){}}f=[]}function ye(e,t,r){v.push({name:e,selector:t,fn:r});if(X){try{r(\"on\")}catch(a){}}}function xe(e){for(var t=0;t<v.length;t++){try{v[t].fn(e)}catch(r){}}}function we(){var e=[],t=ee();for(var r=0;r<t.length;r++){var a=t[r].querySelectorAll(V);for(var i=0;i<a.length;i++){var o=false;for(var s=0;s<v.length;s++){try{if(a[i].matches(v[s].selector)){o=true;break}}catch(R){}}if(!o){e.push(a[i])}}}return e}function Se(e){if(C===0){return}if(we().length===0){return}var t=e?\"on\":\"off\";try{if(n.sessionStorage.getItem(K)===t){return}n.sessionStorage.setItem(K,t)}catch(r){return}n.location.reload()}function re(){return!G()}var X=re();var ne=b();function E(){var e=re(),t=b(),r=e!==X?true:t!==ne;ne=t;if(!r){if(!e){c()}return}X=e;if(e){be()}xe(e?\"on\":\"off\");if(!e){c()}try{l.dispatchEvent(new CustomEvent(\"nexus:live-map\",{detail:{granted:e}}))}catch(a){}Se(e)}function ae(){U();if(n.MutationObserver){var e=new n.MutationObserver(function(){if(!G()){return}c()});e.observe(l.documentElement,{childList:true,subtree:true});setTimeout(function(){e.disconnect()},2e4)}}if(l.readyState===\"loading\"){l.addEventListener(\"DOMContentLoaded\",ae)}else{ae()}n.addEventListener(\"load\",function(){setTimeout(U,400)});l.addEventListener(\"nexus-consent:ready\",E);l.addEventListener(\"nexus-consent:change\",E);var ie=0;var Ee=setInterval(function(){ie++;E();if(ie>40){clearInterval(Ee)}},400);n.NXData={url:function(e){return p(e)},table:B,base:u,on:D,stats:function(){return JSON.parse(JSON.stringify(k))}};n.NXLive={allowed:d,blocked:g,grant:te,register:ye,hosts:T.length,data:n.NXData}})();<\/script><style>.pix-dark-mode-switch, .bx-color-mode-toggle, .color-switcher, .page-headline { display: none !important; }<\/style><script type=\"text\/x-nexus\" class=\"_iub_cs_skip\" id=\"nxe-mount\" data-nx-run=\"mount\">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<\/script><script class=\"_iub_cs_skip\" id=\"nxe-boot\">if(typeof window.__nxStill!==\"function\")window.__nxStill=function(){try{if(document.documentElement.hasAttribute(\"data-nx-still\"))return true;if(document.body?\/(?:^|\\s)mdp-readabler-stop-animations(?:\\s|$)\/.test(document.body.className):false)return true;var _=JSON.parse(window.localStorage.getItem(\"readabler\")||\"{}\");return _?_.stopAnimations===true||_.stopAnimations===\"true\"||_.stopAnimations===1:false}catch(K){return false}};(function(){function _(r,i){var f=atob(r),o=new Uint8Array(f.length),e;for(e=0;e< f.length;e++){o[e]=f.charCodeAt(e)}var s=0,a=0,u=0,n=new Uint8Array(Math.max(1024,o.length*6)),t=0;var c=[3,4,5,6,7,8,9,10,11,13,15,17,19,23,27,31,35,43,51,59,67,83,99,115,131,163,195,227,258];var d=[0,0,0,0,0,0,0,0,1,1,1,1,2,2,2,2,3,3,3,3,4,4,4,4,5,5,5,5,0];var m=[1,2,3,4,5,7,9,13,17,25,33,49,65,97,129,193,257,385,513,769,1025,1537,2049,3073,4097,6145,8193,12289,16385,24577];var E=[0,0,0,0,1,1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13];var lt=[16,17,18,0,8,7,9,6,10,5,11,4,12,3,13,2,14,1,15];function b(h){while(u< h){if(s>=o.length){throw new Error(\"nx-inflate: truncated\")}a|=o[s++]<< u;u+=8}var w=a%(1<< h);a>>>=h;u-=h;return w}function S(h,w,v){var g=new Uint16Array(16),A=new Uint16Array(16),p=new Uint16Array(v),x;for(x=0;x< v;x++){g[h[w+x]]++}g[0]=0;for(x=1;x<16;x++){A[x]=A[x-1]+g[x-1]}for(x=0;x< v;x++){if(h[w+x]){p[A[h[w+x]]++]=x}}return{count:g,sym:p}}function P(h){var w=0,v=0,g=0,A,p;for(A=1;A<16;A++){w|=b(1);p=h.count[A];if(w-p< v){return h.sym[g+(w-v)]}g+=p;v+=p;v<<=1;w<<=1}throw new Error(\"nx-inflate: bad code\")}function B(h){if(t+h<=n.length){return}var w=new Uint8Array(Math.max(n.length*2,t+h));w.set(n.subarray(0,t));n=w}var q=null,Z=null,k=0;while(!k){k=b(1);var J=b(2),H,F;if(J===0){a=0;u=0;var R=o[s]|o[s+1]<<8;s+=4;B(R);n.set(o.subarray(s,s+R),t);t+=R;s+=R;continue}if(J===1){if(!q){var tt=new Uint8Array(288),nt=new Uint8Array(30);for(e=0;e<288;e++){tt[e]=e<144?8:e<256?9:e<280?7:8}for(e=0;e<30;e++){nt[e]=5}q=S(tt,0,288);Z=S(nt,0,30)}H=q;F=Z}else if(J===2){var G=b(5)+257,et=b(5)+1,xt=b(4)+4,N=new Uint8Array(320),rt=new Uint8Array(19);for(e=0;e< xt;e++){rt[lt[e]]=b(3)}var ht=S(rt,0,19),I=0;while(I< G+et){var $=P(ht),X=0,at=0;if($<16){N[I++]=$;continue}if($===16){if(!I){throw new Error(\"nx-inflate: bad repeat\")}at=N[I-1];X=3+b(2)}else if($===17){X=3+b(3)}else{X=11+b(7)}while(X--){N[I++]=at}}H=S(N,0,G);F=S(N,G,et)}else{throw new Error(\"nx-inflate: bad block\")}for(;;){var y=P(H);if(y<256){B(1);n[t++]=y;continue}if(y===256){break}y-=257;var it=c[y]+b(d[y]),ot=P(F),ut=m[ot]+b(E[ot]);if(ut>t){throw new Error(\"nx-inflate: bad distance\")}B(it);for(var ft=0;ft< it;ft++){n[t]=n[t-ut];t++}}}return i?n.subarray(0,t):new TextDecoder(\"utf-8\").decode(n.subarray(0,t))}if(typeof window.__nxInflate!==\"function\"){window.__nxInflate=_}function K(r){var i=_(r,true),f=i[0]|i[1]<<8|i[2]<<16|i[3]<<24;var o=i.subarray(4+f);function e(s,a){var u=\"\",n=o.subarray(s,s+a);for(var t=0;a>t;t+=8192){u+=String.fromCharCode.apply(null,n.subarray(t,t+8192))}return btoa(u)}return JSON.parse(new TextDecoder(\"utf-8\").decode(i.subarray(4,4+f)),function(s,a){return a?a.$b?e(a.$b[0],a.$b[1]):a:a})}if(typeof window.__nxUnpack!==\"function\"){window.__nxUnpack=K}if(typeof window.__nxLate!==\"function\"){window.__nxLate=function(r,i){if(document.readyState!==\"loading\"){return null}if(!document.querySelector('template[data-nx-libs-last~=\"'+r+'\"]')){return null}return new Promise(function(f,o){document.addEventListener(\"DOMContentLoaded\",function(){var e=i();if(e){f(e)}else{o(new Error(\"nx-late: \"+r))}},{once:true})})}}if(typeof window.__nxAsset!==\"function\"){var U={};window.__nxAsset=function(r,i){if(U[r]){return U[r]}var f=document.getElementById(\"nxe-boot\"),o=[],e=window.NX_ASSET_BASE,s=f?f.getAttribute(\"data-nx-asset-base\"):\"\";if(e){o.push(String(e))}if(s){o.push(s)}o.push(\"\/wp-content\/uploads\/nexus-assets\/\");function a(t){if(!i){return t}return crypto.subtle.digest(\"SHA-256\",new TextEncoder().encode(t)).then(function(c){if(\"sha256-\"+btoa(String.fromCharCode.apply(null,new Uint8Array(c)))!==i){throw new Error(\"nx-asset: integrity\")}return t})}function u(t){if(t>=o.length){return Promise.reject(new Error(\"nx-asset: \"+r))}var c=o[t].charAt(o[t].length-1)===\"\/\"?o[t]:o[t]+\"\/\";return fetch(c+r,{credentials:\"omit\"}).then(function(d){if(!d.ok){throw new Error(\"nx-asset: \"+d.status)}return d.text()}).then(a).then(null,function(){return u(t+1)})}var n=u(0);U[r]=n;n.then(null,function(){delete U[r]});return n}}if(typeof window.__nxText!==\"function\"){window.__nxText=function(r){if(!r){return Promise.reject(new Error(\"nx-text: none\"))}var i=r.getAttribute(\"data-nx-asset\");if(i?!r.textContent:false){return window.__nxAsset(i,r.getAttribute(\"data-nx-sri\")||\"\")}return Promise.resolve(r.textContent)}}var j=null;function Q(r){var i=window.NX_RUNTIME||{},f=i.base||window.NX_RUNTIME_BASE||\"\";if(!f||!window.fetch){return Promise.resolve(null)}if(!j){j=fetch(f+\"manifest.json\",{credentials:\"same-origin\",cache:\"no-store\"}).then(function(o){return o.ok?o.json():null}).then(null,function(){return null})}return j.then(function(o){var e=o?(o.files||o)[r.replace(\/\\.[0-9a-f]{12}(\\.js)$\/,\"$1\")]:null;return e?e.file?[f+e.file,e.sri||\"\"]:null:null})}function st(r){var i=r.getAttribute(\"data-nx-asset\");if(i?!r.textContent:false){return window.__nxAsset(i,r.getAttribute(\"data-nx-sri\")||\"\").then(function(n){return window.__nxInflate(n)})}var f=r.getAttribute(\"data-nx-src\");if(f?!r.textContent:false){var o=window.NX_RUNTIME||{},e=o.base||window.NX_RUNTIME_BASE||\"\",s=(o.files||{})[f.replace(\/\\.[0-9a-f]{12}(\\.js)$\/,\"$1\")]||null,a=[];if(e){a.push([e+f,r.getAttribute(\"data-nx-sri\")||\"\"])}if(s?!!s.url:false){a.push([s.url,s.sri||\"\"])}var u=function(n){if(n===a.length?!a.live:false){a.live=true;return Q(f).then(function(c){if(!c){throw new Error(\"nx-lazy: \"+f)}a.push(c);return u(n)})}if(n>=a.length){return Promise.reject(new Error(\"nx-lazy: \"+f))}var t={credentials:\"same-origin\"};if(a[n][1]){t.integrity=a[n][1]}return fetch(a[n][0],t).then(function(c){if(!c.ok){throw new Error(\"nx-lazy: \"+c.status)}return c.text()}).then(null,function(){return u(n+1)})};return u(0)}return Promise.resolve(window.__nxInflate(r.textContent))}function ct(r){var i=r[0].getAttribute(\"data-nx-on-sight\")||\"[data-nx-map]\",f=null,o=false;function e(){if(o){return}o=true;if(f){f.disconnect()}var a=document.querySelectorAll(\"script[data-nx-on-sight][data-nx-asset]:not([data-nx-run])\"),u=[];for(var n=0;n!==a.length;n++){(function(t){if(t.textContent){return}u.push(window.__nxAsset(t.getAttribute(\"data-nx-asset\"),t.getAttribute(\"data-nx-sri\")||\"\").then(function(c){t.textContent=c;t.removeAttribute(\"data-nx-asset\")},function(){t.setAttribute(\"data-nx-ran\",\"failed\")}))})(a[n])}Promise.all(u.concat(r.map(function(t){return st(t).then(null,function(){return null})}))).then(function(t){var c=t.slice(u.length);for(var d=0;d!==r.length;d++){if(c[d]===null){r[d].setAttribute(\"data-nx-ran\",\"failed\");continue}var m=document.createElement(\"script\");m.className=\"_iub_cs_skip\";m.setAttribute(\"data-nx-runtime\",r[d].getAttribute(\"data-nx-run\"));m.textContent=c[d];(document.head||document.documentElement).appendChild(m);r[d].setAttribute(\"data-nx-ran\",\"true\")}try{document.dispatchEvent(new CustomEvent(\"nexus:lazy-ready\"))}catch(E){}})}function s(){if(o){return}var a=[document],u=document.querySelectorAll(\".nxe-host\"),n=[],t,c;for(t=0;t!==u.length;t++){if(u[t].shadowRoot){a.push(u[t].shadowRoot)}}for(t=0;t!==a.length;t++){c=a[t].querySelectorAll(i);for(var d=0;d!==c.length;d++){n.push(c[d])}}if(!n.length){return}if(!window.IntersectionObserver){e();return}f=f||new IntersectionObserver(function(m){for(var E=0;E!==m.length;E++){if(m[E].isIntersecting){e();return}}},{rootMargin:\"800px 0px 800px 0px\"});for(t=0;t!==n.length;t++){if(!n[t].__nxLazySeen){n[t].__nxLazySeen=true;f.observe(n[t])}}}document.addEventListener(\"DOMContentLoaded\",s);document.addEventListener(\"nexus:runtime-ready\",s);window.addEventListener(\"load\",s);setTimeout(s,0)}var V=document.querySelectorAll(\"script[data-nx-run]\"),C=[],z=[];for(var D=0;D< V.length;D++){var l=V[D];if(l.hasAttribute(\"data-nx-ran\")){continue}if(l.hasAttribute(\"data-nx-on-sight\")){l.setAttribute(\"data-nx-ran\",\"waiting\");z.push(l);continue}if(l.hasAttribute(\"data-nx-src\")?!l.textContent:false){l.setAttribute(\"data-nx-ran\",\"loading\");C.push(l);continue}if(l.hasAttribute(\"data-nx-asset\")?!l.textContent:false){l.setAttribute(\"data-nx-ran\",\"loading\");C.push(l);continue}l.setAttribute(\"data-nx-ran\",\"true\");try{var L=document.createElement(\"script\");L.className=\"_iub_cs_skip\";L.setAttribute(\"data-nx-runtime\",l.getAttribute(\"data-nx-run\"));L.textContent=window.__nxInflate(l.textContent);(document.head||document.documentElement).appendChild(L)}catch(r){l.setAttribute(\"data-nx-ran\",\"failed\")}}if(z.length){ct(z)}if(!C.length){return}var W=window.NX_RUNTIME||{},Y=W.base||window.NX_RUNTIME_BASE||\"\",T=window.__nxMount,O=[];if(typeof T===\"function\"){window.__nxMount=function(r){O.push(r)}}function dt(){if(typeof T===\"function\"){window.__nxMount=T;for(var r=0;r< O.length;r++){try{T(O[r])}catch(i){}}}try{document.dispatchEvent(new CustomEvent(\"nexus:runtime-ready\"))}catch(i){}}function M(r){if(r>=C.length){dt();return}var i=C[r],f=i.getAttribute(\"data-nx-src\")||\"\",o=W.files||{},e=[];if(i.hasAttribute(\"data-nx-asset\")){window.__nxAsset(i.getAttribute(\"data-nx-asset\"),i.getAttribute(\"data-nx-sri\")||\"\").then(function(u){var n=document.createElement(\"script\");n.className=\"_iub_cs_skip\";n.setAttribute(\"data-nx-runtime\",i.getAttribute(\"data-nx-run\"));n.textContent=window.__nxInflate(u);(document.head||document.documentElement).appendChild(n);i.setAttribute(\"data-nx-ran\",\"true\")}).then(null,function(){i.setAttribute(\"data-nx-ran\",\"failed\")}).then(function(){M(r+1)});return}var s=o[f.replace(\/\\.[0-9a-f]{12}(\\.js)$\/,\"$1\")]||null;if(Y){e.push([Y+f,i.getAttribute(\"data-nx-sri\")||\"\"])}if(s?!!s.url:false){e.push([s.url,s.sri||\"\"])}function a(u){if(u===e.length?!e.live:false){e.live=true;Q(f).then(function(t){if(t){e.push(t)}a(u)});return}if(u>=e.length){i.setAttribute(\"data-nx-ran\",\"failed\");M(r+1);return}var n=document.createElement(\"script\");n.className=\"_iub_cs_skip\";n.setAttribute(\"data-nx-runtime\",i.getAttribute(\"data-nx-run\"));if(e[u][1]){n.integrity=e[u][1]}n.onload=function(){i.setAttribute(\"data-nx-ran\",\"true\");M(r+1)};n.onerror=function(){if(n.parentNode){n.parentNode.removeChild(n)}a(u+1)};n.src=e[u][0];(document.head||document.documentElement).appendChild(n)}a(0)}M(0)})();<\/script><div class=\"nxe-host\" data-nxe-embed=\"nr-gcri-editions-xt-04-full\"><div class=\"nxe\" id=\"nxe-nr-gcri-editions-xt-04-full\" data-inst=\"gcri\" data-host=\"gcri\" data-nr-kit=\"true\" data-nr-pub=\"true\" data-theme=\"light\" data-grammar=\"atlas\" lang=\"en\" data-nx-css=\"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\"><style>#nxe-nr-gcri-editions-xt-04-full.nxe{display:block;box-sizing:border-box;max-width:1180px;margin:0 auto;padding:0 16px;font-family:ui-sans-serif,system-ui,-apple-system,\"Segoe UI\",sans-serif;line-height:1.55;overflow-wrap:break-word}#nxe-nr-gcri-editions-xt-04-full.nxe :where(*,*::before,*::after){box-sizing:inherit}#nxe-nr-gcri-editions-xt-04-full.nxe :where(section,header,footer,nav,aside){display:block;margin:0 0 32px}#nxe-nr-gcri-editions-xt-04-full.nxe :where(h1,h2,h3,h4){line-height:1.2;margin:24px 0 12px;font-weight:600}#nxe-nr-gcri-editions-xt-04-full.nxe :where(p,ul,ol,dl,table,figure,details){margin:0 0 16px}#nxe-nr-gcri-editions-xt-04-full.nxe :where(ul,ol){padding-left:20px}#nxe-nr-gcri-editions-xt-04-full.nxe a{color:inherit;text-decoration:underline;text-underline-offset:2px}#nxe-nr-gcri-editions-xt-04-full.nxe table{border-collapse:collapse;width:100%;display:block;overflow-x:auto}#nxe-nr-gcri-editions-xt-04-full.nxe :where(th,td){padding:6px 8px;text-align:left;vertical-align:top;border-bottom:1px solid;border-color:inherit}#nxe-nr-gcri-editions-xt-04-full.nxe svg{display:none}#nxe-nr-gcri-editions-xt-04-full.nxe svg.nx-i{display:inline-block;width:18px;height:18px;vertical-align:-3px}#nxe-nr-gcri-editions-xt-04-full.nxe :where([role=\"tablist\"],[role=\"toolbar\"],[hidden],button,.nx-theme-toggle,.nx-live-slot){display:none}#nxe-nr-gcri-editions-xt-04-full.nxe img{max-width:100%;height:auto}<\/style><svg class=\"nx-defs\" aria-hidden=\"true\" focusable=\"false\" width=\"0\" height=\"0\"><defs><linearGradient id=\"nx-gi\" x1=\"0\" y1=\"0\" x2=\"1\" y2=\"1\"><stop offset=\"0\" class=\"nx-gi-a\"\/><stop offset=\"0.55\" class=\"nx-gi-b\"\/><stop offset=\"1\" class=\"nx-gi-c\"\/><\/linearGradient><linearGradient id=\"nx-giu\" gradientUnits=\"userSpaceOnUse\" x1=\"0\" y1=\"0\" x2=\"800\" y2=\"0\"><stop offset=\"0\" class=\"nx-gi-a\"\/><stop offset=\"0.55\" class=\"nx-gi-b\"\/><stop offset=\"1\" class=\"nx-gi-c\"\/><\/linearGradient><linearGradient id=\"nx-gp\" x1=\"0\" y1=\"0\" x2=\"1\" y2=\"1\"><stop offset=\"0\" class=\"nx-gp-a\"\/><stop offset=\"1\" class=\"nx-gp-b\"\/><\/linearGradient><\/defs><\/svg><div class=\"nrp\"><div class=\"nrp-wrap\"><p class=\"nrj-draft\" data-nrj-shared=\"draft\" role=\"note\"><strong>Draft, not yet released.<\/strong> In stewardship review. Not indexed until the first approved release.<\/p><article class=\"nrp-flow\"><header class=\"nrp-hero\"><div class=\"nrp-hero-grid\"><div><ul class=\"nrp-eyerow\"><li class=\"nf-ui-eyebrow\">Reports<\/li><li class=\"nf-ui-eyebrow\">Baseline Edition 2026<\/li><li class=\"nf-ui-eyebrow\">Complete edition<\/li><\/ul><span class=\"nrp-rule\" aria-hidden=\"true\"><\/span><h1 class=\"pp-hero-title nrp-hero-title-l\">Exponential Technology Report 2026: Synthetic Biology and Bioengineering<\/h1><p class=\"nrp-lede\"><\/p><div class=\"nrp-actions\"><button class=\"nf-ui-btn\" data-variant=\"primary\" type=\"button\" data-nrp-act=\"print\" hidden><svg class=\"nrp-i\" viewBox=\"0 0 24 24\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M6 18H4a2 2 0 0 1-2-2v-5a2 2 0 0 1 2-2h16a2 2 0 0 1 2 2v5a2 2 0 0 1-2 2h-2\"\/><path d=\"M6 9V3a1 1 0 0 1 1-1h10a1 1 0 0 1 1 1v6\"\/><rect x=\"6\" y=\"14\" width=\"12\" height=\"8\" rx=\"1\"\/><\/svg>Print or save as PDF<\/button><a class=\"nf-ui-btn\" data-variant=\"secondary\" href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/\"><svg class=\"nrp-i\" viewBox=\"0 0 24 24\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M19 12H5\"\/><path d=\"m12 19-7-7 7-7\"\/><\/svg>Edition home<\/a><\/div><p class=\"nrp-note nrp-noprint\">Choose A4 or Letter in the print dialog; running heads and page numbers are added in print. This is a review copy: the signed PDF with its DOI is issued at release.<\/p><\/div><div><div class=\"nrp-cover\"><div class=\"nrp-cover-top\"><span class=\"nf-ui-eyebrow\">Reports<\/span><span class=\"nf-ui-eyebrow\">XT-04<\/span><\/div><span class=\"nrp-cover-rule\" aria-hidden=\"true\"><\/span><p class=\"nrp-cover-k\">Exponential Technology<\/p><p class=\"nrp-cover-t\">Synthetic Biology and Bioengineering 2026<\/p><p class=\"nrp-cover-s\"><\/p><div class=\"nrp-cover-foot\"><span>Baseline Edition 2026<\/span><span>NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE<\/span><span><abbr title=\"The Global Centre for Risk and Innovation\">GCRI<\/abbr> for the Nexus Consortium<\/span><\/div><\/div><\/div><\/div><\/header><section class=\"nrp-block nrp-imprint\" aria-label=\"Imprint\"><p class=\"nf-ui-eyebrow\">Imprint<\/p><dl class=\"nrp-dl\"><dt>Editor<\/dt><dd>Saeed Valadbaygi, Chief Steward and Managing Editor, the Global Centre for Risk and Innovation (GCRI)<\/dd><dt>Publisher of record<\/dt><dd>The Global Centre for Risk and Innovation (GCRI) for the Nexus Consortium, Toronto<\/dd><dt>Report number<\/dt><dd class=\"nrp-mono\">NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE<\/dd><dt>Evidence close<\/dt><dd>30 September 2026, cut DC-XTECH-SYNBIO-GLOBAL-2026-B0<\/dd><dt>Status<\/dt><dd>Draft under stewardship review; not yet released<\/dd><dt>DOI and UNI<\/dt><dd>Issued at deposit<\/dd><dt>Licence<\/dt><dd>CC BY 4.0 for Nexus-authored text, tables and figures; third-party material keeps its own licence<\/dd><dt>Cite as<\/dt><dd>Valadbaygi, S. (Ed.). (2026). Exponential Technology Report 2026: Synthetic Biology and Bioengineering (Baseline Edition 2026, Report No. NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE) [Draft under review]. The Global Centre for Risk and Innovation (GCRI). https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/<\/dd><\/dl><\/section><section class=\"nrp-block\" aria-label=\"Contents\"><p class=\"nf-ui-eyebrow\">Contents<\/p><ol class=\"nrp-rows\"><li><span class=\"nrp-rows-i\">\u00b7<\/span><p class=\"nrp-rows-t\"><a href=\"#nx-nrp-xt-04-part-summary\">Executive summary<\/a><\/p><\/li><li><span class=\"nrp-rows-i\">1<\/span><p class=\"nrp-rows-t\"><a href=\"#nx-nrp-xt-04-part-coupled-system\">Chapter 1. Synthetic biology is a build capability and a governance test<\/a><\/p><\/li><li><span class=\"nrp-rows-i\">2<\/span><p class=\"nrp-rows-t\"><a href=\"#nx-nrp-xt-04-part-findings\">Chapter 2. Key findings<\/a><\/p><\/li><li><span class=\"nrp-rows-i\">3<\/span><p class=\"nrp-rows-t\"><a href=\"#nx-nrp-xt-04-part-systems-and-sectors\">Chapter 3. Systems and sectors at baseline<\/a><\/p><\/li><li><span class=\"nrp-rows-i\">4<\/span><p class=\"nrp-rows-t\"><a href=\"#nx-nrp-xt-04-part-risk-and-capability\">Chapter 4. Risks and capability<\/a><\/p><\/li><li><span class=\"nrp-rows-i\">5<\/span><p class=\"nrp-rows-t\"><a href=\"#nx-nrp-xt-04-part-scenario\">Chapter 5. Design capability outpaces screening and oversight<\/a><\/p><\/li><li><span class=\"nrp-rows-i\">6<\/span><p class=\"nrp-rows-t\"><a href=\"#nx-nrp-xt-04-part-lenses-and-readings\">Chapter 6. Readings from the other desks<\/a><\/p><\/li><li><span class=\"nrp-rows-i\">7<\/span><p class=\"nrp-rows-t\"><a href=\"#nx-nrp-xt-04-part-agenda\">Chapter 7. The 2027 agenda<\/a><\/p><\/li><li><span class=\"nrp-rows-i\">8<\/span><p class=\"nrp-rows-t\"><a href=\"#nx-nrp-xt-04-part-systems-in-depth\">Chapter 8. Systems in depth<\/a><\/p><\/li><li><span class=\"nrp-rows-i\">A<\/span><p class=\"nrp-rows-t\"><a href=\"#nx-nrp-xt-04-part-methodology\">Annex A. Methodology<\/a><\/p><\/li><li><span class=\"nrp-rows-i\">B<\/span><p class=\"nrp-rows-t\"><a href=\"#nx-nrp-xt-04-part-data\">Annex B. Data appendix<\/a><\/p><\/li><li><span class=\"nrp-rows-i\">C<\/span><p class=\"nrp-rows-t\"><a href=\"#nx-nrp-xt-04-part-references\">Annex C. References and record<\/a><\/p><\/li><\/ol><\/section><div class=\"nrp-part\" id=\"nx-nrp-xt-04-part-summary\"><header class=\"nrp-chap-head\" id=\"nx-nrp-xt-04-cs-top\"><ul class=\"nrp-eyerow\"><li class=\"nf-ui-eyebrow\"><a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/\">Synthetic Biology and Bioengineering 2026<\/a><\/li><li class=\"nf-ui-eyebrow\">Executive summary<\/li><\/ul><span class=\"nrp-rule\" aria-hidden=\"true\"><\/span><h2 class=\"pp-hero-title\">Executive summary<\/h2><p class=\"nrp-lede\">The edition on a few pages: the abstract, the key messages, the headline finding and what each steward reads in it.<\/p><p class=\"nrp-chap-meta\"><span>7 min read<\/span><span>1 figure<\/span><span>0 tables<\/span><span>15 notes<\/span><span>NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE<\/span><\/p><\/header><section class=\"nrp-block\" id=\"nx-nrp-xt-04-cs-s1\" aria-labelledby=\"nx-nrp-xt-04-cs-s1-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-cs-s1-h\"><span class=\"nrp-num\">S.1<\/span><span>Abstract<\/span><\/h2><div class=\"nrp-prose\"><p>Synthetic biology matters to the Nexus programme in three ways. It is a build capability: whole genomes are now designed and written, and in 2025 a bacterium was reported with a 57-codon genetic code, down from the standard 64<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n1\" id=\"nx-nrp-xt-04-cs-r1\" aria-label=\"Note 1\">1<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n2\" id=\"nx-nrp-xt-04-cs-r2\" aria-label=\"Note 2\">2<\/a><\/sup>. It is a manufacturing base, built from DNA synthesis, biofoundries and fermentation capacity that few sources count. It is also a biosecurity question, because design tools and cheap DNA lower the barrier to harm as well as to benefit. The build evidence is strong at the scale of single organisms. A synthetic E. coli genome recoded 18,214 codons in 2019<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n3\" id=\"nx-nrp-xt-04-cs-r3\" aria-label=\"Note 3\">3<\/a><\/sup>, and by 2023 six and a half synthetic yeast chromosomes had been combined in one strain<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n4\" id=\"nx-nrp-xt-04-cs-r4\" aria-label=\"Note 4\">4<\/a><\/sup>. Design tools have matured: a 2016 automation tool built 60 genetic circuits and 45 worked in every output state<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n6\" id=\"nx-nrp-xt-04-cs-r6\" aria-label=\"Note 6\">6<\/a><\/sup>. Therapies built with CRISPR reached patients, and 29 of 30 evaluable patients in one trial were free of severe crises for 12 months<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n8\" id=\"nx-nrp-xt-04-cs-r8\" aria-label=\"Note 8\">8<\/a><\/sup>. The risk evidence is newer. A 2025 study found that open machine-learning design software could produce protein variants that screening tools often missed, and it reported patches that improved detection<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n13\" id=\"nx-nrp-xt-04-cs-r13\" aria-label=\"Note 13\">13<\/a><\/sup>. Governance is moving but uneven. A US commission asked Congress in April 2025 for at least USD 15 billion over five years<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n14\" id=\"nx-nrp-xt-04-cs-r14\" aria-label=\"Note 14\">14<\/a><\/sup>, the EU proposed a Biotech Act on 16 December 2025<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n22\" id=\"nx-nrp-xt-04-cs-r22\" aria-label=\"Note 22\">22<\/a><\/sup>, and the OECD found in May 2026 that implementation of anticipatory governance remains uneven<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n18\" id=\"nx-nrp-xt-04-cs-r18\" aria-label=\"Note 18\">18<\/a><\/sup>. Company revenue is a <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-c1\" data-tc=\"NRS-C1 weak-signal\" data-tk=\"Nexus risk vocabulary\" data-td=\"An early, fragmentary indication of a possible change that is not yet clearly recognised or understood.\" data-ts=\"NRS-C1\" data-tr=\"draft\">weak signal<\/a>: Ginkgo Bioworks reported USD 170.2 million for 2025, down from USD 227.0 million<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n17\" id=\"nx-nrp-xt-04-cs-r17\" aria-label=\"Note 17\">17<\/a><\/sup>. The physical footprint of fermentation is the least measured part. This baseline sets out what the evidence supports and where it is thin. It forecasts no capability date and ranks no country or company.<\/p><\/div><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-cs-s2\" aria-labelledby=\"nx-nrp-xt-04-cs-s2-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-cs-s2-h\"><span class=\"nrp-num\">S.2<\/span><span>Key messages<\/span><\/h2><p class=\"nrp-stand\">Six readings that frame the synthetic biology baseline, and the eight questions this edition answers, each with its status and source.<\/p><ol class=\"nrp-km\"><li><p class=\"nrp-km-t\">A bacterium with a 57-codon code and a yeast strain with six and a half synthetic chromosomes.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n2\" aria-label=\"Note 2\">2<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n4\" aria-label=\"Note 4\">4<\/a><\/sup><\/p><p class=\"nrp-km-m\"><span>How far has genome writing come?<\/span><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/p><\/li><li><p class=\"nrp-km-t\">Yes at the scale of tens of circuits and designed binders, in peer-reviewed tests.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n6\" aria-label=\"Note 6\">6<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n7\" id=\"nx-nrp-xt-04-cs-r7\" aria-label=\"Note 7\">7<\/a><\/sup><\/p><p class=\"nrp-km-m\"><span>Can circuits and proteins be designed by software?<\/span><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/p><\/li><li><p class=\"nrp-km-t\">A CRISPR therapy was authorised in the US in December 2023.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n8\" aria-label=\"Note 8\">8<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n9\" id=\"nx-nrp-xt-04-cs-r9\" aria-label=\"Note 9\">9<\/a><\/sup><\/p><p class=\"nrp-km-m\"><span>Do engineered therapies reach patients?<\/span><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/p><\/li><li><p class=\"nrp-km-t\">A 2025 study found tools often missed redesigned sequences; patches helped.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n13\" aria-label=\"Note 13\">13<\/a><\/sup><\/p><p class=\"nrp-km-m\"><span>Is DNA screening keeping up with design tools?<\/span><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/p><\/li><li><p class=\"nrp-km-t\">A US commission report, an EU proposal, OECD and CBD work; uneven implementation.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n14\" aria-label=\"Note 14\">14<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n18\" aria-label=\"Note 18\">18<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n22\" aria-label=\"Note 22\">22<\/a><\/sup><\/p><p class=\"nrp-km-m\"><span>What does governance look like?<\/span><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/p><\/li><li><p class=\"nrp-km-t\">Company results are mixed: Ginkgo revenue fell in 2025, Twist raised its 2026 guidance.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n16\" id=\"nx-nrp-xt-04-cs-r16\" aria-label=\"Note 16\">16<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n17\" aria-label=\"Note 17\">17<\/a><\/sup><\/p><p class=\"nrp-km-m\"><span>What does the money look like?<\/span><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/p><\/li><li><p class=\"nrp-km-t\">Not published on a common basis; no figure bound.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n24\" id=\"nx-nrp-xt-04-cs-r24\" aria-label=\"Note 24\">24<\/a><\/sup><\/p><p class=\"nrp-km-m\"><span>What is the physical footprint?<\/span><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Expert input<\/span><\/p><\/li><li><p class=\"nrp-km-t\">Whether screening and governance keep pace with design and cheap DNA. SCN-XT04-DSG-01<\/p><p class=\"nrp-km-m\"><span>What will 2027 test first?<\/span><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Expert input<\/span><\/p><\/li><\/ol><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-cs-s3\" aria-labelledby=\"nx-nrp-xt-04-cs-s3-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-cs-s3-h\"><span class=\"nrp-num\">S.3<\/span><span>Headline finding<\/span><\/h2><p class=\"nrp-find-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 4<\/span><span class=\"nrp-find-id\">NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-BLD-001<\/span><\/p><p class=\"nrp-km-t\">A bacterium with a 57-codon genetic code was reported in Science in 2025, seven codons fewer than the standard 64, with over 101,000 codon changes in a synthetic genome of about 4 million base pairs.<\/p><figure class=\"nrp-fig\" id=\"nx-nrp-xt-04-cs-fig1\" aria-labelledby=\"nx-nrp-xt-04-cs-fig1-t\"><figcaption class=\"nrp-figcap\"><span class=\"nf-ui-eyebrow\">Figure S.1<\/span><span class=\"nf-ui-title\" data-level=\"card\" id=\"nx-nrp-xt-04-cs-fig1-t\">Codons in the genetic code<\/span><\/figcaption><div class=\"nrp-tblw\"><table class=\"nrp-tbl nrp-bars\"><thead><tr><th scope=\"col\">Item<\/th><th scope=\"col\"><span class=\"nrp-sr\">Bar, scaled to the largest value<\/span><\/th><th scope=\"col\">Value<\/th><\/tr><\/thead><tbody><tr><th scope=\"row\">Standard genetic code<\/th><td class=\"nrp-barc\"><svg class=\"nrp-svg nrp-barsvg\" viewBox=\"0 0 100 8\" preserveAspectRatio=\"none\" aria-hidden=\"true\" focusable=\"false\"><rect class=\"nrp-track\" x=\"0\" y=\"0\" width=\"100\" height=\"8\"\/><rect class=\"nrp-bar\" x=\"0\" y=\"0\" width=\"100.0\" height=\"8\"\/><\/svg><\/td><td class=\"nrp-mono\">64<\/td><\/tr><tr><th scope=\"row\">Syn61 strain (2019)<\/th><td class=\"nrp-barc\"><svg class=\"nrp-svg nrp-barsvg\" viewBox=\"0 0 100 8\" preserveAspectRatio=\"none\" aria-hidden=\"true\" focusable=\"false\"><rect class=\"nrp-track\" x=\"0\" y=\"0\" width=\"100\" height=\"8\"\/><rect class=\"nrp-bar\" x=\"0\" y=\"0\" width=\"95.3\" height=\"8\"\/><\/svg><\/td><td class=\"nrp-mono\">61<\/td><\/tr><tr><th scope=\"row\">Syn57 strain (2025)<\/th><td class=\"nrp-barc\"><svg class=\"nrp-svg nrp-barsvg\" viewBox=\"0 0 100 8\" preserveAspectRatio=\"none\" aria-hidden=\"true\" focusable=\"false\"><rect class=\"nrp-track\" x=\"0\" y=\"0\" width=\"100\" height=\"8\"\/><rect class=\"nrp-bar\" x=\"0\" y=\"0\" width=\"89.1\" height=\"8\"\/><\/svg><\/td><td class=\"nrp-mono\">57<\/td><\/tr><\/tbody><\/table><\/div><p class=\"nrp-fig-src\">Sources: MRC Laboratory of Molecular Biology<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n2\" aria-label=\"Note 2\">2<\/a><\/sup>; Nature 569 (2019)<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n3\" aria-label=\"Note 3\">3<\/a><\/sup>. Each bar counts codons in the code of that organism.<\/p><\/figure><p class=\"nrp-p\">Whole-genome design and writing now works at the scale of a bacterial genome. The authors state aims such as further compression and tests of viral resistance; those are plans, not results<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n1\" aria-label=\"Note 1\">1<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n2\" aria-label=\"Note 2\">2<\/a><\/sup>. The result shows capability on one organism and says nothing about industrial use, cost or safety in the field.<\/p><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-cs-s4\" aria-labelledby=\"nx-nrp-xt-04-cs-s4-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-cs-s4-h\"><span class=\"nrp-num\">S.4<\/span><span>At a glance<\/span><\/h2><div class=\"pp-cells nrp-cells-3\"><div class=\"nrp-cell\"><span class=\"pp-metric\">57<\/span><span class=\"nrp-cell-u\">codons<\/span><p>Syn57 genetic code<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n2\" aria-label=\"Note 2\">2<\/a><\/sup><\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">6.5<\/span><span class=\"nrp-cell-u\">chromosomes<\/span><p>synthetic yeast in one strain<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n4\" aria-label=\"Note 4\">4<\/a><\/sup><\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">97<\/span><span class=\"nrp-cell-u\">%<\/span><p>exa-cel trial, 29 of 30<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n8\" aria-label=\"Note 8\">8<\/a><\/sup><\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">49<\/span><span class=\"nrp-cell-u\">recommendations<\/span><p>US commission, 2025<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n14\" aria-label=\"Note 14\">14<\/a><\/sup><\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">170.2<\/span><span class=\"nrp-cell-u\">USD million<\/span><p>Ginkgo revenue, 2025<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n17\" aria-label=\"Note 17\">17<\/a><\/sup><\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">25<\/span><span class=\"nrp-cell-u\">awards<\/span><p>US bioindustrial planning awards, 2024<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cs-n24\" aria-label=\"Note 24\">24<\/a><\/sup><\/p><\/div><\/div><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-cs-s5\" aria-labelledby=\"nx-nrp-xt-04-cs-s5-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-cs-s5-h\"><span class=\"nrp-num\">S.5<\/span><span>What each steward reads in it<\/span><\/h2><div class=\"nrp-cards\" data-n=\"3\"><article class=\"nf-ui-card nrp-card\"><p class=\"nf-ui-eyebrow\">GCRI \u00b7 KEY T<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">Technical Truth<\/h3><p>The evidence supports reading synthetic biology as a build capability, a manufacturing base and a governance test.<\/p><\/article><article class=\"nf-ui-card nrp-card\"><p class=\"nf-ui-eyebrow\"><abbr title=\"The Global Risks Forum\">GRF<\/abbr> \u00b7 KEY M<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">Public Meaning<\/h3><p>For most people synthetic biology arrives as a medicine, a food label or a warning about misuse.<\/p><\/article><article class=\"nf-ui-card nrp-card\"><p class=\"nf-ui-eyebrow\"><abbr title=\"The Global Risks Alliance\">GRA<\/abbr> \u00b7 KEY F<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">Capital Meaning<\/h3><p>Readiness implications only. Company results are mixed and public programmes are at the planning stage.<\/p><\/article><article class=\"nf-ui-card nrp-card\"><p class=\"nf-ui-eyebrow\">NEXUS<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">Synthesis<\/h3><p>Synthetic biology is well described by single results and thinly measured as a system.<\/p><\/article><\/div><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-cs-s6\" aria-labelledby=\"nx-nrp-xt-04-cs-s6-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-cs-s6-h\"><span class=\"nrp-num\">S.6<\/span><span>What this edition is, and is not<\/span><\/h2><div class=\"pp-cells nrp-cells-3\"><div class=\"nrp-cell\"><h3 class=\"nf-ui-title\" data-level=\"card\">What this edition is<\/h3><p>A baseline: the 2026 state of synthetic biology and bioengineering as infrastructure and the couplings through which it carries risk into other <a class=\"nx-link nx-term\" href=\"https:\/\/docs.therisk.global\/organization\/systems\" data-tc=\"Systems\" data-tk=\"Nexus Standards\" data-td=\"The twenty Nexus systems, NXS-CMD to NXS-LAB\">systems<\/a>. It synthesises published evidence and ranks no country, company or asset.<\/p><\/div><div class=\"nrp-cell\"><h3 class=\"nf-ui-title\" data-level=\"card\">What it is not<\/h3><p>Not a forecast of any capability date, a technology ranking, an endorsement of any company or an assessment of any laboratory or programme. Biosafety, biosecurity, export-control and funding rules are decisions of competent authorities.<\/p><\/div><div class=\"nrp-cell\"><h3 class=\"nf-ui-title\" data-level=\"card\">What comes next<\/h3><p>National, regional and sector evidence feeds the 2027 synthetic biology edition through the federation. Each edition reports what changed against this baseline: observations, source revisions, method changes, scenario updates and corrections.<\/p><\/div><\/div><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-cs-notes\" aria-labelledby=\"nx-nrp-xt-04-cs-notes-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-cs-notes-h\"><span>Notes<\/span><\/h2><p class=\"nrp-note\">Numbers are the edition&#8217;s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. <a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/references\/\">Annex C, references<\/a><\/p><ol class=\"nrp-notes\"><li id=\"nx-nrp-xt-04-cs-n1\"><span class=\"nrp-notes-n\">1<\/span><span>Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cs-r1\" aria-label=\"Back to the first call of note 1\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cs-n2\"><span class=\"nrp-notes-n\">2<\/span><span>MRC Laboratory of Molecular Biology (ed.), Syn57 represents a new chapter in the genetic code of life (news page, 1 August 2025; over 101,000 codons recoded; 64 to 57 codons; genome of about 4 megabases built from 38 fragments of about 100 kilobases). MRC Laboratory of Molecular Biology, Cambridge. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cs-r2\" aria-label=\"Back to the first call of note 2\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cs-n3\"><span class=\"nrp-notes-n\">3<\/span><span>Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cs-r3\" aria-label=\"Back to the first call of note 3\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cs-n4\"><span class=\"nrp-notes-n\">4<\/span><span>Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cs-r4\" aria-label=\"Back to the first call of note 4\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cs-n6\"><span class=\"nrp-notes-n\">6<\/span><span>Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cs-r6\" aria-label=\"Back to the first call of note 6\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cs-n8\"><span class=\"nrp-notes-n\">8<\/span><span>Frangoul, H. et al., Exagamglogene autotemcel for severe sickle cell disease, New England Journal of Medicine 390 (18), 1649 to 1662, 2024 (record read via Europe PMC: 44 treated; 29 of 30 evaluable free of severe crises for 12 months; median follow-up 19.3 months). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cs-r8\" aria-label=\"Back to the first call of note 8\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cs-n13\"><span class=\"nrp-notes-n\">13<\/span><span>Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cs-r13\" aria-label=\"Back to the first call of note 13\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cs-n14\"><span class=\"nrp-notes-n\">14<\/span><span>Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cs-r14\" aria-label=\"Back to the first call of note 14\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cs-n22\"><span class=\"nrp-notes-n\">22<\/span><span>Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cs-r22\" aria-label=\"Back to the first call of note 22\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cs-n18\"><span class=\"nrp-notes-n\">18<\/span><span>OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cs-r18\" aria-label=\"Back to the first call of note 18\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cs-n17\"><span class=\"nrp-notes-n\">17<\/span><span>Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cs-r17\" aria-label=\"Back to the first call of note 17\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cs-n7\"><span class=\"nrp-notes-n\">7<\/span><span>Watson, J.L. et al., De novo design of protein structure and function with RFdiffusion, Nature 620, 1089 to 1100, 2023 (record read via Europe PMC). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cs-r7\" aria-label=\"Back to the first call of note 7\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cs-n9\"><span class=\"nrp-notes-n\">9<\/span><span>US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy and Lyfgenia; ages 12 and over; 29 of 31 evaluable Casgevy patients free of severe crises for at least 12 months). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cs-r9\" aria-label=\"Back to the first call of note 9\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cs-n16\"><span class=\"nrp-notes-n\">16<\/span><span>Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cs-r16\" aria-label=\"Back to the first call of note 16\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cs-n24\"><span class=\"nrp-notes-n\">24<\/span><span>US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cs-r24\" aria-label=\"Back to the first call of note 24\">back<\/a><\/span><\/li><\/ol><\/section><\/div><div class=\"nrp-part\" id=\"nx-nrp-xt-04-part-coupled-system\"><header class=\"nrp-chap-head\" id=\"nx-nrp-xt-04-c1-top\"><ul class=\"nrp-eyerow\"><li class=\"nf-ui-eyebrow\"><a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/\">Synthetic Biology and Bioengineering 2026<\/a><\/li><li class=\"nf-ui-eyebrow\">Chapter 1<\/li><\/ul><span class=\"nrp-rule\" aria-hidden=\"true\"><\/span><h2 class=\"pp-hero-title\">Synthetic biology is a build capability and a governance test<\/h2><p class=\"nrp-lede\">Part I describes systems and their couplings. It ranks no country or operator and assesses no authority.<\/p><p class=\"nrp-chap-meta\"><span>7 min read<\/span><span>2 figures<\/span><span>1 table<\/span><span>17 notes<\/span><span>NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE<\/span><\/p><\/header><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c1-s1\" aria-labelledby=\"nx-nrp-xt-04-c1-s1-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c1-s1-h\"><span class=\"nrp-num\">1.1<\/span><span>The questions this part answers<\/span><\/h2><h3 class=\"nrp-h3\">Key questions<\/h3><ul class=\"nrp-list\"><li>Where is synthetic biology risk concentrated?<\/li><li>Which couplings carry synthetic biology shocks into other <a class=\"nx-link nx-term\" href=\"https:\/\/docs.therisk.global\/organization\/systems\" data-tc=\"Systems\" data-tk=\"Nexus Standards\" data-td=\"The twenty Nexus systems, NXS-CMD to NXS-LAB\">systems<\/a>?<\/li><li>Which synthetic biology capabilities hold under compound stress?<\/li><li>What must 2027 evidence measure first?<\/li><\/ul><h3 class=\"nrp-h3\">In this part<\/h3><ul class=\"nrp-chips\"><li class=\"nf-ui-chip\">Narrative<\/li><li class=\"nf-ui-chip\">Headline finding<\/li><li class=\"nf-ui-chip\">Lead figure<\/li><li class=\"nf-ui-chip\">Five footprint and governance chapters<\/li><li class=\"nf-ui-chip\">Twelve-domain reading<\/li><li class=\"nf-ui-chip\">Sector screens<\/li><li class=\"nf-ui-chip\">Dependency matrix<\/li><li class=\"nf-ui-chip\">Risk objects<\/li><li class=\"nf-ui-chip\">Capability ladder<\/li><li class=\"nf-ui-chip\">Scenario<\/li><li class=\"nf-ui-chip\">Three lenses<\/li><li class=\"nf-ui-chip\">Portfolio<\/li><\/ul><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c1-s2\" aria-labelledby=\"nx-nrp-xt-04-c1-s2-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c1-s2-h\"><span class=\"nrp-num\">1.2<\/span><span>The argument<\/span><\/h2><div class=\"nrp-prose\"><p>Synthetic biology is usually told as a story of products. The 2026 evidence reads it as three things at once: a capability to design and write living <a class=\"nx-link nx-term\" href=\"https:\/\/docs.therisk.global\/organization\/systems\" data-tc=\"Systems\" data-tk=\"Nexus Standards\" data-td=\"The twenty Nexus systems, NXS-CMD to NXS-LAB\">systems<\/a>, a manufacturing base that needs DNA, instruments, feedstock and people, and a governance test for oversight that was written for slower tools<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n1\" id=\"nx-nrp-xt-04-c1-r1\" aria-label=\"Note 1\">1<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n13\" id=\"nx-nrp-xt-04-c1-r13\" aria-label=\"Note 13\">13<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n18\" id=\"nx-nrp-xt-04-c1-r18\" aria-label=\"Note 18\">18<\/a><\/sup>.<\/p><p>The build evidence is strong at small scale. A bacterium now runs on a 57-codon genetic code, and a yeast strain carries six and a half synthetic chromosomes<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n2\" id=\"nx-nrp-xt-04-c1-r2\" aria-label=\"Note 2\">2<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n4\" id=\"nx-nrp-xt-04-c1-r4\" aria-label=\"Note 4\">4<\/a><\/sup>. Software built 60 genetic circuits and 45 worked in every output state<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n6\" id=\"nx-nrp-xt-04-c1-r6\" aria-label=\"Note 6\">6<\/a><\/sup>. These are results on single organisms, not industrial platforms.<\/p><p>The risk evidence is newer and sharper. A 2025 study found that screening tools often missed protein variants redesigned with open software, and patches improved detection<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n13\" aria-label=\"Note 13\">13<\/a><\/sup>. A 2024 policy forum asked for broad discussion of <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-h101\" data-tc=\"NHS-1 tech.biotech.mirror-life\" data-tk=\"Frontier and exponential technology \u00b7 Biotechnology and synthetic biology\" data-td=\"Creation and escape of organisms built from mirror-image molecules, which could evade immune defences, predators and decay in people, animals and plants and spread unchecked through ecosystems.\" data-ts=\"NRS-H101\" data-tr=\"draft\" data-tx=\"https:\/\/risksindex.com\/hazards\/tech\/\" data-txl=\"Frontier and exponential technology\">mirror life<\/a><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n12\" id=\"nx-nrp-xt-04-c1-r12\" aria-label=\"Note 12\">12<\/a><\/sup>. Governance is moving: a US commission report, an EU proposal and OECD and CBD work all appeared between 2022 and 2026, but implementation is uneven<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n14\" id=\"nx-nrp-xt-04-c1-r14\" aria-label=\"Note 14\">14<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n18\" aria-label=\"Note 18\">18<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n20\" id=\"nx-nrp-xt-04-c1-r20\" aria-label=\"Note 20\">20<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n22\" id=\"nx-nrp-xt-04-c1-r22\" aria-label=\"Note 22\">22<\/a><\/sup>.<\/p><p>The physical base is the least measured part. Company revenue is mixed, with Ginkgo Bioworks down and Twist Bioscience guiding up<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n16\" id=\"nx-nrp-xt-04-c1-r16\" aria-label=\"Note 16\">16<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n17\" id=\"nx-nrp-xt-04-c1-r17\" aria-label=\"Note 17\">17<\/a><\/sup>. Energy, water, feedstock, capacity and workforce figures are not published on a common basis.<\/p><\/div><figure class=\"nrp-fig\" id=\"nx-nrp-xt-04-c1-fig1\" aria-labelledby=\"nx-nrp-xt-04-c1-fig1-t\"><figcaption class=\"nrp-figcap\"><span class=\"nf-ui-eyebrow\">Figure 1.1<\/span><span class=\"nf-ui-title\" data-level=\"card\" id=\"nx-nrp-xt-04-c1-fig1-t\">How much recoding has been built? Codons changed in a synthetic genome, thousands<\/span><p class=\"nrp-fig-what\">The number of recoded codons rose about fivefold between two strains from the same research line. The Syn57 figure is stated as over 101,000, so the ratio is a lower bound<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n2\" aria-label=\"Note 2\">2<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n3\" id=\"nx-nrp-xt-04-c1-r3\" aria-label=\"Note 3\">3<\/a><\/sup>.<\/p><\/figcaption><div class=\"nrp-tblw\"><table class=\"nrp-tbl nrp-bars\"><thead><tr><th scope=\"col\">Item<\/th><th scope=\"col\"><span class=\"nrp-sr\">Bar, scaled to the largest value<\/span><\/th><th scope=\"col\">Value<\/th><\/tr><\/thead><tbody><tr><th scope=\"row\">Syn61 strain, 2019: 18,214 codons<\/th><td class=\"nrp-barc\"><svg class=\"nrp-svg nrp-barsvg\" viewBox=\"0 0 100 8\" preserveAspectRatio=\"none\" aria-hidden=\"true\" focusable=\"false\"><rect class=\"nrp-track\" x=\"0\" y=\"0\" width=\"100\" height=\"8\"\/><rect class=\"nrp-bar\" x=\"0\" y=\"0\" width=\"18.0\" height=\"8\"\/><\/svg><\/td><td class=\"nrp-mono\">18.2<\/td><\/tr><tr><th scope=\"row\">Syn57 strain, 2025: over 101,000 codons<\/th><td class=\"nrp-barc\"><svg class=\"nrp-svg nrp-barsvg\" viewBox=\"0 0 100 8\" preserveAspectRatio=\"none\" aria-hidden=\"true\" focusable=\"false\"><rect class=\"nrp-track\" x=\"0\" y=\"0\" width=\"100\" height=\"8\"\/><rect class=\"nrp-bar\" x=\"0\" y=\"0\" width=\"100.0\" height=\"8\"\/><\/svg><\/td><td class=\"nrp-mono\">101<\/td><\/tr><\/tbody><\/table><\/div><p class=\"nrp-fig-src\">Source: as cited in the note to this figure. Year 2025.<\/p><p class=\"nrp-fig-src\">Figure ID FIG-XTECH-SYNBIO-GLOBAL-2026-BASELINE-01-003<\/p><\/figure><div class=\"pp-cells nrp-cells-3\"><div class=\"nrp-cell\"><span class=\"pp-metric\">101<\/span><span class=\"nrp-cell-u\">thousand codons<\/span><p>recoded in Syn57, lower bound<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n2\" aria-label=\"Note 2\">2<\/a><\/sup><\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">18.2<\/span><span class=\"nrp-cell-u\">thousand codons<\/span><p>recoded in Syn61<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n3\" aria-label=\"Note 3\">3<\/a><\/sup><\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">38<\/span><span class=\"nrp-cell-u\">fragments<\/span><p>of about 100,000 base pairs each<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n2\" aria-label=\"Note 2\">2<\/a><\/sup><\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">4<\/span><span class=\"nrp-cell-u\">million base pairs<\/span><p>approximate genome size<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n1\" aria-label=\"Note 1\">1<\/a><\/sup><\/p><\/div><\/div><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c1-s3\" aria-labelledby=\"nx-nrp-xt-04-c1-s3-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c1-s3-h\"><span class=\"nrp-num\">1.3<\/span><span>Twenty couplings between five systems<\/span><\/h2><p class=\"nrp-stand\">The synthetic biology-centred matrix types the twenty couplings between the five core <a class=\"nx-link nx-term\" href=\"https:\/\/docs.therisk.global\/organization\/systems\" data-tc=\"Systems\" data-tk=\"Nexus Standards\" data-td=\"The twenty Nexus systems, NXS-CMD to NXS-LAB\">systems<\/a>, read for their synthetic biology content. Strengths are Nexus estimates (ESTIMATED) from the cited evidence and analogue events; they set the graph that 2027 evidence will test.<\/p><figure class=\"nrp-fig\" id=\"nx-nrp-xt-04-c1-fig2\" aria-labelledby=\"nx-nrp-xt-04-c1-fig2-t\"><figcaption class=\"nrp-figcap\"><span class=\"nf-ui-eyebrow\">Figure 1.2<\/span><span class=\"nf-ui-title\" data-level=\"card\" id=\"nx-nrp-xt-04-c1-fig2-t\">Couplings between the five systems<\/span><p class=\"nrp-fig-what\">Each line is one coupling from one system to another, drawn by the strength the edition assigns. Strengths are Nexus estimates from the cited evidence and analogue events.<\/p><\/figcaption><svg class=\"nrp-svg nrp-ring\" viewBox=\"0 0 340 340\" role=\"img\" aria-label=\"Coupling ring: 20 typed couplings between water, energy, food, health and biodiversity. The matrix in the next table carries every value.\" data-nx-z=\"tZZvb6JAEIe\/ymRf4wrLH+ECJjZH00vvrvHSpK+37FRIEQysZ\/32lwUtaD0bu\/KGEBgzz\/x8YAhXXKaQ5LyuI1JUqxGKBRIQXPLRJiJP8eyegIjIL2tiUtOwfWrCnDkT6hieTV1ggUtdw2IBZQRqWZWvONpkQqYRsd4vCF6nvKr4NiI2OGQaykzmOH3iEiuQJcQFVovtN9jEs3sKRQmiTNZLLCQKyLPiNRy3PwjHinYafpXZNCzHpSaoc89gE4\/6X4e+LUuxR15VZYJ1DRt104B10Q1wDXbLC6hjqKMPAaOOLvod8lymw+ZtMYv6hmXadAKOo+\/ITVaK7C9WdSa3A8be8xnmzPIp283QzXbxDK3eaohmmuvnfggduJQZzDLpREv0jrpv+guiqGWZvAI29wdJvYG2Xerq2N7xD6X7AXXrR\/Ok6vjeUZ8T\/qrZd460U3i7N42G8cqYIX3vIzPHV8EHLrW1ttGeeahl9CFn07BNi3o6ju+ZBzP8gJk1oM1zqWH4nvmU393bpV6vVvmVDO8Chnlgv38FaPjd5j2g4X1kxekY6qj3udVBD6X4MbVpMJdpfm911P01NAyz41B\/tzk1BO+ITyme5FmRJTwHgUteiOsY3tHCPGDUa7\/NNQTvkw+oeZ+7pfUD5YuG5cfkh64\/Z+Xomdco4GWNeX399NXq9PYPq4b2x2NcU\/5fD9\/jP7PH+KQ7+1V6ZitR5v6Xc7+JlrseFLBYZAVihQISzHOQKVZ8lWENFfIkhRWXGRayPp5h0R+gKAWSaZhkVZIjJG8RaXQhkKjcGsOriDCPjKehxDcJXcU2Ig5TJ+r6iBdJWlYRWWZC5EimT7PHcKzuTMPx4tOmjZht052dH7ruSlSFbauKk23j3\/ElbZVIbdvdP\/KxbVuiKnxTVZxse\/vwcEFbpcD5rm3FJ03vfl4SsdLxfMJtxScB3\/zoT\/oP\"><\/svg><ul class=\"nrp-legend\"><li><span class=\"nrp-key\" data-w=\"STRONG\"><\/span>Strong<\/li><li><span class=\"nrp-key\" data-w=\"MODERATE\"><\/span>Moderate<\/li><li><span class=\"nrp-key\" data-w=\"WEAK\"><\/span>Weak<\/li><\/ul><p class=\"nrp-fig-src\">Source: this edition&#8217;s coupling matrix (Table 1.1); status Estimated.<\/p><\/figure><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c1-tab1\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 1.1<\/span><span class=\"nrp-tbl-t\">Coupling matrix: from the row system to the column system<\/span><\/caption><thead><tr><th scope=\"col\">From, to<\/th><th scope=\"col\">WAT<\/th><th scope=\"col\">ENE<\/th><th scope=\"col\">FOO<\/th><th scope=\"col\">HLT<\/th><th scope=\"col\">BIO<\/th><\/tr><\/thead><tbody><tr><td><b>WAT<\/b> Water<\/td><td><span aria-label=\"same system\">\u00b7<\/span><\/td><td>WEAK<br><span class=\"nrp-cell-u\">no documented link<\/span><\/td><td>WEAK<br><span class=\"nrp-cell-u\">process water, undocumented<\/span><\/td><td>WEAK<br><span class=\"nrp-cell-u\">no documented link<\/span><\/td><td>WEAK<br><span class=\"nrp-cell-u\">process water, undocumented<\/span><\/td><\/tr><tr><td><b>ENE<\/b> Energy<\/td><td>WEAK<br><span class=\"nrp-cell-u\">no documented link<\/span><\/td><td><span aria-label=\"same system\">\u00b7<\/span><\/td><td>WEAK<br><span class=\"nrp-cell-u\">feedstock energy, undocumented<\/span><\/td><td>WEAK<br><span class=\"nrp-cell-u\">no documented link<\/span><\/td><td>WEAK<br><span class=\"nrp-cell-u\">process energy, undocumented<\/span><\/td><\/tr><tr><td><b>FOO<\/b> Food<\/td><td>WEAK<br><span class=\"nrp-cell-u\">no documented link<\/span><\/td><td>WEAK<br><span class=\"nrp-cell-u\">no documented link<\/span><\/td><td><span aria-label=\"same system\">\u00b7<\/span><\/td><td>WEAK<br><span class=\"nrp-cell-u\">no documented link<\/span><\/td><td>WEAK<br><span class=\"nrp-cell-u\">feedstock supply, undocumented<\/span><\/td><\/tr><tr><td><b>HLT<\/b> Health<\/td><td>WEAK<br><span class=\"nrp-cell-u\">no documented link<\/span><\/td><td>WEAK<br><span class=\"nrp-cell-u\">no documented link<\/span><\/td><td>WEAK<br><span class=\"nrp-cell-u\">no documented link<\/span><\/td><td><span aria-label=\"same system\">\u00b7<\/span><\/td><td>WEAK<br><span class=\"nrp-cell-u\">clinical demand, undocumented<\/span><\/td><\/tr><tr><td><b>BIO<\/b> Biodiversity<\/td><td>WEAK<br><span class=\"nrp-cell-u\">no documented link<\/span><\/td><td>WEAK<br><span class=\"nrp-cell-u\">bio-based fuels, undocumented<\/span><\/td><td>WEAK<br><span class=\"nrp-cell-u\">no documented link<\/span><\/td><td>MODERATE<br><span class=\"nrp-cell-u\">engineered cell therapies reach patients<\/span><\/td><td><span aria-label=\"same system\">\u00b7<\/span><\/td><\/tr><\/tbody><tfoot><tr><td colspan=\"6\">Strength: strong, moderate or weak; a Nexus estimate (status Estimated) from cited evidence and analogue events. The scale is defined in Annex A.<\/td><\/tr><\/tfoot><\/table><\/div><h3 class=\"nrp-h3\">Transmission paths<\/h3><ol class=\"nrp-rows\"><li><span class=\"nrp-rows-i\">01<\/span><p class=\"nrp-rows-t\">DAT \u2192 BIO \u2192 SEC<\/p><p class=\"nrp-rows-x\">Design tools and sequence data lower the barrier to misuse faster than screening adapts.<\/p><p class=\"nrp-rows-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span> 2025 screening study<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n13\" aria-label=\"Note 13\">13<\/a><\/sup><\/p><\/li><li><span class=\"nrp-rows-i\">02<\/span><p class=\"nrp-rows-t\">BIO \u2192 HLT<\/p><p class=\"nrp-rows-x\">Engineered cell therapies move from research to patients.<\/p><p class=\"nrp-rows-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span> exa-cel trial and regulator announcement<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n8\" id=\"nx-nrp-xt-04-c1-r8\" aria-label=\"Note 8\">8<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n9\" id=\"nx-nrp-xt-04-c1-r9\" aria-label=\"Note 9\">9<\/a><\/sup><\/p><\/li><li><span class=\"nrp-rows-i\">03<\/span><p class=\"nrp-rows-t\">FIN \u2192 INF<\/p><p class=\"nrp-rows-x\">Public programmes fund manufacturing planning.<\/p><p class=\"nrp-rows-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span> US programme awards<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n23\" id=\"nx-nrp-xt-04-c1-r23\" aria-label=\"Note 23\">23<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n24\" id=\"nx-nrp-xt-04-c1-r24\" aria-label=\"Note 24\">24<\/a><\/sup><\/p><\/li><li><span class=\"nrp-rows-i\">04<\/span><p class=\"nrp-rows-t\">ENE \u2192 BIO<\/p><p class=\"nrp-rows-x\">Process energy and feedstock constrain manufacturing at scale.<\/p><p class=\"nrp-rows-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Inferred<\/span> no figure bound<\/p><\/li><li><span class=\"nrp-rows-i\">05<\/span><p class=\"nrp-rows-t\">GOV \u2192 BIO<\/p><p class=\"nrp-rows-x\">Frameworks and proposals set oversight and incentives.<\/p><p class=\"nrp-rows-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span> US, EU and OECD documents<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n14\" aria-label=\"Note 14\">14<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n18\" aria-label=\"Note 18\">18<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c1-n22\" aria-label=\"Note 22\">22<\/a><\/sup><\/p><\/li><\/ol><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c1-notes\" aria-labelledby=\"nx-nrp-xt-04-c1-notes-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c1-notes-h\"><span>Notes<\/span><\/h2><p class=\"nrp-note\">Numbers are the edition&#8217;s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. <a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/references\/\">Annex C, references<\/a><\/p><ol class=\"nrp-notes\"><li id=\"nx-nrp-xt-04-c1-n1\"><span class=\"nrp-notes-n\">1<\/span><span>Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c1-r1\" aria-label=\"Back to the first call of note 1\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c1-n13\"><span class=\"nrp-notes-n\">13<\/span><span>Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c1-r13\" aria-label=\"Back to the first call of note 13\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c1-n18\"><span class=\"nrp-notes-n\">18<\/span><span>OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c1-r18\" aria-label=\"Back to the first call of note 18\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c1-n2\"><span class=\"nrp-notes-n\">2<\/span><span>MRC Laboratory of Molecular Biology (ed.), Syn57 represents a new chapter in the genetic code of life (news page, 1 August 2025; over 101,000 codons recoded; 64 to 57 codons; genome of about 4 megabases built from 38 fragments of about 100 kilobases). MRC Laboratory of Molecular Biology, Cambridge. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c1-r2\" aria-label=\"Back to the first call of note 2\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c1-n4\"><span class=\"nrp-notes-n\">4<\/span><span>Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c1-r4\" aria-label=\"Back to the first call of note 4\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c1-n6\"><span class=\"nrp-notes-n\">6<\/span><span>Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c1-r6\" aria-label=\"Back to the first call of note 6\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c1-n12\"><span class=\"nrp-notes-n\">12<\/span><span>Confronting risks of <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-h101\" data-tc=\"NHS-1 tech.biotech.mirror-life\" data-tk=\"Frontier and exponential technology \u00b7 Biotechnology and synthetic biology\" data-td=\"Creation and escape of organisms built from mirror-image molecules, which could evade immune defences, predators and decay in people, animals and plants and spread unchecked through ecosystems.\" data-ts=\"NRS-H101\" data-tr=\"draft\" data-tx=\"https:\/\/risksindex.com\/hazards\/tech\/\" data-txl=\"Frontier and exponential technology\">mirror life<\/a>, Science 386, 1351 to 1353, 2024 (record read via Europe PMC; the record gives only a one-line abstract calling for broad discussion). American Association for the Advancement of Science, Washington. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c1-r12\" aria-label=\"Back to the first call of note 12\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c1-n14\"><span class=\"nrp-notes-n\">14<\/span><span>Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c1-r14\" aria-label=\"Back to the first call of note 14\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c1-n20\"><span class=\"nrp-notes-n\">20<\/span><span>Secretariat of the Convention on Biological Diversity (ed.), Synthetic biology (programme page; decisions X\/13 to 16\/21; AHTEG; <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-c1\" data-tc=\"NRS-C1 horizon-scanning\" data-tk=\"Nexus risk vocabulary\" data-td=\"Systematic searching for early signs of potentially important developments, threats and opportunities at the margins of current thinking.\" data-ts=\"NRS-C1\" data-tr=\"draft\" data-tg=\"https:\/\/globalriskforum.com\/glossary\/horizon-scanning\/\" data-tgl=\"Global Risks Forum glossary\">horizon scanning<\/a>; thematic action plan). CBD Secretariat, Montreal. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c1-r20\" aria-label=\"Back to the first call of note 20\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c1-n22\"><span class=\"nrp-notes-n\">22<\/span><span>Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c1-r22\" aria-label=\"Back to the first call of note 22\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c1-n16\"><span class=\"nrp-notes-n\">16<\/span><span>Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c1-r16\" aria-label=\"Back to the first call of note 16\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c1-n17\"><span class=\"nrp-notes-n\">17<\/span><span>Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c1-r17\" aria-label=\"Back to the first call of note 17\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c1-n3\"><span class=\"nrp-notes-n\">3<\/span><span>Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c1-r3\" aria-label=\"Back to the first call of note 3\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c1-n8\"><span class=\"nrp-notes-n\">8<\/span><span>Frangoul, H. et al., Exagamglogene autotemcel for severe sickle cell disease, New England Journal of Medicine 390 (18), 1649 to 1662, 2024 (record read via Europe PMC: 44 treated; 29 of 30 evaluable free of severe crises for 12 months; median follow-up 19.3 months). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c1-r8\" aria-label=\"Back to the first call of note 8\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c1-n9\"><span class=\"nrp-notes-n\">9<\/span><span>US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy and Lyfgenia; ages 12 and over; 29 of 31 evaluable Casgevy patients free of severe crises for at least 12 months). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c1-r9\" aria-label=\"Back to the first call of note 9\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c1-n23\"><span class=\"nrp-notes-n\">23<\/span><span>BioMADE (ed.), DoD approves USD 87 million for newest bioindustrial manufacturing innovation institute (news page; seven years; the page shows Oct 20 and a 2023 footer, the press release is dated 2020 in search listings). BioMADE, Saint Paul. Observation year 2020. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c1-r23\" aria-label=\"Back to the first call of note 23\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c1-n24\"><span class=\"nrp-notes-n\">24<\/span><span>US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c1-r24\" aria-label=\"Back to the first call of note 24\">back<\/a><\/span><\/li><\/ol><\/section><\/div><div class=\"nrp-part\" id=\"nx-nrp-xt-04-part-findings\"><header class=\"nrp-chap-head\" id=\"nx-nrp-xt-04-c2-top\"><ul class=\"nrp-eyerow\"><li class=\"nf-ui-eyebrow\"><a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/\">Synthetic Biology and Bioengineering 2026<\/a><\/li><li class=\"nf-ui-eyebrow\">Chapter 2<\/li><\/ul><span class=\"nrp-rule\" aria-hidden=\"true\"><\/span><h2 class=\"pp-hero-title\">Key findings<\/h2><p class=\"nrp-lede\">Twelve findings carry the synthetic biology baseline. They are grouped by coupling and never ranked. Each resolves to its source or, where Nexus analysis is involved, to its stated method.<\/p><p class=\"nrp-chap-meta\"><span>9 min read<\/span><span>1 figure<\/span><span>0 tables<\/span><span>28 notes<\/span><span>NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE<\/span><\/p><\/header><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c2-s1\" aria-labelledby=\"nx-nrp-xt-04-c2-s1-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c2-s1-h\"><span class=\"nrp-num\">2.1<\/span><span>Headline finding<\/span><\/h2><p class=\"nrp-find-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 4<\/span><a class=\"nrp-find-id\" href=\"#nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-BLD-001\">NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-BLD-001<\/a><\/p><p class=\"nrp-km-t\">A bacterium with a 57-codon genetic code was reported in Science in 2025, seven codons fewer than the standard 64, with over 101,000 codon changes in a synthetic genome of about 4 million base pairs.<\/p><figure class=\"nrp-fig\" id=\"nx-nrp-xt-04-c2-fig1\" aria-labelledby=\"nx-nrp-xt-04-c2-fig1-t\"><figcaption class=\"nrp-figcap\"><span class=\"nf-ui-eyebrow\">Figure 2.1<\/span><span class=\"nf-ui-title\" data-level=\"card\" id=\"nx-nrp-xt-04-c2-fig1-t\">Codons in the genetic code<\/span><\/figcaption><div class=\"nrp-tblw\"><table class=\"nrp-tbl nrp-bars\"><thead><tr><th scope=\"col\">Item<\/th><th scope=\"col\"><span class=\"nrp-sr\">Bar, scaled to the largest value<\/span><\/th><th scope=\"col\">Value<\/th><\/tr><\/thead><tbody><tr><th scope=\"row\">Standard genetic code<\/th><td class=\"nrp-barc\"><svg class=\"nrp-svg nrp-barsvg\" viewBox=\"0 0 100 8\" preserveAspectRatio=\"none\" aria-hidden=\"true\" focusable=\"false\"><rect class=\"nrp-track\" x=\"0\" y=\"0\" width=\"100\" height=\"8\"\/><rect class=\"nrp-bar\" x=\"0\" y=\"0\" width=\"100.0\" height=\"8\"\/><\/svg><\/td><td class=\"nrp-mono\">64<\/td><\/tr><tr><th scope=\"row\">Syn61 strain (2019)<\/th><td class=\"nrp-barc\"><svg class=\"nrp-svg nrp-barsvg\" viewBox=\"0 0 100 8\" preserveAspectRatio=\"none\" aria-hidden=\"true\" focusable=\"false\"><rect class=\"nrp-track\" x=\"0\" y=\"0\" width=\"100\" height=\"8\"\/><rect class=\"nrp-bar\" x=\"0\" y=\"0\" width=\"95.3\" height=\"8\"\/><\/svg><\/td><td class=\"nrp-mono\">61<\/td><\/tr><tr><th scope=\"row\">Syn57 strain (2025)<\/th><td class=\"nrp-barc\"><svg class=\"nrp-svg nrp-barsvg\" viewBox=\"0 0 100 8\" preserveAspectRatio=\"none\" aria-hidden=\"true\" focusable=\"false\"><rect class=\"nrp-track\" x=\"0\" y=\"0\" width=\"100\" height=\"8\"\/><rect class=\"nrp-bar\" x=\"0\" y=\"0\" width=\"89.1\" height=\"8\"\/><\/svg><\/td><td class=\"nrp-mono\">57<\/td><\/tr><\/tbody><\/table><\/div><p class=\"nrp-fig-src\">Sources: MRC Laboratory of Molecular Biology<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n2\" id=\"nx-nrp-xt-04-c2-r2\" aria-label=\"Note 2\">2<\/a><\/sup>; Nature 569 (2019)<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n3\" id=\"nx-nrp-xt-04-c2-r3\" aria-label=\"Note 3\">3<\/a><\/sup>. Each bar counts codons in the code of that organism.<\/p><\/figure><h3 class=\"nrp-h3\">Implication<\/h3><p class=\"nrp-p\">Whole-genome design and writing now works at the scale of a bacterial genome. The authors state aims such as further compression and tests of viral resistance; those are plans, not results<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n1\" id=\"nx-nrp-xt-04-c2-r1\" aria-label=\"Note 1\">1<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n2\" aria-label=\"Note 2\">2<\/a><\/sup>. The result shows capability on one organism and says nothing about industrial use, cost or safety in the field.<\/p><h3 class=\"nrp-h3\">What would move it<\/h3><p class=\"nrp-p\">Peer-reviewed tests of viral resistance, independent replication and any published cost of whole-genome synthesis would each move this finding.<\/p><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c2-s2\" aria-labelledby=\"nx-nrp-xt-04-c2-s2-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c2-s2-h\"><span class=\"nrp-num\">2.2<\/span><span>BLD<\/span><\/h2><ol class=\"nrp-find\"><li id=\"nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-BLD-001\"><p class=\"nrp-find-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 4<\/span><a class=\"nrp-find-id\" href=\"#nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-BLD-001\">NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-BLD-001<\/a><\/p><p class=\"nrp-find-t\">A bacterium with a 57-codon genetic code was reported in 2025. Its synthetic genome of about 4 million base pairs carries over 101,000 codon changes and was built from 38 fragments of about 100,000 base pairs; an earlier strain recoded 18,214 codons and uses 61 codons.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n1\" aria-label=\"Note 1\">1<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n2\" aria-label=\"Note 2\">2<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n3\" aria-label=\"Note 3\">3<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n44\" id=\"nx-nrp-xt-04-c2-r44\" aria-label=\"Note 44\">44<\/a><\/sup><\/p><\/li><li id=\"nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-BLD-002\"><p class=\"nrp-find-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 4<\/span><a class=\"nrp-find-id\" href=\"#nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-BLD-002\">NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-BLD-002<\/a><\/p><p class=\"nrp-find-t\">By 2023 a single yeast strain carried six and a half synthetic chromosomes, over half of the synthetic yeast genome design; in 2010 the first cell run by a chemically synthesised genome had a 1.08 million base pair genome.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n4\" id=\"nx-nrp-xt-04-c2-r4\" aria-label=\"Note 4\">4<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n5\" id=\"nx-nrp-xt-04-c2-r5\" aria-label=\"Note 5\">5<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n43\" id=\"nx-nrp-xt-04-c2-r43\" aria-label=\"Note 43\">43<\/a><\/sup><\/p><\/li><li id=\"nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-BLD-003\"><p class=\"nrp-find-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 4<\/span><a class=\"nrp-find-id\" href=\"#nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-BLD-003\">NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-BLD-003<\/a><\/p><p class=\"nrp-find-t\">A 2016 design automation tool built 60 genetic circuits in E. coli, 45 worked in every output state and 92% of output states matched predictions; a 2023 generative method designed protein binders, and one binder to influenza hemagglutinin matched its design model in a cryo-EM structure.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n6\" id=\"nx-nrp-xt-04-c2-r6\" aria-label=\"Note 6\">6<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n7\" id=\"nx-nrp-xt-04-c2-r7\" aria-label=\"Note 7\">7<\/a><\/sup><\/p><\/li><\/ol><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c2-s3\" aria-labelledby=\"nx-nrp-xt-04-c2-s3-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c2-s3-h\"><span class=\"nrp-num\">2.3<\/span><span>CLN<\/span><\/h2><ol class=\"nrp-find\"><li id=\"nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-CLN-004\"><p class=\"nrp-find-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 4<\/span><a class=\"nrp-find-id\" href=\"#nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-CLN-004\">NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-CLN-004<\/a><\/p><p class=\"nrp-find-t\">A CRISPR-edited cell therapy was authorised by the US regulator on 8 December 2023; in a phase 3 study 29 of 30 evaluable patients (97%) were free of severe crises for 12 months, and in 2025 a patient-specific base-editing therapy was given to one infant.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n8\" id=\"nx-nrp-xt-04-c2-r8\" aria-label=\"Note 8\">8<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n9\" id=\"nx-nrp-xt-04-c2-r9\" aria-label=\"Note 9\">9<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n10\" id=\"nx-nrp-xt-04-c2-r10\" aria-label=\"Note 10\">10<\/a><\/sup><\/p><\/li><\/ol><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c2-s4\" aria-labelledby=\"nx-nrp-xt-04-c2-s4-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c2-s4-h\"><span class=\"nrp-num\">2.4<\/span><span>Security<\/span><\/h2><ol class=\"nrp-find\"><li id=\"nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-SEC-005\"><p class=\"nrp-find-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 4<\/span><a class=\"nrp-find-id\" href=\"#nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-SEC-005\">NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-SEC-005<\/a><\/p><p class=\"nrp-find-t\">A 2025 Science study found that current screening tools often failed to detect sequences redesigned with open machine-learning protein design software, and reported patches that substantially improved detection.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n13\" id=\"nx-nrp-xt-04-c2-r13\" aria-label=\"Note 13\">13<\/a><\/sup><\/p><\/li><li id=\"nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-SEC-006\"><p class=\"nrp-find-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 3<\/span><a class=\"nrp-find-id\" href=\"#nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-SEC-006\">NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-SEC-006<\/a><\/p><p class=\"nrp-find-t\">A 2024 Science policy forum on <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-h101\" data-tc=\"NHS-1 tech.biotech.mirror-life\" data-tk=\"Frontier and exponential technology \u00b7 Biotechnology and synthetic biology\" data-td=\"Creation and escape of organisms built from mirror-image molecules, which could evade immune defences, predators and decay in people, animals and plants and spread unchecked through ecosystems.\" data-ts=\"NRS-H101\" data-tr=\"draft\" data-tx=\"https:\/\/risksindex.com\/hazards\/tech\/\" data-txl=\"Frontier and exponential technology\">mirror life<\/a> called for broad discussion on a path forward.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n12\" id=\"nx-nrp-xt-04-c2-r12\" aria-label=\"Note 12\">12<\/a><\/sup><\/p><\/li><\/ol><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c2-s5\" aria-labelledby=\"nx-nrp-xt-04-c2-s5-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c2-s5-h\"><span class=\"nrp-num\">2.5<\/span><span>Governance<\/span><\/h2><ol class=\"nrp-find\"><li id=\"nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-GOV-007\"><p class=\"nrp-find-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 2<\/span><a class=\"nrp-find-id\" href=\"#nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-GOV-007\">NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-GOV-007<\/a><\/p><p class=\"nrp-find-t\">Executive Order 14292 of May 2025 gave OSTP 90 days to revise or replace the 2024 US framework for nucleic acid synthesis screening; a Congressional Research Service note found in July 2026 that it could not determine whether either had been revised, and sources differ on whether the framework is in force.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n25\" id=\"nx-nrp-xt-04-c2-r25\" aria-label=\"Note 25\">25<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n26\" id=\"nx-nrp-xt-04-c2-r26\" aria-label=\"Note 26\">26<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n27\" id=\"nx-nrp-xt-04-c2-r27\" aria-label=\"Note 27\">27<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n30\" id=\"nx-nrp-xt-04-c2-r30\" aria-label=\"Note 30\">30<\/a><\/sup><\/p><\/li><li id=\"nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-GOV-008\"><p class=\"nrp-find-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 3<\/span><a class=\"nrp-find-id\" href=\"#nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-GOV-008\">NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-GOV-008<\/a><\/p><p class=\"nrp-find-t\">The US National Security Commission on Emerging Biotechnology delivered its final report on 8 April 2025 with 49 recommendations and a call for at least USD 15 billion over five years.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n14\" id=\"nx-nrp-xt-04-c2-r14\" aria-label=\"Note 14\">14<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n15\" id=\"nx-nrp-xt-04-c2-r15\" aria-label=\"Note 15\">15<\/a><\/sup><\/p><\/li><li id=\"nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-GOV-009\"><p class=\"nrp-find-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 2<\/span><a class=\"nrp-find-id\" href=\"#nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-GOV-009\">NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-GOV-009<\/a><\/p><p class=\"nrp-find-t\">The European Commission proposed a Biotech Act on 16 December 2025, centred on health biotechnology, with an investment pilot with the European Investment Bank Group, a 12-month certificate extension and biodefence measures; a second act on the wider ecosystem was expected in the third quarter of 2026.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n22\" id=\"nx-nrp-xt-04-c2-r22\" aria-label=\"Note 22\">22<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n28\" id=\"nx-nrp-xt-04-c2-r28\" aria-label=\"Note 28\">28<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n29\" id=\"nx-nrp-xt-04-c2-r29\" aria-label=\"Note 29\">29<\/a><\/sup><\/p><\/li><li id=\"nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-GOV-010\"><p class=\"nrp-find-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 3<\/span><a class=\"nrp-find-id\" href=\"#nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-GOV-010\">NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-GOV-010<\/a><\/p><p class=\"nrp-find-t\">The OECD found in May 2026 that governments are moving toward adaptive synthetic biology governance but that implementation remains uneven; the CBD asked in decision 16\/21 for a thematic action plan on capacity building and technology transfer.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n18\" id=\"nx-nrp-xt-04-c2-r18\" aria-label=\"Note 18\">18<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n19\" id=\"nx-nrp-xt-04-c2-r19\" aria-label=\"Note 19\">19<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n20\" id=\"nx-nrp-xt-04-c2-r20\" aria-label=\"Note 20\">20<\/a><\/sup><\/p><\/li><\/ol><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c2-s6\" aria-labelledby=\"nx-nrp-xt-04-c2-s6-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c2-s6-h\"><span class=\"nrp-num\">2.6<\/span><span>Finance<\/span><\/h2><ol class=\"nrp-find\"><li id=\"nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-FIN-011\"><p class=\"nrp-find-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 2<\/span><a class=\"nrp-find-id\" href=\"#nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-FIN-011\">NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-FIN-011<\/a><\/p><p class=\"nrp-find-t\">Ginkgo Bioworks reported revenue of USD 170.2 million for 2025 against USD 227.0 million for 2024, and Twist Bioscience reported USD 332.8 million for the nine months to 30 June 2026 with full-year guidance of USD 456 to 457 million. These are company statements.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n16\" id=\"nx-nrp-xt-04-c2-r16\" aria-label=\"Note 16\">16<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c2-n17\" id=\"nx-nrp-xt-04-c2-r17\" aria-label=\"Note 17\">17<\/a><\/sup><\/p><\/li><\/ol><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c2-s7\" aria-labelledby=\"nx-nrp-xt-04-c2-s7-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c2-s7-h\"><span class=\"nrp-num\">2.7<\/span><span>Systemic<\/span><\/h2><ol class=\"nrp-find\"><li id=\"nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-SYS-012\"><p class=\"nrp-find-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Expert input<\/span><span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 2<\/span><a class=\"nrp-find-id\" href=\"#nx-NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-SYS-012\">NRF-XTECH-SYNBIO-GLOBAL-2026-BASELINE-SYS-012<\/a><\/p><p class=\"nrp-find-t\">The leading compound pathway for 2027 testing is design capability and cheap DNA moving faster than screening practice and governance, while the footprint of the manufacturing base stays unmeasured. \u00a7 scenario<\/p><\/li><\/ol><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c2-notes\" aria-labelledby=\"nx-nrp-xt-04-c2-notes-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c2-notes-h\"><span>Notes<\/span><\/h2><p class=\"nrp-note\">Numbers are the edition&#8217;s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. <a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/references\/\">Annex C, references<\/a><\/p><ol class=\"nrp-notes\"><li id=\"nx-nrp-xt-04-c2-n2\"><span class=\"nrp-notes-n\">2<\/span><span>MRC Laboratory of Molecular Biology (ed.), Syn57 represents a new chapter in the genetic code of life (news page, 1 August 2025; over 101,000 codons recoded; 64 to 57 codons; genome of about 4 megabases built from 38 fragments of about 100 kilobases). MRC Laboratory of Molecular Biology, Cambridge. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r2\" aria-label=\"Back to the first call of note 2\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n3\"><span class=\"nrp-notes-n\">3<\/span><span>Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r3\" aria-label=\"Back to the first call of note 3\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n1\"><span class=\"nrp-notes-n\">1<\/span><span>Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r1\" aria-label=\"Back to the first call of note 1\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n44\"><span class=\"nrp-notes-n\">44<\/span><span>UNVERIFIED, not opened: bioRxiv preprint of the Syn57 study, Escherichia coli with a 57-codon genetic code, 2025, identified from a search result; the page returned HTTP 429. Cold Spring Harbor Laboratory, New York. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r44\" aria-label=\"Back to the first call of note 44\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n4\"><span class=\"nrp-notes-n\">4<\/span><span>Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r4\" aria-label=\"Back to the first call of note 4\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n5\"><span class=\"nrp-notes-n\">5<\/span><span>Gibson, D.G. et al., Creation of a bacterial cell controlled by a chemically synthesised genome, Science 329 (5987), 52 to 56, 2010 (record read via Europe PMC: 1.08 million base pair genome). American Association for the Advancement of Science, Washington. Observation year 2010. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r5\" aria-label=\"Back to the first call of note 5\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n43\"><span class=\"nrp-notes-n\">43<\/span><span>UNVERIFIED, not opened: Richardson, S.M. et al., Design of a synthetic yeast genome, Science 355, 1040 to 1044, 2017, cited from memory. Observation year 2017. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r43\" aria-label=\"Back to the first call of note 43\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n6\"><span class=\"nrp-notes-n\">6<\/span><span>Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r6\" aria-label=\"Back to the first call of note 6\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n7\"><span class=\"nrp-notes-n\">7<\/span><span>Watson, J.L. et al., De novo design of protein structure and function with RFdiffusion, Nature 620, 1089 to 1100, 2023 (record read via Europe PMC). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r7\" aria-label=\"Back to the first call of note 7\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n8\"><span class=\"nrp-notes-n\">8<\/span><span>Frangoul, H. et al., Exagamglogene autotemcel for severe sickle cell disease, New England Journal of Medicine 390 (18), 1649 to 1662, 2024 (record read via Europe PMC: 44 treated; 29 of 30 evaluable free of severe crises for 12 months; median follow-up 19.3 months). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r8\" aria-label=\"Back to the first call of note 8\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n9\"><span class=\"nrp-notes-n\">9<\/span><span>US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy and Lyfgenia; ages 12 and over; 29 of 31 evaluable Casgevy patients free of severe crises for at least 12 months). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r9\" aria-label=\"Back to the first call of note 9\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n10\"><span class=\"nrp-notes-n\">10<\/span><span>Musunuru, K. et al., Patient-specific in vivo gene editing to treat a rare genetic disease, New England Journal of Medicine 392 (22), 2235 to 2243, 2025 (record read via Europe PMC: one infant; two infusions at about 7 and 8 months). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r10\" aria-label=\"Back to the first call of note 10\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n13\"><span class=\"nrp-notes-n\">13<\/span><span>Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r13\" aria-label=\"Back to the first call of note 13\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n12\"><span class=\"nrp-notes-n\">12<\/span><span>Confronting risks of <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-h101\" data-tc=\"NHS-1 tech.biotech.mirror-life\" data-tk=\"Frontier and exponential technology \u00b7 Biotechnology and synthetic biology\" data-td=\"Creation and escape of organisms built from mirror-image molecules, which could evade immune defences, predators and decay in people, animals and plants and spread unchecked through ecosystems.\" data-ts=\"NRS-H101\" data-tr=\"draft\" data-tx=\"https:\/\/risksindex.com\/hazards\/tech\/\" data-txl=\"Frontier and exponential technology\">mirror life<\/a>, Science 386, 1351 to 1353, 2024 (record read via Europe PMC; the record gives only a one-line abstract calling for broad discussion). American Association for the Advancement of Science, Washington. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r12\" aria-label=\"Back to the first call of note 12\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n25\"><span class=\"nrp-notes-n\">25<\/span><span>UNVERIFIED, not opened: Office of Science and Technology Policy (ed.), Framework for Nucleic Acid Synthesis Screening, April 2024, taken from search-result summaries; a fetch of the page was refused by the fetch tool. OSTP, Washington. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r25\" aria-label=\"Back to the first call of note 25\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n26\"><span class=\"nrp-notes-n\">26<\/span><span>UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r26\" aria-label=\"Back to the first call of note 26\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n27\"><span class=\"nrp-notes-n\">27<\/span><span>UNVERIFIED, not opened: Congressional Research Service (ed.), report on artificial intelligence and biosecurity risks (reported in July 2026 as unable to determine whether the 2024 framework or the 2025 policy had been revised), taken from a trade news summary. Library of Congress, Washington. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r27\" aria-label=\"Back to the first call of note 27\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n30\"><span class=\"nrp-notes-n\">30<\/span><span>UNVERIFIED, not opened: Engineering Biology Research Consortium (ed.), response on nucleic acid synthesis screening under Executive Order 14292, November 2025, listed in search results only. EBRC, Emeryville. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r30\" aria-label=\"Back to the first call of note 30\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n14\"><span class=\"nrp-notes-n\">14<\/span><span>Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r14\" aria-label=\"Back to the first call of note 14\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n15\"><span class=\"nrp-notes-n\">15<\/span><span>Federation of American Scientists (ed.), Translating Vision into Action: FAS commentary on the NSCEB final report (commentary page; six pillars; cites over USD 210 billion of US GDP and over 640,000 jobs for the bioeconomy; secondary and advocacy-leaning source). Federation of American Scientists, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r15\" aria-label=\"Back to the first call of note 15\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n22\"><span class=\"nrp-notes-n\">22<\/span><span>Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r22\" aria-label=\"Back to the first call of note 22\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n28\"><span class=\"nrp-notes-n\">28<\/span><span>UNVERIFIED, not opened: European Commission (ed.), Proposal for a Biotech Act, COM(2025) 1022, 16 December 2025, taken from law firm and regulator summaries; the Commission page was not retrieved. European Commission, Brussels. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r28\" aria-label=\"Back to the first call of note 28\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n29\"><span class=\"nrp-notes-n\">29<\/span><span>UNVERIFIED, not opened: European Parliament (ed.), Legislative train entry for the European Biotech Act II (second act expected in the third quarter of 2026), taken from a search-result summary; the page returned no content. European Parliament, Brussels. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r29\" aria-label=\"Back to the first call of note 29\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n18\"><span class=\"nrp-notes-n\">18<\/span><span>OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r18\" aria-label=\"Back to the first call of note 18\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n19\"><span class=\"nrp-notes-n\">19<\/span><span>OECD (ed.), Synthetic biology, AI and automation: a forward-looking technology assessment, OECD Science, Technology and Industry Policy Papers No. 187, 4 December 2025 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r19\" aria-label=\"Back to the first call of note 19\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n20\"><span class=\"nrp-notes-n\">20<\/span><span>Secretariat of the Convention on Biological Diversity (ed.), Synthetic biology (programme page; decisions X\/13 to 16\/21; AHTEG; <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-c1\" data-tc=\"NRS-C1 horizon-scanning\" data-tk=\"Nexus risk vocabulary\" data-td=\"Systematic searching for early signs of potentially important developments, threats and opportunities at the margins of current thinking.\" data-ts=\"NRS-C1\" data-tr=\"draft\" data-tg=\"https:\/\/globalriskforum.com\/glossary\/horizon-scanning\/\" data-tgl=\"Global Risks Forum glossary\">horizon scanning<\/a>; thematic action plan). CBD Secretariat, Montreal. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r20\" aria-label=\"Back to the first call of note 20\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n16\"><span class=\"nrp-notes-n\">16<\/span><span>Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r16\" aria-label=\"Back to the first call of note 16\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c2-n17\"><span class=\"nrp-notes-n\">17<\/span><span>Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c2-r17\" aria-label=\"Back to the first call of note 17\">back<\/a><\/span><\/li><\/ol><\/section><\/div><div class=\"nrp-part\" id=\"nx-nrp-xt-04-part-systems-and-sectors\"><header class=\"nrp-chap-head\" id=\"nx-nrp-xt-04-c3-top\"><ul class=\"nrp-eyerow\"><li class=\"nf-ui-eyebrow\"><a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/\">Synthetic Biology and Bioengineering 2026<\/a><\/li><li class=\"nf-ui-eyebrow\">Chapter 3<\/li><\/ul><span class=\"nrp-rule\" aria-hidden=\"true\"><\/span><h2 class=\"pp-hero-title\">Systems and sectors at baseline<\/h2><p class=\"nrp-chap-meta\"><span>7 min read<\/span><span>0 figures<\/span><span>2 tables<\/span><span>18 notes<\/span><span>NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE<\/span><\/p><\/header><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c3-s1\" aria-labelledby=\"nx-nrp-xt-04-c3-s1-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c3-s1-h\"><span class=\"nrp-num\">3.1<\/span><span>Where each system stood at evidence close<\/span><\/h2><div class=\"pp-cells nrp-cells-3\"><article class=\"nrp-cell\"><p class=\"nf-ui-eyebrow\">BLD \u00b7 Genomes<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">Codons in the genetic code of the Syn57 strain<\/h3><span class=\"pp-metric\">57<\/span><span class=\"nrp-cell-u\">codons<\/span><p>down from 64; over 101,000 codon changes.<\/p><p class=\"nrp-cell-foot\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><span>2025<\/span><span>Science<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n1\" id=\"nx-nrp-xt-04-c3-r1\" aria-label=\"Note 1\">1<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n2\" id=\"nx-nrp-xt-04-c3-r2\" aria-label=\"Note 2\">2<\/a><\/sup><\/span><\/p><\/article><article class=\"nrp-cell\"><p class=\"nf-ui-eyebrow\">BLD \u00b7 Yeast<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">Synthetic yeast chromosomes combined in one strain<\/h3><span class=\"pp-metric\">6.5<\/span><span class=\"nrp-cell-u\">chromosomes<\/span><p>over half of the synthetic genome in one strain.<\/p><p class=\"nrp-cell-foot\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><span>2023<\/span><span>Cell<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n4\" id=\"nx-nrp-xt-04-c3-r4\" aria-label=\"Note 4\">4<\/a><\/sup><\/span><\/p><\/article><article class=\"nrp-cell\"><p class=\"nf-ui-eyebrow\">CLN \u00b7 Therapy<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">Patients free of severe crises for 12 months, exa-cel trial<\/h3><span class=\"pp-metric\">97<\/span><span class=\"nrp-cell-u\">%<\/span><p>29 of 30 evaluable patients.<\/p><p class=\"nrp-cell-foot\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><span>2024<\/span><span>NEJM<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n8\" id=\"nx-nrp-xt-04-c3-r8\" aria-label=\"Note 8\">8<\/a><\/sup><\/span><\/p><\/article><article class=\"nrp-cell\"><p class=\"nf-ui-eyebrow\">GOV \u00b7 Governance<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">Minimum federal funding recommended by a US commission<\/h3><span class=\"pp-metric\">15<\/span><span class=\"nrp-cell-u\">USD billion<\/span><p>over five years; a recommendation, not spending.<\/p><p class=\"nrp-cell-foot\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><span>2025<\/span><span>CRS<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n14\" id=\"nx-nrp-xt-04-c3-r14\" aria-label=\"Note 14\">14<\/a><\/sup><\/span><\/p><\/article><article class=\"nrp-cell\"><p class=\"nf-ui-eyebrow\">FIN \u00b7 Finance<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">Ginkgo Bioworks revenue<\/h3><span class=\"pp-metric\">170.2<\/span><span class=\"nrp-cell-u\">USD million<\/span><p>down from USD 227.0 million in 2024; company filing.<\/p><p class=\"nrp-cell-foot\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><span>2025<\/span><span>company filing<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n17\" id=\"nx-nrp-xt-04-c3-r17\" aria-label=\"Note 17\">17<\/a><\/sup><\/span><\/p><\/article><article class=\"nrp-cell\"><p class=\"nf-ui-eyebrow\">SYS \u00b7 Cross-system<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">Awards in the US distributed bioindustrial manufacturing programme<\/h3><span class=\"pp-metric\">25<\/span><span class=\"nrp-cell-u\">awards<\/span><p>USD 42 million in total by September 2024.<\/p><p class=\"nrp-cell-foot\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><span>2024<\/span><span>programme page<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n24\" id=\"nx-nrp-xt-04-c3-r24\" aria-label=\"Note 24\">24<\/a><\/sup><\/span><\/p><\/article><\/div><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c3-s2\" aria-labelledby=\"nx-nrp-xt-04-c3-s2-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c3-s2-h\"><span class=\"nrp-num\">3.2<\/span><span>Domain posture<\/span><\/h2><p class=\"nrp-stand\">Each of the twelve coupled domains is read through synthetic biology, in words, not scored. The coupling column names the dependency that carries synthetic biology risk into each domain.<\/p><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c3-tab1\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 3.1<\/span><span class=\"nrp-tbl-t\">Each domain read in words, not scored<\/span><\/caption><thead><tr><th scope=\"col\">Domain<\/th><th scope=\"col\">Posture at baseline<\/th><th scope=\"col\">Coupling<\/th><th scope=\"col\">Status<\/th><\/tr><\/thead><tbody><tr><td><span class=\"nrp-mono\">WAT<\/span><\/td><td>Process water use of fermentation and facilities is not published on a common basis.<\/td><td><span class=\"nrp-mono\">WAT \u2192 BIO<\/span><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Expert input<\/span> <span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 1<\/span><\/td><\/tr><tr><td><span class=\"nrp-mono\">ENE<\/span><\/td><td>Energy use of biomanufacturing at scale is not bound; no figure used.<\/td><td><span class=\"nrp-mono\">ENE \u2194 BIO<\/span><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Expert input<\/span> <span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 1<\/span><\/td><\/tr><tr><td><span class=\"nrp-mono\">FOO<\/span><\/td><td>No coupling documented at baseline in the sources read; precision fermentation and crop work are not evidenced here.<\/td><td><span class=\"nrp-mono\">none documented<\/span><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Expert input<\/span> <span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 1<\/span><\/td><\/tr><tr><td><span class=\"nrp-mono\">HLT<\/span><\/td><td>A CRISPR therapy was authorised in 2023 and 29 of 30 evaluable trial patients had no severe crises for 12 months.<\/td><td><span class=\"nrp-mono\">BIO \u2192 HLT<\/span><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span> <span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 4<\/span><\/td><\/tr><tr><td><span class=\"nrp-mono\">BIO<\/span><\/td><td>The core system: recoded genomes, synthetic yeast chromosomes, designed circuits and proteins.<\/td><td><span class=\"nrp-mono\">the core system<\/span><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span> <span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 4<\/span><\/td><\/tr><tr><td><span class=\"nrp-mono\">CLI<\/span><\/td><td>Bio-based production could change emissions; no figure bound here.<\/td><td><span class=\"nrp-mono\">none documented<\/span><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Expert input<\/span> <span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 1<\/span><\/td><\/tr><tr><td><span class=\"nrp-mono\">INF<\/span><\/td><td>US planning awards and an institute for bioindustrial manufacturing; capacity itself is not counted.<\/td><td><span class=\"nrp-mono\">FIN \u2192 INF<\/span><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span> <span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 3<\/span><\/td><\/tr><tr><td><span class=\"nrp-mono\">FIN<\/span><\/td><td>Company revenue is mixed: Ginkgo fell to USD 170.2 million, Twist guided to USD 456 to 457 million.<\/td><td><span class=\"nrp-mono\">FIN \u2192 BIO<\/span><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span> <span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 2<\/span><\/td><\/tr><tr><td><span class=\"nrp-mono\">DAT<\/span><\/td><td>Design tools and sequence data couple to screening; the 2025 study tested that link.<\/td><td><span class=\"nrp-mono\">DAT \u2192 BIO<\/span><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span> <span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 4<\/span><\/td><\/tr><tr><td><span class=\"nrp-mono\">AIC<\/span><\/td><td>Machine-learning design tools are part of the build capability and of the screening problem.<\/td><td><span class=\"nrp-mono\">AIC \u2192 BIO<\/span><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span> <span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 4<\/span><\/td><\/tr><tr><td><span class=\"nrp-mono\">MIN<\/span><\/td><td>Reagent, instrument and feedstock dependence is not documented in the sources read.<\/td><td><span class=\"nrp-mono\">none documented<\/span><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Expert input<\/span> <span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 1<\/span><\/td><\/tr><tr><td><span class=\"nrp-mono\">TRD<\/span><\/td><td>Export controls and biosecurity rules shape access to tools and materials; text not bound.<\/td><td><span class=\"nrp-mono\">BIO \u2194 TRD<\/span><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Inferred<\/span> <span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 2<\/span><\/td><\/tr><\/tbody><\/table><\/div><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c3-s3\" aria-labelledby=\"nx-nrp-xt-04-c3-s3-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c3-s3-h\"><span class=\"nrp-num\">3.3<\/span><span>Sector screens<\/span><\/h2><p class=\"nrp-stand\">All sixteen sectors are screened for their dependence on synthetic biology, on the same grammar as every national edition. The evidence column describes coverage of the baseline evidence, not the performance of the sector.<\/p><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c3-tab2\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 3.2<\/span><span class=\"nrp-tbl-t\">Sectors: baseline evidence and the exposure to watch<\/span><\/caption><thead><tr><th scope=\"col\">Code<\/th><th scope=\"col\">Sector<\/th><th scope=\"col\">Baseline evidence<\/th><th scope=\"col\">Exposure to watch<\/th><th scope=\"col\">Evidence coverage<\/th><\/tr><\/thead><tbody><tr><td><span class=\"nrp-mono\">GS-00<\/span><\/td><td>Cross-system<\/td><td>synthetic biology couples to health, food, finance and biosecurity<\/td><td>design and screening gap<\/td><td>THIN<\/td><\/tr><tr><td><span class=\"nrp-mono\">GS-01<\/span><\/td><td>Water<\/td><td>process water use not published<\/td><td>facility siting<\/td><td>THIN<\/td><\/tr><tr><td><span class=\"nrp-mono\">GS-02<\/span><\/td><td>Energy<\/td><td>energy footprint of manufacturing not bound<\/td><td>load from large facilities<\/td><td>THIN<\/td><\/tr><tr><td><span class=\"nrp-mono\">GS-03<\/span><\/td><td>Food<\/td><td>no documented coupling in the sources read<\/td><td>none documented<\/td><td>THIN<\/td><\/tr><tr><td><span class=\"nrp-mono\">GS-04<\/span><\/td><td>Health<\/td><td>authorised CRISPR therapy and trial results<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n8\" aria-label=\"Note 8\">8<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n9\" id=\"nx-nrp-xt-04-c3-r9\" aria-label=\"Note 9\">9<\/a><\/sup><\/td><td>access and cost<\/td><td>PARTIAL<\/td><\/tr><tr><td><span class=\"nrp-mono\">GS-05<\/span><\/td><td>Finance<\/td><td>company filings give a <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-c1\" data-tc=\"NRS-C1 weak-signal\" data-tk=\"Nexus risk vocabulary\" data-td=\"An early, fragmentary indication of a possible change that is not yet clearly recognised or understood.\" data-ts=\"NRS-C1\" data-tr=\"draft\">weak signal<\/a><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n16\" id=\"nx-nrp-xt-04-c3-r16\" aria-label=\"Note 16\">16<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n17\" aria-label=\"Note 17\">17<\/a><\/sup><\/td><td>funding gaps<\/td><td>PARTIAL<\/td><\/tr><tr><td><span class=\"nrp-mono\">GS-06<\/span><\/td><td>Development<\/td><td>access to tools and skills<\/td><td>widening gaps<\/td><td>THIN<\/td><\/tr><tr><td><span class=\"nrp-mono\">GS-07<\/span><\/td><td>Climate<\/td><td>footprint at scale not bound<\/td><td>energy and feedstock demand<\/td><td>THIN<\/td><\/tr><tr><td><span class=\"nrp-mono\">GS-08<\/span><\/td><td>Disaster<\/td><td>no documented coupling<\/td><td>none documented<\/td><td>THIN<\/td><\/tr><tr><td><span class=\"nrp-mono\">GS-09<\/span><\/td><td>Infrastructure<\/td><td>manufacturing planning awards<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n23\" id=\"nx-nrp-xt-04-c3-r23\" aria-label=\"Note 23\">23<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n24\" aria-label=\"Note 24\">24<\/a><\/sup><\/td><td>capacity not counted<\/td><td>THIN<\/td><\/tr><tr><td><span class=\"nrp-mono\">GS-10<\/span><\/td><td>Cities<\/td><td>no documented coupling<\/td><td>none documented<\/td><td>THIN<\/td><\/tr><tr><td><span class=\"nrp-mono\">GS-11<\/span><\/td><td>Biodiversity<\/td><td>gene drive and release questions<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n11\" id=\"nx-nrp-xt-04-c3-r11\" aria-label=\"Note 11\">11<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n20\" id=\"nx-nrp-xt-04-c3-r20\" aria-label=\"Note 20\">20<\/a><\/sup><\/td><td>release and oversight<\/td><td>PARTIAL<\/td><\/tr><tr><td><span class=\"nrp-mono\">GS-12<\/span><\/td><td>Earth observation<\/td><td>no documented coupling<\/td><td>none documented<\/td><td>THIN<\/td><\/tr><tr><td><span class=\"nrp-mono\">GS-13<\/span><\/td><td>Cyber and digital<\/td><td>screening of machine-designed sequences<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n13\" id=\"nx-nrp-xt-04-c3-r13\" aria-label=\"Note 13\">13<\/a><\/sup><\/td><td>sequence data handling<\/td><td>PARTIAL<\/td><\/tr><tr><td><span class=\"nrp-mono\">GS-14<\/span><\/td><td>Policy<\/td><td>US, EU, OECD and CBD instruments<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n14\" aria-label=\"Note 14\">14<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n18\" id=\"nx-nrp-xt-04-c3-r18\" aria-label=\"Note 18\">18<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n20\" aria-label=\"Note 20\">20<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n22\" id=\"nx-nrp-xt-04-c3-r22\" aria-label=\"Note 22\">22<\/a><\/sup><\/td><td>uneven implementation<\/td><td>PARTIAL<\/td><\/tr><tr><td><span class=\"nrp-mono\">GS-15<\/span><\/td><td>Science<\/td><td>strong peer-reviewed base<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n1\" aria-label=\"Note 1\">1<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n3\" id=\"nx-nrp-xt-04-c3-r3\" aria-label=\"Note 3\">3<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n4\" aria-label=\"Note 4\">4<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n6\" id=\"nx-nrp-xt-04-c3-r6\" aria-label=\"Note 6\">6<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c3-n7\" id=\"nx-nrp-xt-04-c3-r7\" aria-label=\"Note 7\">7<\/a><\/sup><\/td><td>common benchmarks<\/td><td>GOOD<\/td><\/tr><\/tbody><\/table><\/div><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c3-notes\" aria-labelledby=\"nx-nrp-xt-04-c3-notes-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c3-notes-h\"><span>Notes<\/span><\/h2><p class=\"nrp-note\">Numbers are the edition&#8217;s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. <a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/references\/\">Annex C, references<\/a><\/p><ol class=\"nrp-notes\"><li id=\"nx-nrp-xt-04-c3-n1\"><span class=\"nrp-notes-n\">1<\/span><span>Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c3-r1\" aria-label=\"Back to the first call of note 1\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c3-n2\"><span class=\"nrp-notes-n\">2<\/span><span>MRC Laboratory of Molecular Biology (ed.), Syn57 represents a new chapter in the genetic code of life (news page, 1 August 2025; over 101,000 codons recoded; 64 to 57 codons; genome of about 4 megabases built from 38 fragments of about 100 kilobases). MRC Laboratory of Molecular Biology, Cambridge. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c3-r2\" aria-label=\"Back to the first call of note 2\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c3-n4\"><span class=\"nrp-notes-n\">4<\/span><span>Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c3-r4\" aria-label=\"Back to the first call of note 4\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c3-n8\"><span class=\"nrp-notes-n\">8<\/span><span>Frangoul, H. et al., Exagamglogene autotemcel for severe sickle cell disease, New England Journal of Medicine 390 (18), 1649 to 1662, 2024 (record read via Europe PMC: 44 treated; 29 of 30 evaluable free of severe crises for 12 months; median follow-up 19.3 months). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c3-r8\" aria-label=\"Back to the first call of note 8\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c3-n14\"><span class=\"nrp-notes-n\">14<\/span><span>Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c3-r14\" aria-label=\"Back to the first call of note 14\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c3-n17\"><span class=\"nrp-notes-n\">17<\/span><span>Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c3-r17\" aria-label=\"Back to the first call of note 17\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c3-n24\"><span class=\"nrp-notes-n\">24<\/span><span>US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c3-r24\" aria-label=\"Back to the first call of note 24\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c3-n9\"><span class=\"nrp-notes-n\">9<\/span><span>US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy and Lyfgenia; ages 12 and over; 29 of 31 evaluable Casgevy patients free of severe crises for at least 12 months). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c3-r9\" aria-label=\"Back to the first call of note 9\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c3-n16\"><span class=\"nrp-notes-n\">16<\/span><span>Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c3-r16\" aria-label=\"Back to the first call of note 16\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c3-n23\"><span class=\"nrp-notes-n\">23<\/span><span>BioMADE (ed.), DoD approves USD 87 million for newest bioindustrial manufacturing innovation institute (news page; seven years; the page shows Oct 20 and a 2023 footer, the press release is dated 2020 in search listings). BioMADE, Saint Paul. Observation year 2020. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c3-r23\" aria-label=\"Back to the first call of note 23\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c3-n11\"><span class=\"nrp-notes-n\">11<\/span><span>Kyrou, K. et al., A CRISPR-Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes, Nature Biotechnology 36, 1062 to 1066, 2018 (record read via Europe PMC; laboratory cages only). Springer Nature, London. Observation year 2018. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c3-r11\" aria-label=\"Back to the first call of note 11\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c3-n20\"><span class=\"nrp-notes-n\">20<\/span><span>Secretariat of the Convention on Biological Diversity (ed.), Synthetic biology (programme page; decisions X\/13 to 16\/21; AHTEG; <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-c1\" data-tc=\"NRS-C1 horizon-scanning\" data-tk=\"Nexus risk vocabulary\" data-td=\"Systematic searching for early signs of potentially important developments, threats and opportunities at the margins of current thinking.\" data-ts=\"NRS-C1\" data-tr=\"draft\" data-tg=\"https:\/\/globalriskforum.com\/glossary\/horizon-scanning\/\" data-tgl=\"Global Risks Forum glossary\">horizon scanning<\/a>; thematic action plan). CBD Secretariat, Montreal. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c3-r20\" aria-label=\"Back to the first call of note 20\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c3-n13\"><span class=\"nrp-notes-n\">13<\/span><span>Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c3-r13\" aria-label=\"Back to the first call of note 13\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c3-n18\"><span class=\"nrp-notes-n\">18<\/span><span>OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c3-r18\" aria-label=\"Back to the first call of note 18\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c3-n22\"><span class=\"nrp-notes-n\">22<\/span><span>Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c3-r22\" aria-label=\"Back to the first call of note 22\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c3-n3\"><span class=\"nrp-notes-n\">3<\/span><span>Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c3-r3\" aria-label=\"Back to the first call of note 3\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c3-n6\"><span class=\"nrp-notes-n\">6<\/span><span>Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c3-r6\" aria-label=\"Back to the first call of note 6\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c3-n7\"><span class=\"nrp-notes-n\">7<\/span><span>Watson, J.L. et al., De novo design of protein structure and function with RFdiffusion, Nature 620, 1089 to 1100, 2023 (record read via Europe PMC). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c3-r7\" aria-label=\"Back to the first call of note 7\">back<\/a><\/span><\/li><\/ol><\/section><\/div><div class=\"nrp-part\" id=\"nx-nrp-xt-04-part-risk-and-capability\"><header class=\"nrp-chap-head\" id=\"nx-nrp-xt-04-c4-top\"><ul class=\"nrp-eyerow\"><li class=\"nf-ui-eyebrow\"><a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/\">Synthetic Biology and Bioengineering 2026<\/a><\/li><li class=\"nf-ui-eyebrow\">Chapter 4<\/li><\/ul><span class=\"nrp-rule\" aria-hidden=\"true\"><\/span><h2 class=\"pp-hero-title\">Risks and capability<\/h2><p class=\"nrp-lede\">Four synthetic biology risk objects open the portfolio. Order carries no rank. Each is read across driver, exposure, vulnerability, capacity, cascade and consequence.<\/p><p class=\"nrp-chap-meta\"><span>6 min read<\/span><span>0 figures<\/span><span>1 table<\/span><span>23 notes<\/span><span>NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE<\/span><\/p><\/header><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c4-s1\" aria-labelledby=\"nx-nrp-xt-04-c4-s1-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c4-s1-h\"><span class=\"nrp-num\">4.1<\/span><span>Risk objects<\/span><\/h2><p class=\"nrp-stand\">Each risk is read across the chain from hazard to consequence, with its status and evidence-quality level.<\/p><ol class=\"nrp-find\"><li><p class=\"nrp-find-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Inferred<\/span><span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 3<\/span><span class=\"nrp-find-id\">RSK-XT04-SEC-001<\/span><\/p><h3 class=\"nrp-h4\">Design capability outpaces screening<\/h3><dl class=\"nrp-dl\"><dt>Driver<\/dt><dd>open machine-learning design tools and low-cost DNA<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n7\" id=\"nx-nrp-xt-04-c4-r7\" aria-label=\"Note 7\">7<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n13\" id=\"nx-nrp-xt-04-c4-r13\" aria-label=\"Note 13\">13<\/a><\/sup><\/dd><dt>Exposure<\/dt><dd>sequence-handling and synthesis providers<\/dd><dt>Vulnerability<\/dt><dd>uneven screening practice; benchtop and small providers<\/dd><dt>Capacity<\/dt><dd>screening guidance, patches and oversight frameworks<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n13\" aria-label=\"Note 13\">13<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n25\" id=\"nx-nrp-xt-04-c4-r25\" aria-label=\"Note 25\">25<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n31\" id=\"nx-nrp-xt-04-c4-r31\" aria-label=\"Note 31\">31<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n32\" id=\"nx-nrp-xt-04-c4-r32\" aria-label=\"Note 32\">32<\/a><\/sup><\/dd><dt>Cascade<\/dt><dd>DAT \u2192 BIO \u2192 HLT<\/dd><dt>Horizon<\/dt><dd>1 to 5 years<\/dd><\/dl><\/li><li><p class=\"nrp-find-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Inferred<\/span><span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 3<\/span><span class=\"nrp-find-id\">RSK-XT04-GOV-002<\/span><\/p><h3 class=\"nrp-h4\">Fragmented and shifting oversight<\/h3><dl class=\"nrp-dl\"><dt>Driver<\/dt><dd>unclear status of the US framework; separate EU and CBD tracks<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n20\" id=\"nx-nrp-xt-04-c4-r20\" aria-label=\"Note 20\">20<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n22\" id=\"nx-nrp-xt-04-c4-r22\" aria-label=\"Note 22\">22<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n26\" id=\"nx-nrp-xt-04-c4-r26\" aria-label=\"Note 26\">26<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n27\" id=\"nx-nrp-xt-04-c4-r27\" aria-label=\"Note 27\">27<\/a><\/sup><\/dd><dt>Exposure<\/dt><dd>research collaboration; cross-border orders<\/dd><dt>Vulnerability<\/dt><dd>uneven implementation across jurisdictions<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n18\" id=\"nx-nrp-xt-04-c4-r18\" aria-label=\"Note 18\">18<\/a><\/sup><\/dd><dt>Capacity<\/dt><dd>OECD and WHO guidance; national strategies<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n18\" aria-label=\"Note 18\">18<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n21\" id=\"nx-nrp-xt-04-c4-r21\" aria-label=\"Note 21\">21<\/a><\/sup><\/dd><dt>Cascade<\/dt><dd>GOV \u2192 BIO, FIN<\/dd><dt>Horizon<\/dt><dd>1 to 5 years<\/dd><\/dl><\/li><li><p class=\"nrp-find-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Expert input<\/span><span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 2<\/span><span class=\"nrp-find-id\">RSK-XT04-SUP-003<\/span><\/p><h3 class=\"nrp-h4\">Manufacturing base thinner than headlines<\/h3><dl class=\"nrp-dl\"><dt>Driver<\/dt><dd>mixed company results and planning-stage public awards<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n16\" id=\"nx-nrp-xt-04-c4-r16\" aria-label=\"Note 16\">16<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n17\" id=\"nx-nrp-xt-04-c4-r17\" aria-label=\"Note 17\">17<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n24\" id=\"nx-nrp-xt-04-c4-r24\" aria-label=\"Note 24\">24<\/a><\/sup><\/dd><dt>Exposure<\/dt><dd>products that depend on scale-up<\/dd><dt>Vulnerability<\/dt><dd>few counted facilities; unmeasured feedstock needs<\/dd><dt>Capacity<\/dt><dd>institute and awards programme<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n23\" id=\"nx-nrp-xt-04-c4-r23\" aria-label=\"Note 23\">23<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n24\" aria-label=\"Note 24\">24<\/a><\/sup><\/dd><dt>Cascade<\/dt><dd>FIN \u2192 INF \u2192 BIO<\/dd><dt>Horizon<\/dt><dd>1 to 10 years<\/dd><\/dl><\/li><li><p class=\"nrp-find-m\"><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Inferred<\/span><span class=\"nrp-eql\" title=\"Evidence-quality level, 1 to 5\">EQL 2<\/span><span class=\"nrp-find-id\">RSK-XT04-ENV-004<\/span><\/p><h3 class=\"nrp-h4\">Release and novel-organism questions<\/h3><dl class=\"nrp-dl\"><dt>Driver<\/dt><dd>gene drives and organisms with altered codes or chirality<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n1\" id=\"nx-nrp-xt-04-c4-r1\" aria-label=\"Note 1\">1<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n11\" id=\"nx-nrp-xt-04-c4-r11\" aria-label=\"Note 11\">11<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n12\" id=\"nx-nrp-xt-04-c4-r12\" aria-label=\"Note 12\">12<\/a><\/sup><\/dd><dt>Exposure<\/dt><dd>ecosystems; public trust<\/dd><dt>Vulnerability<\/dt><dd>limited field evidence; international rules still forming<\/dd><dt>Capacity<\/dt><dd>CBD process and protocol<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n20\" aria-label=\"Note 20\">20<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n35\" id=\"nx-nrp-xt-04-c4-r35\" aria-label=\"Note 35\">35<\/a><\/sup><\/dd><dt>Cascade<\/dt><dd>BIO \u2192 BIO biodiversity <a class=\"nx-link nx-term\" href=\"https:\/\/docs.therisk.global\/organization\/systems\" data-tc=\"Systems\" data-tk=\"Nexus Standards\" data-td=\"The twenty Nexus systems, NXS-CMD to NXS-LAB\">systems<\/a><\/dd><dt>Horizon<\/dt><dd>5 to 10 years<\/dd><\/dl><\/li><\/ol><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c4-s2\" aria-labelledby=\"nx-nrp-xt-04-c4-s2-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c4-s2-h\"><span class=\"nrp-num\">4.2<\/span><span>Capability ladder<\/span><\/h2><p class=\"nrp-stand\">Existence is not readiness. Each of the fifteen capability functions is placed on the ladder by the strongest public evidence for synthetic biology at the global level.<\/p><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c4-tab1\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 4.1<\/span><span class=\"nrp-tbl-t\">Capabilities on the ladder of evidence: listed, exists, demonstrated, tested<\/span><\/caption><thead><tr><th scope=\"col\">Function<\/th><th scope=\"col\">Rung<\/th><th scope=\"col\">Level<\/th><th scope=\"col\">Strongest public evidence at baseline<\/th><\/tr><\/thead><tbody><tr><td>Prevention and mitigation<\/td><td><span class=\"nrp-ladder\" aria-hidden=\"true\"><i data-on=\"true\"><\/i><i data-on=\"true\"><\/i><i><\/i><i><\/i><\/span><\/td><td>EXISTS<\/td><td>screening guidance and dual-use frameworks published<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n21\" aria-label=\"Note 21\">21<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n25\" aria-label=\"Note 25\">25<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n31\" aria-label=\"Note 31\">31<\/a><\/sup><\/td><\/tr><tr><td>Monitoring and observation<\/td><td><span class=\"nrp-ladder\" aria-hidden=\"true\"><i data-on=\"true\"><\/i><i><\/i><i><\/i><i><\/i><\/span><\/td><td>LISTED<\/td><td>no common tracker of synthesis orders or screening coverage<\/td><\/tr><tr><td><a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-c1\" data-tc=\"NRS-C1 early-warning\" data-tk=\"Nexus risk vocabulary\" data-td=\"Timely, actionable information about an impending hazard that lets people and institutions act to reduce harm before it occurs.\" data-ts=\"NRS-C1\" data-tr=\"draft\">Early warning<\/a><\/td><td><span class=\"nrp-ladder\" aria-hidden=\"true\"><i data-on=\"true\"><\/i><i><\/i><i><\/i><i><\/i><\/span><\/td><td>LISTED<\/td><td><a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-c1\" data-tc=\"NRS-C1 horizon-scanning\" data-tk=\"Nexus risk vocabulary\" data-td=\"Systematic searching for early signs of potentially important developments, threats and opportunities at the margins of current thinking.\" data-ts=\"NRS-C1\" data-tr=\"draft\" data-tg=\"https:\/\/globalriskforum.com\/glossary\/horizon-scanning\/\" data-tgl=\"Global Risks Forum glossary\">horizon scanning<\/a> exists under the CBD but is scaled back<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n20\" aria-label=\"Note 20\">20<\/a><\/sup><\/td><\/tr><tr><td>Preparedness and planning<\/td><td><span class=\"nrp-ladder\" aria-hidden=\"true\"><i data-on=\"true\"><\/i><i data-on=\"true\"><\/i><i><\/i><i><\/i><\/span><\/td><td>EXISTS<\/td><td>US commission report, EU proposal and OECD papers<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n14\" id=\"nx-nrp-xt-04-c4-r14\" aria-label=\"Note 14\">14<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n18\" aria-label=\"Note 18\">18<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n22\" aria-label=\"Note 22\">22<\/a><\/sup><\/td><\/tr><tr><td>Redundancy and reserves<\/td><td><span class=\"nrp-ladder\" aria-hidden=\"true\"><i data-on=\"true\"><\/i><i><\/i><i><\/i><i><\/i><\/span><\/td><td>LISTED<\/td><td>manufacturing capacity and reserves not counted<\/td><\/tr><tr><td>Response<\/td><td><span class=\"nrp-ladder\" aria-hidden=\"true\"><i data-on=\"true\"><\/i><i><\/i><i><\/i><i><\/i><\/span><\/td><td>LISTED<\/td><td>no tested response to a misuse event described in the sources<\/td><\/tr><tr><td>Continuity of critical services<\/td><td><span class=\"nrp-ladder\" aria-hidden=\"true\"><i data-on=\"true\"><\/i><i><\/i><i><\/i><i><\/i><\/span><\/td><td>LISTED<\/td><td>not reviewed<\/td><\/tr><tr><td>Recovery<\/td><td><span class=\"nrp-ladder\" aria-hidden=\"true\"><i data-on=\"true\"><\/i><i><\/i><i><\/i><i><\/i><\/span><\/td><td>LISTED<\/td><td>not applicable at baseline; no event to recover from<\/td><\/tr><tr><td>Adaptation<\/td><td><span class=\"nrp-ladder\" aria-hidden=\"true\"><i data-on=\"true\"><\/i><i data-on=\"true\"><\/i><i><\/i><i><\/i><\/span><\/td><td>EXISTS<\/td><td>anticipatory governance principles in OECD work<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n18\" aria-label=\"Note 18\">18<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n19\" id=\"nx-nrp-xt-04-c4-r19\" aria-label=\"Note 19\">19<\/a><\/sup><\/td><\/tr><tr><td><a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-c1\" data-tc=\"NRS-C1 social-protection\" data-tk=\"Nexus risk vocabulary\" data-td=\"Public policies and programmes that help people manage risk and reduce poverty and vulnerability across their lives.\" data-ts=\"NRS-C1\" data-tr=\"draft\">Social protection<\/a><\/td><td><span class=\"nrp-ladder\" aria-hidden=\"true\"><i data-on=\"true\"><\/i><i><\/i><i><\/i><i><\/i><\/span><\/td><td>LISTED<\/td><td>not applicable at baseline<\/td><\/tr><tr><td>Finance and insurance<\/td><td><span class=\"nrp-ladder\" aria-hidden=\"true\"><i data-on=\"true\"><\/i><i><\/i><i><\/i><i><\/i><\/span><\/td><td>LISTED<\/td><td>public and private investment not on a common basis<\/td><\/tr><tr><td>Institutional coordination<\/td><td><span class=\"nrp-ladder\" aria-hidden=\"true\"><i data-on=\"true\"><\/i><i data-on=\"true\"><\/i><i><\/i><i><\/i><\/span><\/td><td>EXISTS<\/td><td>WHO, CBD and OECD processes<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n18\" aria-label=\"Note 18\">18<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n20\" aria-label=\"Note 20\">20<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n21\" aria-label=\"Note 21\">21<\/a><\/sup><\/td><\/tr><tr><td>Technical infrastructure<\/td><td><span class=\"nrp-ladder\" aria-hidden=\"true\"><i data-on=\"true\"><\/i><i data-on=\"true\"><\/i><i><\/i><i><\/i><\/span><\/td><td>EXISTS<\/td><td>bioindustrial institute and planning awards<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n23\" aria-label=\"Note 23\">23<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n24\" aria-label=\"Note 24\">24<\/a><\/sup><\/td><\/tr><tr><td>Workforce<\/td><td><span class=\"nrp-ladder\" aria-hidden=\"true\"><i data-on=\"true\"><\/i><i><\/i><i><\/i><i><\/i><\/span><\/td><td>LISTED<\/td><td>skills gaps reported in policy documents; no figure bound<\/td><\/tr><tr><td>Research capacity<\/td><td><span class=\"nrp-ladder\" aria-hidden=\"true\"><i><\/i><i><\/i><i><\/i><i><\/i><\/span><\/td><td>ADEQUATE<\/td><td>strong peer-reviewed base<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n1\" aria-label=\"Note 1\">1<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n4\" id=\"nx-nrp-xt-04-c4-r4\" aria-label=\"Note 4\">4<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n6\" id=\"nx-nrp-xt-04-c4-r6\" aria-label=\"Note 6\">6<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c4-n7\" aria-label=\"Note 7\">7<\/a><\/sup><\/td><\/tr><\/tbody><tfoot><tr><td colspan=\"4\">A capability listed in policy is not a tested one; each rung is the strongest public evidence at baseline.<\/td><\/tr><\/tfoot><\/table><\/div><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c4-notes\" aria-labelledby=\"nx-nrp-xt-04-c4-notes-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c4-notes-h\"><span>Notes<\/span><\/h2><p class=\"nrp-note\">Numbers are the edition&#8217;s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. <a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/references\/\">Annex C, references<\/a><\/p><ol class=\"nrp-notes\"><li id=\"nx-nrp-xt-04-c4-n7\"><span class=\"nrp-notes-n\">7<\/span><span>Watson, J.L. et al., De novo design of protein structure and function with RFdiffusion, Nature 620, 1089 to 1100, 2023 (record read via Europe PMC). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r7\" aria-label=\"Back to the first call of note 7\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n13\"><span class=\"nrp-notes-n\">13<\/span><span>Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r13\" aria-label=\"Back to the first call of note 13\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n25\"><span class=\"nrp-notes-n\">25<\/span><span>UNVERIFIED, not opened: Office of Science and Technology Policy (ed.), Framework for Nucleic Acid Synthesis Screening, April 2024, taken from search-result summaries; a fetch of the page was refused by the fetch tool. OSTP, Washington. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r25\" aria-label=\"Back to the first call of note 25\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n31\"><span class=\"nrp-notes-n\">31<\/span><span>UNVERIFIED, not opened: International Gene Synthesis Consortium (ed.), Harmonized Screening Protocol, cited from memory. IGSC. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r31\" aria-label=\"Back to the first call of note 31\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n32\"><span class=\"nrp-notes-n\">32<\/span><span>UNVERIFIED, not opened: UK Government (ed.), screening guidance on synthetic nucleic acids, 2024, cited from memory. Department for Science, Innovation and Technology, London. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r32\" aria-label=\"Back to the first call of note 32\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n20\"><span class=\"nrp-notes-n\">20<\/span><span>Secretariat of the Convention on Biological Diversity (ed.), Synthetic biology (programme page; decisions X\/13 to 16\/21; AHTEG; <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-c1\" data-tc=\"NRS-C1 horizon-scanning\" data-tk=\"Nexus risk vocabulary\" data-td=\"Systematic searching for early signs of potentially important developments, threats and opportunities at the margins of current thinking.\" data-ts=\"NRS-C1\" data-tr=\"draft\" data-tg=\"https:\/\/globalriskforum.com\/glossary\/horizon-scanning\/\" data-tgl=\"Global Risks Forum glossary\">horizon scanning<\/a>; thematic action plan). CBD Secretariat, Montreal. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r20\" aria-label=\"Back to the first call of note 20\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n22\"><span class=\"nrp-notes-n\">22<\/span><span>Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r22\" aria-label=\"Back to the first call of note 22\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n26\"><span class=\"nrp-notes-n\">26<\/span><span>UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r26\" aria-label=\"Back to the first call of note 26\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n27\"><span class=\"nrp-notes-n\">27<\/span><span>UNVERIFIED, not opened: Congressional Research Service (ed.), report on artificial intelligence and biosecurity risks (reported in July 2026 as unable to determine whether the 2024 framework or the 2025 policy had been revised), taken from a trade news summary. Library of Congress, Washington. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r27\" aria-label=\"Back to the first call of note 27\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n18\"><span class=\"nrp-notes-n\">18<\/span><span>OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r18\" aria-label=\"Back to the first call of note 18\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n21\"><span class=\"nrp-notes-n\">21<\/span><span>World Health Organization (ed.), Global guidance framework for the responsible use of the life sciences: mitigating biorisks and governing <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-c1\" data-tc=\"NRS-C1 dual-use-research\" data-tk=\"Nexus risk vocabulary\" data-td=\"Legitimate research whose knowledge, methods or products could also be misused to cause serious harm.\" data-ts=\"NRS-C1\" data-tr=\"draft\">dual-use research<\/a> (publication page, 13 September 2022). WHO, Geneva. Observation year 2022. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r21\" aria-label=\"Back to the first call of note 21\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n16\"><span class=\"nrp-notes-n\">16<\/span><span>Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r16\" aria-label=\"Back to the first call of note 16\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n17\"><span class=\"nrp-notes-n\">17<\/span><span>Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r17\" aria-label=\"Back to the first call of note 17\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n24\"><span class=\"nrp-notes-n\">24<\/span><span>US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r24\" aria-label=\"Back to the first call of note 24\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n23\"><span class=\"nrp-notes-n\">23<\/span><span>BioMADE (ed.), DoD approves USD 87 million for newest bioindustrial manufacturing innovation institute (news page; seven years; the page shows Oct 20 and a 2023 footer, the press release is dated 2020 in search listings). BioMADE, Saint Paul. Observation year 2020. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r23\" aria-label=\"Back to the first call of note 23\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n1\"><span class=\"nrp-notes-n\">1<\/span><span>Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r1\" aria-label=\"Back to the first call of note 1\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n11\"><span class=\"nrp-notes-n\">11<\/span><span>Kyrou, K. et al., A CRISPR-Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes, Nature Biotechnology 36, 1062 to 1066, 2018 (record read via Europe PMC; laboratory cages only). Springer Nature, London. Observation year 2018. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r11\" aria-label=\"Back to the first call of note 11\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n12\"><span class=\"nrp-notes-n\">12<\/span><span>Confronting risks of <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-h101\" data-tc=\"NHS-1 tech.biotech.mirror-life\" data-tk=\"Frontier and exponential technology \u00b7 Biotechnology and synthetic biology\" data-td=\"Creation and escape of organisms built from mirror-image molecules, which could evade immune defences, predators and decay in people, animals and plants and spread unchecked through ecosystems.\" data-ts=\"NRS-H101\" data-tr=\"draft\" data-tx=\"https:\/\/risksindex.com\/hazards\/tech\/\" data-txl=\"Frontier and exponential technology\">mirror life<\/a>, Science 386, 1351 to 1353, 2024 (record read via Europe PMC; the record gives only a one-line abstract calling for broad discussion). American Association for the Advancement of Science, Washington. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r12\" aria-label=\"Back to the first call of note 12\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n35\"><span class=\"nrp-notes-n\">35<\/span><span>UNVERIFIED, not opened: Cartagena Protocol on Biosafety to the Convention on Biological Diversity, 2000, cited from memory. CBD Secretariat, Montreal. Observation year 2000. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r35\" aria-label=\"Back to the first call of note 35\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n14\"><span class=\"nrp-notes-n\">14<\/span><span>Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r14\" aria-label=\"Back to the first call of note 14\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n19\"><span class=\"nrp-notes-n\">19<\/span><span>OECD (ed.), Synthetic biology, AI and automation: a forward-looking technology assessment, OECD Science, Technology and Industry Policy Papers No. 187, 4 December 2025 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r19\" aria-label=\"Back to the first call of note 19\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n4\"><span class=\"nrp-notes-n\">4<\/span><span>Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r4\" aria-label=\"Back to the first call of note 4\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c4-n6\"><span class=\"nrp-notes-n\">6<\/span><span>Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c4-r6\" aria-label=\"Back to the first call of note 6\">back<\/a><\/span><\/li><\/ol><\/section><\/div><div class=\"nrp-part\" id=\"nx-nrp-xt-04-part-scenario\"><header class=\"nrp-chap-head\" id=\"nx-nrp-xt-04-c5-top\"><ul class=\"nrp-eyerow\"><li class=\"nf-ui-eyebrow\"><a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/\">Synthetic Biology and Bioengineering 2026<\/a><\/li><li class=\"nf-ui-eyebrow\">Chapter 5<\/li><\/ul><span class=\"nrp-rule\" aria-hidden=\"true\"><\/span><h2 class=\"pp-hero-title\">Design capability outpaces screening and oversight<\/h2><p class=\"nrp-lede\">A conditional statement under stated assumptions, never a prediction.<\/p><p class=\"nrp-chap-meta\"><span>2 min read<\/span><span>0 figures<\/span><span>0 tables<\/span><span>2 notes<\/span><span>NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE<\/span><\/p><\/header><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c5-s1\" aria-labelledby=\"nx-nrp-xt-04-c5-s1-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c5-s1-h\"><span class=\"nrp-num\">5.1<\/span><span>Assumptions<\/span><\/h2><p class=\"nrp-stand\">Scenario SCN-XT04-DSG-01: what is assumed, and what is held constant.<\/p><dl class=\"nrp-dl\"><dt>Baseline<\/dt><dd>the 2026 reference state in this edition<\/dd><dt>Drivers<\/dt><dd>design tools and low-cost DNA improve faster than screening practice and framework text<\/dd><dt>Analogues<\/dt><dd>the 2025 screening study and the 2025 executive order<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c5-n13\" id=\"nx-nrp-xt-04-c5-r13\" aria-label=\"Note 13\">13<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c5-n26\" id=\"nx-nrp-xt-04-c5-r26\" aria-label=\"Note 26\">26<\/a><\/sup><\/dd><dt>Interventions<\/dt><dd>none modelled: the specification describes the unmitigated case<\/dd><dt>Run state<\/dt><dd>narrative specification; quantified run scheduled for 2027<\/dd><\/dl><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c5-s2\" aria-labelledby=\"nx-nrp-xt-04-c5-s2-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c5-s2-h\"><span class=\"nrp-num\">5.2<\/span><span>The cascade, step by step<\/span><\/h2><ol class=\"nrp-rows\"><li><span class=\"nrp-rows-i\">1<\/span><p class=\"nrp-rows-t\">AIC \u2192 BIO<\/p><p class=\"nrp-rows-x\">design tools make novel sequences easier to produce<\/p><p class=\"nrp-rows-m\">2023<\/p><\/li><li><span class=\"nrp-rows-i\">2<\/span><p class=\"nrp-rows-t\">DAT \u2192 SEC<\/p><p class=\"nrp-rows-x\">screening tools miss some redesigned sequences<\/p><p class=\"nrp-rows-m\">2025<\/p><\/li><li><span class=\"nrp-rows-i\">3<\/span><p class=\"nrp-rows-t\">GOV \u2192 SEC<\/p><p class=\"nrp-rows-x\">framework text is revised while practice differs by provider<\/p><p class=\"nrp-rows-m\">2025<\/p><\/li><li><span class=\"nrp-rows-i\">4<\/span><p class=\"nrp-rows-t\">FIN \u2192 INF<\/p><p class=\"nrp-rows-x\">investment concentrates in providers with in-house screening<\/p><p class=\"nrp-rows-m\">2026<\/p><\/li><li><span class=\"nrp-rows-i\">5<\/span><p class=\"nrp-rows-t\">GOV \u2192 TRD<\/p><p class=\"nrp-rows-x\">national rules and export controls diverge<\/p><p class=\"nrp-rows-m\">2026<\/p><\/li><li><span class=\"nrp-rows-i\">6<\/span><p class=\"nrp-rows-t\">BIO \u2192 HLT<\/p><p class=\"nrp-rows-x\">public trust in engineered products is tested<\/p><p class=\"nrp-rows-m\">2025<\/p><\/li><\/ol><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c5-s3\" aria-labelledby=\"nx-nrp-xt-04-c5-s3-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c5-s3-h\"><span class=\"nrp-num\">5.3<\/span><span>The scenario as a table of steps<\/span><\/h2><p class=\"nx-p\">How the shock in scenario SCN-XT04-DSG-01 would travel through Synthetic Biology and Bioengineering&#8217;s coupled <a class=\"nx-link nx-term\" href=\"https:\/\/docs.therisk.global\/organization\/systems\" data-tc=\"Systems\" data-tk=\"Nexus Standards\" data-td=\"The twenty Nexus systems, NXS-CMD to NXS-LAB\">systems<\/a>, step by step, under the assumptions the edition states.<\/p><div class=\"nx-table-wrap\"><table class=\"nx-table\" data-stack=\"true\"><thead><tr><th scope=\"col\">Step<\/th><th scope=\"col\">What happens<\/th><th scope=\"col\">Source<\/th><\/tr><\/thead><tbody><tr><td data-label=\"Step\">01 AI compute to biodiversity<\/td><td data-label=\"What happens\">Design tools make novel sequences easier to produce. Analogue or source: 2023.<\/td><td data-label=\"Source\">Edition XT-04, scenario SCN-XT04-DSG-01, step 1<\/td><\/tr><tr><td data-label=\"Step\">02 DAT to security<\/td><td data-label=\"What happens\">Screening tools miss some redesigned sequences. Analogue or source: 2025.<\/td><td data-label=\"Source\">Edition XT-04, scenario SCN-XT04-DSG-01, step 2<\/td><\/tr><tr><td data-label=\"Step\">03 Governance to security<\/td><td data-label=\"What happens\">Framework text is revised while practice differs by provider. Analogue or source: 2025.<\/td><td data-label=\"Source\">Edition XT-04, scenario SCN-XT04-DSG-01, step 3<\/td><\/tr><tr><td data-label=\"Step\">04 Finance to infrastructure<\/td><td data-label=\"What happens\">Investment concentrates in providers with in-house screening. Analogue or source: 2026.<\/td><td data-label=\"Source\">Edition XT-04, scenario SCN-XT04-DSG-01, step 4<\/td><\/tr><tr><td data-label=\"Step\">05 Governance to trade<\/td><td data-label=\"What happens\">National rules and export controls diverge. Analogue or source: 2026.<\/td><td data-label=\"Source\">Edition XT-04, scenario SCN-XT04-DSG-01, step 5<\/td><\/tr><tr><td data-label=\"Step\">06 Biodiversity to health<\/td><td data-label=\"What happens\">Public trust in engineered products is tested. Analogue or source: 2025.<\/td><td data-label=\"Source\">Edition XT-04, scenario SCN-XT04-DSG-01, step 6<\/td><\/tr><\/tbody><\/table><\/div><p class=\"nx-note nx-mt-2\">A teaching model of a conditional scenario under the edition&#8217;s stated assumptions: not a forecast, not a prediction and not a warning. Sources: <a class=\"nx-link\" href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/scenario\/\" rel=\"noopener\">Synthetic Biology and Bioengineering 2026, scenario SCN-XT04-DSG-01<\/a> (2026); Synthetic Biology and Bioengineering 2026, references (NR-CIT-1) (2026).<\/p><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c5-notes\" aria-labelledby=\"nx-nrp-xt-04-c5-notes-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c5-notes-h\"><span>Notes<\/span><\/h2><p class=\"nrp-note\">Numbers are the edition&#8217;s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. <a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/references\/\">Annex C, references<\/a><\/p><ol class=\"nrp-notes\"><li id=\"nx-nrp-xt-04-c5-n13\"><span class=\"nrp-notes-n\">13<\/span><span>Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c5-r13\" aria-label=\"Back to the first call of note 13\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c5-n26\"><span class=\"nrp-notes-n\">26<\/span><span>UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c5-r26\" aria-label=\"Back to the first call of note 26\">back<\/a><\/span><\/li><\/ol><\/section><\/div><div class=\"nrp-part\" id=\"nx-nrp-xt-04-part-lenses-and-readings\"><header class=\"nrp-chap-head\" id=\"nx-nrp-xt-04-c6-top\"><ul class=\"nrp-eyerow\"><li class=\"nf-ui-eyebrow\"><a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/\">Synthetic Biology and Bioengineering 2026<\/a><\/li><li class=\"nf-ui-eyebrow\">Chapter 6<\/li><\/ul><span class=\"nrp-rule\" aria-hidden=\"true\"><\/span><h2 class=\"pp-hero-title\">Readings from the other desks<\/h2><p class=\"nrp-lede\">The synthetic biology baseline is read through each steward\u2019s lens, then once as a whole. Each lens is a projection of reviewed findings, not a separate argument. The other desks&#8217; own editions of this subject are listed first, as cross-references, not copies.<\/p><p class=\"nrp-chap-meta\"><span>16 min read<\/span><span>0 figures<\/span><span>8 tables<\/span><span>40 notes<\/span><span>NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE<\/span><\/p><\/header><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c6-s1\" aria-labelledby=\"nx-nrp-xt-04-c6-s1-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c6-s1-h\"><span class=\"nrp-num\">6.1<\/span><span>The other desks&#8217; editions of this subject<\/span><\/h2><p class=\"nrp-stand\">Federation: each desk writes its own edition for the subjects in its remit. Until a desk releases, its edition shows its frame and the reading this edition printed for it.<\/p><div class=\"nrp-tblw\"><table class=\"nrp-tbl\"><thead><tr><th scope=\"col\">Desk<\/th><th scope=\"col\">Edition<\/th><th scope=\"col\">State<\/th><th scope=\"col\">Identifier<\/th><\/tr><\/thead><tbody><tr data-host=\"true\"><th scope=\"row\">GCRI Systems Evidence<\/th><td>No edition of this subject at this desk in the 2026 Baseline cycle<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Not in this cycle<\/span><\/td><td class=\"nrp-mono\"><\/td><\/tr><tr><th scope=\"row\">GRF Public Deliberation<\/th><td>Outside this desk&#8217;s remit<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Not in remit<\/span><\/td><td class=\"nrp-mono\"><\/td><\/tr><tr><th scope=\"row\">GRA Capital Readiness<\/th><td>Outside this desk&#8217;s remit<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Not in remit<\/span><\/td><td class=\"nrp-mono\"><\/td><\/tr><tr><th scope=\"row\">Standards Progress<\/th><td>No edition of this subject at this desk in the 2026 Baseline cycle<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Not in this cycle<\/span><\/td><td class=\"nrp-mono\"><\/td><\/tr><tr><th scope=\"row\">Academy Capability<\/th><td>No edition of this subject at this desk in the 2026 Baseline cycle<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Not in this cycle<\/span><\/td><td class=\"nrp-mono\"><\/td><\/tr><tr><th scope=\"row\">Index Measurement<\/th><td>Outside this desk&#8217;s remit<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Not in remit<\/span><\/td><td class=\"nrp-mono\"><\/td><\/tr><\/tbody><\/table><\/div><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c6-s2\" aria-labelledby=\"nx-nrp-xt-04-c6-s2-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c6-s2-h\"><span class=\"nrp-num\">6.2<\/span><span>Three lenses<\/span><\/h2><p class=\"nrp-stand\">One edition, read by each steward. The lens of this site comes first.<\/p><div class=\"nrp-cards\" data-n=\"3\"><article class=\"nf-ui-card nrp-card\" data-host=\"true\"><p class=\"nf-ui-eyebrow\">GCRI \u00b7 KEY T<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">Technical Truth<\/h3><p>The evidence supports reading synthetic biology as a build capability, a manufacturing base and a governance test. Build results are strong on single organisms, risk evidence is newer, and the physical footprint is unmeasured. Evidence is strongest for peer-reviewed results and weakest for energy, capacity and screening coverage.<\/p><p class=\"nrp-note\">BLD-001 \u00b7 SEC-005 \u00b7 GOV-007 \u00b7 SYS-012<\/p><\/article><article class=\"nf-ui-card nrp-card\"><p class=\"nf-ui-eyebrow\">GRF \u00b7 KEY M<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">Public Meaning<\/h3><p>For most people synthetic biology arrives as a medicine, a food label or a warning about misuse. The baseline asks that public debate separate peer-reviewed results from company statements and plans, and keep oversight of both benefit and risk in view.<\/p><p class=\"nrp-note\">CLN-004 \u00b7 SEC-005 \u00b7 SEC-006<\/p><\/article><article class=\"nf-ui-card nrp-card\"><p class=\"nf-ui-eyebrow\">GRA \u00b7 KEY F<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">Capital Meaning<\/h3><p>Readiness implications only. Company results are mixed and public programmes are at the planning stage<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n16\" id=\"nx-nrp-xt-04-c6-r16\" aria-label=\"Note 16\">16<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n17\" id=\"nx-nrp-xt-04-c6-r17\" aria-label=\"Note 17\">17<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n24\" id=\"nx-nrp-xt-04-c6-r24\" aria-label=\"Note 24\">24<\/a><\/sup>. These show where finance-readiness evidence will matter. Nothing here is advice, a rating or an approval.<\/p><p class=\"nrp-note\">FIN-011 \u00b7 GOV-008<\/p><\/article><article class=\"nf-ui-card nrp-card\"><p class=\"nf-ui-eyebrow\">NEXUS<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">Synthesis<\/h3><p>Synthetic biology is well described by single results and thinly measured as a system. The 2027 programme should count screening coverage, publish a comparable footprint and test the design and screening gap before the next framework revision.<\/p><p class=\"nrp-note\">SYS-012 \u00b7 Q-01 \u00b7 Q-02<\/p><\/article><\/div><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c6-s3\" aria-labelledby=\"nx-nrp-xt-04-c6-s3-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c6-s3-h\"><span class=\"nrp-num\">6.3<\/span><span>Standards, Academy and steward contributions<\/span><\/h2><p class=\"nrp-stand\">How the <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/\" data-tc=\"Nexus Standards\" data-tk=\"Nexus Standards\" data-td=\"The foundation standards\">Nexus Standards<\/a> drafts, the Risk Academy and the three stewards feed each quarterly edition for synthetic biology. The standards are a preparatory working draft (2026) and are cited as drafts, never as adopted standards.<\/p><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c6-tab1\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 6.1<\/span><span class=\"nrp-tbl-t\">The quarterly rhythm every edition follows<\/span><\/caption><thead><tr><th scope=\"col\">Quarter<\/th><th scope=\"col\">Edition<\/th><th scope=\"col\">Question<\/th><th scope=\"col\">Boundary<\/th><\/tr><\/thead><tbody><tr><td>Q1<\/td><td>State and Agenda<\/td><td>What matters this year, and what is the starting position?<\/td><td>observed baseline stays distinct from planned work<\/td><\/tr><tr><td>Q2<\/td><td>Evidence and Build<\/td><td>What new evidence and capability exist?<\/td><td>a configured capability is not a validated result<\/td><\/tr><tr><td>Q3<\/td><td><a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-c1\" data-tc=\"NRS-C1 stress-test\" data-tk=\"Nexus risk vocabulary\" data-td=\"An assessment of how a system, portfolio or institution would perform under severe but plausible adverse scenarios, to find weaknesses before they are revealed by events.\" data-ts=\"NRS-C1\" data-tr=\"draft\">Stress Test<\/a> and Readiness<\/td><td>What do scenarios and tests show?<\/td><td>simulated loss or performance is not observed impact<\/td><\/tr><tr><td>Q4<\/td><td>Annual Synthesis and Renewal<\/td><td>What changed in the year, and what renews?<\/td><td>release follows review, not event publicity deadlines<\/td><\/tr><\/tbody><\/table><\/div><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c6-tab2\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 6.2<\/span><span class=\"nrp-tbl-t\">Who contributes what each quarter<\/span><\/caption><thead><tr><th scope=\"col\">Steward or body<\/th><th scope=\"col\">Role<\/th><th scope=\"col\">Contribution route<\/th><\/tr><\/thead><tbody><tr><td>GCRI Canada<\/td><td>Lead Institution and Consortium Secretariat; publisher of record; technical truth (key T)<\/td><td>science and practice communities \u00b7 GCRI gateway<\/td><\/tr><tr><td>The Global Risks Forum (GRF)<\/td><td>leadership, dialogue and the <a class=\"nx-link\" href=\"https:\/\/docs.therisk.global\/organization\/programme\/universe\">Universe<\/a> programme; public meaning (key M)<\/td><td>policy, Universe and national adoption \u00b7 GRF gateway<\/td><\/tr><tr><td>The Global Risks Alliance (GRA)<\/td><td>finance, insurance and development readiness; capital meaning (key F)<\/td><td>finance and insurance \u00b7 GRA gateway<\/td><\/tr><tr><td>Nexus Standards<\/td><td>preparatory drafts on vocabulary, hazards, indicators and methods<\/td><td>Standards site \u00b7 working groups HAZ, IND, MTH, FIN, AI<\/td><\/tr><tr><td>Risk Academy<\/td><td>learning pathways tied to the agenda questions<\/td><td>Academy gateway \u00b7 learning by review<\/td><\/tr><tr><td>Nexus Standards and Academy<\/td><td>technology chapter inputs: GCRI evidence, NXS standards, RA capability<\/td><td>technology editorial board<\/td><\/tr><\/tbody><\/table><\/div><div class=\"nrp-split\"><div><h3 class=\"nrp-h3\">Standards drafts used in this edition<\/h3><ul class=\"nrp-list\"><li>Risk vocabulary NRS-C1 (424 terms) for terms in the glossary<\/li><li>Hazard atlas NHS-1 1.1.0 (905 hazards in 120 families) for risk objects<\/li><li>Seven risk classes: global, catastrophic, existential, emerging, planetary, exponential, frontier-tech<\/li><\/ul><\/div><div><h3 class=\"nrp-h3\">Standards calendar to watch<\/h3><ul class=\"nrp-list\"><li>Founding calls from 20 October 2026; working groups meet from 5 November 2026<\/li><li>Inaugural Global Standards Council session, 12 January 2027<\/li><li>Quarterly reviews in March, June, September and December, aligned with each edition<\/li><\/ul><\/div><\/div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">boundary<\/p><p>Nothing here certifies. A Nexus attestation records an evaluation under a mandate; it confers no certification, endorsement or approval. Adoption of any standard is a decision of the competent standards body.<\/p><\/aside><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c6-s4\" aria-labelledby=\"nx-nrp-xt-04-c6-s4-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c6-s4-h\"><span class=\"nrp-num\">6.4<\/span><span>GCRI reading: the model card<\/span><\/h2><p class=\"nrp-p\">GCRI&#8217;s reading of this edition is its model card: what the national model is, what it computes and where it stops. It is printed in full in Annex A, with the methods it belongs to. <a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/methodology\/\">Annex A, methodology<\/a><\/p><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c6-s5\" aria-labelledby=\"nx-nrp-xt-04-c6-s5-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c6-s5-h\"><span class=\"nrp-num\">6.5<\/span><span>Global Risks Forum reading: editorial essays<\/span><\/h2><p class=\"nrp-stand\">Four signed essays by the <a class=\"nx-link\" href=\"https:\/\/docs.therisk.global\/organization\/programme\/reports\">Reports<\/a> editorial team set out the positions this edition takes. They are interpretation, labelled as such; the evidence they draw on is in the findings register.<\/p><div class=\"nrp-cards\"><article class=\"nf-ui-card nrp-card\"><p class=\"nf-ui-eyebrow\">Synthetic biology is a build capability, a manufacturing base and a governance test. The first is advancing fast, the second is thinly measured and the third is unevenly implemented. Keeping them apart avoids both hype and alarm.<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">EDITORIAL ESSAY \u00b7 01<\/h3><p>Three stories, one field<\/p><\/article><article class=\"nf-ui-card nrp-card\"><p class=\"nf-ui-eyebrow\">A peer-reviewed experiment, a policy proposal and a company announcement carry different weight. This edition labels each, and treats company revenue and guidance as weak evidence.<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">EDITORIAL ESSAY \u00b7 02<\/h3><p>Separate results, plans and statements<\/p><\/article><article class=\"nf-ui-card nrp-card\"><p class=\"nf-ui-eyebrow\">Feedstock, energy, water, DNA supply and capacity are rarely counted. A published footprint would show whether scale is limited by biology, supply or money.<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">EDITORIAL ESSAY \u00b7 03<\/h3><p>The footprint is the blind spot<\/p><\/article><article class=\"nf-ui-card nrp-card\"><p class=\"nf-ui-eyebrow\">Screening and dual-use frameworks were written before generative design tools. Evidence shows gaps and fixes, and the work is practice, coverage and shared text across jurisdictions.<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">EDITORIAL ESSAY \u00b7 04<\/h3><p>Oversight has to keep pace with design<\/p><\/article><\/div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">boundary<\/p><p>Essays are signed views of the editorial team. Contributed articles from regional consortia, national pathways and invited experts begin with the 2027 global edition, each with its own review route and disclosures.<\/p><\/aside><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c6-s6\" aria-labelledby=\"nx-nrp-xt-04-c6-s6-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c6-s6-h\"><span class=\"nrp-num\">6.6<\/span><span>Global Risks Alliance reading: 2027 synthetic biology readiness pack<\/span><\/h2><p class=\"nrp-stand\">The registers that open the 2027 global cycle. At baseline each is initialised from this edition.<\/p><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c6-tab3\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 6.3<\/span><span class=\"nrp-tbl-t\">2027 synthetic biology readiness pack<\/span><\/caption><thead><tr><th scope=\"col\">Item<\/th><th scope=\"col\">Register<\/th><th scope=\"col\">State at baseline<\/th><th scope=\"col\">First 2027 entry<\/th><\/tr><\/thead><tbody><tr><td>E1<\/td><td>Synthetic biology risk state delta<\/td><td>baseline set by this edition<\/td><td>changes against the baseline<\/td><\/tr><tr><td>E2<\/td><td>WEFH+B state delta<\/td><td>five global system readings set<\/td><td>indicator updates and freshness<\/td><\/tr><tr><td>E3<\/td><td>Agenda and Portfolio movement<\/td><td>eight agenda items \u00b7 6 proposed objects<\/td><td>admission decisions<\/td><\/tr><tr><td>E4<\/td><td>Federation delivery register<\/td><td>national chapters in preparation<\/td><td>national chapters<\/td><\/tr><tr><td>E5<\/td><td>Consortium capability register<\/td><td>national consortia forming<\/td><td>first contributions<\/td><\/tr><tr><td>E6<\/td><td>Leadership questions and challenges<\/td><td>none yet<\/td><td>first challenge log<\/td><\/tr><tr><td>E7<\/td><td>Foundry technical state<\/td><td>national environments prepared<\/td><td>first federation cut<\/td><\/tr><tr><td>E8<\/td><td>Publication candidates<\/td><td>twelve findings carried forward<\/td><td>PUBLISH \u00b7 HOLD dispositions<\/td><\/tr><tr><td>E9<\/td><td>Universe readiness<\/td><td>one candidate mission<\/td><td>admission and role spine<\/td><\/tr><tr><td>E10<\/td><td>Correction register<\/td><td>none<\/td><td>first federation-wide cycle<\/td><\/tr><\/tbody><\/table><\/div><h3 class=\"nrp-h3\">Publication dispositions<\/h3><ul class=\"nrp-chips\"><li class=\"nf-ui-chip\">Publish<\/li><li class=\"nf-ui-chip\">Hold<\/li><li class=\"nf-ui-chip\">Needs evidence<\/li><li class=\"nf-ui-chip\">Restricted<\/li><li class=\"nf-ui-chip\">Superseded<\/li><\/ul><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">boundary<\/p><p>Programme progress is not real-world risk improvement. These registers record the work of the Nexus programme; they report on no state or organisation.<\/p><\/aside><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c6-s7\" aria-labelledby=\"nx-nrp-xt-04-c6-s7-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c6-s7-h\"><span class=\"nrp-num\">6.7<\/span><span>Nexus Standards reading: standards and regulatory watch<\/span><\/h2><p class=\"nrp-stand\">Instruments and published guidance that shape the <a class=\"nx-link nx-term\" href=\"https:\/\/docs.therisk.global\/organization\/systems\" data-tc=\"Systems\" data-tk=\"Nexus Standards\" data-td=\"The twenty Nexus systems, NXS-CMD to NXS-LAB\">systems<\/a> in this edition, by status on the retrieval date. The edition assesses no one\u2019s compliance.<\/p><ul class=\"nrp-chips\"><li class=\"nf-ui-chip\">IN FORCE<\/li><li class=\"nf-ui-chip\">PUBLISHED<\/li><li class=\"nf-ui-chip\">DRAFT<\/li><li class=\"nf-ui-chip\">PUBLISHED \u00b7 VOLUNTARY<\/li><\/ul><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c6-tab4\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 6.4<\/span><span class=\"nrp-tbl-t\">Standards and regulatory watch<\/span><\/caption><thead><tr><th scope=\"col\">Instrument<\/th><th scope=\"col\">Body<\/th><th scope=\"col\">Scope<\/th><th scope=\"col\">Status<\/th><th scope=\"col\">Relevance<\/th><\/tr><\/thead><tbody><tr><td>Global guidance framework for the life sciences<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n21\" id=\"nx-nrp-xt-04-c6-r21\" aria-label=\"Note 21\">21<\/a><\/sup><\/td><td>WHO<\/td><td>global<\/td><td>PUBLISHED 2022<\/td><td>dual-use governance<\/td><\/tr><tr><td>Framework for nucleic acid synthesis screening<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n25\" id=\"nx-nrp-xt-04-c6-r25\" aria-label=\"Note 25\">25<\/a><\/sup><\/td><td>OSTP<\/td><td>US<\/td><td>PUBLISHED 2024<\/td><td>screening; status after 2025 order unclear<\/td><\/tr><tr><td>Executive Order 14292<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n26\" id=\"nx-nrp-xt-04-c6-r26\" aria-label=\"Note 26\">26<\/a><\/sup><\/td><td>US President<\/td><td>US<\/td><td>IN FORCE 2025<\/td><td>research safety and framework revision<\/td><\/tr><tr><td>Harmonised screening protocol<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n31\" id=\"nx-nrp-xt-04-c6-r31\" aria-label=\"Note 31\">31<\/a><\/sup><\/td><td>IGSC<\/td><td>industry, global<\/td><td>PUBLISHED \u00b7 VOLUNTARY<\/td><td>screening practice<\/td><\/tr><tr><td>Screening guidance for synthetic nucleic acids<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n32\" id=\"nx-nrp-xt-04-c6-r32\" aria-label=\"Note 32\">32<\/a><\/sup><\/td><td>UK Government<\/td><td>UK<\/td><td>PUBLISHED \u00b7 VOLUNTARY<\/td><td>screening practice<\/td><\/tr><tr><td>ISO 20688-2 on gene synthesis<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n36\" id=\"nx-nrp-xt-04-c6-r36\" aria-label=\"Note 36\">36<\/a><\/sup><\/td><td>ISO<\/td><td>global<\/td><td>PUBLISHED \u00b7 VOLUNTARY<\/td><td>production requirements<\/td><\/tr><tr><td>Biotech Act proposal<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n22\" id=\"nx-nrp-xt-04-c6-r22\" aria-label=\"Note 22\">22<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n28\" id=\"nx-nrp-xt-04-c6-r28\" aria-label=\"Note 28\">28<\/a><\/sup><\/td><td>European Commission<\/td><td>EU<\/td><td>DRAFT<\/td><td>health biotechnology and biodefence<\/td><\/tr><tr><td>CBD decisions 15\/31 and 16\/21<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n20\" id=\"nx-nrp-xt-04-c6-r20\" aria-label=\"Note 20\">20<\/a><\/sup><\/td><td>CBD parties<\/td><td>global<\/td><td>PUBLISHED<\/td><td><a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-c1\" data-tc=\"NRS-C1 horizon-scanning\" data-tk=\"Nexus risk vocabulary\" data-td=\"Systematic searching for early signs of potentially important developments, threats and opportunities at the margins of current thinking.\" data-ts=\"NRS-C1\" data-tr=\"draft\" data-tg=\"https:\/\/globalriskforum.com\/glossary\/horizon-scanning\/\" data-tgl=\"Global Risks Forum glossary\">horizon scanning<\/a> and action plan<\/td><\/tr><tr><td>Cartagena Protocol<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n35\" id=\"nx-nrp-xt-04-c6-r35\" aria-label=\"Note 35\">35<\/a><\/sup><\/td><td>CBD parties<\/td><td>global<\/td><td>IN FORCE<\/td><td>living modified organisms<\/td><\/tr><tr><td>Biological Weapons Convention<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n34\" id=\"nx-nrp-xt-04-c6-r34\" aria-label=\"Note 34\">34<\/a><\/sup><\/td><td>States Parties<\/td><td>global<\/td><td>IN FORCE<\/td><td>prohibition<\/td><\/tr><\/tbody><\/table><\/div><div class=\"nrp-split\"><div><h3 class=\"nrp-h3\">Changed since 2024<\/h3><ul class=\"nrp-list\"><li>The EU proposed a Biotech Act on 16 December 2025<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n22\" aria-label=\"Note 22\">22<\/a><\/sup><\/li><li>The OECD published its anticipatory governance paper on 21 May 2026<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n18\" id=\"nx-nrp-xt-04-c6-r18\" aria-label=\"Note 18\">18<\/a><\/sup><\/li><li>The US executive order of May 2025 set a 90-day deadline for a revised screening framework<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n26\" aria-label=\"Note 26\">26<\/a><\/sup><\/li><\/ul><\/div><div><h3 class=\"nrp-h3\">To watch in 2027<\/h3><ul class=\"nrp-list\"><li>The EU second Biotech Act, expected in the third quarter of 2026<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n29\" id=\"nx-nrp-xt-04-c6-r29\" aria-label=\"Note 29\">29<\/a><\/sup><\/li><li>The CBD thematic action plan for COP-17<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n20\" aria-label=\"Note 20\">20<\/a><\/sup><\/li><li>Any replacement US screening framework<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n25\" aria-label=\"Note 25\">25<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n27\" id=\"nx-nrp-xt-04-c6-r27\" aria-label=\"Note 27\">27<\/a><\/sup><\/li><\/ul><\/div><\/div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">evidence<\/p><p>Status is read from the issuing body on the retrieval date. Instruments open for signature or awaiting ratification are labelled as such; a change in status opens a review task for every finding that relies on the instrument.<\/p><\/aside><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c6-s8\" aria-labelledby=\"nx-nrp-xt-04-c6-s8-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c6-s8-h\"><span class=\"nrp-num\">6.8<\/span><span>Risk Academy reading: literature and evidence review, science and assessments<\/span><\/h2><p class=\"nrp-stand\">The review behind this edition covers synthetic biology assessments, peer-reviewed science and the institutional reports that bind its findings. Systematic reviews for each agenda item begin in 2027.<\/p><h3 class=\"nrp-h3\">Review protocol<\/h3><dl class=\"nrp-dl\"><dt>Question<\/dt><dd>What does the published evidence establish about synthetic biology and bioengineering as infrastructure and its couplings?<\/dd><dt>Sources searched<\/dt><dd>peer-reviewed journals; regulator and agency pages; policy papers; company filings<\/dd><dt>Window<\/dt><dd>releases available at evidence close, 30 September 2026<\/dd><dt>Selection<\/dt><dd>sources that bind or contextualise a finding in this edition<\/dd><dt>Next step<\/dt><dd>systematic reviews for agenda items 01 to 05 in 2027<\/dd><\/dl><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c6-tab5\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 6.5<\/span><span class=\"nrp-tbl-t\">Peer-reviewed science<\/span><\/caption><thead><tr><th scope=\"col\">Reference<\/th><th scope=\"col\">Type<\/th><th scope=\"col\">Year<\/th><th scope=\"col\">Role<\/th><th scope=\"col\">Used for<\/th><\/tr><\/thead><tbody><tr><td>Robertson et al.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n1\" id=\"nx-nrp-xt-04-c6-r1\" aria-label=\"Note 1\">1<\/a><\/sup><\/td><td>journal article<\/td><td>2025<\/td><td>supports<\/td><td>recoded genome<\/td><\/tr><tr><td>Fredens et al.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n3\" id=\"nx-nrp-xt-04-c6-r3\" aria-label=\"Note 3\">3<\/a><\/sup><\/td><td>journal article<\/td><td>2019<\/td><td>supports<\/td><td>recoded genome<\/td><\/tr><tr><td>Sc2.0 consortium paper<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n4\" id=\"nx-nrp-xt-04-c6-r4\" aria-label=\"Note 4\">4<\/a><\/sup><\/td><td>journal article<\/td><td>2023<\/td><td>supports<\/td><td>synthetic yeast<\/td><\/tr><tr><td>Gibson et al.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n5\" id=\"nx-nrp-xt-04-c6-r5\" aria-label=\"Note 5\">5<\/a><\/sup><\/td><td>journal article<\/td><td>2010<\/td><td>context<\/td><td>first synthetic cell<\/td><\/tr><tr><td>Nielsen et al.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n6\" id=\"nx-nrp-xt-04-c6-r6\" aria-label=\"Note 6\">6<\/a><\/sup><\/td><td>journal article<\/td><td>2016<\/td><td>supports<\/td><td>circuit design<\/td><\/tr><tr><td>Watson et al.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n7\" id=\"nx-nrp-xt-04-c6-r7\" aria-label=\"Note 7\">7<\/a><\/sup><\/td><td>journal article<\/td><td>2023<\/td><td>supports<\/td><td>protein design<\/td><\/tr><tr><td>Frangoul et al.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n8\" id=\"nx-nrp-xt-04-c6-r8\" aria-label=\"Note 8\">8<\/a><\/sup><\/td><td>journal article<\/td><td>2024<\/td><td>supports<\/td><td>cell therapy<\/td><\/tr><tr><td>Musunuru et al.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n10\" id=\"nx-nrp-xt-04-c6-r10\" aria-label=\"Note 10\">10<\/a><\/sup><\/td><td>journal article<\/td><td>2025<\/td><td>context<\/td><td>patient-specific therapy<\/td><\/tr><\/tbody><\/table><\/div><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c6-tab6\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 6.6<\/span><span class=\"nrp-tbl-t\">Foundational methods<\/span><\/caption><thead><tr><th scope=\"col\">Reference<\/th><th scope=\"col\">Issuer<\/th><th scope=\"col\">Year<\/th><th scope=\"col\">Role<\/th><th scope=\"col\">Used for<\/th><\/tr><\/thead><tbody><tr><td>Kyrou et al.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n11\" id=\"nx-nrp-xt-04-c6-r11\" aria-label=\"Note 11\">11<\/a><\/sup><\/td><td>journal article<\/td><td>2018<\/td><td>context<\/td><td>gene drive<\/td><\/tr><tr><td><a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-h101\" data-tc=\"NHS-1 tech.biotech.mirror-life\" data-tk=\"Frontier and exponential technology \u00b7 Biotechnology and synthetic biology\" data-td=\"Creation and escape of organisms built from mirror-image molecules, which could evade immune defences, predators and decay in people, animals and plants and spread unchecked through ecosystems.\" data-ts=\"NRS-H101\" data-tr=\"draft\" data-tx=\"https:\/\/risksindex.com\/hazards\/tech\/\" data-txl=\"Frontier and exponential technology\">Mirror life<\/a> policy forum<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n12\" id=\"nx-nrp-xt-04-c6-r12\" aria-label=\"Note 12\">12<\/a><\/sup><\/td><td>journal article<\/td><td>2024<\/td><td>context<\/td><td>risk discussion<\/td><\/tr><tr><td>Screening study<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n13\" id=\"nx-nrp-xt-04-c6-r13\" aria-label=\"Note 13\">13<\/a><\/sup><\/td><td>journal article<\/td><td>2025<\/td><td>supports<\/td><td>screening gaps<\/td><\/tr><tr><td>Jinek et al.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n38\" id=\"nx-nrp-xt-04-c6-r38\" aria-label=\"Note 38\">38<\/a><\/sup><\/td><td>journal article<\/td><td>2012<\/td><td>framework<\/td><td>CRISPR programmable cutting<\/td><\/tr><tr><td>Gibson et al.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n39\" id=\"nx-nrp-xt-04-c6-r39\" aria-label=\"Note 39\">39<\/a><\/sup><\/td><td>journal article<\/td><td>2009<\/td><td>framework<\/td><td>DNA assembly<\/td><\/tr><tr><td>Ro et al.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n40\" id=\"nx-nrp-xt-04-c6-r40\" aria-label=\"Note 40\">40<\/a><\/sup><\/td><td>journal article<\/td><td>2006<\/td><td>framework<\/td><td>engineered yeast production<\/td><\/tr><tr><td>Elowitz and Leibler<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n41\" id=\"nx-nrp-xt-04-c6-r41\" aria-label=\"Note 41\">41<\/a><\/sup><\/td><td>journal article<\/td><td>2000<\/td><td>framework<\/td><td>synthetic oscillator<\/td><\/tr><tr><td>Gardner, Cantor and Collins<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n42\" id=\"nx-nrp-xt-04-c6-r42\" aria-label=\"Note 42\">42<\/a><\/sup><\/td><td>journal article<\/td><td>2000<\/td><td>framework<\/td><td>genetic toggle switch<\/td><\/tr><tr><td>Richardson et al.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n43\" id=\"nx-nrp-xt-04-c6-r43\" aria-label=\"Note 43\">43<\/a><\/sup><\/td><td>journal article<\/td><td>2017<\/td><td>framework<\/td><td>synthetic yeast design<\/td><\/tr><\/tbody><\/table><\/div><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c6-tab7\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 6.7<\/span><span class=\"nrp-tbl-t\">Standards, policy and governance<\/span><\/caption><thead><tr><th scope=\"col\">Reference<\/th><th scope=\"col\">Issuer<\/th><th scope=\"col\">Year<\/th><th scope=\"col\">Role<\/th><th scope=\"col\">Used for<\/th><\/tr><\/thead><tbody><tr><td>US commission report, CRS note<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n14\" id=\"nx-nrp-xt-04-c6-r14\" aria-label=\"Note 14\">14<\/a><\/sup><\/td><td>Congressional Research Service<\/td><td>2025<\/td><td>supports<\/td><td>recommendations<\/td><\/tr><tr><td>OECD anticipatory governance<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n18\" aria-label=\"Note 18\">18<\/a><\/sup><\/td><td>OECD<\/td><td>2026<\/td><td>supports<\/td><td>governance<\/td><\/tr><tr><td>OECD technology assessment<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n19\" id=\"nx-nrp-xt-04-c6-r19\" aria-label=\"Note 19\">19<\/a><\/sup><\/td><td>OECD<\/td><td>2025<\/td><td>supports<\/td><td>convergence and risks<\/td><\/tr><tr><td>CBD synthetic biology page<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n20\" aria-label=\"Note 20\">20<\/a><\/sup><\/td><td>CBD secretariat<\/td><td>2026<\/td><td>supports<\/td><td>decisions<\/td><\/tr><tr><td>WHO framework<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n21\" aria-label=\"Note 21\">21<\/a><\/sup><\/td><td>WHO<\/td><td>2022<\/td><td>supports<\/td><td>dual-use guidance<\/td><\/tr><tr><td>Biodefense report<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n33\" id=\"nx-nrp-xt-04-c6-r33\" aria-label=\"Note 33\">33<\/a><\/sup><\/td><td>National Academies<\/td><td>2018<\/td><td>context<\/td><td>biodefence background<\/td><\/tr><tr><td>EU proposal summary<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n22\" aria-label=\"Note 22\">22<\/a><\/sup><\/td><td>law firm summary<\/td><td>2025<\/td><td>context<\/td><td>proposal content<\/td><\/tr><\/tbody><\/table><\/div><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c6-tab8\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 6.8<\/span><span class=\"nrp-tbl-t\">Industry, funding and field overviews<\/span><\/caption><thead><tr><th scope=\"col\">Reference<\/th><th scope=\"col\">Issuer<\/th><th scope=\"col\">Year<\/th><th scope=\"col\">Role<\/th><th scope=\"col\">Used for<\/th><\/tr><\/thead><tbody><tr><td>FAS commentary<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n15\" id=\"nx-nrp-xt-04-c6-r15\" aria-label=\"Note 15\">15<\/a><\/sup><\/td><td>Federation of American Scientists<\/td><td>2025<\/td><td>context<\/td><td>bioeconomy figures<\/td><\/tr><tr><td>Twist Bioscience filing<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n16\" aria-label=\"Note 16\">16<\/a><\/sup><\/td><td>company<\/td><td>2026<\/td><td>context<\/td><td><a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-c1\" data-tc=\"NRS-C1 weak-signal\" data-tk=\"Nexus risk vocabulary\" data-td=\"An early, fragmentary indication of a possible change that is not yet clearly recognised or understood.\" data-ts=\"NRS-C1\" data-tr=\"draft\">weak signal<\/a><\/td><\/tr><tr><td>Ginkgo Bioworks filing<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n17\" aria-label=\"Note 17\">17<\/a><\/sup><\/td><td>company<\/td><td>2026<\/td><td>context<\/td><td>weak signal<\/td><\/tr><tr><td>BioMADE page<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n23\" id=\"nx-nrp-xt-04-c6-r23\" aria-label=\"Note 23\">23<\/a><\/sup><\/td><td>institute<\/td><td>2020<\/td><td>context<\/td><td>infrastructure<\/td><\/tr><tr><td>Programme page<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n24\" aria-label=\"Note 24\">24<\/a><\/sup><\/td><td>US manufacturing programme<\/td><td>2024<\/td><td>supports<\/td><td>planning awards<\/td><\/tr><tr><td>Bio Revolution report<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n37\" id=\"nx-nrp-xt-04-c6-r37\" aria-label=\"Note 37\">37<\/a><\/sup><\/td><td>McKinsey<\/td><td>2020<\/td><td>context<\/td><td>economy<\/td><\/tr><\/tbody><\/table><\/div><div class=\"nrp-split\"><div><h3 class=\"nrp-h3\">Where the evidence agrees<\/h3><ul class=\"nrp-list\"><li>Whole-genome design and writing works at the scale of one organism<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n1\" aria-label=\"Note 1\">1<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n3\" aria-label=\"Note 3\">3<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n4\" aria-label=\"Note 4\">4<\/a><\/sup><\/li><li>Screening tools need updating for machine-designed sequences<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n13\" aria-label=\"Note 13\">13<\/a><\/sup><\/li><li>Governance is moving but implementation is uneven<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n14\" aria-label=\"Note 14\">14<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n18\" aria-label=\"Note 18\">18<\/a><\/sup><\/li><\/ul><\/div><div><h3 class=\"nrp-h3\">Where it is unsettled<\/h3><ul class=\"nrp-list\"><li>Whether screening practice and framework text keep pace with design tools<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n13\" aria-label=\"Note 13\">13<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n26\" aria-label=\"Note 26\">26<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n27\" aria-label=\"Note 27\">27<\/a><\/sup><\/li><li>How large the energy, water and feedstock footprint of manufacturing will be<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n24\" aria-label=\"Note 24\">24<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n37\" aria-label=\"Note 37\">37<\/a><\/sup><\/li><li>How company results map to the health of the sector<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n16\" aria-label=\"Note 16\">16<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n17\" aria-label=\"Note 17\">17<\/a><\/sup><\/li><\/ul><\/div><\/div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">PREPRINTS<\/p><p>Three sources<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n24\" aria-label=\"Note 24\">24<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n25\" aria-label=\"Note 25\">25<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c6-n26\" aria-label=\"Note 26\">26<\/a><\/sup> are preprints and are labelled as not peer-reviewed. They contextualise findings; none binds a finding on its own.<\/p><\/aside><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c6-notes\" aria-labelledby=\"nx-nrp-xt-04-c6-notes-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c6-notes-h\"><span>Notes<\/span><\/h2><p class=\"nrp-note\">Numbers are the edition&#8217;s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. <a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/references\/\">Annex C, references<\/a><\/p><ol class=\"nrp-notes\"><li id=\"nx-nrp-xt-04-c6-n16\"><span class=\"nrp-notes-n\">16<\/span><span>Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r16\" aria-label=\"Back to the first call of note 16\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n17\"><span class=\"nrp-notes-n\">17<\/span><span>Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r17\" aria-label=\"Back to the first call of note 17\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n24\"><span class=\"nrp-notes-n\">24<\/span><span>US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r24\" aria-label=\"Back to the first call of note 24\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n21\"><span class=\"nrp-notes-n\">21<\/span><span>World Health Organization (ed.), Global guidance framework for the responsible use of the life sciences: mitigating biorisks and governing <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-c1\" data-tc=\"NRS-C1 dual-use-research\" data-tk=\"Nexus risk vocabulary\" data-td=\"Legitimate research whose knowledge, methods or products could also be misused to cause serious harm.\" data-ts=\"NRS-C1\" data-tr=\"draft\">dual-use research<\/a> (publication page, 13 September 2022). WHO, Geneva. Observation year 2022. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r21\" aria-label=\"Back to the first call of note 21\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n25\"><span class=\"nrp-notes-n\">25<\/span><span>UNVERIFIED, not opened: Office of Science and Technology Policy (ed.), Framework for Nucleic Acid Synthesis Screening, April 2024, taken from search-result summaries; a fetch of the page was refused by the fetch tool. OSTP, Washington. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r25\" aria-label=\"Back to the first call of note 25\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n26\"><span class=\"nrp-notes-n\">26<\/span><span>UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r26\" aria-label=\"Back to the first call of note 26\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n31\"><span class=\"nrp-notes-n\">31<\/span><span>UNVERIFIED, not opened: International Gene Synthesis Consortium (ed.), Harmonized Screening Protocol, cited from memory. IGSC. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r31\" aria-label=\"Back to the first call of note 31\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n32\"><span class=\"nrp-notes-n\">32<\/span><span>UNVERIFIED, not opened: UK Government (ed.), screening guidance on synthetic nucleic acids, 2024, cited from memory. Department for Science, Innovation and Technology, London. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r32\" aria-label=\"Back to the first call of note 32\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n36\"><span class=\"nrp-notes-n\">36<\/span><span>UNVERIFIED, not opened: International Organization for Standardization (ed.), ISO 20688-2, requirements for the production and quality control of synthesised gene fragments, genes and genome-scale constructs, cited from memory. ISO, Geneva. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r36\" aria-label=\"Back to the first call of note 36\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n22\"><span class=\"nrp-notes-n\">22<\/span><span>Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r22\" aria-label=\"Back to the first call of note 22\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n28\"><span class=\"nrp-notes-n\">28<\/span><span>UNVERIFIED, not opened: European Commission (ed.), Proposal for a Biotech Act, COM(2025) 1022, 16 December 2025, taken from law firm and regulator summaries; the Commission page was not retrieved. European Commission, Brussels. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r28\" aria-label=\"Back to the first call of note 28\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n20\"><span class=\"nrp-notes-n\">20<\/span><span>Secretariat of the Convention on Biological Diversity (ed.), Synthetic biology (programme page; decisions X\/13 to 16\/21; AHTEG; <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-c1\" data-tc=\"NRS-C1 horizon-scanning\" data-tk=\"Nexus risk vocabulary\" data-td=\"Systematic searching for early signs of potentially important developments, threats and opportunities at the margins of current thinking.\" data-ts=\"NRS-C1\" data-tr=\"draft\" data-tg=\"https:\/\/globalriskforum.com\/glossary\/horizon-scanning\/\" data-tgl=\"Global Risks Forum glossary\">horizon scanning<\/a>; thematic action plan). CBD Secretariat, Montreal. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r20\" aria-label=\"Back to the first call of note 20\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n35\"><span class=\"nrp-notes-n\">35<\/span><span>UNVERIFIED, not opened: Cartagena Protocol on Biosafety to the Convention on Biological Diversity, 2000, cited from memory. CBD Secretariat, Montreal. Observation year 2000. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r35\" aria-label=\"Back to the first call of note 35\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n34\"><span class=\"nrp-notes-n\">34<\/span><span>UNVERIFIED, not opened: Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on their Destruction, 1972, cited from memory. United Nations, Geneva. Observation year 1972. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r34\" aria-label=\"Back to the first call of note 34\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n18\"><span class=\"nrp-notes-n\">18<\/span><span>OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r18\" aria-label=\"Back to the first call of note 18\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n29\"><span class=\"nrp-notes-n\">29<\/span><span>UNVERIFIED, not opened: European Parliament (ed.), Legislative train entry for the European Biotech Act II (second act expected in the third quarter of 2026), taken from a search-result summary; the page returned no content. European Parliament, Brussels. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r29\" aria-label=\"Back to the first call of note 29\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n27\"><span class=\"nrp-notes-n\">27<\/span><span>UNVERIFIED, not opened: Congressional Research Service (ed.), report on artificial intelligence and biosecurity risks (reported in July 2026 as unable to determine whether the 2024 framework or the 2025 policy had been revised), taken from a trade news summary. Library of Congress, Washington. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r27\" aria-label=\"Back to the first call of note 27\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n1\"><span class=\"nrp-notes-n\">1<\/span><span>Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r1\" aria-label=\"Back to the first call of note 1\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n3\"><span class=\"nrp-notes-n\">3<\/span><span>Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r3\" aria-label=\"Back to the first call of note 3\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n4\"><span class=\"nrp-notes-n\">4<\/span><span>Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r4\" aria-label=\"Back to the first call of note 4\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n5\"><span class=\"nrp-notes-n\">5<\/span><span>Gibson, D.G. et al., Creation of a bacterial cell controlled by a chemically synthesised genome, Science 329 (5987), 52 to 56, 2010 (record read via Europe PMC: 1.08 million base pair genome). American Association for the Advancement of Science, Washington. Observation year 2010. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r5\" aria-label=\"Back to the first call of note 5\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n6\"><span class=\"nrp-notes-n\">6<\/span><span>Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r6\" aria-label=\"Back to the first call of note 6\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n7\"><span class=\"nrp-notes-n\">7<\/span><span>Watson, J.L. et al., De novo design of protein structure and function with RFdiffusion, Nature 620, 1089 to 1100, 2023 (record read via Europe PMC). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r7\" aria-label=\"Back to the first call of note 7\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n8\"><span class=\"nrp-notes-n\">8<\/span><span>Frangoul, H. et al., Exagamglogene autotemcel for severe sickle cell disease, New England Journal of Medicine 390 (18), 1649 to 1662, 2024 (record read via Europe PMC: 44 treated; 29 of 30 evaluable free of severe crises for 12 months; median follow-up 19.3 months). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r8\" aria-label=\"Back to the first call of note 8\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n10\"><span class=\"nrp-notes-n\">10<\/span><span>Musunuru, K. et al., Patient-specific in vivo gene editing to treat a rare genetic disease, New England Journal of Medicine 392 (22), 2235 to 2243, 2025 (record read via Europe PMC: one infant; two infusions at about 7 and 8 months). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r10\" aria-label=\"Back to the first call of note 10\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n11\"><span class=\"nrp-notes-n\">11<\/span><span>Kyrou, K. et al., A CRISPR-Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes, Nature Biotechnology 36, 1062 to 1066, 2018 (record read via Europe PMC; laboratory cages only). Springer Nature, London. Observation year 2018. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r11\" aria-label=\"Back to the first call of note 11\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n12\"><span class=\"nrp-notes-n\">12<\/span><span>Confronting risks of <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-h101\" data-tc=\"NHS-1 tech.biotech.mirror-life\" data-tk=\"Frontier and exponential technology \u00b7 Biotechnology and synthetic biology\" data-td=\"Creation and escape of organisms built from mirror-image molecules, which could evade immune defences, predators and decay in people, animals and plants and spread unchecked through ecosystems.\" data-ts=\"NRS-H101\" data-tr=\"draft\" data-tx=\"https:\/\/risksindex.com\/hazards\/tech\/\" data-txl=\"Frontier and exponential technology\">mirror life<\/a>, Science 386, 1351 to 1353, 2024 (record read via Europe PMC; the record gives only a one-line abstract calling for broad discussion). American Association for the Advancement of Science, Washington. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r12\" aria-label=\"Back to the first call of note 12\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n13\"><span class=\"nrp-notes-n\">13<\/span><span>Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r13\" aria-label=\"Back to the first call of note 13\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n38\"><span class=\"nrp-notes-n\">38<\/span><span>UNVERIFIED, not opened: Jinek, M. et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, Science 337, 816 to 821, 2012, cited from memory. Observation year 2012. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r38\" aria-label=\"Back to the first call of note 38\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n39\"><span class=\"nrp-notes-n\">39<\/span><span>UNVERIFIED, not opened: Gibson, D.G. et al., Enzymatic assembly of DNA molecules up to several hundred kilobases, Nature Methods 6, 343 to 345, 2009, cited from memory. Observation year 2009. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r39\" aria-label=\"Back to the first call of note 39\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n40\"><span class=\"nrp-notes-n\">40<\/span><span>UNVERIFIED, not opened: Ro, D.-K. et al., Production of the antimalarial drug precursor artemisinic acid in engineered yeast, Nature 440, 940 to 943, 2006, cited from memory. Observation year 2006. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r40\" aria-label=\"Back to the first call of note 40\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n41\"><span class=\"nrp-notes-n\">41<\/span><span>UNVERIFIED, not opened: Elowitz, M.B. and Leibler, S., A synthetic oscillatory network of transcriptional regulators, Nature 403, 335 to 338, 2000, cited from memory. Observation year 2000. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r41\" aria-label=\"Back to the first call of note 41\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n42\"><span class=\"nrp-notes-n\">42<\/span><span>UNVERIFIED, not opened: Gardner, T.S., Cantor, C.R. and Collins, J.J., <a class=\"nx-link\" href=\"https:\/\/nexustandards.com\/cities\/construction-and-real-estate\/\">Construction<\/a> of a genetic toggle switch in Escherichia coli, Nature 403, 339 to 342, 2000, cited from memory. Observation year 2000. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r42\" aria-label=\"Back to the first call of note 42\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n43\"><span class=\"nrp-notes-n\">43<\/span><span>UNVERIFIED, not opened: Richardson, S.M. et al., Design of a synthetic yeast genome, Science 355, 1040 to 1044, 2017, cited from memory. Observation year 2017. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r43\" aria-label=\"Back to the first call of note 43\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n14\"><span class=\"nrp-notes-n\">14<\/span><span>Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r14\" aria-label=\"Back to the first call of note 14\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n19\"><span class=\"nrp-notes-n\">19<\/span><span>OECD (ed.), Synthetic biology, AI and automation: a forward-looking technology assessment, OECD Science, Technology and Industry Policy Papers No. 187, 4 December 2025 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r19\" aria-label=\"Back to the first call of note 19\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n33\"><span class=\"nrp-notes-n\">33<\/span><span>UNVERIFIED, not opened: National Academies of Sciences, Engineering, and Medicine (eds.), Biodefense in the Age of Synthetic Biology, 2018, cited from memory; a fetch returned an unrelated page. National Academies Press, Washington. Observation year 2018. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r33\" aria-label=\"Back to the first call of note 33\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n15\"><span class=\"nrp-notes-n\">15<\/span><span>Federation of American Scientists (ed.), Translating Vision into Action: FAS commentary on the NSCEB final report (commentary page; six pillars; cites over USD 210 billion of US GDP and over 640,000 jobs for the bioeconomy; secondary and advocacy-leaning source). Federation of American Scientists, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r15\" aria-label=\"Back to the first call of note 15\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n23\"><span class=\"nrp-notes-n\">23<\/span><span>BioMADE (ed.), DoD approves USD 87 million for newest bioindustrial manufacturing innovation institute (news page; seven years; the page shows Oct 20 and a 2023 footer, the press release is dated 2020 in search listings). BioMADE, Saint Paul. Observation year 2020. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r23\" aria-label=\"Back to the first call of note 23\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c6-n37\"><span class=\"nrp-notes-n\">37<\/span><span>UNVERIFIED, not opened: McKinsey Global Institute (ed.), The Bio Revolution: Innovations transforming economies, societies, and our lives, May 2020, cited from memory; the fetch returned a service error and no figure is used. McKinsey and Company, New York. Observation year 2020. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c6-r37\" aria-label=\"Back to the first call of note 37\">back<\/a><\/span><\/li><\/ol><\/section><\/div><div class=\"nrp-part\" id=\"nx-nrp-xt-04-part-agenda\"><header class=\"nrp-chap-head\" id=\"nx-nrp-xt-04-c7-top\"><ul class=\"nrp-eyerow\"><li class=\"nf-ui-eyebrow\"><a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/\">Synthetic Biology and Bioengineering 2026<\/a><\/li><li class=\"nf-ui-eyebrow\">Chapter 7<\/li><\/ul><span class=\"nrp-rule\" aria-hidden=\"true\"><\/span><h2 class=\"pp-hero-title\">The 2027 agenda<\/h2><p class=\"nrp-lede\">Eight bounded questions open the 2027 synthetic biology agenda. Each comes from a baseline finding, names the initiative that will carry it and the first output due in the 2027 synthetic biology edition.<\/p><p class=\"nrp-chap-meta\"><span>5 min read<\/span><span>0 figures<\/span><span>6 tables<\/span><span>4 notes<\/span><span>NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE<\/span><\/p><\/header><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c7-s1\" aria-labelledby=\"nx-nrp-xt-04-c7-s1-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c7-s1-h\"><span class=\"nrp-num\">7.1<\/span><span>Questions for the operational series<\/span><\/h2><ol class=\"nrp-rows\"><li><span class=\"nrp-rows-i\">Q-01<\/span><p class=\"nrp-rows-t\">How well do synthesis providers screen orders, and how do practices differ by country?<\/p><p class=\"nrp-rows-m\">INI-XT04-SCR-01 \u00b7 screening coverage; first output: screening practice register.<\/p><\/li><li><span class=\"nrp-rows-i\">Q-02<\/span><p class=\"nrp-rows-t\">What do fermentation and cell-free manufacturing need in energy, water and feedstock at commercial scale?<\/p><p class=\"nrp-rows-m\">INI-XT04-ENE-02 \u00b7 manufacturing footprint; first output: footprint estimates by process.<\/p><\/li><li><span class=\"nrp-rows-i\">Q-03<\/span><p class=\"nrp-rows-t\">Which DNA synthesis, instrument and reagent steps are single points of failure?<\/p><p class=\"nrp-rows-m\">INI-XT04-SUP-03 \u00b7 DNA supply chain; first output: dependence map.<\/p><\/li><li><span class=\"nrp-rows-i\">Q-04<\/span><p class=\"nrp-rows-t\">How much biofoundry and bioindustrial capacity exists, and where?<\/p><p class=\"nrp-rows-m\">INI-XT04-CAP-04 \u00b7 manufacturing capacity; first output: capacity table.<\/p><\/li><li><span class=\"nrp-rows-i\">Q-05<\/span><p class=\"nrp-rows-t\">How can public and private investment in synthetic biology be counted on one basis?<\/p><p class=\"nrp-rows-m\">INI-XT04-FIN-05 \u00b7 investment on a common basis; first output: investment table.<\/p><\/li><li><span class=\"nrp-rows-i\">Q-06<\/span><p class=\"nrp-rows-t\">Which national frameworks set screening or oversight rules, and how do they differ?<\/p><p class=\"nrp-rows-m\">To be admitted in 2027; first output: framework overlay.<\/p><\/li><li><span class=\"nrp-rows-i\">Q-07<\/span><p class=\"nrp-rows-t\">What workforce exists for design, biofoundry operation and biosafety oversight?<\/p><p class=\"nrp-rows-m\">To be admitted in 2027; first output: scoping note.<\/p><\/li><li><span class=\"nrp-rows-i\">Q-08<\/span><p class=\"nrp-rows-t\">Which readiness capabilities have been tested in real incidents, and which are only planned?<\/p><p class=\"nrp-rows-m\">Readiness capability register; first output: rung evidence for 15 functions.<\/p><\/li><\/ol><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c7-s2\" aria-labelledby=\"nx-nrp-xt-04-c7-s2-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c7-s2-h\"><span class=\"nrp-num\">7.2<\/span><span>Portfolio proposed for the Q1 2027 alignment<\/span><\/h2><p class=\"nrp-stand\">Five initiatives and one Universe mission candidate are proposed for the 2027 synthetic biology portfolio. They are programme objects: no partner, funder or member is attached to them in this edition.<\/p><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c7-tab1\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 7.1<\/span><span class=\"nrp-tbl-t\">Objects proposed for the first operational quarter<\/span><\/caption><thead><tr><th scope=\"col\">ID<\/th><th scope=\"col\">Object<\/th><th scope=\"col\">Kind<\/th><th scope=\"col\">Question<\/th><th scope=\"col\">State<\/th><\/tr><\/thead><tbody><tr><td><span class=\"nrp-mono\">INI-XT04-SCR-01<\/span><\/td><td>Screening coverage<\/td><td>Initiative<\/td><td>Q-01<\/td><td>PROPOSED<\/td><\/tr><tr><td><span class=\"nrp-mono\">INI-XT04-ENE-02<\/span><\/td><td>Manufacturing footprint<\/td><td>Initiative<\/td><td>Q-02<\/td><td>PROPOSED<\/td><\/tr><tr><td><span class=\"nrp-mono\">INI-XT04-SUP-03<\/span><\/td><td>DNA supply chain<\/td><td>Initiative<\/td><td>Q-03<\/td><td>PROPOSED<\/td><\/tr><tr><td><span class=\"nrp-mono\">INI-XT04-CAP-04<\/span><\/td><td>Manufacturing capacity<\/td><td>Initiative<\/td><td>Q-04<\/td><td>PROPOSED<\/td><\/tr><tr><td><span class=\"nrp-mono\">INI-XT04-FIN-05<\/span><\/td><td>Investment on a common basis<\/td><td>Initiative<\/td><td>Q-05<\/td><td>PROPOSED<\/td><\/tr><tr><td><span class=\"nrp-mono\">MSN-XT04-2027-01<\/span><\/td><td>Design and screening Universe mission<\/td><td>Mission<\/td><td>Q-01<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"caution\" aria-hidden=\"true\"><\/span>Candidate<\/span><\/td><\/tr><\/tbody><\/table><\/div><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c7-s3\" aria-labelledby=\"nx-nrp-xt-04-c7-s3-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c7-s3-h\"><span class=\"nrp-num\">7.3<\/span><span>The pathway<\/span><\/h2><p class=\"nrp-stand\">The synthetic biology edition reads national readiness chapters, the coupled sector reports on health, food and biosecurity, and the global edition through one governed evidence graph. At baseline the federation is designed; the global energy, health and food editions are drafted. This page states what exists today and what comes next.<\/p><ol class=\"nrp-rows\"><li><span class=\"nrp-rows-i\">01<\/span><p class=\"nrp-rows-t\">National readiness chapters<\/p><p class=\"nrp-rows-x\">biotechnology and biosecurity readiness in each national edition<\/p><p class=\"nrp-rows-m\">IN PREPARATION \u00b7 national baselines<\/p><\/li><li><span class=\"nrp-rows-i\">02<\/span><p class=\"nrp-rows-t\">Sector couplings<\/p><p class=\"nrp-rows-x\">GS-03 food \u00b7 GS-04 health \u00b7 XT-05 genomics \u00b7 SR-08 biosecurity<\/p><p class=\"nrp-rows-m\">GS-04 DRAFTED \u00b7 sector baselines<\/p><\/li><li><span class=\"nrp-rows-i\">03<\/span><p class=\"nrp-rows-t\">Technology system model<\/p><p class=\"nrp-rows-x\">platforms, DNA supply, manufacturing, workforce, governance<\/p><p class=\"nrp-rows-m\">v0 SPECIFIED \u00b7 v1 with federation evidence<\/p><\/li><li><span class=\"nrp-rows-i\">04<\/span><p class=\"nrp-rows-t\">Strategic links<\/p><p class=\"nrp-rows-x\">SR-08 health security \u00b7 SR-13 strategic technology<\/p><p class=\"nrp-rows-m\">PLANNED \u00b7 strategic baselines<\/p><\/li><li><span class=\"nrp-rows-i\">05<\/span><p class=\"nrp-rows-t\">Universe<\/p><p class=\"nrp-rows-x\">annual proving environment<\/p><p class=\"nrp-rows-m\">CANDIDATE MISSION \u00b7 mandate in 2027<\/p><\/li><li><span class=\"nrp-rows-i\">06<\/span><p class=\"nrp-rows-t\">XT-04 report<\/p><p class=\"nrp-rows-x\">this series<\/p><p class=\"nrp-rows-m\">BASELINE DRAFT \u00b7 2027 annual edition<\/p><\/li><li><span class=\"nrp-rows-i\">07<\/span><p class=\"nrp-rows-t\">Evidence and correction<\/p><p class=\"nrp-rows-x\">one graph, many projections<\/p><p class=\"nrp-rows-m\">OPEN \u00b7 first correction cycle in 2027<\/p><\/li><\/ol><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c7-s4\" aria-labelledby=\"nx-nrp-xt-04-c7-s4-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c7-s4-h\"><span class=\"nrp-num\">7.4<\/span><span>Universe 2027: evidence pack for the synthetic biology candidate mission<\/span><\/h2><ol class=\"nrp-rows\"><li><span class=\"nrp-rows-i\">01<\/span><p class=\"nrp-rows-x\">Mandate<\/p><\/li><li><span class=\"nrp-rows-i\">02<\/span><p class=\"nrp-rows-x\">Core Build \u00b7 1 month<\/p><\/li><li><span class=\"nrp-rows-i\">03<\/span><p class=\"nrp-rows-x\">Action \u00b7 1 week<\/p><\/li><li><span class=\"nrp-rows-i\">04<\/span><p class=\"nrp-rows-x\">Evidence seal<\/p><\/li><li><span class=\"nrp-rows-i\">05<\/span><p class=\"nrp-rows-x\">Portfolio correction<\/p><\/li><li><span class=\"nrp-rows-i\">06<\/span><p class=\"nrp-rows-x\">Next mandate<\/p><\/li><\/ol><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c7-tab2\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 7.2<\/span><span class=\"nrp-tbl-t\">Universe 2027: evidence pack for the synthetic biology candidate mission<\/span><\/caption><thead><tr><th scope=\"col\">Item<\/th><th scope=\"col\">Record<\/th><th scope=\"col\">State<\/th><th scope=\"col\">Timing<\/th><\/tr><\/thead><tbody><tr><td>F1<\/td><td>Annual mandate record<\/td><td>PLANNED<\/td><td>after the Q2 2027 alignment<\/td><\/tr><tr><td>F2<\/td><td>Core Build record<\/td><td>PLANNED<\/td><td>one month before the exercise<\/td><\/tr><tr><td>F3<\/td><td>Exercise evidence<\/td><td>PLANNED<\/td><td>during the Action week<\/td><\/tr><tr><td>F4<\/td><td>Decision packets<\/td><td>PLANNED<\/td><td>exercise state only<\/td><\/tr><tr><td>F5<\/td><td>Proof receipts<\/td><td>PLANNED<\/td><td>scoped to each recorded check<\/td><\/tr><tr><td>F6<\/td><td>After-action report<\/td><td>PLANNED<\/td><td>within one quarter<\/td><\/tr><tr><td>F7<\/td><td>Upgrade docket<\/td><td>PLANNED<\/td><td>routed to the Portfolio<\/td><\/tr><tr><td>F8<\/td><td>Portfolio renewal<\/td><td>PLANNED<\/td><td>2027 global annual edition<\/td><\/tr><tr><td>F9<\/td><td>Public synthesis<\/td><td>PLANNED<\/td><td>public-safe extracts only<\/td><\/tr><\/tbody><\/table><\/div><h3 class=\"nrp-h3\">Mission<\/h3><dl class=\"nrp-dl\"><dt>ID<\/dt><dd>MSN-XT04-2027-01 \u00b7 Design and screening Universe mission<\/dd><dt>Role spine<\/dt><dd>Leadership sponsor \u00b7 Institutional anchor \u00b7 Mission lead: drawn from national pathways<\/dd><dt>Receiving actors<\/dt><dd>to be identified with the mandate<\/dd><\/dl><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">boundary<\/p><p>Simulation success is not deployment approval; demonstration is not certification; finance readiness is not financing secured.<\/p><\/aside><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c7-s5\" aria-labelledby=\"nx-nrp-xt-04-c7-s5-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c7-s5-h\"><span class=\"nrp-num\">7.5<\/span><span>Handoffs and routing<\/span><\/h2><p class=\"nrp-stand\">Where the baseline\u2019s findings go next. A handoff routes a finding for awareness, review or work; it transfers no authority.<\/p><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c7-tab3\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 7.3<\/span><span class=\"nrp-tbl-t\">Handoffs and routing<\/span><\/caption><thead><tr><th scope=\"col\">Finding<\/th><th scope=\"col\">Routed to<\/th><th scope=\"col\">Purpose<\/th><th scope=\"col\">Class<\/th><\/tr><\/thead><tbody><tr><td>BLD-001 \u00b7 recoded genomes<\/td><td>INI-XT04-CAP-04<\/td><td>manufacturing capacity<\/td><td>PUBLIC<\/td><\/tr><tr><td>CLN-004 \u00b7 engineered therapies<\/td><td>INI-XT04-FIN-05<\/td><td>investment on a common basis<\/td><td>PUBLIC<\/td><\/tr><tr><td>SEC-005 \u00b7 screening gaps<\/td><td>INI-XT04-SCR-01<\/td><td>screening coverage<\/td><td>PUBLIC<\/td><\/tr><tr><td>GOV-007 \u00b7 US framework<\/td><td>regional consortia<\/td><td>framework overlay<\/td><td>PUBLIC<\/td><\/tr><tr><td>GOV-009 \u00b7 EU proposal<\/td><td>regional consortia<\/td><td>framework overlay<\/td><td>PUBLIC<\/td><\/tr><tr><td>GOV-010 \u00b7 OECD and CBD<\/td><td>INI-XT04-SUP-03<\/td><td>DNA supply chain<\/td><td>PUBLIC<\/td><\/tr><tr><td>FIN-011 \u00b7 company filings<\/td><td>INI-XT04-ENE-02 \u00b7 key F review<\/td><td>manufacturing footprint<\/td><td>PUBLIC<\/td><\/tr><tr><td>SYS-012 \u00b7 compound pathway<\/td><td>MSN-XT04-2027-01<\/td><td>Universe candidate<\/td><td>CONSORTIUM<\/td><\/tr><\/tbody><\/table><\/div><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c7-tab4\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 7.4<\/span><span class=\"nrp-tbl-t\">Routing rules by publication class<\/span><\/caption><thead><tr><th scope=\"col\">Class<\/th><th scope=\"col\">Where it goes<\/th><th scope=\"col\">Who can see it<\/th><\/tr><\/thead><tbody><tr><td>PUBLIC<\/td><td>the published edition and its evidence bundle<\/td><td>anyone<\/td><\/tr><tr><td>CONSORTIUM<\/td><td>governed rooms of the federation<\/td><td>consortium members under agreement<\/td><\/tr><tr><td>CONTROLLED<\/td><td>need-to-know channels<\/td><td>named competent actors only<\/td><\/tr><\/tbody><\/table><\/div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">CODES ARE NOT JOINS<\/p><p>Series codes in this edition (XT-04 and its relatives) are Reports codes. Codes in other indices can look alike. This edition makes no join on a code alone: a join needs a registry record that names both subjects.<\/p><\/aside><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">boundary<\/p><p>Handoffs carry findings to Nexus programme objects and steward reviews. States and organisations receive public editions as published; nothing here instructs them.<\/p><\/aside><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c7-s6\" aria-labelledby=\"nx-nrp-xt-04-c7-s6-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c7-s6-h\"><span class=\"nrp-num\">7.6<\/span><span>Feeds and signal register<\/span><\/h2><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c7-tab5\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 7.5<\/span><span class=\"nrp-tbl-t\">Feeds watched from 2027<\/span><\/caption><thead><tr><th scope=\"col\">Feed<\/th><th scope=\"col\">Producer<\/th><th scope=\"col\">Latency<\/th><th scope=\"col\">Feeds into<\/th><\/tr><\/thead><tbody><tr><td>Journals and preprint servers on genome writing and design<\/td><td>peer review and preprints<\/td><td>continuous<\/td><td>BLD-001<\/td><\/tr><tr><td>Regulator announcements on engineered therapies<\/td><td>US Food and Drug Administration<\/td><td>per event<\/td><td>CLN-004<\/td><\/tr><tr><td>Screening and dual-use policy pages<\/td><td>agencies and industry consortia<\/td><td>per release<\/td><td>SEC-005<\/td><\/tr><tr><td>EU Biotech Act pages<\/td><td>European Commission<\/td><td>per release<\/td><td>GOV-009<\/td><\/tr><tr><td>OECD science and technology policy papers<\/td><td>OECD<\/td><td>per release<\/td><td>GOV-010<\/td><\/tr><tr><td>Company earnings releases<\/td><td>Twist Bioscience, Ginkgo Bioworks<\/td><td>quarterly<\/td><td>FIN-011<\/td><\/tr><tr><td>CBD synthetic biology page<\/td><td>CBD secretariat<\/td><td>per meeting<\/td><td>GOV-010<\/td><\/tr><\/tbody><\/table><\/div><h3 class=\"nrp-h3\">Escalation routes<\/h3><ul class=\"nrp-chips\"><li class=\"nf-ui-chip\">none \u00b7 keep monitoring<\/li><li class=\"nf-ui-chip\">research question<\/li><li class=\"nf-ui-chip\">project<\/li><li class=\"nf-ui-chip\">risk object<\/li><li class=\"nf-ui-chip\">annual publication<\/li><li class=\"nf-ui-chip\">signal report<\/li><\/ul><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c7-tab6\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 7.6<\/span><span class=\"nrp-tbl-t\">Signals at baseline<\/span><\/caption><thead><tr><th scope=\"col\">ID<\/th><th scope=\"col\">Signal<\/th><th scope=\"col\">Corroboration<\/th><th scope=\"col\">Systems<\/th><th scope=\"col\">Route<\/th><\/tr><\/thead><tbody><tr><td>SIG-XT04-001<\/td><td>A 57-codon genetic code was reported in 2025<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c7-n1\" id=\"nx-nrp-xt-04-c7-r1\" aria-label=\"Note 1\">1<\/a><\/sup><\/td><td>CORROBORATED<\/td><td>BLD<\/td><td>research question Q-05<\/td><\/tr><tr><td>SIG-XT04-002<\/td><td>Screening tools missed redesigned sequences in a 2025 study<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c7-n13\" id=\"nx-nrp-xt-04-c7-r13\" aria-label=\"Note 13\">13<\/a><\/sup><\/td><td>PARTIAL<\/td><td>SEC \u00b7 DAT<\/td><td>research question Q-01<\/td><\/tr><tr><td>SIG-XT04-003<\/td><td>No public replacement for the US framework was found<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c7-n26\" id=\"nx-nrp-xt-04-c7-r26\" aria-label=\"Note 26\">26<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c7-n27\" id=\"nx-nrp-xt-04-c7-r27\" aria-label=\"Note 27\">27<\/a><\/sup><\/td><td>PARTIAL<\/td><td>GOV<\/td><td>research question Q-06<\/td><\/tr><\/tbody><\/table><\/div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">boundary<\/p><p>A signal is not a warning. Signal records never substitute for official alerting or early-warning authorities, and they bypass no publication control.<\/p><\/aside><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c7-notes\" aria-labelledby=\"nx-nrp-xt-04-c7-notes-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c7-notes-h\"><span>Notes<\/span><\/h2><p class=\"nrp-note\">Numbers are the edition&#8217;s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. <a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/references\/\">Annex C, references<\/a><\/p><ol class=\"nrp-notes\"><li id=\"nx-nrp-xt-04-c7-n1\"><span class=\"nrp-notes-n\">1<\/span><span>Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c7-r1\" aria-label=\"Back to the first call of note 1\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c7-n13\"><span class=\"nrp-notes-n\">13<\/span><span>Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c7-r13\" aria-label=\"Back to the first call of note 13\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c7-n26\"><span class=\"nrp-notes-n\">26<\/span><span>UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c7-r26\" aria-label=\"Back to the first call of note 26\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c7-n27\"><span class=\"nrp-notes-n\">27<\/span><span>UNVERIFIED, not opened: Congressional Research Service (ed.), report on artificial intelligence and biosecurity risks (reported in July 2026 as unable to determine whether the 2024 framework or the 2025 policy had been revised), taken from a trade news summary. Library of Congress, Washington. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c7-r27\" aria-label=\"Back to the first call of note 27\">back<\/a><\/span><\/li><\/ol><\/section><\/div><div class=\"nrp-part\" id=\"nx-nrp-xt-04-part-systems-in-depth\"><header class=\"nrp-chap-head\" id=\"nx-nrp-xt-04-c8-top\"><ul class=\"nrp-eyerow\"><li class=\"nf-ui-eyebrow\"><a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/\">Synthetic Biology and Bioengineering 2026<\/a><\/li><li class=\"nf-ui-eyebrow\">Chapter 8<\/li><\/ul><span class=\"nrp-rule\" aria-hidden=\"true\"><\/span><h2 class=\"pp-hero-title\">Systems in depth<\/h2><p class=\"nrp-lede\">One section per system: its state at evidence close, its exposures and what the operational series will watch.<\/p><p class=\"nrp-chap-meta\"><span>10 min read<\/span><span>0 figures<\/span><span>5 tables<\/span><span>25 notes<\/span><span>NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE<\/span><\/p><\/header><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c8-s1\" aria-labelledby=\"nx-nrp-xt-04-c8-s1-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c8-s1-h\"><span class=\"nrp-num\">8.1<\/span><span>Genome, circuit and protein design platforms<\/span><\/h2><p class=\"nrp-stand\">Biological design now spans whole genomes, genetic circuits and designed proteins. Evidence is strongest where peer review exists and weakest for industrial performance.<\/p><div class=\"pp-cells nrp-cells-3\"><div class=\"nrp-cell\"><span class=\"pp-metric\">57<\/span><span class=\"nrp-cell-u\">codons<\/span><p>Syn57 genetic code<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n2\" id=\"nx-nrp-xt-04-c8-r2\" aria-label=\"Note 2\">2<\/a><\/sup><\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">60<\/span><span class=\"nrp-cell-u\">circuits<\/span><p>built by one design tool, 2016<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n6\" id=\"nx-nrp-xt-04-c8-r6\" aria-label=\"Note 6\">6<\/a><\/sup><\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">6.5<\/span><span class=\"nrp-cell-u\">chromosomes<\/span><p>synthetic yeast in one strain<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n4\" id=\"nx-nrp-xt-04-c8-r4\" aria-label=\"Note 4\">4<\/a><\/sup><\/p><\/div><\/div><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c8-tab1\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 8.1<\/span><span class=\"nrp-tbl-t\">State at baseline<\/span><\/caption><thead><tr><th scope=\"col\">Component<\/th><th scope=\"col\">State<\/th><th scope=\"col\">Evidence<\/th><th scope=\"col\">Status<\/th><\/tr><\/thead><tbody><tr><td>Recoded bacterial genomes<\/td><td>a 57-codon code reported in 2025; 61 codons in 2019<\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n1\" id=\"nx-nrp-xt-04-c8-r1\" aria-label=\"Note 1\">1<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n2\" aria-label=\"Note 2\">2<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n3\" id=\"nx-nrp-xt-04-c8-r3\" aria-label=\"Note 3\">3<\/a><\/sup><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><\/tr><tr><td>Synthetic yeast<\/td><td>six and a half chromosomes combined in one strain<\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n4\" aria-label=\"Note 4\">4<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n43\" id=\"nx-nrp-xt-04-c8-r43\" aria-label=\"Note 43\">43<\/a><\/sup><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><\/tr><tr><td>Circuit design software<\/td><td>45 of 60 circuits worked in every output state<\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n6\" aria-label=\"Note 6\">6<\/a><\/sup><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><\/tr><tr><td>Protein design software<\/td><td>generative binder design tested by structure<\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n7\" id=\"nx-nrp-xt-04-c8-r7\" aria-label=\"Note 7\">7<\/a><\/sup><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><\/tr><\/tbody><\/table><\/div><div class=\"nrp-split\"><div><h3 class=\"nrp-h3\">Couplings<\/h3><ul class=\"nrp-list\"><li>AIC \u2192 BIO design tools<\/li><li>DAT \u2192 BIO sequence data<\/li><li>FIN \u2192 BIO funding<\/li><\/ul><\/div><div><h3 class=\"nrp-h3\">Evidence to bind in 2027<\/h3><ul class=\"nrp-list\"><li>industrial performance of engineered strains<\/li><li>cost of genome synthesis<\/li><\/ul><\/div><\/div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">WHAT TO WATCH<\/p><p>Replication and viral-resistance tests; completion of the synthetic yeast genome; new design benchmarks.<\/p><\/aside><h3 class=\"nrp-h3\">Related editions<\/h3><ul class=\"nrp-chips\"><li class=\"nf-ui-chip\">GLB Global Systems<\/li><li class=\"nf-ui-chip\">GS-04 Health and One Health<\/li><li class=\"nf-ui-chip\">GS-03 Food and Agrifood Systems<\/li><li class=\"nf-ui-chip\">XT-05 Genomics and Gene Editing<\/li><li class=\"nf-ui-chip\">SR-08 Health Security, One Health and Biosecurity<\/li><li class=\"nf-ui-chip\">XT-01 Artificial Intelligence and Agentic Systems<\/li><\/ul><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">boundary<\/p><p>This chapter describes published results. It endorses no laboratory or company and forecasts no capability date.<\/p><\/aside><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c8-s2\" aria-labelledby=\"nx-nrp-xt-04-c8-s2-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c8-s2-h\"><span class=\"nrp-num\">8.2<\/span><span>Energy, water and feedstock for biomanufacturing<\/span><\/h2><p class=\"nrp-stand\">Fermentation and cell-free production need energy, process water and sugar or other feedstock. No source read counts them on a common basis.<\/p><div class=\"pp-cells nrp-cells-3\"><div class=\"nrp-cell\"><span class=\"pp-metric\">0<\/span><span class=\"nrp-cell-u\">figures<\/span><p>bound for energy, water and feedstock in this edition<\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">25<\/span><span class=\"nrp-cell-u\">awards<\/span><p>US planning awards for bioindustrial plants, 2024<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n24\" id=\"nx-nrp-xt-04-c8-r24\" aria-label=\"Note 24\">24<\/a><\/sup><\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">87<\/span><span class=\"nrp-cell-u\">USD million<\/span><p>US institute award over seven years<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n23\" id=\"nx-nrp-xt-04-c8-r23\" aria-label=\"Note 23\">23<\/a><\/sup><\/p><\/div><\/div><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c8-tab2\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 8.2<\/span><span class=\"nrp-tbl-t\">State at baseline<\/span><\/caption><thead><tr><th scope=\"col\">Component<\/th><th scope=\"col\">State<\/th><th scope=\"col\">Evidence<\/th><th scope=\"col\">Status<\/th><\/tr><\/thead><tbody><tr><td>Process energy<\/td><td>not published on a common basis; no figure used<\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n24\" aria-label=\"Note 24\">24<\/a><\/sup><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Expert input<\/span><\/td><\/tr><tr><td>Process water<\/td><td>not published on a common basis; no figure used<\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n24\" aria-label=\"Note 24\">24<\/a><\/sup><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Expert input<\/span><\/td><\/tr><tr><td>Feedstock<\/td><td>demand not bound; economy-level reports not opened<\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n37\" id=\"nx-nrp-xt-04-c8-r37\" aria-label=\"Note 37\">37<\/a><\/sup><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Expert input<\/span><\/td><\/tr><tr><td>Siting and planning<\/td><td>US awards fund plant planning, not construction<\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n24\" aria-label=\"Note 24\">24<\/a><\/sup><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><\/tr><\/tbody><\/table><\/div><div class=\"nrp-split\"><div><h3 class=\"nrp-h3\">Couplings<\/h3><ul class=\"nrp-list\"><li>ENE \u2194 BIO process energy<\/li><li>WAT \u2192 BIO process water<\/li><li>FOO \u2192 BIO feedstock<\/li><\/ul><\/div><div><h3 class=\"nrp-h3\">Evidence to bind in 2027<\/h3><ul class=\"nrp-list\"><li>energy, water and feedstock per tonne of product<\/li><li>plant counts and utilisation<\/li><\/ul><\/div><\/div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">WHAT TO WATCH<\/p><p>Life-cycle studies; plant announcements; programme follow-on awards.<\/p><\/aside><h3 class=\"nrp-h3\">Related editions<\/h3><ul class=\"nrp-chips\"><li class=\"nf-ui-chip\">GLB Global Systems<\/li><li class=\"nf-ui-chip\">GS-04 Health and One Health<\/li><li class=\"nf-ui-chip\">GS-03 Food and Agrifood Systems<\/li><li class=\"nf-ui-chip\">XT-05 Genomics and Gene Editing<\/li><li class=\"nf-ui-chip\">SR-08 Health Security, One Health and Biosecurity<\/li><li class=\"nf-ui-chip\">XT-01 Artificial Intelligence and Agentic Systems<\/li><\/ul><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">boundary<\/p><p>This chapter describes physical dependencies. It assesses no company or facility.<\/p><\/aside><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c8-s3\" aria-labelledby=\"nx-nrp-xt-04-c8-s3-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c8-s3-h\"><span class=\"nrp-num\">8.3<\/span><span>DNA, instruments and manufacturing capacity<\/span><\/h2><p class=\"nrp-stand\">The build base starts with synthesised DNA, instruments and reagents and ends in pilot and commercial plants. Public sources count programmes more than capacity.<\/p><div class=\"pp-cells nrp-cells-3\"><div class=\"nrp-cell\"><span class=\"pp-metric\">332.8<\/span><span class=\"nrp-cell-u\">USD million<\/span><p>Twist Bioscience revenue, nine months to 30 June 2026<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n16\" id=\"nx-nrp-xt-04-c8-r16\" aria-label=\"Note 16\">16<\/a><\/sup><\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">48<\/span><span class=\"nrp-cell-u\">%<\/span><p>share of Twist third-quarter revenue from DNA synthesis and protein solutions, derived<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n16\" aria-label=\"Note 16\">16<\/a><\/sup><\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">42<\/span><span class=\"nrp-cell-u\">USD million<\/span><p>US planning awards to September 2024<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n24\" aria-label=\"Note 24\">24<\/a><\/sup><\/p><\/div><\/div><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c8-tab3\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 8.3<\/span><span class=\"nrp-tbl-t\">State at baseline<\/span><\/caption><thead><tr><th scope=\"col\">Component<\/th><th scope=\"col\">State<\/th><th scope=\"col\">Evidence<\/th><th scope=\"col\">Status<\/th><\/tr><\/thead><tbody><tr><td>DNA synthesis<\/td><td>one provider reports USD 56.6 million for the segment in one quarter<\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n16\" aria-label=\"Note 16\">16<\/a><\/sup><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><\/tr><tr><td>Instruments and reagents<\/td><td>dependence not documented in the sources read<\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n36\" id=\"nx-nrp-xt-04-c8-r36\" aria-label=\"Note 36\">36<\/a><\/sup><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Expert input<\/span><\/td><\/tr><tr><td>Institute<\/td><td>USD 87 million over seven years for a manufacturing institute<\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n23\" aria-label=\"Note 23\">23<\/a><\/sup><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><\/tr><tr><td>Plant capacity<\/td><td>not counted in the sources read<\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n24\" aria-label=\"Note 24\">24<\/a><\/sup><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Expert input<\/span><\/td><\/tr><\/tbody><\/table><\/div><div class=\"nrp-split\"><div><h3 class=\"nrp-h3\">Couplings<\/h3><ul class=\"nrp-list\"><li>MIN \u2192 BIO reagents<\/li><li>TRD \u2192 BIO export controls<\/li><li>FIN \u2192 INF plants<\/li><\/ul><\/div><div><h3 class=\"nrp-h3\">Evidence to bind in 2027<\/h3><ul class=\"nrp-list\"><li>synthesis capacity by provider and country<\/li><li>instrument and reagent dependence<\/li><\/ul><\/div><\/div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">WHAT TO WATCH<\/p><p>Company filings; programme awards; gene synthesis standards.<\/p><\/aside><h3 class=\"nrp-h3\">Related editions<\/h3><ul class=\"nrp-chips\"><li class=\"nf-ui-chip\">GLB Global Systems<\/li><li class=\"nf-ui-chip\">GS-04 Health and One Health<\/li><li class=\"nf-ui-chip\">GS-03 Food and Agrifood Systems<\/li><li class=\"nf-ui-chip\">XT-05 Genomics and Gene Editing<\/li><li class=\"nf-ui-chip\">SR-08 Health Security, One Health and Biosecurity<\/li><li class=\"nf-ui-chip\">XT-01 Artificial Intelligence and Agentic Systems<\/li><\/ul><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">boundary<\/p><p>This chapter describes supply dependencies in public sources. It assesses no company, state or export-control decision.<\/p><\/aside><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c8-s4\" aria-labelledby=\"nx-nrp-xt-04-c8-s4-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c8-s4-h\"><span class=\"nrp-num\">8.4<\/span><span>Economy, investment and workforce<\/span><\/h2><p class=\"nrp-stand\">Company results are mixed and the sector has no common investment series. Workforce numbers are the thinnest part of the evidence.<\/p><div class=\"pp-cells nrp-cells-3\"><div class=\"nrp-cell\"><span class=\"pp-metric\">170.2<\/span><span class=\"nrp-cell-u\">USD million<\/span><p>Ginkgo Bioworks revenue, 2025<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n17\" id=\"nx-nrp-xt-04-c8-r17\" aria-label=\"Note 17\">17<\/a><\/sup><\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">227.0<\/span><span class=\"nrp-cell-u\">USD million<\/span><p>Ginkgo Bioworks revenue, 2024<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n17\" aria-label=\"Note 17\">17<\/a><\/sup><\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">15<\/span><span class=\"nrp-cell-u\">USD billion<\/span><p>minimum funding recommended by a US commission<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n14\" id=\"nx-nrp-xt-04-c8-r14\" aria-label=\"Note 14\">14<\/a><\/sup><\/p><\/div><\/div><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c8-tab4\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 8.4<\/span><span class=\"nrp-tbl-t\">State at baseline<\/span><\/caption><thead><tr><th scope=\"col\">Component<\/th><th scope=\"col\">State<\/th><th scope=\"col\">Evidence<\/th><th scope=\"col\">Status<\/th><\/tr><\/thead><tbody><tr><td>Company revenue<\/td><td>Ginkgo fell about 25% in 2025; Twist guided to USD 456 to 457 million for fiscal 2026<\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n16\" aria-label=\"Note 16\">16<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n17\" aria-label=\"Note 17\">17<\/a><\/sup><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><\/tr><tr><td>Public programmes<\/td><td>US commission recommends at least USD 15 billion over five years; a recommendation<\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n14\" aria-label=\"Note 14\">14<\/a><\/sup><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><\/tr><tr><td>Bioeconomy size<\/td><td>commentary cites over USD 210 billion of US GDP; secondary figure<\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n15\" id=\"nx-nrp-xt-04-c8-r15\" aria-label=\"Note 15\">15<\/a><\/sup><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><\/tr><tr><td>Workforce<\/td><td>skills gaps reported in policy; no figure bound<\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n14\" aria-label=\"Note 14\">14<\/a><\/sup><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Expert input<\/span><\/td><\/tr><\/tbody><\/table><\/div><div class=\"nrp-split\"><div><h3 class=\"nrp-h3\">Couplings<\/h3><ul class=\"nrp-list\"><li>FIN \u2192 BIO scale-up<\/li><li>HLT \u2192 BIO clinical demand<\/li><li>FIN \u2192 INF plants<\/li><\/ul><\/div><div><h3 class=\"nrp-h3\">Evidence to bind in 2027<\/h3><ul class=\"nrp-list\"><li>investment on a common basis<\/li><li>workforce size and skills gaps<\/li><\/ul><\/div><\/div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">WHAT TO WATCH<\/p><p>The next earnings releases; national strategy updates; EU second Biotech Act funding provisions.<\/p><\/aside><h3 class=\"nrp-h3\">Related editions<\/h3><ul class=\"nrp-chips\"><li class=\"nf-ui-chip\">GLB Global Systems<\/li><li class=\"nf-ui-chip\">GS-04 Health and One Health<\/li><li class=\"nf-ui-chip\">GS-03 Food and Agrifood Systems<\/li><li class=\"nf-ui-chip\">XT-05 Genomics and Gene Editing<\/li><li class=\"nf-ui-chip\">SR-08 Health Security, One Health and Biosecurity<\/li><li class=\"nf-ui-chip\">XT-01 Artificial Intelligence and Agentic Systems<\/li><\/ul><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">boundary<\/p><p>This chapter describes company and public figures as reported. It gives no investment advice and endorses no company.<\/p><\/aside><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c8-s5\" aria-labelledby=\"nx-nrp-xt-04-c8-s5-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c8-s5-h\"><span class=\"nrp-num\">8.5<\/span><span>Biosecurity and governance watch<\/span><\/h2><p class=\"nrp-stand\">The nearest governance test is whether screening and oversight keep pace with design tools. Frameworks exist, and their status and implementation differ by jurisdiction.<\/p><div class=\"pp-cells nrp-cells-3\"><div class=\"nrp-cell\"><span class=\"pp-metric\">49<\/span><span class=\"nrp-cell-u\">recommendations<\/span><p>US commission report, 2025<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n14\" aria-label=\"Note 14\">14<\/a><\/sup><\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">90<\/span><span class=\"nrp-cell-u\">days<\/span><p>deadline in the 2025 order for a revised screening framework<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n26\" id=\"nx-nrp-xt-04-c8-r26\" aria-label=\"Note 26\">26<\/a><\/sup><\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">2022<\/span><span class=\"nrp-cell-u\">framework<\/span><p>WHO global guidance on dual-use life sciences<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n21\" id=\"nx-nrp-xt-04-c8-r21\" aria-label=\"Note 21\">21<\/a><\/sup><\/p><\/div><\/div><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-c8-tab5\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table 8.5<\/span><span class=\"nrp-tbl-t\">State at baseline<\/span><\/caption><thead><tr><th scope=\"col\">Component<\/th><th scope=\"col\">State<\/th><th scope=\"col\">Evidence<\/th><th scope=\"col\">Status<\/th><\/tr><\/thead><tbody><tr><td>Screening<\/td><td>a 2025 study found tools often missed redesigned sequences; patches helped<\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n13\" id=\"nx-nrp-xt-04-c8-r13\" aria-label=\"Note 13\">13<\/a><\/sup><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><\/tr><tr><td>US framework<\/td><td>2024 framework; 2025 order; current status unclear in sources read<\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n25\" id=\"nx-nrp-xt-04-c8-r25\" aria-label=\"Note 25\">25<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n26\" aria-label=\"Note 26\">26<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n27\" id=\"nx-nrp-xt-04-c8-r27\" aria-label=\"Note 27\">27<\/a><\/sup><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><\/tr><tr><td>EU<\/td><td>Biotech Act proposal of 16 December 2025 with biodefence measures<\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n22\" id=\"nx-nrp-xt-04-c8-r22\" aria-label=\"Note 22\">22<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n28\" id=\"nx-nrp-xt-04-c8-r28\" aria-label=\"Note 28\">28<\/a><\/sup><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><\/tr><tr><td>Global<\/td><td>WHO guidance, CBD decisions, OECD papers, Cartagena Protocol<\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n18\" id=\"nx-nrp-xt-04-c8-r18\" aria-label=\"Note 18\">18<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n20\" id=\"nx-nrp-xt-04-c8-r20\" aria-label=\"Note 20\">20<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n21\" aria-label=\"Note 21\">21<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-c8-n35\" id=\"nx-nrp-xt-04-c8-r35\" aria-label=\"Note 35\">35<\/a><\/sup><\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><\/tr><\/tbody><\/table><\/div><div class=\"nrp-split\"><div><h3 class=\"nrp-h3\">Couplings<\/h3><ul class=\"nrp-list\"><li>DAT \u2192 BIO sequence data<\/li><li>GOV \u2192 SEC screening rules<\/li><li>GOV \u2192 TRD export controls<\/li><\/ul><\/div><div><h3 class=\"nrp-h3\">Evidence to bind in 2027<\/h3><ul class=\"nrp-list\"><li>screening coverage by provider<\/li><li>text of the current US framework<\/li><\/ul><\/div><\/div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">WHAT TO WATCH<\/p><p>A replacement US framework; EU second act; CBD action plan for COP-17; follow-up screening studies.<\/p><\/aside><h3 class=\"nrp-h3\">Related editions<\/h3><ul class=\"nrp-chips\"><li class=\"nf-ui-chip\">GLB Global Systems<\/li><li class=\"nf-ui-chip\">GS-04 Health and One Health<\/li><li class=\"nf-ui-chip\">GS-03 Food and Agrifood Systems<\/li><li class=\"nf-ui-chip\">XT-05 Genomics and Gene Editing<\/li><li class=\"nf-ui-chip\">SR-08 Health Security, One Health and Biosecurity<\/li><li class=\"nf-ui-chip\">XT-01 Artificial Intelligence and Agentic Systems<\/li><\/ul><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">boundary<\/p><p>This chapter describes policy in public sources. It confers no certification on any product or provider and assesses no government or company.<\/p><\/aside><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-c8-notes\" aria-labelledby=\"nx-nrp-xt-04-c8-notes-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-c8-notes-h\"><span>Notes<\/span><\/h2><p class=\"nrp-note\">Numbers are the edition&#8217;s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. <a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/references\/\">Annex C, references<\/a><\/p><ol class=\"nrp-notes\"><li id=\"nx-nrp-xt-04-c8-n2\"><span class=\"nrp-notes-n\">2<\/span><span>MRC Laboratory of Molecular Biology (ed.), Syn57 represents a new chapter in the genetic code of life (news page, 1 August 2025; over 101,000 codons recoded; 64 to 57 codons; genome of about 4 megabases built from 38 fragments of about 100 kilobases). MRC Laboratory of Molecular Biology, Cambridge. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r2\" aria-label=\"Back to the first call of note 2\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n6\"><span class=\"nrp-notes-n\">6<\/span><span>Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r6\" aria-label=\"Back to the first call of note 6\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n4\"><span class=\"nrp-notes-n\">4<\/span><span>Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r4\" aria-label=\"Back to the first call of note 4\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n1\"><span class=\"nrp-notes-n\">1<\/span><span>Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r1\" aria-label=\"Back to the first call of note 1\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n3\"><span class=\"nrp-notes-n\">3<\/span><span>Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r3\" aria-label=\"Back to the first call of note 3\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n43\"><span class=\"nrp-notes-n\">43<\/span><span>UNVERIFIED, not opened: Richardson, S.M. et al., Design of a synthetic yeast genome, Science 355, 1040 to 1044, 2017, cited from memory. Observation year 2017. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r43\" aria-label=\"Back to the first call of note 43\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n7\"><span class=\"nrp-notes-n\">7<\/span><span>Watson, J.L. et al., De novo design of protein structure and function with RFdiffusion, Nature 620, 1089 to 1100, 2023 (record read via Europe PMC). Springer Nature, London. Observation year 2023. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r7\" aria-label=\"Back to the first call of note 7\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n24\"><span class=\"nrp-notes-n\">24<\/span><span>US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r24\" aria-label=\"Back to the first call of note 24\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n23\"><span class=\"nrp-notes-n\">23<\/span><span>BioMADE (ed.), DoD approves USD 87 million for newest bioindustrial manufacturing innovation institute (news page; seven years; the page shows Oct 20 and a 2023 footer, the press release is dated 2020 in search listings). BioMADE, Saint Paul. Observation year 2020. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r23\" aria-label=\"Back to the first call of note 23\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n37\"><span class=\"nrp-notes-n\">37<\/span><span>UNVERIFIED, not opened: McKinsey Global Institute (ed.), The Bio Revolution: Innovations transforming economies, societies, and our lives, May 2020, cited from memory; the fetch returned a service error and no figure is used. McKinsey and Company, New York. Observation year 2020. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r37\" aria-label=\"Back to the first call of note 37\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n16\"><span class=\"nrp-notes-n\">16<\/span><span>Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r16\" aria-label=\"Back to the first call of note 16\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n36\"><span class=\"nrp-notes-n\">36<\/span><span>UNVERIFIED, not opened: International Organization for Standardization (ed.), ISO 20688-2, requirements for the production and quality control of synthesised gene fragments, genes and genome-scale constructs, cited from memory. ISO, Geneva. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r36\" aria-label=\"Back to the first call of note 36\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n17\"><span class=\"nrp-notes-n\">17<\/span><span>Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r17\" aria-label=\"Back to the first call of note 17\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n14\"><span class=\"nrp-notes-n\">14<\/span><span>Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r14\" aria-label=\"Back to the first call of note 14\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n15\"><span class=\"nrp-notes-n\">15<\/span><span>Federation of American Scientists (ed.), Translating Vision into Action: FAS commentary on the NSCEB final report (commentary page; six pillars; cites over USD 210 billion of US GDP and over 640,000 jobs for the bioeconomy; secondary and advocacy-leaning source). Federation of American Scientists, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r15\" aria-label=\"Back to the first call of note 15\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n26\"><span class=\"nrp-notes-n\">26<\/span><span>UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r26\" aria-label=\"Back to the first call of note 26\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n21\"><span class=\"nrp-notes-n\">21<\/span><span>World Health Organization (ed.), Global guidance framework for the responsible use of the life sciences: mitigating biorisks and governing <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-c1\" data-tc=\"NRS-C1 dual-use-research\" data-tk=\"Nexus risk vocabulary\" data-td=\"Legitimate research whose knowledge, methods or products could also be misused to cause serious harm.\" data-ts=\"NRS-C1\" data-tr=\"draft\">dual-use research<\/a> (publication page, 13 September 2022). WHO, Geneva. Observation year 2022. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r21\" aria-label=\"Back to the first call of note 21\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n13\"><span class=\"nrp-notes-n\">13<\/span><span>Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r13\" aria-label=\"Back to the first call of note 13\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n25\"><span class=\"nrp-notes-n\">25<\/span><span>UNVERIFIED, not opened: Office of Science and Technology Policy (ed.), Framework for Nucleic Acid Synthesis Screening, April 2024, taken from search-result summaries; a fetch of the page was refused by the fetch tool. OSTP, Washington. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r25\" aria-label=\"Back to the first call of note 25\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n27\"><span class=\"nrp-notes-n\">27<\/span><span>UNVERIFIED, not opened: Congressional Research Service (ed.), report on artificial intelligence and biosecurity risks (reported in July 2026 as unable to determine whether the 2024 framework or the 2025 policy had been revised), taken from a trade news summary. Library of Congress, Washington. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r27\" aria-label=\"Back to the first call of note 27\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n22\"><span class=\"nrp-notes-n\">22<\/span><span>Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r22\" aria-label=\"Back to the first call of note 22\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n28\"><span class=\"nrp-notes-n\">28<\/span><span>UNVERIFIED, not opened: European Commission (ed.), Proposal for a Biotech Act, COM(2025) 1022, 16 December 2025, taken from law firm and regulator summaries; the Commission page was not retrieved. European Commission, Brussels. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r28\" aria-label=\"Back to the first call of note 28\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n18\"><span class=\"nrp-notes-n\">18<\/span><span>OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r18\" aria-label=\"Back to the first call of note 18\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n20\"><span class=\"nrp-notes-n\">20<\/span><span>Secretariat of the Convention on Biological Diversity (ed.), Synthetic biology (programme page; decisions X\/13 to 16\/21; AHTEG; <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-c1\" data-tc=\"NRS-C1 horizon-scanning\" data-tk=\"Nexus risk vocabulary\" data-td=\"Systematic searching for early signs of potentially important developments, threats and opportunities at the margins of current thinking.\" data-ts=\"NRS-C1\" data-tr=\"draft\" data-tg=\"https:\/\/globalriskforum.com\/glossary\/horizon-scanning\/\" data-tgl=\"Global Risks Forum glossary\">horizon scanning<\/a>; thematic action plan). CBD Secretariat, Montreal. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r20\" aria-label=\"Back to the first call of note 20\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-c8-n35\"><span class=\"nrp-notes-n\">35<\/span><span>UNVERIFIED, not opened: Cartagena Protocol on Biosafety to the Convention on Biological Diversity, 2000, cited from memory. CBD Secretariat, Montreal. Observation year 2000. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-c8-r35\" aria-label=\"Back to the first call of note 35\">back<\/a><\/span><\/li><\/ol><\/section><\/div><div class=\"nrp-part\" id=\"nx-nrp-xt-04-part-methodology\"><header class=\"nrp-chap-head\" id=\"nx-nrp-xt-04-ca-top\"><ul class=\"nrp-eyerow\"><li class=\"nf-ui-eyebrow\"><a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/\">Synthetic Biology and Bioengineering 2026<\/a><\/li><li class=\"nf-ui-eyebrow\">Annex A<\/li><\/ul><span class=\"nrp-rule\" aria-hidden=\"true\"><\/span><h2 class=\"pp-hero-title\">Methodology<\/h2><p class=\"nrp-lede\">How the edition was made: methods, the model card, the evidence cut and its age, the acceptance record and the glossary.<\/p><p class=\"nrp-chap-meta\"><span>14 min read<\/span><span>0 figures<\/span><span>13 tables<\/span><span>17 notes<\/span><span>NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE<\/span><\/p><\/header><section class=\"nrp-block\" id=\"nx-nrp-xt-04-ca-s1\" aria-labelledby=\"nx-nrp-xt-04-ca-s1-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-ca-s1-h\"><span class=\"nrp-num\">A.1<\/span><span>Methods<\/span><\/h2><p class=\"nrp-stand\">The global baseline uses published values and four simple derivations. Each is shown in full so that any reader can reproduce it.<\/p><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-ca-tab1\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table A.1<\/span><span class=\"nrp-tbl-t\">Methods<\/span><\/caption><thead><tr><th scope=\"col\">No.<\/th><th scope=\"col\">Derivation<\/th><th scope=\"col\">Calculation<\/th><th scope=\"col\">Result<\/th><\/tr><\/thead><tbody><tr><td>(1)<\/td><td>Fall in codons from the standard code to Syn57<\/td><td>64 minus 57<\/td><td>7 codons<\/td><\/tr><tr><td>(2)<\/td><td>Growth in recoded codons, Syn57 against Syn61 (lower bound)<\/td><td>101,000 \u00f7 18,214<\/td><td>about 5.5 times<\/td><\/tr><tr><td>(3)<\/td><td>Change in Ginkgo Bioworks revenue, 2024 to 2025<\/td><td>(170.155 minus 227.043) \u00f7 227.043<\/td><td>about minus 25%<\/td><\/tr><tr><td>(4)<\/td><td>Share of Twist Bioscience third-quarter revenue from DNA synthesis and protein solutions<\/td><td>56.6 \u00f7 118.4<\/td><td>about 48%<\/td><\/tr><\/tbody><\/table><\/div><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-ca-tab2\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table A.2<\/span><span class=\"nrp-tbl-t\">Coupling strength scale (matrix and model card)<\/span><\/caption><thead><tr><th scope=\"col\">Strength<\/th><th scope=\"col\">Definition<\/th><\/tr><\/thead><tbody><tr><td>STRONG<\/td><td>a disruption in the source system has historically changed the target system\u2019s service or output within one season, in more than one region<\/td><\/tr><tr><td>MODERATE<\/td><td>an effect is documented but buffered or slower<\/td><\/tr><tr><td>WEAK<\/td><td>an effect is plausible but not documented at global scale<\/td><\/tr><\/tbody><\/table><\/div><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-ca-tab3\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table A.3<\/span><span class=\"nrp-tbl-t\">Status grammar<\/span><\/caption><thead><tr><th scope=\"col\">Label<\/th><th scope=\"col\">Rule<\/th><\/tr><\/thead><tbody><tr><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><td>value as issued by its source, with year<\/td><\/tr><tr><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Inferred<\/span><\/td><td>reasoned from cited evidence; never a measurement<\/td><\/tr><tr><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Estimated<\/span><\/td><td>Nexus analytical value with stated method<\/td><\/tr><tr><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"caution\" aria-hidden=\"true\"><\/span>Scenario<\/span><\/td><td>conditional on stated assumptions<\/td><\/tr><tr><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Expert input<\/span><\/td><td>structured editorial judgement awaiting evidence<\/td><\/tr><\/tbody><\/table><\/div><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-ca-s2\" aria-labelledby=\"nx-nrp-xt-04-ca-s2-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-ca-s2-h\"><span class=\"nrp-num\">A.2<\/span><span>Model card, Synthetic biology System Model v0<\/span><\/h2><dl class=\"nrp-dl\"><dt>Model ID<\/dt><dd>MDL-XT04-SYNBIO \u00b7 v0.1<\/dd><dt>Purpose<\/dt><dd>represent synthetic biology as a build capability and manufacturing base coupled to health, food, energy, feedstock, finance, workforce and biosecurity<\/dd><dt>Family<\/dt><dd>graph-based system of <a class=\"nx-link nx-term\" href=\"https:\/\/docs.therisk.global\/organization\/systems\" data-tc=\"Systems\" data-tk=\"Nexus Standards\" data-td=\"The twenty Nexus systems, NXS-CMD to NXS-LAB\">systems<\/a><\/dd><dt>Inputs<\/dt><dd>the cited sources of this edition; no proprietary data<\/dd><dt>Method<\/dt><dd>expert-specified coupling strengths (STRONG \u00b7 MODERATE \u00b7 WEAK) from assessments and analogue events<\/dd><dt>Validation<\/dt><dd>none yet, first validation against federation evidence in 2027<\/dd><dt>Uncertainty<\/dt><dd>qualitative; strengths are hypotheses, not measurements<\/dd><dt>Domain of validity<\/dt><dd>global scale; not for asset-, site- or country-level use<\/dd><dt>Reproducibility<\/dt><dd>strength table and sources published in this edition<\/dd><\/dl><div class=\"pp-cells nrp-cells-3\"><div class=\"nrp-cell\"><span class=\"pp-metric\">20<\/span><span class=\"nrp-cell-u\">couplings<\/span><p>typed in v0<\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">0<\/span><span class=\"nrp-cell-u\">strong<\/span><p>documented within one season<\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">1<\/span><span class=\"nrp-cell-u\">moderate<\/span><p>documented, buffered<\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">19<\/span><span class=\"nrp-cell-u\">weak<\/span><p>plausible, undocumented<\/p><\/div><\/div><div class=\"nrp-split\"><div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">SUITABLE FOR<\/p><p>framing the 2027 agenda; choosing which couplings to measure first; explaining the three readings of synthetic biology as capability, manufacturing base and governance test.<\/p><\/aside><\/div><div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">NOT SUITABLE FOR<\/p><p>quantitative loss estimates, country comparisons or rankings, operational decisions, or any claim about a specific asset.<\/p><\/aside><\/div><\/div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">VERSIONING<\/p><p>Models are immutable by version. A change to any coupling, rule or weight produces v0.2 with its own card and correction note.<\/p><\/aside><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-ca-s3\" aria-labelledby=\"nx-nrp-xt-04-ca-s3-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-ca-s3-h\"><span class=\"nrp-num\">A.3<\/span><span>The baseline evidence cut<\/span><\/h2><p class=\"nrp-stand\">Every Nexus edition is published from a frozen evidence cut. The global baseline cut is documentary: it pins the exact edition of every source cited. Federation cuts begin with the first national Foundry cuts in 2027.<\/p><dl class=\"nrp-dl\"><dt>Cut ID<\/dt><dd>DC-XTECH-SYNBIO-GLOBAL-2026-B0<\/dd><dt>Type<\/dt><dd>baseline documentary cut<\/dd><dt>Resolution policy<\/dt><dd>pinned \u00b7 as of 30 September 2026<\/dd><dt>Sources pinned<\/dt><dd>44 cited sources, each at the edition and access date in the references<\/dd><dt>Model runs<\/dt><dd>none at baseline, analytical values are stated with their method<\/dd><dt>Digest<\/dt><dd>computed at <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-h5\" data-tc=\"NHS-1 atmo.thermal.hard-freeze\" data-tk=\"Atmosphere and weather \u00b7 Thermal extremes\" data-td=\"Air temperature falling well below freezing for hours, killing crops, bursting pipes and stopping water flow.\" data-ts=\"NRS-H5\" data-tr=\"draft\" data-tx=\"https:\/\/risksindex.com\/hazards\/atmo\/\" data-txl=\"Atmosphere and weather\">freeze<\/a> and recorded in the publication record<\/dd><dt>Supersedes<\/dt><dd>nothing, first cut of the series<\/dd><dt>Superseded by<\/dt><dd>the 2027 synthetic biology annual cut<\/dd><\/dl><h3 class=\"nrp-h3\">Lineage<\/h3><ol class=\"nrp-rows\"><li><span class=\"nrp-rows-i\">01<\/span><p class=\"nrp-rows-x\">source edition<\/p><\/li><li><span class=\"nrp-rows-i\">02<\/span><p class=\"nrp-rows-x\">pinned citation<\/p><\/li><li><span class=\"nrp-rows-i\">03<\/span><p class=\"nrp-rows-x\">finding<\/p><\/li><li><span class=\"nrp-rows-i\">04<\/span><p class=\"nrp-rows-x\">page<\/p><\/li><li><span class=\"nrp-rows-i\">05<\/span><p class=\"nrp-rows-x\">publication record<\/p><\/li><\/ol><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-ca-tab4\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table A.4<\/span><span class=\"nrp-tbl-t\">From the baseline cut to the federation cut<\/span><\/caption><thead><tr><th scope=\"col\">Element<\/th><th scope=\"col\">Baseline 2026<\/th><th scope=\"col\">2027 global annual<\/th><\/tr><\/thead><tbody><tr><td>Sources<\/td><td>cited global publications, pinned by edition<\/td><td>national, regional and sector cuts through one graph<\/td><\/tr><tr><td>Analysis<\/td><td>stated methods and editorial estimates<\/td><td>typed analysis specifications<\/td><\/tr><tr><td>Models<\/td><td>Synthetic biology System Model v0 specification<\/td><td>model runs with receipts<\/td><\/tr><tr><td>Findings<\/td><td>twelve baseline findings<\/td><td>findings re-bound to federation evidence<\/td><\/tr><tr><td>Review<\/td><td>five passes scheduled<\/td><td>five passes on the exact digest<\/td><\/tr><\/tbody><\/table><\/div><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-ca-s4\" aria-labelledby=\"nx-nrp-xt-04-ca-s4-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-ca-s4-h\"><span class=\"nrp-num\">A.4<\/span><span>Evidence age and coverage<\/span><\/h2><p class=\"nrp-stand\">A 2026 global edition rests on evidence observed in many different years. This page shows each time base, so that no single year label hides older evidence.<\/p><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-ca-tab5\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table A.5<\/span><span class=\"nrp-tbl-t\">Evidence age and coverage<\/span><\/caption><thead><tr><th scope=\"col\">Indicator<\/th><th scope=\"col\">Observed<\/th><th scope=\"col\">Released<\/th><th scope=\"col\">Cadence<\/th><th scope=\"col\">Next release<\/th><\/tr><\/thead><tbody><tr><td>Recoded genome results<\/td><td>2019 to 2025<\/td><td>Nature 2019 \u00b7 Science Oct 2025<\/td><td>one-off<\/td><td>follow-up papers<\/td><\/tr><tr><td>Synthetic yeast<\/td><td>2023<\/td><td>Cell Dec 2023<\/td><td>one-off<\/td><td>completion papers<\/td><\/tr><tr><td>Screening study<\/td><td>2025<\/td><td>Science Oct 2025<\/td><td>one-off<\/td><td>follow-up studies<\/td><\/tr><tr><td>US commission report<\/td><td>2025<\/td><td>Apr 2025<\/td><td>one-off<\/td><td>legislation<\/td><\/tr><tr><td>US screening framework<\/td><td>2024 \u00b7 2025 order<\/td><td>Apr 2024 \u00b7 May 2025<\/td><td>periodic<\/td><td>replacement text<\/td><\/tr><tr><td>EU Biotech Act<\/td><td>2025<\/td><td>Dec 2025<\/td><td>periodic<\/td><td>second act<\/td><\/tr><tr><td>OECD governance paper<\/td><td>2026<\/td><td>May 2026<\/td><td>one-off<\/td><td>next policy paper<\/td><\/tr><tr><td>Company results<\/td><td>2025 to 2026<\/td><td>Feb 2026 \u00b7 Aug 2026<\/td><td>quarterly<\/td><td>next earnings<\/td><\/tr><\/tbody><\/table><\/div><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-ca-tab6\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table A.6<\/span><span class=\"nrp-tbl-t\">Coverage by system at baseline<\/span><\/caption><thead><tr><th scope=\"col\">System<\/th><th scope=\"col\">Coverage<\/th><th scope=\"col\">Thinnest dimension<\/th><\/tr><\/thead><tbody><tr><td>Build capability<\/td><td>GOOD<\/td><td>industrial-scale performance<\/td><\/tr><tr><td>Clinical<\/td><td>PARTIAL<\/td><td>long-term outcomes<\/td><\/tr><tr><td>Biosecurity<\/td><td>PARTIAL<\/td><td>screening coverage<\/td><\/tr><tr><td>Governance<\/td><td>PARTIAL<\/td><td>text of replacement US framework<\/td><\/tr><tr><td>Investment<\/td><td>THIN<\/td><td>common basis for public and private<\/td><\/tr><tr><td>Energy and feedstock<\/td><td>THIN<\/td><td>fermentation footprint<\/td><\/tr><tr><td>Capacity<\/td><td>THIN<\/td><td>biofoundry and plant counts<\/td><\/tr><tr><td>Skills<\/td><td>THIN<\/td><td>workforce numbers<\/td><\/tr><\/tbody><\/table><\/div><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-ca-tab7\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table A.7<\/span><span class=\"nrp-tbl-t\">Designed empty states: what is not bound, what would fill it and why<\/span><\/caption><thead><tr><th scope=\"col\">Field<\/th><th scope=\"col\">Source that would fill it<\/th><th scope=\"col\">Blocker<\/th><\/tr><\/thead><tbody><tr><td>Energy, water and feedstock use of biomanufacturing at scale<\/td><td>producers, national laboratories, peer-reviewed life-cycle studies<\/td><td>not retrieved on a common basis; no study opened<\/td><\/tr><tr><td>DNA synthesis capacity and screening coverage by provider and country<\/td><td>providers, industry consortia, national agencies<\/td><td>no consolidated series found; screening pages not opened<\/td><\/tr><tr><td>Status and text of the US screening framework after the 2025 order<\/td><td>OSTP and White House publications<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-ca-n25\" id=\"nx-nrp-xt-04-ca-r25\" aria-label=\"Note 25\">25<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-ca-n26\" id=\"nx-nrp-xt-04-ca-r26\" aria-label=\"Note 26\">26<\/a><\/sup><\/td><td>a fetch of the framework page was refused by the tool; status taken from search summaries and a CRS note summary<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-ca-n27\" id=\"nx-nrp-xt-04-ca-r27\" aria-label=\"Note 27\">27<\/a><\/sup><\/td><\/tr><tr><td>European Commission text of the Biotech Act proposal<\/td><td>European Commission proposal COM(2025) 1022<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-ca-n28\" id=\"nx-nrp-xt-04-ca-r28\" aria-label=\"Note 28\">28<\/a><\/sup><\/td><td>primary page not retrieved; content taken from a law firm summary<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-ca-n22\" id=\"nx-nrp-xt-04-ca-r22\" aria-label=\"Note 22\">22<\/a><\/sup><\/td><\/tr><tr><td>Status of the EU second Biotech Act<\/td><td>European Commission, European Parliament legislative train<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-ca-n29\" id=\"nx-nrp-xt-04-ca-r29\" aria-label=\"Note 29\">29<\/a><\/sup><\/td><td>the page returned no content; timing is a Q3 2026 expectation from summaries<\/td><\/tr><tr><td>Public and private investment in synthetic biology on one basis<\/td><td>national statistics, OECD, industry surveys<\/td><td>not retrieved; only two company filings used<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-ca-n16\" id=\"nx-nrp-xt-04-ca-r16\" aria-label=\"Note 16\">16<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-ca-n17\" id=\"nx-nrp-xt-04-ca-r17\" aria-label=\"Note 17\">17<\/a><\/sup><\/td><\/tr><tr><td>Biofoundry and fermentation capacity by country<\/td><td>industry and trade statistics<\/td><td>not retrieved<\/td><\/tr><tr><td>Programme totals for the US distributed bioindustrial manufacturing awards after September 2024<\/td><td>US manufacturing programme pages<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-ca-n24\" id=\"nx-nrp-xt-04-ca-r24\" aria-label=\"Note 24\">24<\/a><\/sup><\/td><td>the page read lists totals to September 2024 only<\/td><\/tr><tr><td>Bioeconomy size from a primary statistical source<\/td><td>national accounts, OECD<\/td><td>only a secondary commentary figure read<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-ca-n15\" id=\"nx-nrp-xt-04-ca-r15\" aria-label=\"Note 15\">15<\/a><\/sup><\/td><\/tr><tr><td>Workforce size and skills gaps<\/td><td>national statistics, OECD, industry surveys<\/td><td>not retrieved; capability rung stays LISTED<\/td><\/tr><tr><td>Independent replication and viral-resistance tests of recoded strains<\/td><td>peer-reviewed papers<\/td><td>not found at evidence close<\/td><\/tr><tr><td>Long-term outcomes of engineered therapies<\/td><td>trial follow-up publications<\/td><td>only the cited trial and one case report read<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-ca-n8\" id=\"nx-nrp-xt-04-ca-r8\" aria-label=\"Note 8\">8<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-ca-n10\" id=\"nx-nrp-xt-04-ca-r10\" aria-label=\"Note 10\">10<\/a><\/sup><\/td><\/tr><tr><td><a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-h101\" data-tc=\"NHS-1 tech.biotech.mirror-life\" data-tk=\"Frontier and exponential technology \u00b7 Biotechnology and synthetic biology\" data-td=\"Creation and escape of organisms built from mirror-image molecules, which could evade immune defences, predators and decay in people, animals and plants and spread unchecked through ecosystems.\" data-ts=\"NRS-H101\" data-tr=\"draft\" data-tx=\"https:\/\/risksindex.com\/hazards\/tech\/\" data-txl=\"Frontier and exponential technology\">Mirror life<\/a> <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-c1\" data-tc=\"NRS-C1 risk-assessment\" data-tk=\"Nexus risk vocabulary\" data-td=\"The overall process of identifying, analysing and evaluating risk to inform decisions.\" data-ts=\"NRS-C1\" data-tr=\"draft\" data-tg=\"https:\/\/nexustandards.com\/glossary\/risk-assessment\/\" data-tgl=\"Nexus Standards glossary\">risk assessment<\/a> beyond the policy forum<\/td><td>peer-reviewed risk studies<\/td><td>only the forum abstract read<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-ca-n12\" id=\"nx-nrp-xt-04-ca-r12\" aria-label=\"Note 12\">12<\/a><\/sup><\/td><\/tr><tr><td>Capability rungs beyond guidance and planning<\/td><td>agencies, operators, laboratories<\/td><td>not reviewed<\/td><\/tr><\/tbody><\/table><\/div><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-ca-s5\" aria-labelledby=\"nx-nrp-xt-04-ca-s5-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-ca-s5-h\"><span class=\"nrp-num\">A.5<\/span><span>Evidence cards, two anchor sources<\/span><\/h2><div class=\"nrp-cards\"><article class=\"nf-ui-card nrp-card\"><p class=\"nf-ui-eyebrow\">Published in Science 390 (2025) by Robertson and colleagues; news page of 1 August 2025. One-off. Role: binds BLD-001. Coverage: one organism in one laboratory line.<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">EVD-XT04-001<\/h3><p>Escherichia coli with a 57-codon genetic code<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-ca-n1\" id=\"nx-nrp-xt-04-ca-r1\" aria-label=\"Note 1\">1<\/a><\/sup><\/p><\/article><article class=\"nf-ui-card nrp-card\"><p class=\"nf-ui-eyebrow\">Published in Science 390 (2025). One-off study. Role: binds SEC-005. Coverage: screening tools and open design software; no sequence detail is reproduced here.<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">EVD-XT04-002<\/h3><p>Strengthening nucleic acid biosecurity screening against generative protein design tools<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-ca-n13\" id=\"nx-nrp-xt-04-ca-r13\" aria-label=\"Note 13\">13<\/a><\/sup><\/p><\/article><\/div><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-ca-tab8\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table A.8<\/span><span class=\"nrp-tbl-t\">Quality dimensions at baseline<\/span><\/caption><thead><tr><th scope=\"col\">Dimension<\/th><th scope=\"col\">EVD-XT04-001<\/th><th scope=\"col\">EVD-XT04-002<\/th><\/tr><\/thead><tbody><tr><td>Completeness<\/td><td>one organism; about 4 million base pairs<\/td><td>a set of screening tools and design software<\/td><\/tr><tr><td>Timeliness<\/td><td>news page about 12 weeks before the journal date<\/td><td>journal publication in 2025<\/td><\/tr><tr><td>Revision<\/td><td>preprint and journal versions<\/td><td>patches reported after testing<\/td><\/tr><tr><td>Method transparency<\/td><td>methods published in the paper<\/td><td>details limited for security reasons<\/td><\/tr><tr><td>External validation<\/td><td>peer review<\/td><td>peer review<\/td><\/tr><\/tbody><\/table><\/div><h3 class=\"nrp-h3\">Evidence cards to follow in 2027<\/h3><ul class=\"nrp-list\"><li>Robertson et al.<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-ca-n1\" aria-label=\"Note 1\">1<\/a><\/sup>: viral resistance and replication<\/li><li>Science screening study<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-ca-n13\" aria-label=\"Note 13\">13<\/a><\/sup>: follow-up on patches and coverage<\/li><li>US framework<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-ca-n25\" aria-label=\"Note 25\">25<\/a><\/sup>: replacement text<\/li><li>European Commission<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-ca-n28\" aria-label=\"Note 28\">28<\/a><\/sup>: proposal text<\/li><\/ul><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-ca-s6\" aria-labelledby=\"nx-nrp-xt-04-ca-s6-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-ca-s6-h\"><span class=\"nrp-num\">A.6<\/span><span>Publication acceptance record<\/span><\/h2><p class=\"nrp-stand\">Editorial self-check at evidence close. Every applicable item carries a disposition; the remaining items are review, approval and deposit.<\/p><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-ca-tab9\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table A.9<\/span><span class=\"nrp-tbl-t\">Publication acceptance record<\/span><\/caption><thead><tr><th scope=\"col\">Group<\/th><th scope=\"col\">Area<\/th><th scope=\"col\">Items<\/th><th scope=\"col\">Pass<\/th><th scope=\"col\">N\/A<\/th><th scope=\"col\">Pending<\/th><\/tr><\/thead><tbody><tr><td>D1<\/td><td>Identity and scope<\/td><td>8<\/td><td>8<\/td><td>0<\/td><td>0<\/td><\/tr><tr><td>D2<\/td><td>Source and data<\/td><td>12<\/td><td>9<\/td><td>1<\/td><td>2<\/td><\/tr><tr><td>D3<\/td><td>Analysis and models<\/td><td>12<\/td><td>3<\/td><td>8<\/td><td>1<\/td><\/tr><tr><td>D4<\/td><td>Findings and claims<\/td><td>9<\/td><td>8<\/td><td>0<\/td><td>1<\/td><\/tr><tr><td>D5<\/td><td>Figures, tables, maps<\/td><td>10<\/td><td>6<\/td><td>2<\/td><td>2<\/td><\/tr><tr><td>D6<\/td><td>Editorial and citations<\/td><td>10<\/td><td>8<\/td><td>0<\/td><td>2<\/td><\/tr><tr><td>D7<\/td><td>Review and approval<\/td><td>13<\/td><td>0<\/td><td>0<\/td><td>13<\/td><\/tr><tr><td>D8<\/td><td>Artefact and design<\/td><td>12<\/td><td>7<\/td><td>0<\/td><td>5<\/td><\/tr><tr><td>D9<\/td><td>Registry and release<\/td><td>9<\/td><td>0<\/td><td>0<\/td><td>9<\/td><\/tr><\/tbody><\/table><\/div><div class=\"nrp-split\"><div><h3 class=\"nrp-h3\">Publication gate<\/h3><dl class=\"nrp-dl\"><dt>Conditions met<\/dt><dd>14 of 23 at evidence close<\/dd><dt>Blocking problems<\/dt><dd>none recorded<\/dd><dt>Open conditions<\/dt><dd>reviews, approval of the exact digest, deposit, registry pointer<\/dd><\/dl><\/div><div><h3 class=\"nrp-h3\">Not applicable at baseline<\/h3><dl class=\"nrp-dl\"><dt>Model runs<\/dt><dd>first runs in Q1 2027<\/dd><dt>Maps<\/dt><dd>plates in Q2 2027<\/dd><dt>Waivers<\/dt><dd>none<\/dd><\/dl><\/div><\/div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">evidence<\/p><p>Dispositions are recorded item by item in the machine-readable checklist. A FAIL on any item blocks release.<\/p><\/aside><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-ca-s7\" aria-labelledby=\"nx-nrp-xt-04-ca-s7-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-ca-s7-h\"><span class=\"nrp-num\">A.7<\/span><span>Status words<\/span><\/h2><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-ca-tab10\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table A.10<\/span><span class=\"nrp-tbl-t\">The status every value carries<\/span><\/caption><thead><tr><th scope=\"col\">Status<\/th><th scope=\"col\">What it means<\/th><\/tr><\/thead><tbody><tr><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"positive\" aria-hidden=\"true\"><\/span>Observed<\/span><\/td><td>Measured directly and published by the source.<\/td><\/tr><tr><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><td>Published statistics of an official or institutional source.<\/td><\/tr><tr><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Declared<\/span><\/td><td>Stated by the body concerned; not independently measured.<\/td><\/tr><tr><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Estimated<\/span><\/td><td>A Nexus estimate from cited evidence, with its method in Annex A.<\/td><\/tr><tr><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Modelled<\/span><\/td><td>Produced by a stated model from cited inputs.<\/td><\/tr><tr><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Inferred<\/span><\/td><td>Reasoned from cited evidence; not measured.<\/td><\/tr><tr><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"caution\" aria-hidden=\"true\"><\/span>Forecast<\/span><\/td><td>A projection by the cited source.<\/td><\/tr><tr><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"caution\" aria-hidden=\"true\"><\/span>Simulated<\/span><\/td><td>A simulation result under stated assumptions.<\/td><\/tr><tr><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"caution\" aria-hidden=\"true\"><\/span>Scenario<\/span><\/td><td>A conditional statement under stated assumptions; never a prediction.<\/td><\/tr><tr><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"neutral\" aria-hidden=\"true\"><\/span>Expert input<\/span><\/td><td>Expert judgement, recorded with its basis.<\/td><\/tr><tr><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"caution\" aria-hidden=\"true\"><\/span>Candidate<\/span><\/td><td>Proposed for a later edition; not yet evidence.<\/td><\/tr><\/tbody><tfoot><tr><td colspan=\"2\">Evidence-quality levels (EQL 1 to 5) grade the source behind a value; they are not a score of the subject.<\/td><\/tr><\/tfoot><\/table><\/div><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-ca-s8\" aria-labelledby=\"nx-nrp-xt-04-ca-s8-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-ca-s8-h\"><span class=\"nrp-num\">A.8<\/span><span>How the edition is made, released and corrected<\/span><\/h2><p class=\"nx-p\">Every edition is built from a sealed evidence cut, reviewed under three keys, signed and deposited before any site shows it as published; corrections go to <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/\" data-tc=\"Nexus Standards\" data-tk=\"Nexus Standards\" data-td=\"The foundation standards\">Nexus Standards<\/a> as change proposals and feed the next cut.<\/p><div class=\"nx-table-wrap\"><table class=\"nx-table\" data-stack=\"true\"><thead><tr><th scope=\"col\">Step<\/th><th scope=\"col\">What happens<\/th><th scope=\"col\">Source<\/th><\/tr><\/thead><tbody><tr><td data-label=\"Step\">01 Evidence arrives from the pillars<\/td><td data-label=\"What happens\">Foundry seals observations and indicator series, Universe hands over after-action and scenario findings, and contributions are screened at every gateway, including this site&#8217;s.<\/td><td data-label=\"Source\"><\/td><\/tr><tr><td data-label=\"Step\">02 The cut is sealed<\/td><td data-label=\"What happens\">On the cut date the evidence is pinned under one identifier, so anyone can rebuild the edition from exactly what it was built on.<\/td><td data-label=\"Source\"><\/td><\/tr><tr><td data-label=\"Step\">03 The edition is assembled<\/td><td data-label=\"What happens\">The edition is drafted from its template and content pack. Agents may draft; they never publish and never decide.<\/td><td data-label=\"Source\"><\/td><\/tr><tr><td data-label=\"Step\">04 The keys turn<\/td><td data-label=\"What happens\">At the publisher of record the truth key comes first: every value is checked against its source or stated method before the meaning and capital keys turn. No edition moves on until every key has been turned by a named steward.<\/td><td data-label=\"Source\"><\/td><\/tr><tr><td data-label=\"Step\">05 The gate opens<\/td><td data-label=\"What happens\">A named approver releases one exact digest of the edition; any change after this point is a new version, never a silent edit.<\/td><td data-label=\"Source\"><\/td><\/tr><tr><td data-label=\"Step\">06 Signed and deposited<\/td><td data-label=\"What happens\">The PDF, the web edition and the data bundle are signed together with a manifest and an RO-Crate description, and deposited on Zenodo with a concept and a version DOI.<\/td><td data-label=\"Source\"><\/td><\/tr><tr><td data-label=\"Step\">07 Published on its desk&#8217;s site<\/td><td data-label=\"What happens\">Only then does the edition show as published on its desk&#8217;s Reports site, and the Collection lists it as a part.<\/td><td data-label=\"Source\"><\/td><\/tr><tr><td data-label=\"Step\">08 Corrections go to Standards<\/td><td data-label=\"What happens\">Method and correction findings go to Nexus Standards as change proposals; citations, corrections and new contributions feed the next evidence cut.<\/td><td data-label=\"Source\"><\/td><\/tr><\/tbody><\/table><\/div><p class=\"nx-note nx-mt-2\">A teaching model of the process, not a forecast and not a record of any run; dates and counts on this page come from the programme record. Sources: <a class=\"nx-link\" href=\"https:\/\/therisk.global\/nexus-reports\/governance\/\" rel=\"noopener\">Reports governance at GCRI Canada<\/a> (2026); Zenodo, repository of record for Reports deposits (2026).<\/p><p class=\"nrp-note\">Lifecycle, one state at a time: Draft, Computed, Evidence bound, Reviewed, Approved for release, Published, Corrected, Superseded. This edition is a draft.<\/p><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-ca-s9\" aria-labelledby=\"nx-nrp-xt-04-ca-s9-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-ca-s9-h\"><span class=\"nrp-num\">A.9<\/span><span>Glossary and abbreviations<\/span><\/h2><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-ca-tab11\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table A.11<\/span><span class=\"nrp-tbl-t\">Series terms<\/span><\/caption><thead><tr><th scope=\"col\">Term<\/th><th scope=\"col\">Meaning<\/th><\/tr><\/thead><tbody><tr><td>Baseline Edition<\/td><td>the inaugural annual edition that fixes the reference state for the series<\/td><\/tr><tr><td>WEFH+B<\/td><td>water, energy, food, health and biodiversity, the <a class=\"nx-link nx-term\" href=\"https:\/\/docs.therisk.global\/organization\/governance-in-operation\/national-nexus\" data-tc=\"National Nexus\" data-tk=\"Nexus Standards\" data-td=\"The national model: the NNC, the NLC and the NWG as its three participation pillars, with the National Desk, Model and Portfolio and the NSC as the standards function of the NNC (OR-13)\">national nexus<\/a> core<\/td><\/tr><tr><td>Coupling<\/td><td>a typed dependency through which one system transmits to another<\/td><\/tr><tr><td><a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-c1\" data-tc=\"NRS-C1 protection-gap\" data-tk=\"Nexus risk vocabulary\" data-td=\"The difference between total economic losses from hazards and the share covered by insurance or other pre-arranged protection, leaving households, firms and governments to absorb the rest.\" data-ts=\"NRS-C1\" data-tr=\"draft\" data-tg=\"https:\/\/globalriskalliance.com\/glossary\/protection-gap\/\" data-tgl=\"Global Risks Alliance glossary\">Protection gap<\/a><\/td><td>the share of losses not covered by insurance<\/td><\/tr><tr><td>Capability ladder<\/td><td>LISTED \u2192 EXISTS \u2192 ADEQUATE \u2192 TESTED \u2192 DEMONSTRATED<\/td><\/tr><tr><td>EQL<\/td><td>evidence-quality level, 1\u20135<\/td><\/tr><tr><td>Evidence cut<\/td><td>a frozen resolution of exact sources and versions<\/td><\/tr><tr><td>NNC \u00b7 NLC \u00b7 NWG<\/td><td>National Nexus Consortium \u00b7 National Leadership Council \u00b7 National Working Groups<\/td><\/tr><\/tbody><\/table><\/div><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-ca-tab12\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table A.12<\/span><span class=\"nrp-tbl-t\">Abbreviations used in this edition<\/span><\/caption><thead><tr><th scope=\"col\">Abbreviation<\/th><th scope=\"col\">Expansion<\/th><\/tr><\/thead><tbody><tr><td>AHTEG<\/td><td>Ad Hoc Technical Expert Group<\/td><\/tr><tr><td>BWC<\/td><td>Biological Weapons Convention<\/td><\/tr><tr><td>CBD<\/td><td>Convention on Biological Diversity<\/td><\/tr><tr><td>CRS<\/td><td>Congressional Research Service<\/td><\/tr><tr><td>DBIMP<\/td><td>Distributed Bioindustrial Manufacturing Program<\/td><\/tr><tr><td>EO<\/td><td>executive order<\/td><\/tr><tr><td>FDA<\/td><td>US Food and Drug Administration<\/td><\/tr><tr><td>IGSC<\/td><td>International Gene Synthesis Consortium<\/td><\/tr><tr><td>NSCEB<\/td><td>National Security Commission on Emerging Biotechnology<\/td><\/tr><tr><td>OECD<\/td><td>Organisation for Economic Co-operation and Development<\/td><\/tr><tr><td>OSTP<\/td><td>Office of Science and Technology Policy<\/td><\/tr><tr><td>SPC<\/td><td>supplementary protection certificate<\/td><\/tr><\/tbody><\/table><\/div><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-ca-s10\" aria-labelledby=\"nx-nrp-xt-04-ca-s10-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-ca-s10-h\"><span class=\"nrp-num\">A.10<\/span><span>Technical annex<\/span><\/h2><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-ca-tab13\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table A.13<\/span><span class=\"nrp-tbl-t\">Technical annex<\/span><\/caption><thead><tr><th scope=\"col\">Item<\/th><th scope=\"col\">Annex<\/th><th scope=\"col\">Contents<\/th><th scope=\"col\">Status<\/th><\/tr><\/thead><tbody><tr><td>A.1<\/td><td>Indicator definitions<\/td><td>the global indicator set, with units and sources<\/td><td>IN THIS EDITION<\/td><\/tr><tr><td>A.2<\/td><td>Coupling strengths<\/td><td>the twenty-cell matrix and its rationale<\/td><td>IN THIS EDITION<\/td><\/tr><tr><td>A.3<\/td><td>Scenario specification<\/td><td>SCN-XT04-DSG-01 assumptions and signposts<\/td><td>IN THIS EDITION<\/td><\/tr><tr><td>A.4<\/td><td>Capability placements<\/td><td>rung evidence for fifteen functions<\/td><td>IN THIS EDITION<\/td><\/tr><tr><td>A.5<\/td><td>Model diagnostics<\/td><td>first runs and validation<\/td><td>2027<\/td><\/tr><tr><td>A.6<\/td><td>Sensitivity analyses<\/td><td>influence of coupling strengths<\/td><td>2027<\/td><\/tr><tr><td>A.7<\/td><td>Cluster notes<\/td><td>cards for the major platform, DNA supply and manufacturing clusters<\/td><td>2027<\/td><\/tr><tr><td>A.8<\/td><td>Review statements<\/td><td>pass-by-pass review record<\/td><td>AT RELEASE<\/td><\/tr><\/tbody><\/table><\/div><h3 class=\"nrp-h3\">A.1 \u00b7 indicator definition: codons recoded<\/h3><dl class=\"nrp-dl\"><dt>Construct<\/dt><dd>number of codon positions in a genome replaced by a synonymous codon<\/dd><dt>Unit<\/dt><dd>count of codons<\/dd><dt>Method<\/dt><dd>genome design, fragment synthesis and assembly<\/dd><dt>Source<\/dt><dd>Nature 569 (2019)<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-ca-n3\" id=\"nx-nrp-xt-04-ca-r3\" aria-label=\"Note 3\">3<\/a><\/sup>; Science 390 (2025) and the research institute news page<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-ca-n2\" id=\"nx-nrp-xt-04-ca-r2\" aria-label=\"Note 2\">2<\/a><\/sup><\/dd><dt>Uncertainty<\/dt><dd>the Syn57 count is stated as over 101,000, a lower bound<\/dd><dt>Known limits<\/dt><dd>counts may include sense codons and a stop codon; one lineage of organisms<\/dd><\/dl><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">evidence<\/p><p>Annexes carry the same evidence, review and correction rules as the chapters and are versioned with the edition.<\/p><\/aside><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-ca-notes\" aria-labelledby=\"nx-nrp-xt-04-ca-notes-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-ca-notes-h\"><span>Notes<\/span><\/h2><p class=\"nrp-note\">Numbers are the edition&#8217;s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. <a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/references\/\">Annex C, references<\/a><\/p><ol class=\"nrp-notes\"><li id=\"nx-nrp-xt-04-ca-n25\"><span class=\"nrp-notes-n\">25<\/span><span>UNVERIFIED, not opened: Office of Science and Technology Policy (ed.), Framework for Nucleic Acid Synthesis Screening, April 2024, taken from search-result summaries; a fetch of the page was refused by the fetch tool. OSTP, Washington. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-ca-r25\" aria-label=\"Back to the first call of note 25\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-ca-n26\"><span class=\"nrp-notes-n\">26<\/span><span>UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-ca-r26\" aria-label=\"Back to the first call of note 26\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-ca-n27\"><span class=\"nrp-notes-n\">27<\/span><span>UNVERIFIED, not opened: Congressional Research Service (ed.), report on artificial intelligence and biosecurity risks (reported in July 2026 as unable to determine whether the 2024 framework or the 2025 policy had been revised), taken from a trade news summary. Library of Congress, Washington. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-ca-r27\" aria-label=\"Back to the first call of note 27\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-ca-n28\"><span class=\"nrp-notes-n\">28<\/span><span>UNVERIFIED, not opened: European Commission (ed.), Proposal for a Biotech Act, COM(2025) 1022, 16 December 2025, taken from law firm and regulator summaries; the Commission page was not retrieved. European Commission, Brussels. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-ca-r28\" aria-label=\"Back to the first call of note 28\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-ca-n22\"><span class=\"nrp-notes-n\">22<\/span><span>Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-ca-r22\" aria-label=\"Back to the first call of note 22\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-ca-n29\"><span class=\"nrp-notes-n\">29<\/span><span>UNVERIFIED, not opened: European Parliament (ed.), Legislative train entry for the European Biotech Act II (second act expected in the third quarter of 2026), taken from a search-result summary; the page returned no content. European Parliament, Brussels. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-ca-r29\" aria-label=\"Back to the first call of note 29\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-ca-n16\"><span class=\"nrp-notes-n\">16<\/span><span>Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-ca-r16\" aria-label=\"Back to the first call of note 16\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-ca-n17\"><span class=\"nrp-notes-n\">17<\/span><span>Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-ca-r17\" aria-label=\"Back to the first call of note 17\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-ca-n24\"><span class=\"nrp-notes-n\">24<\/span><span>US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-ca-r24\" aria-label=\"Back to the first call of note 24\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-ca-n15\"><span class=\"nrp-notes-n\">15<\/span><span>Federation of American Scientists (ed.), Translating Vision into Action: FAS commentary on the NSCEB final report (commentary page; six pillars; cites over USD 210 billion of US GDP and over 640,000 jobs for the bioeconomy; secondary and advocacy-leaning source). Federation of American Scientists, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-ca-r15\" aria-label=\"Back to the first call of note 15\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-ca-n8\"><span class=\"nrp-notes-n\">8<\/span><span>Frangoul, H. et al., Exagamglogene autotemcel for severe sickle cell disease, New England Journal of Medicine 390 (18), 1649 to 1662, 2024 (record read via Europe PMC: 44 treated; 29 of 30 evaluable free of severe crises for 12 months; median follow-up 19.3 months). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-ca-r8\" aria-label=\"Back to the first call of note 8\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-ca-n10\"><span class=\"nrp-notes-n\">10<\/span><span>Musunuru, K. et al., Patient-specific in vivo gene editing to treat a rare genetic disease, New England Journal of Medicine 392 (22), 2235 to 2243, 2025 (record read via Europe PMC: one infant; two infusions at about 7 and 8 months). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-ca-r10\" aria-label=\"Back to the first call of note 10\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-ca-n12\"><span class=\"nrp-notes-n\">12<\/span><span>Confronting risks of <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-h101\" data-tc=\"NHS-1 tech.biotech.mirror-life\" data-tk=\"Frontier and exponential technology \u00b7 Biotechnology and synthetic biology\" data-td=\"Creation and escape of organisms built from mirror-image molecules, which could evade immune defences, predators and decay in people, animals and plants and spread unchecked through ecosystems.\" data-ts=\"NRS-H101\" data-tr=\"draft\" data-tx=\"https:\/\/risksindex.com\/hazards\/tech\/\" data-txl=\"Frontier and exponential technology\">mirror life<\/a>, Science 386, 1351 to 1353, 2024 (record read via Europe PMC; the record gives only a one-line abstract calling for broad discussion). American Association for the Advancement of Science, Washington. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-ca-r12\" aria-label=\"Back to the first call of note 12\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-ca-n1\"><span class=\"nrp-notes-n\">1<\/span><span>Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-ca-r1\" aria-label=\"Back to the first call of note 1\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-ca-n13\"><span class=\"nrp-notes-n\">13<\/span><span>Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-ca-r13\" aria-label=\"Back to the first call of note 13\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-ca-n3\"><span class=\"nrp-notes-n\">3<\/span><span>Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-ca-r3\" aria-label=\"Back to the first call of note 3\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-ca-n2\"><span class=\"nrp-notes-n\">2<\/span><span>MRC Laboratory of Molecular Biology (ed.), Syn57 represents a new chapter in the genetic code of life (news page, 1 August 2025; over 101,000 codons recoded; 64 to 57 codons; genome of about 4 megabases built from 38 fragments of about 100 kilobases). MRC Laboratory of Molecular Biology, Cambridge. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-ca-r2\" aria-label=\"Back to the first call of note 2\">back<\/a><\/span><\/li><\/ol><\/section><\/div><div class=\"nrp-part\" id=\"nx-nrp-xt-04-part-data\"><header class=\"nrp-chap-head\" id=\"nx-nrp-xt-04-cb-top\"><ul class=\"nrp-eyerow\"><li class=\"nf-ui-eyebrow\"><a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/\">Synthetic Biology and Bioengineering 2026<\/a><\/li><li class=\"nf-ui-eyebrow\">Annex B<\/li><\/ul><span class=\"nrp-rule\" aria-hidden=\"true\"><\/span><h2 class=\"pp-hero-title\">Data appendix<\/h2><p class=\"nrp-lede\">The indicator set with its sources, the source registers, the licences of every kind of material and the formats of the edition.<\/p><p class=\"nrp-chap-meta\"><span>11 min read<\/span><span>0 figures<\/span><span>8 tables<\/span><span>22 notes<\/span><span>NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE<\/span><\/p><\/header><section class=\"nrp-block\" id=\"nx-nrp-xt-04-cb-s1\" aria-labelledby=\"nx-nrp-xt-04-cb-s1-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-cb-s1-h\"><span class=\"nrp-num\">B.1<\/span><span>The indicator set<\/span><\/h2><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-cb-tab1\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table B.1<\/span><span class=\"nrp-tbl-t\">Global baseline indicator set<\/span><\/caption><thead><tr><th scope=\"col\">Indicator<\/th><th scope=\"col\">Value<\/th><th scope=\"col\">Unit<\/th><th scope=\"col\">Year<\/th><th scope=\"col\">State<\/th><th scope=\"col\">Source<\/th><\/tr><\/thead><tbody><tr><td>Codons in the standard genetic code<\/td><td><span class=\"nrp-mono\">64<\/span><\/td><td>codons<\/td><td>2025<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n2\" id=\"nx-nrp-xt-04-cb-r2\" aria-label=\"Note 2\">2<\/a><\/sup><\/td><\/tr><tr><td>Codons in the Syn61 strain<\/td><td><span class=\"nrp-mono\">61<\/span><\/td><td>codons<\/td><td>2019<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n3\" id=\"nx-nrp-xt-04-cb-r3\" aria-label=\"Note 3\">3<\/a><\/sup><\/td><\/tr><tr><td>Codons in the Syn57 strain<\/td><td><span class=\"nrp-mono\">57<\/span><\/td><td>codons<\/td><td>2025<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n2\" aria-label=\"Note 2\">2<\/a><\/sup><\/td><\/tr><tr><td>Codons recoded in Syn61<\/td><td><span class=\"nrp-mono\">18,214<\/span><\/td><td>codons<\/td><td>2019<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n3\" aria-label=\"Note 3\">3<\/a><\/sup><\/td><\/tr><tr><td>Codons recoded in Syn57<\/td><td><span class=\"nrp-mono\">&gt;101,000<\/span><\/td><td>codons<\/td><td>2025<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n2\" aria-label=\"Note 2\">2<\/a><\/sup><\/td><\/tr><tr><td>Fragments in the Syn57 assembly<\/td><td><span class=\"nrp-mono\">38<\/span><\/td><td>fragments<\/td><td>2025<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n2\" aria-label=\"Note 2\">2<\/a><\/sup><\/td><\/tr><tr><td>Synthetic yeast chromosomes in one strain<\/td><td><span class=\"nrp-mono\">6.5<\/span><\/td><td>chromosomes<\/td><td>2023<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n4\" id=\"nx-nrp-xt-04-cb-r4\" aria-label=\"Note 4\">4<\/a><\/sup><\/td><\/tr><tr><td>Genome of the first synthetic cell<\/td><td><span class=\"nrp-mono\">1.08<\/span><\/td><td>million base pairs<\/td><td>2010<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n5\" id=\"nx-nrp-xt-04-cb-r5\" aria-label=\"Note 5\">5<\/a><\/sup><\/td><\/tr><tr><td>Genetic circuits built by one tool<\/td><td><span class=\"nrp-mono\">60<\/span><\/td><td>circuits<\/td><td>2016<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n6\" id=\"nx-nrp-xt-04-cb-r6\" aria-label=\"Note 6\">6<\/a><\/sup><\/td><\/tr><tr><td>Circuits correct in every output state<\/td><td><span class=\"nrp-mono\">45<\/span><\/td><td>circuits<\/td><td>2016<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n6\" aria-label=\"Note 6\">6<\/a><\/sup><\/td><\/tr><tr><td>Patients treated in the exa-cel phase 3 study<\/td><td><span class=\"nrp-mono\">44<\/span><\/td><td>patients<\/td><td>2024<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n8\" id=\"nx-nrp-xt-04-cb-r8\" aria-label=\"Note 8\">8<\/a><\/sup><\/td><\/tr><tr><td>Patients free of severe crises for 12 months<\/td><td><span class=\"nrp-mono\">29 of 30<\/span><\/td><td>evaluable patients<\/td><td>2024<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n8\" aria-label=\"Note 8\">8<\/a><\/sup><\/td><\/tr><tr><td>US commission recommendations<\/td><td><span class=\"nrp-mono\">49<\/span><\/td><td>recommendations<\/td><td>2025<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n14\" id=\"nx-nrp-xt-04-cb-r14\" aria-label=\"Note 14\">14<\/a><\/sup><\/td><\/tr><tr><td>US commission funding recommended, minimum<\/td><td><span class=\"nrp-mono\">15<\/span><\/td><td>USD billion over five years<\/td><td>2025<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"caution\" aria-hidden=\"true\"><\/span>Scenario<\/span><\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n14\" aria-label=\"Note 14\">14<\/a><\/sup><\/td><\/tr><tr><td>Twist Bioscience revenue, nine months to 30 June 2026<\/td><td><span class=\"nrp-mono\">332.8<\/span><\/td><td>USD million<\/td><td>2026<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n16\" id=\"nx-nrp-xt-04-cb-r16\" aria-label=\"Note 16\">16<\/a><\/sup><\/td><\/tr><tr><td>Twist Bioscience fiscal 2026 revenue guidance<\/td><td><span class=\"nrp-mono\">456 to 457<\/span><\/td><td>USD million<\/td><td>2026<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"caution\" aria-hidden=\"true\"><\/span>Scenario<\/span><\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n16\" aria-label=\"Note 16\">16<\/a><\/sup><\/td><\/tr><tr><td>Ginkgo Bioworks revenue<\/td><td><span class=\"nrp-mono\">170.2<\/span><\/td><td>USD million<\/td><td>2025<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n17\" id=\"nx-nrp-xt-04-cb-r17\" aria-label=\"Note 17\">17<\/a><\/sup><\/td><\/tr><tr><td>Ginkgo Bioworks net loss<\/td><td><span class=\"nrp-mono\">312.8<\/span><\/td><td>USD million<\/td><td>2025<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n17\" aria-label=\"Note 17\">17<\/a><\/sup><\/td><\/tr><tr><td>US planning awards for bioindustrial manufacturing, cumulative to September 2024<\/td><td><span class=\"nrp-mono\">25<\/span><\/td><td>awards<\/td><td>2024<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n24\" id=\"nx-nrp-xt-04-cb-r24\" aria-label=\"Note 24\">24<\/a><\/sup><\/td><\/tr><tr><td>Funding of those awards, cumulative to September 2024<\/td><td><span class=\"nrp-mono\">42<\/span><\/td><td>USD million<\/td><td>2024<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n24\" aria-label=\"Note 24\">24<\/a><\/sup><\/td><\/tr><tr><td>Award for the bioindustrial manufacturing institute<\/td><td><span class=\"nrp-mono\">87<\/span><\/td><td>USD million over seven years<\/td><td>2020<\/td><td><span class=\"nrp-st\"><span class=\"nf-ui-dot\" data-tone=\"info\" aria-hidden=\"true\"><\/span>Reported<\/span><\/td><td><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n23\" id=\"nx-nrp-xt-04-cb-r23\" aria-label=\"Note 23\">23<\/a><\/sup><\/td><\/tr><\/tbody><\/table><\/div><div class=\"nrp-actions nrp-noprint\"><a class=\"nf-ui-btn\" data-variant=\"secondary\" href=\"data:text\/csv;charset=utf-8,Indicator%2CValue%2CUnit%2CYear%2CState%2CSource%0ACodons%20in%20the%20standard%20genetic%20code%2C64%2Ccodons%2C2025%2CREPORTED%2C%5B2%5D%0ACodons%20in%20the%20Syn61%20strain%2C61%2Ccodons%2C2019%2CREPORTED%2C%5B3%5D%0ACodons%20in%20the%20Syn57%20strain%2C57%2Ccodons%2C2025%2CREPORTED%2C%5B2%5D%0ACodons%20recoded%20in%20Syn61%2C%2218%2C214%22%2Ccodons%2C2019%2CREPORTED%2C%5B3%5D%0ACodons%20recoded%20in%20Syn57%2C%22%3E101%2C000%22%2Ccodons%2C2025%2CREPORTED%2C%5B2%5D%0AFragments%20in%20the%20Syn57%20assembly%2C38%2Cfragments%2C2025%2CREPORTED%2C%5B2%5D%0ASynthetic%20yeast%20chromosomes%20in%20one%20strain%2C6.5%2Cchromosomes%2C2023%2CREPORTED%2C%5B4%5D%0AGenome%20of%20the%20first%20synthetic%20cell%2C1.08%2Cmillion%20base%20pairs%2C2010%2CREPORTED%2C%5B5%5D%0AGenetic%20circuits%20built%20by%20one%20tool%2C60%2Ccircuits%2C2016%2CREPORTED%2C%5B6%5D%0ACircuits%20correct%20in%20every%20output%20state%2C45%2Ccircuits%2C2016%2CREPORTED%2C%5B6%5D%0APatients%20treated%20in%20the%20exa-cel%20phase%203%20study%2C44%2Cpatients%2C2024%2CREPORTED%2C%5B8%5D%0APatients%20free%20of%20severe%20crises%20for%2012%20months%2C29%20of%2030%2Cevaluable%20patients%2C2024%2CREPORTED%2C%5B8%5D%0AUS%20commission%20recommendations%2C49%2Crecommendations%2C2025%2CREPORTED%2C%5B14%5D%0A%22US%20commission%20funding%20recommended%2C%20minimum%22%2C15%2CUSD%20billion%20over%20five%20years%2C2025%2CSCENARIO%2C%5B14%5D%0A%22Twist%20Bioscience%20revenue%2C%20nine%20months%20to%2030%20June%202026%22%2C332.8%2CUSD%20million%2C2026%2CREPORTED%2C%5B16%5D%0ATwist%20Bioscience%20fiscal%202026%20revenue%20guidance%2C456%20to%20457%2CUSD%20million%2C2026%2CSCENARIO%2C%5B16%5D%0AGinkgo%20Bioworks%20revenue%2C170.2%2CUSD%20million%2C2025%2CREPORTED%2C%5B17%5D%0AGinkgo%20Bioworks%20net%20loss%2C312.8%2CUSD%20million%2C2025%2CREPORTED%2C%5B17%5D%0A%22US%20planning%20awards%20for%20bioindustrial%20manufacturing%2C%20cumulative%20to%20September%202024%22%2C25%2Cawards%2C2024%2CREPORTED%2C%5B24%5D%0A%22Funding%20of%20those%20awards%2C%20cumulative%20to%20September%202024%22%2C42%2CUSD%20million%2C2024%2CREPORTED%2C%5B24%5D%0AAward%20for%20the%20bioindustrial%20manufacturing%20institute%2C87%2CUSD%20million%20over%20seven%20years%2C2020%2CREPORTED%2C%5B23%5D%0A\" download=\"NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE-indicators.csv\"><svg class=\"nrp-i\" viewBox=\"0 0 24 24\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M12 15V3\"\/><path d=\"M21 15v4a2 2 0 0 1-2 2H5a2 2 0 0 1-2-2v-4\"\/><path d=\"m7 10 5 5 5-5\"\/><\/svg>Indicators, CSV<\/a><a class=\"nf-ui-btn\" data-variant=\"secondary\" href=\"data:application\/json;charset=utf-8,%7B%0A%20%22edition%22%3A%20%22NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE%22%2C%0A%20%22title%22%3A%20%22Exponential%20Technology%20Report%202026%3A%20Synthetic%20Biology%20and%20Bioengineering%22%2C%0A%20%22status%22%3A%20%22Draft%20under%20stewardship%20review%3B%20not%20yet%20released%22%2C%0A%20%22licence%22%3A%20%22CC-BY-4.0%20for%20the%20edition%20table%3B%20each%20value%20keeps%20its%20source's%20licence%22%2C%0A%20%22columns%22%3A%20%5B%0A%20%20%22Indicator%22%2C%0A%20%20%22Value%22%2C%0A%20%20%22Unit%22%2C%0A%20%20%22Year%22%2C%0A%20%20%22State%22%2C%0A%20%20%22Source%22%0A%20%5D%2C%0A%20%22rows%22%3A%20%5B%0A%20%20%5B%0A%20%20%20%22Codons%20in%20the%20standard%20genetic%20code%22%2C%0A%20%20%20%2264%22%2C%0A%20%20%20%22codons%22%2C%0A%20%20%20%222025%22%2C%0A%20%20%20%22REPORTED%22%2C%0A%20%20%20%22%5B2%5D%22%0A%20%20%5D%2C%0A%20%20%5B%0A%20%20%20%22Codons%20in%20the%20Syn61%20strain%22%2C%0A%20%20%20%2261%22%2C%0A%20%20%20%22codons%22%2C%0A%20%20%20%222019%22%2C%0A%20%20%20%22REPORTED%22%2C%0A%20%20%20%22%5B3%5D%22%0A%20%20%5D%2C%0A%20%20%5B%0A%20%20%20%22Codons%20in%20the%20Syn57%20strain%22%2C%0A%20%20%20%2257%22%2C%0A%20%20%20%22codons%22%2C%0A%20%20%20%222025%22%2C%0A%20%20%20%22REPORTED%22%2C%0A%20%20%20%22%5B2%5D%22%0A%20%20%5D%2C%0A%20%20%5B%0A%20%20%20%22Codons%20recoded%20in%20Syn61%22%2C%0A%20%20%20%2218%2C214%22%2C%0A%20%20%20%22codons%22%2C%0A%20%20%20%222019%22%2C%0A%20%20%20%22REPORTED%22%2C%0A%20%20%20%22%5B3%5D%22%0A%20%20%5D%2C%0A%20%20%5B%0A%20%20%20%22Codons%20recoded%20in%20Syn57%22%2C%0A%20%20%20%22%3E101%2C000%22%2C%0A%20%20%20%22codons%22%2C%0A%20%20%20%222025%22%2C%0A%20%20%20%22REPORTED%22%2C%0A%20%20%20%22%5B2%5D%22%0A%20%20%5D%2C%0A%20%20%5B%0A%20%20%20%22Fragments%20in%20the%20Syn57%20assembly%22%2C%0A%20%20%20%2238%22%2C%0A%20%20%20%22fragments%22%2C%0A%20%20%20%222025%22%2C%0A%20%20%20%22REPORTED%22%2C%0A%20%20%20%22%5B2%5D%22%0A%20%20%5D%2C%0A%20%20%5B%0A%20%20%20%22Synthetic%20yeast%20chromosomes%20in%20one%20strain%22%2C%0A%20%20%20%226.5%22%2C%0A%20%20%20%22chromosomes%22%2C%0A%20%20%20%222023%22%2C%0A%20%20%20%22REPORTED%22%2C%0A%20%20%20%22%5B4%5D%22%0A%20%20%5D%2C%0A%20%20%5B%0A%20%20%20%22Genome%20of%20the%20first%20synthetic%20cell%22%2C%0A%20%20%20%221.08%22%2C%0A%20%20%20%22million%20base%20pairs%22%2C%0A%20%20%20%222010%22%2C%0A%20%20%20%22REPORTED%22%2C%0A%20%20%20%22%5B5%5D%22%0A%20%20%5D%2C%0A%20%20%5B%0A%20%20%20%22Genetic%20circuits%20built%20by%20one%20tool%22%2C%0A%20%20%20%2260%22%2C%0A%20%20%20%22circuits%22%2C%0A%20%20%20%222016%22%2C%0A%20%20%20%22REPORTED%22%2C%0A%20%20%20%22%5B6%5D%22%0A%20%20%5D%2C%0A%20%20%5B%0A%20%20%20%22Circuits%20correct%20in%20every%20output%20state%22%2C%0A%20%20%20%2245%22%2C%0A%20%20%20%22circuits%22%2C%0A%20%20%20%222016%22%2C%0A%20%20%20%22REPORTED%22%2C%0A%20%20%20%22%5B6%5D%22%0A%20%20%5D%2C%0A%20%20%5B%0A%20%20%20%22Patients%20treated%20in%20the%20exa-cel%20phase%203%20study%22%2C%0A%20%20%20%2244%22%2C%0A%20%20%20%22patients%22%2C%0A%20%20%20%222024%22%2C%0A%20%20%20%22REPORTED%22%2C%0A%20%20%20%22%5B8%5D%22%0A%20%20%5D%2C%0A%20%20%5B%0A%20%20%20%22Patients%20free%20of%20severe%20crises%20for%2012%20months%22%2C%0A%20%20%20%2229%20of%2030%22%2C%0A%20%20%20%22evaluable%20patients%22%2C%0A%20%20%20%222024%22%2C%0A%20%20%20%22REPORTED%22%2C%0A%20%20%20%22%5B8%5D%22%0A%20%20%5D%2C%0A%20%20%5B%0A%20%20%20%22US%20commission%20recommendations%22%2C%0A%20%20%20%2249%22%2C%0A%20%20%20%22recommendations%22%2C%0A%20%20%20%222025%22%2C%0A%20%20%20%22REPORTED%22%2C%0A%20%20%20%22%5B14%5D%22%0A%20%20%5D%2C%0A%20%20%5B%0A%20%20%20%22US%20commission%20funding%20recommended%2C%20minimum%22%2C%0A%20%20%20%2215%22%2C%0A%20%20%20%22USD%20billion%20over%20five%20years%22%2C%0A%20%20%20%222025%22%2C%0A%20%20%20%22SCENARIO%22%2C%0A%20%20%20%22%5B14%5D%22%0A%20%20%5D%2C%0A%20%20%5B%0A%20%20%20%22Twist%20Bioscience%20revenue%2C%20nine%20months%20to%2030%20June%202026%22%2C%0A%20%20%20%22332.8%22%2C%0A%20%20%20%22USD%20million%22%2C%0A%20%20%20%222026%22%2C%0A%20%20%20%22REPORTED%22%2C%0A%20%20%20%22%5B16%5D%22%0A%20%20%5D%2C%0A%20%20%5B%0A%20%20%20%22Twist%20Bioscience%20fiscal%202026%20revenue%20guidance%22%2C%0A%20%20%20%22456%20to%20457%22%2C%0A%20%20%20%22USD%20million%22%2C%0A%20%20%20%222026%22%2C%0A%20%20%20%22SCENARIO%22%2C%0A%20%20%20%22%5B16%5D%22%0A%20%20%5D%2C%0A%20%20%5B%0A%20%20%20%22Ginkgo%20Bioworks%20revenue%22%2C%0A%20%20%20%22170.2%22%2C%0A%20%20%20%22USD%20million%22%2C%0A%20%20%20%222025%22%2C%0A%20%20%20%22REPORTED%22%2C%0A%20%20%20%22%5B17%5D%22%0A%20%20%5D%2C%0A%20%20%5B%0A%20%20%20%22Ginkgo%20Bioworks%20net%20loss%22%2C%0A%20%20%20%22312.8%22%2C%0A%20%20%20%22USD%20million%22%2C%0A%20%20%20%222025%22%2C%0A%20%20%20%22REPORTED%22%2C%0A%20%20%20%22%5B17%5D%22%0A%20%20%5D%2C%0A%20%20%5B%0A%20%20%20%22US%20planning%20awards%20for%20bioindustrial%20manufacturing%2C%20cumulative%20to%20September%202024%22%2C%0A%20%20%20%2225%22%2C%0A%20%20%20%22awards%22%2C%0A%20%20%20%222024%22%2C%0A%20%20%20%22REPORTED%22%2C%0A%20%20%20%22%5B24%5D%22%0A%20%20%5D%2C%0A%20%20%5B%0A%20%20%20%22Funding%20of%20those%20awards%2C%20cumulative%20to%20September%202024%22%2C%0A%20%20%20%2242%22%2C%0A%20%20%20%22USD%20million%22%2C%0A%20%20%20%222024%22%2C%0A%20%20%20%22REPORTED%22%2C%0A%20%20%20%22%5B24%5D%22%0A%20%20%5D%2C%0A%20%20%5B%0A%20%20%20%22Award%20for%20the%20bioindustrial%20manufacturing%20institute%22%2C%0A%20%20%20%2287%22%2C%0A%20%20%20%22USD%20million%20over%20seven%20years%22%2C%0A%20%20%20%222020%22%2C%0A%20%20%20%22REPORTED%22%2C%0A%20%20%20%22%5B23%5D%22%0A%20%20%5D%0A%20%5D%0A%7D\" download=\"NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE-indicators.json\"><svg class=\"nrp-i\" viewBox=\"0 0 24 24\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M12 15V3\"\/><path d=\"M21 15v4a2 2 0 0 1-2 2H5a2 2 0 0 1-2-2v-4\"\/><path d=\"m7 10 5 5 5-5\"\/><\/svg>Indicators, JSON<\/a><\/div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">NOTES<\/p><p>Values are rounded as published. Plans, recommendations and guidance are labelled SCENARIO. Company values come from filings and are weak evidence of the sector. Unopened references carry an UNVERIFIED prefix and are listed in the notes. A machine-readable copy of this table is published with the evidence bundle at release.<\/p><\/aside><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-cb-s2\" aria-labelledby=\"nx-nrp-xt-04-cb-s2-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-cb-s2-h\"><span class=\"nrp-num\">B.2<\/span><span>Global source register<\/span><\/h2><p class=\"nrp-stand\">The governed source set behind this edition. Each source keeps its authority, coverage, cadence and role; categories describe origin, not truth.<\/p><h3 class=\"nrp-h3\">Domains bound by the register<\/h3><ul class=\"nrp-chips\"><li class=\"nf-ui-chip\">BLD<\/li><li class=\"nf-ui-chip\">SEC<\/li><li class=\"nf-ui-chip\">GOV<\/li><li class=\"nf-ui-chip\">FIN<\/li><li class=\"nf-ui-chip\">CLN<\/li><li class=\"nf-ui-chip\">ENE<\/li><li class=\"nf-ui-chip\">WAT<\/li><li class=\"nf-ui-chip\">FOO<\/li><li class=\"nf-ui-chip\">CLI<\/li><li class=\"nf-ui-chip\">MIN<\/li><\/ul><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-cb-tab3\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table B.3<\/span><span class=\"nrp-tbl-t\">Global source register<\/span><\/caption><thead><tr><th scope=\"col\">Source<\/th><th scope=\"col\">Category<\/th><th scope=\"col\">Coverage<\/th><th scope=\"col\">Period<\/th><th scope=\"col\">Cadence<\/th><th scope=\"col\">Role<\/th><\/tr><\/thead><tbody><tr><td>Robertson et al. in Science<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n1\" id=\"nx-nrp-xt-04-cb-r1\" aria-label=\"Note 1\">1<\/a><\/sup><\/td><td>peer-reviewed journal<\/td><td>one organism<\/td><td>2025<\/td><td>one-off<\/td><td>genomes<\/td><\/tr><tr><td>MRC Laboratory of Molecular Biology news<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n2\" aria-label=\"Note 2\">2<\/a><\/sup><\/td><td>research institute<\/td><td>one organism<\/td><td>2025<\/td><td>one-off<\/td><td>genomes<\/td><\/tr><tr><td>Cell paper on synthetic yeast<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n4\" aria-label=\"Note 4\">4<\/a><\/sup><\/td><td>peer-reviewed journal<\/td><td>one lineage<\/td><td>2023<\/td><td>one-off<\/td><td>genomes<\/td><\/tr><tr><td>Nielsen et al. in Science<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n6\" aria-label=\"Note 6\">6<\/a><\/sup><\/td><td>peer-reviewed journal<\/td><td>method<\/td><td>2016<\/td><td>one-off<\/td><td>design tools<\/td><\/tr><tr><td>Journal records for therapies<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n8\" aria-label=\"Note 8\">8<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n10\" id=\"nx-nrp-xt-04-cb-r10\" aria-label=\"Note 10\">10<\/a><\/sup><\/td><td>peer-reviewed journal<\/td><td>clinical<\/td><td>2024 and 2025<\/td><td>one-off<\/td><td>clinical<\/td><\/tr><tr><td>FDA announcement<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n9\" id=\"nx-nrp-xt-04-cb-r9\" aria-label=\"Note 9\">9<\/a><\/sup><\/td><td>national regulator<\/td><td>US<\/td><td>2023<\/td><td>one-off<\/td><td>clinical<\/td><\/tr><tr><td>Screening study in Science<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n13\" id=\"nx-nrp-xt-04-cb-r13\" aria-label=\"Note 13\">13<\/a><\/sup><\/td><td>peer-reviewed journal<\/td><td>method<\/td><td>2025<\/td><td>one-off<\/td><td>biosecurity<\/td><\/tr><tr><td>CRS note on the US commission<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n14\" aria-label=\"Note 14\">14<\/a><\/sup><\/td><td>legislative research service<\/td><td>US<\/td><td>2025<\/td><td>one-off<\/td><td>policy<\/td><\/tr><tr><td>OECD policy papers<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n18\" id=\"nx-nrp-xt-04-cb-r18\" aria-label=\"Note 18\">18<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n19\" id=\"nx-nrp-xt-04-cb-r19\" aria-label=\"Note 19\">19<\/a><\/sup><\/td><td>intergovernmental organisation<\/td><td>OECD members<\/td><td>2025 and 2026<\/td><td>periodic<\/td><td>governance<\/td><\/tr><tr><td>Company filings<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n16\" aria-label=\"Note 16\">16<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n17\" aria-label=\"Note 17\">17<\/a><\/sup><\/td><td>company filing<\/td><td>two firms<\/td><td>2025 and 2026<\/td><td>quarterly<\/td><td>investment<\/td><\/tr><\/tbody><\/table><\/div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">FIXTURE PROHIBITION<\/p><p>No demonstration or reference-cartographic fixture is used as evidence in this edition. The publication gate checks every binding against this register.<\/p><\/aside><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-cb-s3\" aria-labelledby=\"nx-nrp-xt-04-cb-s3-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-cb-s3-h\"><span class=\"nrp-num\">B.3<\/span><span>Regional reading, synthetic biology across ten clusters<\/span><\/h2><p class=\"nrp-stand\">Regional plates follow with the regional editions. This page gives the regional reading of synthetic biology infrastructure and governance in table form and ranks no region.<\/p><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-cb-tab4\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table B.4<\/span><span class=\"nrp-tbl-t\">Regional reading, synthetic biology across ten clusters<\/span><\/caption><thead><tr><th scope=\"col\">Region<\/th><th scope=\"col\">Principal hazards<\/th><th scope=\"col\">Systems most exposed<\/th><th scope=\"col\">Baseline evidence<\/th><\/tr><\/thead><tbody><tr><td>North America<\/td><td>research laboratories; federal commission report; screening framework in flux<\/td><td>governance, manufacturing<\/td><td>CRS<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n14\" aria-label=\"Note 14\">14<\/a><\/sup>; programme page<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n24\" aria-label=\"Note 24\">24<\/a><\/sup><\/td><\/tr><tr><td>South America<\/td><td>early national programmes; CBD participation<\/td><td>governance<\/td><td>regional evidence (not bound)<\/td><\/tr><tr><td>Europe<\/td><td>Biotech Act proposal; research strength<\/td><td>governance, research<\/td><td>EU proposal summary<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n22\" id=\"nx-nrp-xt-04-cb-r22\" aria-label=\"Note 22\">22<\/a><\/sup>; OECD<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n18\" aria-label=\"Note 18\">18<\/a><\/sup><\/td><\/tr><tr><td>Eurasia<\/td><td>research programmes<\/td><td>research<\/td><td>regional evidence (not bound)<\/td><\/tr><tr><td>Middle East and North Africa<\/td><td>emerging programmes<\/td><td>governance<\/td><td>regional evidence (not bound)<\/td><\/tr><tr><td>Africa<\/td><td>skills and access; gene drive field programmes<\/td><td>workforce, release<\/td><td>Kyrou<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n11\" id=\"nx-nrp-xt-04-cb-r11\" aria-label=\"Note 11\">11<\/a><\/sup>; regional evidence (not bound)<\/td><\/tr><tr><td>South Asia<\/td><td>national mission programmes<\/td><td>research, skills<\/td><td>regional evidence (not bound)<\/td><\/tr><tr><td>East Asia<\/td><td>manufacturing and research programmes<\/td><td>manufacturing, research<\/td><td>regional evidence (not bound)<\/td><\/tr><tr><td>ASEAN<\/td><td>bioeconomy planning<\/td><td>governance, manufacturing<\/td><td>regional evidence (not bound)<\/td><\/tr><tr><td>Oceania-Pacific<\/td><td>research programmes; skills<\/td><td>research, workforce<\/td><td>regional evidence (not bound)<\/td><\/tr><\/tbody><\/table><\/div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">MAP PLATES WITH THE REGIONAL EDITIONS<\/p><p>Each plate will carry its boundary source and version, projection, resolution, classification, uncertainty encoding and public-safe transform, with text and table alternatives.<\/p><\/aside><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">boundary<\/p><p>Regional readings summarise the cited evidence. They are not risk ratings of any region or country.<\/p><\/aside><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-cb-s4\" aria-labelledby=\"nx-nrp-xt-04-cb-s4-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-cb-s4-h\"><span class=\"nrp-num\">B.4<\/span><span>Cluster card: DNA synthesis and screening chain<\/span><\/h2><ul class=\"nrp-chips\"><li class=\"nf-ui-chip\">supply chain<\/li><li class=\"nf-ui-chip\">DNA synthesis<\/li><li class=\"nf-ui-chip\">screening<\/li><li class=\"nf-ui-chip\">oversight<\/li><\/ul><dl class=\"nrp-dl\"><dt>Systems in view<\/dt><dd>synthesis providers, design tools, sequence data, oversight bodies<\/dd><dt>Defining events<\/dt><dd>the 2025 screening study and the 2025 US executive order<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n13\" aria-label=\"Note 13\">13<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n26\" id=\"nx-nrp-xt-04-cb-r26\" aria-label=\"Note 26\">26<\/a><\/sup><\/dd><dt>Couplings<\/dt><dd>DAT \u2192 BIO sequence data; GOV \u2192 SEC frameworks<\/dd><dt>Capability evidence<\/dt><dd>industry and national guidance exists<sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n31\" id=\"nx-nrp-xt-04-cb-r31\" aria-label=\"Note 31\">31<\/a><\/sup><sup class=\"nrp-fn\"><a href=\"#nx-nrp-xt-04-cb-n32\" id=\"nx-nrp-xt-04-cb-r32\" aria-label=\"Note 32\">32<\/a><\/sup><\/dd><dt>Gaps<\/dt><dd>coverage by provider; benchtop devices; compliance<\/dd><dt>Agenda items<\/dt><dd>Q-01 \u00b7 Q-03<\/dd><\/dl><div class=\"nrp-cards\"><article class=\"nf-ui-card nrp-card\"><p class=\"nf-ui-eyebrow\">Open machine-learning protein design software can produce variants that screening tools often missed [13].<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">TOOLS<\/h3><p>Open design software<\/p><\/article><article class=\"nf-ui-card nrp-card\"><p class=\"nf-ui-eyebrow\">The 2024 US framework and the 2025 order left the current text unclear in sources read [26] [27].<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">RULES<\/h3><p>A framework in flux<\/p><\/article><article class=\"nf-ui-card nrp-card\"><p class=\"nf-ui-eyebrow\">Patches improved detection in the study, and industry and national guidance exists, but coverage is not counted [13] [31] [32].<\/p><h3 class=\"nf-ui-title\" data-level=\"card\">RESPONSE<\/h3><p>Patches and guidance<\/p><\/article><\/div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">evidence<\/p><p>Cluster cards are generated for the major platform and supply clusters in 2027. The DNA synthesis and screening chain is shown first because a peer-reviewed test of it exists.<\/p><\/aside><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-cb-s5\" aria-labelledby=\"nx-nrp-xt-04-cb-s5-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-cb-s5-h\"><span class=\"nrp-num\">B.5<\/span><span>How countries appear in the synthetic biology edition<\/span><\/h2><p class=\"nrp-stand\">Countries enter the synthetic biology edition through the readiness chapters of their own national editions, on one card grammar. They are read against peer distributions and thresholds, never ranked.<\/p><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-cb-tab5\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table B.5<\/span><span class=\"nrp-tbl-t\">How countries appear in the synthetic biology edition<\/span><\/caption><thead><tr><th scope=\"col\">Card field<\/th><th scope=\"col\">What it shows<\/th><th scope=\"col\">Source<\/th><\/tr><\/thead><tbody><tr><td>WEFH+B state<\/td><td>each core system against peer distribution bands<\/td><td>national edition<\/td><\/tr><tr><td>Couplings<\/td><td>the national dependency matrix<\/td><td>national edition<\/td><\/tr><tr><td>Risk objects<\/td><td>the national risk portfolio<\/td><td>national edition<\/td><\/tr><tr><td>Capability rungs<\/td><td>the national capability ladder<\/td><td>national edition<\/td><\/tr><tr><td>Evidence age<\/td><td>oldest and newest source dates<\/td><td>national source register<\/td><\/tr><\/tbody><\/table><\/div><h3 class=\"nrp-h3\">Editions in the 2026 Baseline programme<\/h3><div class=\"pp-cells nrp-cells-3\"><div class=\"nrp-cell\"><span class=\"pp-metric\">26<\/span><span class=\"nrp-cell-u\">national<\/span><p>countries and unions<\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">10<\/span><span class=\"nrp-cell-u\">regional<\/span><p>clusters<\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">16<\/span><span class=\"nrp-cell-u\">global<\/span><p>flagship and sector<\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">14<\/span><span class=\"nrp-cell-u\">strategic<\/span><p><a class=\"nx-link nx-term\" href=\"https:\/\/docs.therisk.global\/organization\/systems\" data-tc=\"Systems\" data-tk=\"Nexus Standards\" data-td=\"The twenty Nexus systems, NXS-CMD to NXS-LAB\">systems<\/a> reports<\/p><\/div><div class=\"nrp-cell\"><span class=\"pp-metric\">20<\/span><span class=\"nrp-cell-u\">frontier<\/span><p>technology reports<\/p><\/div><\/div><h3 class=\"nrp-h3\">How to read a country card<\/h3><ul class=\"nrp-list\"><li>Each system is shown against the distribution of its peers, with thresholds where they exist<\/li><li>Couplings and risk objects come from the country\u2019s own national edition<\/li><li>Capability rungs record evidence, not a judgement of institutions<\/li><li>Evidence age is printed, so older national data are visible as such<\/li><\/ul><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-cb-tab6\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table B.6<\/span><span class=\"nrp-tbl-t\">National Baseline Editions in the 2026 programme<\/span><\/caption><thead><tr><th scope=\"col\">Wave<\/th><th scope=\"col\">Countries and unions<\/th><th scope=\"col\">State<\/th><\/tr><\/thead><tbody><tr><td>W0<\/td><td>Canada<\/td><td>ISSUED<\/td><\/tr><tr><td>W1<\/td><td>United States, United Kingdom, France, Germany, Italy, Japan, European Union, Switzerland<\/td><td>PLANNED<\/td><\/tr><tr><td>W2<\/td><td>Mexico, Brazil, Argentina, T\u00fcrkiye, Russian Federation, Saudi Arabia, United Arab Emirates, South Africa, Senegal, Kenya, African Union, India, China, Republic of Korea, Indonesia, Singapore, Australia<\/td><td>PLANNED<\/td><\/tr><\/tbody><\/table><\/div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">boundary<\/p><p>External rankings, where cited, keep their own method and source. Nexus never converts them into a rating, and each country\u2019s ownership of its national edition is unaffected by its appearance here.<\/p><\/aside><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-cb-s6\" aria-labelledby=\"nx-nrp-xt-04-cb-s6-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-cb-s6-h\"><span class=\"nrp-num\">B.6<\/span><span>Licences<\/span><\/h2><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-cb-tab7\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table B.7<\/span><span class=\"nrp-tbl-t\">Licences of each kind of material<\/span><\/caption><thead><tr><th scope=\"col\">Material<\/th><th scope=\"col\">Licence<\/th><\/tr><\/thead><tbody><tr><td>Text<\/td><td>CC BY 4.0<\/td><\/tr><tr><td>Data<\/td><td>on the licence of each source; Nexus tables CC BY 4.0<\/td><\/tr><tr><td>Figures<\/td><td>Nexus figures CC BY 4.0; third-party as credited<\/td><\/tr><tr><td>Maps<\/td><td>boundary source and licence printed on each plate<\/td><\/tr><tr><td>Metadata<\/td><td>CC0 1.0, as Zenodo publishes it<\/td><\/tr><tr><td>Third-party data, figures and text<\/td><td>The source&#8217;s own licence, credited where it is used; never relicensed<\/td><\/tr><\/tbody><tfoot><tr><td colspan=\"2\">Nexus-authored text, tables and figures: CC BY 4.0 (SPDX CC-BY-4.0). Map plates print their boundary source and licence.<\/td><\/tr><\/tfoot><\/table><\/div><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-cb-s7\" aria-labelledby=\"nx-nrp-xt-04-cb-s7-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-cb-s7-h\"><span class=\"nrp-num\">B.7<\/span><span>Formats and provenance<\/span><\/h2><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-cb-tab8\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table B.8<\/span><span class=\"nrp-tbl-t\">This edition in every format<\/span><\/caption><thead><tr><th scope=\"col\">Format<\/th><th scope=\"col\">Kind<\/th><th scope=\"col\">State<\/th><th scope=\"col\">What it is<\/th><th scope=\"col\">Identifier<\/th><\/tr><\/thead><tbody><tr><td>Web edition<\/td><td><span class=\"nrp-mono\">HTML<\/span><\/td><td><span class=\"nx-nr-out-s\" data-state=\"here\">On this site<\/span><\/td><td>Draft in stewardship review; every value resolves to its source.<\/td><td><span class=\"nrp-mono\">NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE-v1.0.0<\/span><\/td><\/tr><tr><td>Print edition<\/td><td><span class=\"nrp-mono\">PDF<\/span><\/td><td><span class=\"nx-nr-out-s\" data-state=\"release\">At release<\/span><\/td><td>A4 portrait \u00b7 screen, print and archival PDF, signed with the web edition at release.<\/td><td><span class=\"nrp-mono\">NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE-v1.0.0<\/span><\/td><\/tr><tr><td>Indicator data<\/td><td><span class=\"nrp-mono\">CSV \u00b7 JSON<\/span><\/td><td><span class=\"nx-nr-out-s\" data-state=\"here\">On this site<\/span><\/td><td>21 indicators with unit, year, status and source; the machine-readable copy ships with the evidence bundle at release.<\/td><td><span class=\"nrp-mono\">NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE data release v1<\/span><\/td><\/tr><tr><td>Figures<\/td><td><span class=\"nrp-mono\">SVG \u00b7 PNG<\/span><\/td><td><span class=\"nx-nr-out-s\" data-state=\"here\">On this site<\/span><\/td><td>4 on the web edition: headline figure, figure 1.3, coupling instrument, capability ladder.<\/td><td><span class=\"nrp-mono\">FIG-XTECH-SYNBIO-GLOBAL-2026-BASELINE-*<\/span><\/td><\/tr><tr><td>Slides<\/td><td><span class=\"nrp-mono\">PDF<\/span><\/td><td><span class=\"nx-nr-out-s\" data-state=\"none\">Not recorded<\/span><\/td><td>No slide deck is recorded for this edition.<\/td><td><span class=\"nrp-mono\"><\/span><\/td><\/tr><tr><td>Evidence brief<\/td><td><span class=\"nrp-mono\">HTML \u00b7 PDF<\/span><\/td><td><span class=\"nx-nr-out-s\" data-state=\"none\">Not recorded<\/span><\/td><td>No evidence brief is recorded for this edition.<\/td><td><span class=\"nrp-mono\"><\/span><\/td><\/tr><tr><td>Dataset with DOI<\/td><td><span class=\"nrp-mono\">DataCite<\/span><\/td><td><span class=\"nx-nr-out-s\" data-state=\"release\">At release<\/span><\/td><td>Concept and version DOI are minted at deposit; none is recorded yet.<\/td><td><span class=\"nrp-mono\"><\/span><\/td><\/tr><\/tbody><\/table><\/div><h3 class=\"nrp-h3\">Provenance<\/h3><dl class=\"nrp-dl\"><dt>Edition pack<\/dt><dd>The edition&#8217;s content pack (JSON), from which the print and web editions are built<\/dd><dt>Evidence cut<\/dt><dd>DC-XTECH-SYNBIO-GLOBAL-2026-B0, closed 30 September 2026<\/dd><dt>Reproducibility<\/dt><dd>sourced values cited; analytical values reproducible from stated parameters<\/dd><dt>Self-check<\/dt><dd>14 of 23 at evidence close; a fail on any item blocks release<\/dd><dt>Review<\/dt><dd>five passes scheduled before release (in Annex C)<\/dd><dt>Publisher of record<\/dt><dd>GCRI for the Nexus Consortium<\/dd><dt>Corrections<\/dt><dd>Registry correction pathway; upheld corrections are published as notices with a new version<\/dd><\/dl><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-cb-notes\" aria-labelledby=\"nx-nrp-xt-04-cb-notes-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-cb-notes-h\"><span>Notes<\/span><\/h2><p class=\"nrp-note\">Numbers are the edition&#8217;s reference numbers, so a note reads the same in every chapter. The full list, with every source and its licence, is in Annex C. <a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/references\/\">Annex C, references<\/a><\/p><ol class=\"nrp-notes\"><li id=\"nx-nrp-xt-04-cb-n2\"><span class=\"nrp-notes-n\">2<\/span><span>MRC Laboratory of Molecular Biology (ed.), Syn57 represents a new chapter in the genetic code of life (news page, 1 August 2025; over 101,000 codons recoded; 64 to 57 codons; genome of about 4 megabases built from 38 fragments of about 100 kilobases). MRC Laboratory of Molecular Biology, Cambridge. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r2\" aria-label=\"Back to the first call of note 2\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cb-n3\"><span class=\"nrp-notes-n\">3<\/span><span>Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r3\" aria-label=\"Back to the first call of note 3\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cb-n4\"><span class=\"nrp-notes-n\">4<\/span><span>Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r4\" aria-label=\"Back to the first call of note 4\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cb-n5\"><span class=\"nrp-notes-n\">5<\/span><span>Gibson, D.G. et al., Creation of a bacterial cell controlled by a chemically synthesised genome, Science 329 (5987), 52 to 56, 2010 (record read via Europe PMC: 1.08 million base pair genome). American Association for the Advancement of Science, Washington. Observation year 2010. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r5\" aria-label=\"Back to the first call of note 5\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cb-n6\"><span class=\"nrp-notes-n\">6<\/span><span>Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r6\" aria-label=\"Back to the first call of note 6\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cb-n8\"><span class=\"nrp-notes-n\">8<\/span><span>Frangoul, H. et al., Exagamglogene autotemcel for severe sickle cell disease, New England Journal of Medicine 390 (18), 1649 to 1662, 2024 (record read via Europe PMC: 44 treated; 29 of 30 evaluable free of severe crises for 12 months; median follow-up 19.3 months). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r8\" aria-label=\"Back to the first call of note 8\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cb-n14\"><span class=\"nrp-notes-n\">14<\/span><span>Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r14\" aria-label=\"Back to the first call of note 14\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cb-n16\"><span class=\"nrp-notes-n\">16<\/span><span>Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r16\" aria-label=\"Back to the first call of note 16\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cb-n17\"><span class=\"nrp-notes-n\">17<\/span><span>Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r17\" aria-label=\"Back to the first call of note 17\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cb-n24\"><span class=\"nrp-notes-n\">24<\/span><span>US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r24\" aria-label=\"Back to the first call of note 24\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cb-n23\"><span class=\"nrp-notes-n\">23<\/span><span>BioMADE (ed.), DoD approves USD 87 million for newest bioindustrial manufacturing innovation institute (news page; seven years; the page shows Oct 20 and a 2023 footer, the press release is dated 2020 in search listings). BioMADE, Saint Paul. Observation year 2020. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r23\" aria-label=\"Back to the first call of note 23\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cb-n1\"><span class=\"nrp-notes-n\">1<\/span><span>Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r1\" aria-label=\"Back to the first call of note 1\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cb-n10\"><span class=\"nrp-notes-n\">10<\/span><span>Musunuru, K. et al., Patient-specific in vivo gene editing to treat a rare genetic disease, New England Journal of Medicine 392 (22), 2235 to 2243, 2025 (record read via Europe PMC: one infant; two infusions at about 7 and 8 months). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r10\" aria-label=\"Back to the first call of note 10\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cb-n9\"><span class=\"nrp-notes-n\">9<\/span><span>US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy and Lyfgenia; ages 12 and over; 29 of 31 evaluable Casgevy patients free of severe crises for at least 12 months). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r9\" aria-label=\"Back to the first call of note 9\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cb-n13\"><span class=\"nrp-notes-n\">13<\/span><span>Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r13\" aria-label=\"Back to the first call of note 13\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cb-n18\"><span class=\"nrp-notes-n\">18<\/span><span>OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r18\" aria-label=\"Back to the first call of note 18\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cb-n19\"><span class=\"nrp-notes-n\">19<\/span><span>OECD (ed.), Synthetic biology, AI and automation: a forward-looking technology assessment, OECD Science, Technology and Industry Policy Papers No. 187, 4 December 2025 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r19\" aria-label=\"Back to the first call of note 19\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cb-n22\"><span class=\"nrp-notes-n\">22<\/span><span>Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r22\" aria-label=\"Back to the first call of note 22\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cb-n11\"><span class=\"nrp-notes-n\">11<\/span><span>Kyrou, K. et al., A CRISPR-Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes, Nature Biotechnology 36, 1062 to 1066, 2018 (record read via Europe PMC; laboratory cages only). Springer Nature, London. Observation year 2018. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r11\" aria-label=\"Back to the first call of note 11\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cb-n26\"><span class=\"nrp-notes-n\">26<\/span><span>UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r26\" aria-label=\"Back to the first call of note 26\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cb-n31\"><span class=\"nrp-notes-n\">31<\/span><span>UNVERIFIED, not opened: International Gene Synthesis Consortium (ed.), Harmonized Screening Protocol, cited from memory. IGSC. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r31\" aria-label=\"Back to the first call of note 31\">back<\/a><\/span><\/li><li id=\"nx-nrp-xt-04-cb-n32\"><span class=\"nrp-notes-n\">32<\/span><span>UNVERIFIED, not opened: UK Government (ed.), screening guidance on synthetic nucleic acids, 2024, cited from memory. Department for Science, Innovation and Technology, London. Observation year 2024. Accessed 2026-11-03.<a class=\"nrp-notes-back\" href=\"#nx-nrp-xt-04-cb-r32\" aria-label=\"Back to the first call of note 32\">back<\/a><\/span><\/li><\/ol><\/section><\/div><div class=\"nrp-part\" id=\"nx-nrp-xt-04-part-references\"><header class=\"nrp-chap-head\" id=\"nx-nrp-xt-04-cc-top\"><ul class=\"nrp-eyerow\"><li class=\"nf-ui-eyebrow\"><a href=\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/\">Synthetic Biology and Bioengineering 2026<\/a><\/li><li class=\"nf-ui-eyebrow\">Annex C<\/li><\/ul><span class=\"nrp-rule\" aria-hidden=\"true\"><\/span><h2 class=\"pp-hero-title\">References and record<\/h2><p class=\"nrp-lede\">Every source the edition rests on, the publication record, the corrections log and the open record.<\/p><p class=\"nrp-chap-meta\"><span>15 min read<\/span><span>0 figures<\/span><span>1 table<\/span><span>0 notes<\/span><span>NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE<\/span><\/p><\/header><section class=\"nrp-block\" id=\"nx-nrp-xt-04-cc-s1\" aria-labelledby=\"nx-nrp-xt-04-cc-s1-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-cc-s1-h\"><span class=\"nrp-num\">C.1<\/span><span>44 sources<\/span><\/h2><p class=\"nrp-stand\">NR-CIT-1, editor first. A DOI is linked where the source has one; Nexus records carry a <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/uni\/\" data-tc=\"UNI\" data-tk=\"Nexus Standards\" data-td=\"The universal identifier of every Nexus artifact (NS-1)\">UNI<\/a> once the catalogue allocates it (NS-1).<\/p><ol class=\"nrp-notes\"><li id=\"nx-nrp-xt-04-ref-1\"><span class=\"nrp-notes-n\">1<\/span><span>Robertson, W.E. et al., Escherichia coli with a 57-codon genetic code, Science 390 (6771), eady4368, published 23 October 2025 (record read via PubMed, PMID 40743368; the record gives a 4 megabase synthetic genome and six replaced sense codons). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 7, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-2\"><span class=\"nrp-notes-n\">2<\/span><span>MRC Laboratory of Molecular Biology (ed.), Syn57 represents a new chapter in the genetic code of life (news page, 1 August 2025; over 101,000 codons recoded; 64 to 57 codons; genome of about 4 megabases built from 38 fragments of about 100 kilobases). MRC Laboratory of Molecular Biology, Cambridge. Observation year 2025. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-3\"><span class=\"nrp-notes-n\">3<\/span><span>Fredens, J. et al., Total synthesis of Escherichia coli with a recoded genome, Nature 569 (7757), 514 to 518, 2019 (record read via Europe PMC: 18,214 codons recoded; 61-codon genome). Springer Nature, London. Observation year 2019. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 6, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-4\"><span class=\"nrp-notes-n\">4<\/span><span>Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions, Cell 186 (24), 5220 to 5236, 2023 (record read via Europe PMC: 6.5 synthetic chromosomes in one strain; over half of the Sc2.0 genome). Cell Press, Cambridge, Massachusetts. Observation year 2023. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-5\"><span class=\"nrp-notes-n\">5<\/span><span>Gibson, D.G. et al., Creation of a bacterial cell controlled by a chemically synthesised genome, Science 329 (5987), 52 to 56, 2010 (record read via Europe PMC: 1.08 million base pair genome). American Association for the Advancement of Science, Washington. Observation year 2010. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 2, chapter 6<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-6\"><span class=\"nrp-notes-n\">6<\/span><span>Nielsen, A.A.K. et al., Genetic circuit design automation, Science 352 (6281), 2016 (record read via Europe PMC: 60 circuits; 45 correct in all output states; 92% of output states as predicted). American Association for the Advancement of Science, Washington. Observation year 2016. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-7\"><span class=\"nrp-notes-n\">7<\/span><span>Watson, J.L. et al., De novo design of protein structure and function with RFdiffusion, Nature 620, 1089 to 1100, 2023 (record read via Europe PMC). Springer Nature, London. Observation year 2023. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in the summary, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-8\"><span class=\"nrp-notes-n\">8<\/span><span>Frangoul, H. et al., Exagamglogene autotemcel for severe sickle cell disease, New England Journal of Medicine 390 (18), 1649 to 1662, 2024 (record read via Europe PMC: 44 treated; 29 of 30 evaluable free of severe crises for 12 months; median follow-up 19.3 months). Massachusetts Medical Society, Waltham. Observation year 2024. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 6<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-9\"><span class=\"nrp-notes-n\">9<\/span><span>US Food and Drug Administration (ed.), FDA approves first gene therapies to treat patients with sickle cell disease (press announcement, 8 December 2023; Casgevy and Lyfgenia; ages 12 and over; 29 of 31 evaluable Casgevy patients free of severe crises for at least 12 months). FDA, Silver Spring. Observation year 2023. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in the summary, chapter 1, chapter 2, chapter 3<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-10\"><span class=\"nrp-notes-n\">10<\/span><span>Musunuru, K. et al., Patient-specific in vivo gene editing to treat a rare genetic disease, New England Journal of Medicine 392 (22), 2235 to 2243, 2025 (record read via Europe PMC: one infant; two infusions at about 7 and 8 months). Massachusetts Medical Society, Waltham. Observation year 2025. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 2, chapter 6<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-11\"><span class=\"nrp-notes-n\">11<\/span><span>Kyrou, K. et al., A CRISPR-Cas9 gene drive targeting doublesex causes complete population suppression in caged Anopheles gambiae mosquitoes, Nature Biotechnology 36, 1062 to 1066, 2018 (record read via Europe PMC; laboratory cages only). Springer Nature, London. Observation year 2018. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 3, chapter 4, chapter 6<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-12\"><span class=\"nrp-notes-n\">12<\/span><span>Confronting risks of <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-h101\" data-tc=\"NHS-1 tech.biotech.mirror-life\" data-tk=\"Frontier and exponential technology \u00b7 Biotechnology and synthetic biology\" data-td=\"Creation and escape of organisms built from mirror-image molecules, which could evade immune defences, predators and decay in people, animals and plants and spread unchecked through ecosystems.\" data-ts=\"NRS-H101\" data-tr=\"draft\" data-tx=\"https:\/\/risksindex.com\/hazards\/tech\/\" data-txl=\"Frontier and exponential technology\">mirror life<\/a>, Science 386, 1351 to 1353, 2024 (record read via Europe PMC; the record gives only a one-line abstract calling for broad discussion). American Association for the Advancement of Science, Washington. Observation year 2024. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 1, chapter 2, chapter 4, chapter 6<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-13\"><span class=\"nrp-notes-n\">13<\/span><span>Strengthening nucleic acid biosecurity screening against generative protein design tools, Science 390 (6768), 82 to 87, 2025 (record read via Europe PMC; abstract only; no method detail used). American Association for the Advancement of Science, Washington. Observation year 2025. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 5, chapter 6, chapter 7, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-14\"><span class=\"nrp-notes-n\">14<\/span><span>Congressional Research Service (ed.), National Security Commission on Emerging Biotechnology: Final Report and Options for Congress, CRS Insight IN12546, 17 April 2025 (report of 8 April 2025; 49 recommendations; at least USD 15 billion over five years; National Biotechnology Coordination Office). Library of Congress, Washington. Observation year 2025. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-15\"><span class=\"nrp-notes-n\">15<\/span><span>Federation of American Scientists (ed.), Translating Vision into Action: FAS commentary on the NSCEB final report (commentary page; six pillars; cites over USD 210 billion of US GDP and over 640,000 jobs for the bioeconomy; secondary and advocacy-leaning source). Federation of American Scientists, Washington. Observation year 2025. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 2, chapter 6, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-16\"><span class=\"nrp-notes-n\">16<\/span><span>Twist Bioscience Corporation (ed.), Form 8-K exhibit 99.1, results for the fiscal third quarter ended 30 June 2026 (company filing; revenue USD 118.4 million; nine months USD 332.8 million; fiscal 2026 guidance USD 456 to 457 million; company statements and guidance are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2026. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-17\"><span class=\"nrp-notes-n\">17<\/span><span>Ginkgo Bioworks Holdings, Inc. (ed.), Form 8-K exhibit 99.1, fourth quarter and full year 2025 results (company filing of 26 February 2026; revenue USD 170.155 million against USD 227.043 million; net loss USD 312.763 million; company statements are weak evidence). US Securities and Exchange Commission, Washington. Observation year 2025. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-18\"><span class=\"nrp-notes-n\">18<\/span><span>OECD (ed.), Anticipatory governance for responsible innovation in synthetic biology, OECD Science, Technology and Industry Policy Papers No. 193, 21 May 2026 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2026. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-19\"><span class=\"nrp-notes-n\">19<\/span><span>OECD (ed.), Synthetic biology, AI and automation: a forward-looking technology assessment, OECD Science, Technology and Industry Policy Papers No. 187, 4 December 2025 (record read via a bibliographic database; abstract only). OECD Publishing, Paris. Observation year 2025. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 2, chapter 4, chapter 6<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-20\"><span class=\"nrp-notes-n\">20<\/span><span>Secretariat of the Convention on Biological Diversity (ed.), Synthetic biology (programme page; decisions X\/13 to 16\/21; AHTEG; <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-c1\" data-tc=\"NRS-C1 horizon-scanning\" data-tk=\"Nexus risk vocabulary\" data-td=\"Systematic searching for early signs of potentially important developments, threats and opportunities at the margins of current thinking.\" data-ts=\"NRS-C1\" data-tr=\"draft\" data-tg=\"https:\/\/globalriskforum.com\/glossary\/horizon-scanning\/\" data-tgl=\"Global Risks Forum glossary\">horizon scanning<\/a>; thematic action plan). CBD Secretariat, Montreal. Observation year 2026. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-21\"><span class=\"nrp-notes-n\">21<\/span><span>World Health Organization (ed.), Global guidance framework for the responsible use of the life sciences: mitigating biorisks and governing <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/nrs\/#nrs-c1\" data-tc=\"NRS-C1 dual-use-research\" data-tk=\"Nexus risk vocabulary\" data-td=\"Legitimate research whose knowledge, methods or products could also be misused to cause serious harm.\" data-ts=\"NRS-C1\" data-tr=\"draft\">dual-use research<\/a> (publication page, 13 September 2022). WHO, Geneva. Observation year 2022. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 4, chapter 6, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-22\"><span class=\"nrp-notes-n\">22<\/span><span>Baker McKenzie (ed.), EU Biotech Act unveiled: Commission proposal to turn Europe into a biotech powerhouse (law firm summary, 19 December 2025; proposal of 16 December 2025; health focus; investment pilot with the European Investment Bank Group; 12-month certificate extension; biodefence measures; second act expected in Q3 2026). Secondary source, not the Commission text. Observation year 2025. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in the summary, chapter 1, chapter 2, chapter 3, chapter 4, chapter 6, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-23\"><span class=\"nrp-notes-n\">23<\/span><span>BioMADE (ed.), DoD approves USD 87 million for newest bioindustrial manufacturing innovation institute (news page; seven years; the page shows Oct 20 and a 2023 footer, the press release is dated 2020 in search listings). BioMADE, Saint Paul. Observation year 2020. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 1, chapter 3, chapter 4, chapter 6, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-24\"><span class=\"nrp-notes-n\">24<\/span><span>US Manufacturing Program (ed.), Bioindustrial (programme topic page; Distributed Bioindustrial Manufacturing Program awards announced 10 July to 13 September 2024; 25 awards; USD 42 million cumulative). Manufacturing USA, Gaithersburg. Observation year 2024. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in the summary, chapter 1, chapter 3, chapter 4, chapter 6, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-25\"><span class=\"nrp-notes-n\">25<\/span><span>UNVERIFIED, not opened: Office of Science and Technology Policy (ed.), Framework for Nucleic Acid Synthesis Screening, April 2024, taken from search-result summaries; a fetch of the page was refused by the fetch tool. OSTP, Washington. Observation year 2024. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 2, chapter 4, chapter 6, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-26\"><span class=\"nrp-notes-n\">26<\/span><span>UNVERIFIED, not opened: Executive Order 14292, Improving the Safety and Security of Biological Research, 5 May 2025 (90 days to revise or replace the framework), taken from search-result summaries; a fetch of an explainer page was refused by the fetch tool. The White House, Washington. Observation year 2025. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 2, chapter 4, chapter 5, chapter 6, chapter 7, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-27\"><span class=\"nrp-notes-n\">27<\/span><span>UNVERIFIED, not opened: Congressional Research Service (ed.), report on artificial intelligence and biosecurity risks (reported in July 2026 as unable to determine whether the 2024 framework or the 2025 policy had been revised), taken from a trade news summary. Library of Congress, Washington. Observation year 2026. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 2, chapter 4, chapter 6, chapter 7, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-28\"><span class=\"nrp-notes-n\">28<\/span><span>UNVERIFIED, not opened: European Commission (ed.), Proposal for a Biotech Act, COM(2025) 1022, 16 December 2025, taken from law firm and regulator summaries; the Commission page was not retrieved. European Commission, Brussels. Observation year 2025. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 2, chapter 6, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-29\"><span class=\"nrp-notes-n\">29<\/span><span>UNVERIFIED, not opened: European Parliament (ed.), Legislative train entry for the European Biotech Act II (second act expected in the third quarter of 2026), taken from a search-result summary; the page returned no content. European Parliament, Brussels. Observation year 2026. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 2, chapter 6<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-30\"><span class=\"nrp-notes-n\">30<\/span><span>UNVERIFIED, not opened: Engineering Biology Research Consortium (ed.), response on nucleic acid synthesis screening under Executive Order 14292, November 2025, listed in search results only. EBRC, Emeryville. Observation year 2025. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 2<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-31\"><span class=\"nrp-notes-n\">31<\/span><span>UNVERIFIED, not opened: International Gene Synthesis Consortium (ed.), Harmonized Screening Protocol, cited from memory. IGSC. Observation year 2024. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 4, chapter 6<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-32\"><span class=\"nrp-notes-n\">32<\/span><span>UNVERIFIED, not opened: UK Government (ed.), screening guidance on synthetic nucleic acids, 2024, cited from memory. Department for Science, Innovation and Technology, London. Observation year 2024. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 4, chapter 6<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-33\"><span class=\"nrp-notes-n\">33<\/span><span>UNVERIFIED, not opened: National Academies of Sciences, Engineering, and Medicine (eds.), Biodefense in the Age of Synthetic Biology, 2018, cited from memory; a fetch returned an unrelated page. National Academies Press, Washington. Observation year 2018. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 6<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-34\"><span class=\"nrp-notes-n\">34<\/span><span>UNVERIFIED, not opened: Convention on the Prohibition of the Development, Production and Stockpiling of Bacteriological (Biological) and Toxin Weapons and on their Destruction, 1972, cited from memory. United Nations, Geneva. Observation year 1972. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 6<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-35\"><span class=\"nrp-notes-n\">35<\/span><span>UNVERIFIED, not opened: Cartagena Protocol on Biosafety to the Convention on Biological Diversity, 2000, cited from memory. CBD Secretariat, Montreal. Observation year 2000. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 4, chapter 6, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-36\"><span class=\"nrp-notes-n\">36<\/span><span>UNVERIFIED, not opened: International Organization for Standardization (ed.), ISO 20688-2, requirements for the production and quality control of synthesised gene fragments, genes and genome-scale constructs, cited from memory. ISO, Geneva. Observation year 2024. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 6, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-37\"><span class=\"nrp-notes-n\">37<\/span><span>UNVERIFIED, not opened: McKinsey Global Institute (ed.), The Bio Revolution: Innovations transforming economies, societies, and our lives, May 2020, cited from memory; the fetch returned a service error and no figure is used. McKinsey and Company, New York. Observation year 2020. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 6, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-38\"><span class=\"nrp-notes-n\">38<\/span><span>UNVERIFIED, not opened: Jinek, M. et al., A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity, Science 337, 816 to 821, 2012, cited from memory. Observation year 2012. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 6<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-39\"><span class=\"nrp-notes-n\">39<\/span><span>UNVERIFIED, not opened: Gibson, D.G. et al., Enzymatic assembly of DNA molecules up to several hundred kilobases, Nature Methods 6, 343 to 345, 2009, cited from memory. Observation year 2009. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 6<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-40\"><span class=\"nrp-notes-n\">40<\/span><span>UNVERIFIED, not opened: Ro, D.-K. et al., Production of the antimalarial drug precursor artemisinic acid in engineered yeast, Nature 440, 940 to 943, 2006, cited from memory. Observation year 2006. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 6<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-41\"><span class=\"nrp-notes-n\">41<\/span><span>UNVERIFIED, not opened: Elowitz, M.B. and Leibler, S., A synthetic oscillatory network of transcriptional regulators, Nature 403, 335 to 338, 2000, cited from memory. Observation year 2000. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 6<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-42\"><span class=\"nrp-notes-n\">42<\/span><span>UNVERIFIED, not opened: Gardner, T.S., Cantor, C.R. and Collins, J.J., <a class=\"nx-link\" href=\"https:\/\/nexustandards.com\/cities\/construction-and-real-estate\/\">Construction<\/a> of a genetic toggle switch in Escherichia coli, Nature 403, 339 to 342, 2000, cited from memory. Observation year 2000. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 6<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-43\"><span class=\"nrp-notes-n\">43<\/span><span>UNVERIFIED, not opened: Richardson, S.M. et al., Design of a synthetic yeast genome, Science 355, 1040 to 1044, 2017, cited from memory. Observation year 2017. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 2, chapter 6, chapter 8<\/span><\/span><\/li><li id=\"nx-nrp-xt-04-ref-44\"><span class=\"nrp-notes-n\">44<\/span><span>UNVERIFIED, not opened: bioRxiv preprint of the Syn57 study, Escherichia coli with a 57-codon genetic code, 2025, identified from a search result; the page returned HTTP 429. Cold Spring Harbor Laboratory, New York. Observation year 2025. Accessed 2026-11-03. <span class=\"nrp-cell-u\">Cited in chapter 2<\/span><\/span><\/li><\/ol><\/section><section class=\"nrp-block\" id=\"nx-nrp-xt-04-cc-s2\" aria-labelledby=\"nx-nrp-xt-04-cc-s2-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-cc-s2-h\"><span class=\"nrp-num\">C.2<\/span><span>Publication record<\/span><\/h2><div class=\"nrp-split\"><div><h3 class=\"nrp-h3\">Publication<\/h3><dl class=\"nrp-dl\"><dt>Title<\/dt><dd>Exponential Technology Report 2026: Synthetic Biology and Bioengineering, Baseline Edition<\/dd><dt>Series<\/dt><dd>Reports \u00b7 Exponential Technology Series XT-04<\/dd><dt>Edition<\/dt><dd>Baseline Edition 2026 \u00b7 inaugural annual<\/dd><dt>Version<\/dt><dd>v1.0.0 \u00b7 draft for stewardship review<\/dd><dt>Publication ID<\/dt><dd>NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE-v1.0.0<\/dd><dt>Evidence close<\/dt><dd>30 September 2026<\/dd><dt>Publication date<\/dt><dd>October 2026<\/dd><dt>DOI<\/dt><dd>concept and version DOI at deposit<\/dd><\/dl><\/div><div><h3 class=\"nrp-h3\">Publisher<\/h3><dl class=\"nrp-dl\"><dt>Publisher of record<\/dt><dd>The Global Centre for Risk and Innovation (GCRI), for the Nexus Consortium<\/dd><dt>Place<\/dt><dd>Toronto<\/dd><dt>Editor<\/dt><dd>Saeed Valadbaygi, Chief Steward and Managing Editor<\/dd><dt>Stewards<\/dt><dd>GCRI \u00b7 technical truth \u00b7 GRF \u00b7 public meaning \u00b7 GRA \u00b7 capital meaning<\/dd><dt>Licence<\/dt><dd>text CC BY 4.0; data on the terms of each source<\/dd><dt>Copyright<\/dt><dd>\u00a9 2026 GCRI \u00b7 Nexus Consortium<\/dd><dt>Language<\/dt><dd>English (en-GB) source edition<\/dd><dt>Correspondence<\/dt><dd>Registry correction pathway \u00b7 editorial office<\/dd><\/dl><\/div><\/div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">DISCLAIMER<\/p><p>This edition is published for research, planning and public understanding. It is not a government assessment, an official warning, a rating, a certification, investment advice or an operational authorisation. Reasonable care has been taken with every source; consult the cited originals before relying on any value.<\/p><\/aside><h3 class=\"nrp-h3\">Colophon<\/h3><dl class=\"nrp-dl\"><dt>Format<\/dt><dd>A4 portrait \u00b7 screen, print and archival PDF<\/dd><dt>Typefaces<\/dt><dd>Space Grotesk (display) \u00b7 Geist (text) \u00b7 IBM Plex Sans Italic (standfirsts) \u00b7 IBM Plex Mono (data)<\/dd><dt>Design standard<\/dt><dd>Reports Foundational Edition, Volume I, Part VII<\/dd><dt>Accessibility<\/dt><dd>tagged PDF and HTML targets; text alternatives for every figure<\/dd><dt>Production<\/dt><dd>Reports editorial team, GCRI<\/dd><\/dl><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">HOW TO CORRECT THIS EDITION<\/p><p>Report errors, omissions or objections through the Registry correction pathway. Each report is logged and answered; upheld corrections are published as notices with a new version, and the original remains resolvable.<\/p><\/aside><h3 class=\"nrp-h3\">Release path for this version<\/h3><div class=\"nrp-tblw\" id=\"nx-nrp-xt-04-cc-tab1\"><table class=\"nrp-tbl\"><caption><span class=\"nf-ui-eyebrow\">Table C.1<\/span><span class=\"nrp-tbl-t\">Release path for this version<\/span><\/caption><thead><tr><th scope=\"col\">Step<\/th><th scope=\"col\">What happens<\/th><th scope=\"col\">When<\/th><\/tr><\/thead><tbody><tr><td>Draft<\/td><td>editorial self-check complete at evidence close<\/td><td>October 2026<\/td><\/tr><tr><td>Steward review<\/td><td>five passes on the exact draft (keys T \u00b7 M \u00b7 F \u00b7 N)<\/td><td>Q4 2026<\/td><\/tr><tr><td>Approval<\/td><td>publication authority approves the exact digest<\/td><td>before release<\/td><\/tr><tr><td>Deposit<\/td><td>concept and version DOI minted; registry pointer set<\/td><td>at release<\/td><\/tr><tr><td>Succession<\/td><td>the 2027 synthetic biology edition reports changes against this baseline<\/td><td>2027<\/td><\/tr><\/tbody><\/table><\/div><div class=\"nrp-split\"><div><dl class=\"nrp-dl\"><dt>Current version<\/dt><dd>v1.0.0 draft, stewardship review<\/dd><dt>Previous edition<\/dt><dd>none, first edition of the series<\/dd><dt>Next edition<\/dt><dd>NR-XTECH-SYNBIO-GLOBAL-2027-v1.0.0<\/dd><\/dl><\/div><div><dl class=\"nrp-dl\"><dt>Latest version<\/dt><dd>resolve the concept DOI or the registry record<\/dd><dt>Correction route<\/dt><dd>Registry correction pathway<\/dd><dt>Notice types<\/dt><dd>erratum \u00b7 addendum \u00b7 supersession \u00b7 withdrawal<\/dd><\/dl><\/div><\/div><aside class=\"nrp-call\"><p class=\"nf-ui-eyebrow\">NO CORRECTIONS \u2260 NO LIMITS<\/p><p>The absence of corrections does not mean the absence of limitations. Limitations and uncertainty are stated where they arise in the edition.<\/p><\/aside><\/section><div id=\"nx-nr-xt-04-corrections\"><section class=\"nrp-block\" id=\"nx-nrp-xt-04-cc-s3\" aria-labelledby=\"nx-nrp-xt-04-cc-s3-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-cc-s3-h\"><span class=\"nrp-num\">C.3<\/span><span>Corrections log<\/span><\/h2><div class=\"nx-nr-corr\"><p class=\"nx-nr-corr-sum\"><span class=\"nx-nr-corr-n\">0<\/span><span>correction notices. No edition has been released yet, so none can be corrected; the log below lists each edition&#8217;s current version.<\/span><\/p><div class=\"nx-table-wrap\"><table class=\"nx-table nx-rd-table\" data-stack=\"true\"><thead><tr><th scope=\"col\">Edition<\/th><th scope=\"col\">Version<\/th><th scope=\"col\">Date<\/th><th scope=\"col\">State<\/th><th scope=\"col\">Change<\/th><th scope=\"col\">Notice<\/th><\/tr><\/thead><tbody><tr><td data-label=\"Edition\"><span class=\"nx-rd-code\">XT-04<\/span><\/td><td data-label=\"Version\" class=\"nx-rd-mono\">NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE-v1.0.0<\/td><td data-label=\"Date\">October 2026<\/td><td data-label=\"State\">Draft<\/td><td data-label=\"Change\">Baseline Edition 2026, inaugural annual edition,<\/td><td data-label=\"Notice\">None<\/td><\/tr><\/tbody><\/table><\/div><p class=\"nx-rd-source\">Notice types: erratum, addendum, supersession, withdrawal. A correction is a new version with a published notice; the earlier version stays resolvable, and no edition is ever edited in silence.<\/p><\/div><\/section><\/div><div id=\"nx-nr-xt-04-outputs\"><section class=\"nrp-block\" id=\"nx-nrp-xt-04-cc-s4\" aria-labelledby=\"nx-nrp-xt-04-cc-s4-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-cc-s4-h\"><span class=\"nrp-num\">C.4<\/span><span>Open record<\/span><\/h2><div class=\"nx-nr-os\"><div class=\"nx-nr-os-card\"><h3>This edition&#8217;s open record<\/h3><dl class=\"nx-nr-os-kv\"><dt>Publication ID<\/dt><dd>NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE-v1.0.0<\/dd><dt>Desk identifier and series alias<\/dt><dd>NR-XTC-XT-04-2026-BL<\/dd><dt>Collection<\/dt><dd>None<\/dd><dt>DOI<\/dt><dd>Concept and version DOI at deposit, on Zenodo with DataCite metadata<\/dd><dt>Versions<\/dt><dd>Each correction is a new version (isNewVersionOf); the concept DOI resolves to the latest<\/dd><dt>Bundle<\/dt><dd>RO-Crate 1.2 with CITATION.cff, CodeMeta and PROV-O provenance; a signed manifest<\/dd><dt>Licence<\/dt><dd><a class=\"nx-link\" href=\"https:\/\/creativecommons.org\/licenses\/by\/4.0\/\" rel=\"noopener\">CC BY 4.0<\/a> (SPDX CC-BY-4.0) for original material; metadata CC0 1.0<\/dd><\/dl><\/div><div class=\"nx-nr-os-card\"><h3>Credit and identity<\/h3><dl class=\"nx-nr-os-kv\"><dt>ORCID<\/dt><dd>Your iD in the deposit and the contribution record; DataCite can then add the work to your ORCID record<\/dd><dt>ROR<\/dt><dd>Your organisation by its ROR identifier, never by a typed name alone<\/dd><dt>CRediT<\/dt><dd>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualisation, Writing, review and editing<\/dd><dt>Account<\/dt><dd>None needed to contribute; never a password<\/dd><\/dl><\/div><div class=\"nx-nr-os-card\"><h3>Find and follow<\/h3><p class=\"nx-p\">Search the open indexes for Synthetic Biology and Bioengineering; software is cited by its SWHID from Software Heritage, and a quantified scenario run is preregistered on OSF before it is run. Annotation is your choice: Hypothesis opens this page in its own viewer.<\/p><ul class=\"nx-nr-os-links\"><li><a href=\"https:\/\/openalex.org\/works?search=Nexus%20Reports%20Synthetic%20Biology%20and%20Bioengineering\" rel=\"noopener\">OpenAlex<\/a><\/li><li><a href=\"https:\/\/explore.openaire.eu\/search\/find?fv0=Nexus%20Reports%20Synthetic%20Biology%20and%20Bioengineering&amp;f0=q\" rel=\"noopener\">OpenAIRE<\/a><\/li><li><a href=\"https:\/\/search.crossref.org\/search\/works?q=Nexus%20Reports%20Synthetic%20Biology%20and%20Bioengineering\" rel=\"noopener\">Crossref<\/a><\/li><li><a href=\"https:\/\/commons.datacite.org\/?query=Nexus%20Reports%20Synthetic%20Biology%20and%20Bioengineering\" rel=\"noopener\">DataCite Commons<\/a><\/li><li><a href=\"https:\/\/zenodo.org\/search?q=Nexus%20Reports%20Synthetic%20Biology%20and%20Bioengineering\" rel=\"noopener\">Zenodo<\/a><\/li><li><a href=\"https:\/\/archive.softwareheritage.org\/\" rel=\"noopener\">Software Heritage<\/a><\/li><li><a href=\"https:\/\/osf.io\/prereg\/\" rel=\"noopener\">OSF preregistration<\/a><\/li><li><a href=\"https:\/\/via.hypothes.is\/https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/\" rel=\"noopener\">Annotate with Hypothesis<\/a><\/li><\/ul><\/div><div class=\"nx-nr-os-card\"><h3>Mirrors and harvest<\/h3><p class=\"nx-p\">The DOI is canonical. At release each signed bundle is also given an IPFS content identifier and a bloxberg anchor as mirrors; both are listed in the record once they exist. Zenodo exposes every record over OAI-PMH, and reviews and endorsements can arrive through COAR Notify where the repository supports it.<\/p><\/div><\/div><div class=\"nx-mt-3\"><figure class=\"nx-nr-code\"><figcaption class=\"nx-nr-code-cap\">InvenioRDM metadata for a contribution on Synthetic Biology and Bioengineering, prefilled from this page<\/figcaption><pre class=\"nx-nr-pre\" tabindex=\"0\"><code>{&#10;  &quot;metadata&quot;: {&#10;    &quot;resource_type&quot;: {&#10;      &quot;id&quot;: &quot;dataset&quot;&#10;    },&#10;    &quot;title&quot;: &quot;Evidence on Synthetic Biology and Bioengineering for Nexus Reports&quot;,&#10;    &quot;publication_date&quot;: &quot;YYYY-MM-DD&quot;,&#10;    &quot;creators&quot;: [&#10;      {&#10;        &quot;person_or_org&quot;: {&#10;          &quot;type&quot;: &quot;personal&quot;,&#10;          &quot;family_name&quot;: &quot;Your family name&quot;,&#10;          &quot;given_name&quot;: &quot;Your given name&quot;,&#10;          &quot;identifiers&quot;: [&#10;            {&#10;              &quot;scheme&quot;: &quot;orcid&quot;,&#10;              &quot;identifier&quot;: &quot;0000-0000-0000-0000&quot;&#10;            }&#10;          ]&#10;        },&#10;        &quot;affiliations&quot;: [&#10;          {&#10;            &quot;id&quot;: &quot;ROR identifier of your organisation&quot;&#10;          }&#10;        ]&#10;      }&#10;    ],&#10;    &quot;description&quot;: &quot;What it is, where its record is kept and how it bears on Exponential Technology Report 2026: Synthetic Biology and Bioengineering.&quot;,&#10;    &quot;rights&quot;: [&#10;      {&#10;        &quot;id&quot;: &quot;cc-by-4.0&quot;&#10;      }&#10;    ],&#10;    &quot;subjects&quot;: [&#10;      {&#10;        &quot;subject&quot;: &quot;Nexus Reports&quot;&#10;      },&#10;      {&#10;        &quot;subject&quot;: &quot;Synthetic Biology and Bioengineering&quot;&#10;      },&#10;      {&#10;        &quot;subject&quot;: &quot;Exponential Technology Report \u00b7 XT-04&quot;&#10;      }&#10;    ],&#10;    &quot;related_identifiers&quot;: [&#10;      {&#10;        &quot;identifier&quot;: &quot;https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/&quot;,&#10;        &quot;scheme&quot;: &quot;url&quot;,&#10;        &quot;relation_type&quot;: {&#10;          &quot;id&quot;: &quot;issupplementto&quot;&#10;        },&#10;        &quot;resource_type&quot;: {&#10;          &quot;id&quot;: &quot;publication-report&quot;&#10;        }&#10;      }&#10;    ],&#10;    &quot;version&quot;: &quot;1.0.0&quot;&#10;  },&#10;  &quot;custom_fields&quot;: {},&#10;  &quot;access&quot;: {&#10;    &quot;record&quot;: &quot;public&quot;,&#10;    &quot;files&quot;: &quot;public&quot;&#10;  },&#10;  &quot;files&quot;: {&#10;    &quot;enabled&quot;: true&#10;  },&#10;  &quot;parent&quot;: {&#10;    &quot;communities&quot;: {&#10;      &quot;default&quot;: &quot;nexusreports&quot;&#10;    }&#10;  }&#10;}<\/code><\/pre><\/figure><\/div><div class=\"nx-nr-os-hook\" data-nx-research-hub=\"slot\" data-nx-research-context=\"{&quot;org&quot;:&quot;GCRI&quot;,&quot;site&quot;:&quot;gcri&quot;,&quot;url&quot;:&quot;https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/&quot;,&quot;kind&quot;:&quot;edition&quot;,&quot;subject&quot;:&quot;Synthetic Biology and Bioengineering&quot;,&quot;series&quot;:[&quot;Exponential Technology Report \u00b7 XT-04&quot;]}\" hidden><\/div><\/section><\/div><div id=\"nx-nr-xt-04-pillars\"><section class=\"nrp-block\" id=\"nx-nrp-xt-04-cc-s5\" aria-labelledby=\"nx-nrp-xt-04-cc-s5-h\"><h2 class=\"nrp-h2\" id=\"nx-nrp-xt-04-cc-s5-h\"><span class=\"nrp-num\">C.5<\/span><span>Where this edition sits among the six pillars<\/span><\/h2><p class=\"nrp-stand\">Foundry seals the evidence and Universe tests it; Reports publishes it; Standards takes its corrections and Academy teaches from it.<\/p><ol class=\"nx-pl-list\"><li data-pillar=\"foundry\" data-hue=\"infrastructure\"><span class=\"nx-pl-dot\" aria-hidden=\"true\"><\/span><strong>F03 Sealed observations and indicator series<\/strong> <span class=\"nx-pl-in\">Foundry<\/span> Sealed observations and indicator series behind a profile (closeout).<\/li><li data-pillar=\"universe\" data-hue=\"water\"><span class=\"nx-pl-dot\" aria-hidden=\"true\"><\/span><strong>F04 After-action and scenario findings for<\/strong> <span class=\"nx-pl-in\">Universe<\/span> After-action and scenario findings for chapters 10 and 13 (after action review).<\/li><li data-pillar=\"foundry\" data-hue=\"infrastructure\"><span class=\"nx-pl-dot\" aria-hidden=\"true\"><\/span><strong>F05 National Portfolio movement for chapter<\/strong> <span class=\"nx-pl-in\">Foundry<\/span> National Portfolio movement for chapter 11 (after action review).<\/li><li data-pillar=\"standards\" data-hue=\"biodiversity\"><span class=\"nx-pl-dot\" aria-hidden=\"true\"><\/span><strong>Applied in editions<\/strong> <span class=\"nx-pl-in\">Standards<\/span> <a class=\"nx-link nx-term\" href=\"https:\/\/nexustandards.com\/standards\/\" data-tc=\"Nexus Standards\" data-tk=\"Nexus Standards\" data-td=\"The foundation standards\">Nexus Standards<\/a>: applied in editions.<\/li><li data-pillar=\"reports\" data-hue=\"energy\"><span class=\"nx-pl-dot\" aria-hidden=\"true\"><\/span><strong>XT-04 edition<\/strong> <span class=\"nx-pl-in\">Reports<\/span> Synthetic Biology and Bioengineering 2026, published in every format with its sources, citation and corrections.<\/li><li data-pillar=\"standards\" data-hue=\"biodiversity\"><span class=\"nx-pl-dot\" aria-hidden=\"true\"><\/span><strong>F06 Method and correction findings as change<\/strong> <span class=\"nx-pl-in\">Standards<\/span> Method and correction findings as change proposals (correction).<\/li><li data-pillar=\"universe\" data-hue=\"water\"><span class=\"nx-pl-dot\" aria-hidden=\"true\"><\/span><strong>F12 Q4 synthesis informs the next-year<\/strong> <span class=\"nx-pl-in\">Universe<\/span> Q4 synthesis informs the next-year mandate (renewal).<\/li><li data-pillar=\"academy\" data-hue=\"risk\"><span class=\"nx-pl-dot\" aria-hidden=\"true\"><\/span><strong>Taught in the open<\/strong> <span class=\"nx-pl-in\">Academy<\/span> Risk Academy: taught in the open.<\/li><\/ol><p class=\"nx-caption\"><span>What Foundry and Universe hand to this edition, and what it hands to Standards, Universe and Academy. From the programme spine; XT-04 is a drafted Baseline Edition, so these handoffs run from its first operational quarter.<\/span><\/p><ul class=\"nx-pl-legend\" aria-label=\"Pillars\"><li data-pillar=\"labs\" data-hue=\"social\"><span class=\"nx-pl-dot\" aria-hidden=\"true\"><\/span><a class=\"nx-link\" href=\"https:\/\/therisk.global\/nexus-labs\/\">Labs<\/a><\/li><li data-pillar=\"foundry\" data-hue=\"infrastructure\"><span class=\"nx-pl-dot\" aria-hidden=\"true\"><\/span><a class=\"nx-link\" href=\"https:\/\/therisk.global\/nexus-foundry\/\">Foundry<\/a><\/li><li data-pillar=\"universe\" data-hue=\"water\"><span class=\"nx-pl-dot\" aria-hidden=\"true\"><\/span><a class=\"nx-link\" href=\"https:\/\/universe.nexus\/\">Universe<\/a><\/li><li data-pillar=\"standards\" data-hue=\"biodiversity\"><span class=\"nx-pl-dot\" aria-hidden=\"true\"><\/span><a class=\"nx-link\" href=\"https:\/\/nexustandards.com\/\">Nexus Standards<\/a><\/li><li data-pillar=\"reports\" data-hue=\"energy\"><span class=\"nx-pl-dot\" aria-hidden=\"true\"><\/span><a class=\"nx-link\" href=\"https:\/\/therisk.global\/nexus-reports\/\">Reports<\/a><\/li><li data-pillar=\"academy\" data-hue=\"risk\"><span class=\"nx-pl-dot\" aria-hidden=\"true\"><\/span><a class=\"nx-link\" href=\"https:\/\/risksacademy.com\/\">Risk Academy<\/a><\/li><\/ul><div class=\"nx-table-wrap\"><table class=\"nx-table nx-rd-table\" data-stack=\"true\"><thead><tr><th scope=\"col\">Handoff<\/th><th scope=\"col\">Between<\/th><th scope=\"col\">What crosses, and when<\/th><\/tr><\/thead><tbody><tr data-pillar=\"foundry\"><td><span class=\"nx-rd-code\">F03<\/span><\/td><td>Foundry to Reports<\/td><td>Sealed observations and indicator series behind a profile (closeout).<\/td><\/tr><tr data-pillar=\"universe\"><td><span class=\"nx-rd-code\">F04<\/span><\/td><td>Universe to Reports<\/td><td>After-action and scenario findings for chapters 10 and 13 (after action review).<\/td><\/tr><tr data-pillar=\"foundry\"><td><span class=\"nx-rd-code\">F05<\/span><\/td><td>Foundry to Reports<\/td><td>National Portfolio movement for chapter 11 (after action review).<\/td><\/tr><tr data-pillar=\"standards\"><td><span class=\"nx-rd-code\">Ring<\/span><\/td><td>Nexus Standards to Reports<\/td><td>Nexus Standards: applied in editions.<\/td><\/tr><tr data-pillar=\"standards\"><td><span class=\"nx-rd-code\">F06<\/span><\/td><td>Reports to Nexus Standards<\/td><td>Method and correction findings as change proposals (correction).<\/td><\/tr><tr data-pillar=\"universe\"><td><span class=\"nx-rd-code\">F12<\/span><\/td><td>Reports to Universe<\/td><td>Q4 synthesis informs the next-year mandate (renewal).<\/td><\/tr><tr data-pillar=\"academy\"><td><span class=\"nx-rd-code\">Ring<\/span><\/td><td>Reports to Risk Academy<\/td><td>Risk Academy: taught in the open.<\/td><\/tr><\/tbody><\/table><\/div><\/section><\/div><\/div><\/article><\/div><\/div><div class=\"nrp-noprint\"><section id=\"nx-sec-nr-gateway\" class=\"nx-section\" data-hue=\"systemic\" data-tone=\"alt\" aria-labelledby=\"nx-nr-gateway-h\"><div class=\"nx-container\"><div class=\"nx-section-head\"><div class=\"nx-eyebrow-row\"><span class=\"nx-eyebrow\">Reports<\/span><span class=\"nx-rule\" aria-hidden=\"true\"><\/span><span class=\"nx-eyebrow\">Contribute<\/span><\/div><h2 id=\"nx-nr-gateway-h\" class=\"nx-section-title\">Send evidence or a correction on Synthetic Biology and Bioengineering.<\/h2><p class=\"nx-lede\">Reports is the Consortium&#8217;s quarterly publication, written by six desks. This page sits with the GCRI <a class=\"nx-link nx-term\" href=\"https:\/\/docs.therisk.global\/organization\/systems\" data-tc=\"Systems\" data-tk=\"Nexus Standards\" data-td=\"The twenty Nexus systems, NXS-CMD to NXS-LAB\">Systems<\/a> Evidence desk. What you know about this subject can become evidence, a case or a correction in the next edition, credited to you and published under CC BY 4.0 where it is your own work. Sent to the wrong desk, it is forwarded, not refused.<\/p><div class=\"nx-chips\"><span class=\"nx-chip\">GCRI Systems Evidence desk<\/span><span class=\"nx-chip\">Exponential Technology<\/span><\/div><\/div><div class=\"nx-section-body\"><ul class=\"nx-dest\"><li><a class=\"nx-dest-card\" href=\"https:\/\/therisk.global\/nexus-reports\/write-to-us\/contact\/\"><span class=\"nx-dest-top\"><span class=\"nx-dest-rel\">Email<\/span><span class=\"nx-dest-host\">Gateway GW-GCRI<\/span><\/span><span class=\"nx-dest-title\">Send it from this page<\/span><span class=\"nx-dest-why\">Evidence, a correction, a case, a method, a review, a translation or profile input. It arrives tagged with this page, so the editor who owns it receives it.<\/span><span class=\"nx-dest-go\" aria-hidden=\"true\"><svg class=\"nx-arrow\" viewBox=\"0 0 16 16\" aria-hidden=\"true\"><path d=\"M3 8h10M9 4l4 4-4 4\"\/><\/svg><\/span><\/a><\/li><li><a class=\"nx-dest-card\" href=\"https:\/\/therisk.global\/nexus-reports\/open-science\/#nx-sec-zenodo\"><span class=\"nx-dest-top\"><span class=\"nx-dest-rel\">Zenodo<\/span><span class=\"nx-dest-host\">Open deposit<\/span><\/span><span class=\"nx-dest-title\">Deposit it and submit to the community<\/span><span class=\"nx-dest-why\">Publish your own record on Zenodo with your ORCID iD, then submit it to the Reports community there. Curators review it; the DOI stays yours.<\/span><span class=\"nx-dest-go\" aria-hidden=\"true\"><svg class=\"nx-arrow\" viewBox=\"0 0 16 16\" aria-hidden=\"true\"><path d=\"M3 8h10M9 4l4 4-4 4\"\/><\/svg><\/span><\/a><\/li><li><a class=\"nx-dest-card\" href=\"https:\/\/therisk.global\/nexus-reports\/contribute\/#nx-sec-routing\"><span class=\"nx-dest-top\"><span class=\"nx-dest-rel\">Reports<\/span><span class=\"nx-dest-host\">GCRI<\/span><\/span><span class=\"nx-dest-title\">See which desk takes what you have<\/span><span class=\"nx-dest-why\">The routing table opens the contribution page: what you have, the desk that takes it, how each contribution is reviewed and credited, and the licence.<\/span><span class=\"nx-dest-go\" aria-hidden=\"true\"><svg class=\"nx-arrow\" viewBox=\"0 0 16 16\" aria-hidden=\"true\"><path d=\"M3 8h10M9 4l4 4-4 4\"\/><\/svg><\/span><\/a><\/li><\/ul><div class=\"nx-live-slot\" data-nxf-slot=\"contribute\" data-nxf-kind=\"workflow\" data-nxf-resource=\"nexus:\/\/gcri\/nexus-reports\/editions\/xt-04\/full#contribute\" data-nxf-title=\"Contribute evidence\" data-nxf-height=\"480\" hidden><\/div><p class=\"nx-note nx-mt-3\">Never send personal data, sensitive infrastructure detail or anything you have no right to share. A contribution is reviewed before use; sending it confers no authorship or editorial rights, and sponsorship never buys a finding.<\/p><\/div><\/div><\/section><\/div><p class=\"nx-note\" data-nr-rights=\"true\"><a class=\"nx-link\" rel=\"license\" href=\"https:\/\/creativecommons.org\/licenses\/by\/4.0\/\">CC BY 4.0<\/a> Free to read. Text and figures: CC BY 4.0. Data: CC0 1.0. Authors keep copyright. Published by GCRI Canada.<\/p><section class=\"nx-section nx-deeper-band\" aria-labelledby=\"nx-deeper-therisk-global-nexus-reports-editions-xt-04-full-h\"><div class=\"nx-container\"><nav class=\"nx-deeper\" aria-labelledby=\"nx-deeper-therisk-global-nexus-reports-editions-xt-04-full-h\" data-nx-deeper=\"3\" data-nx-resources=\"1 1 1\"><h2 class=\"nx-deeper-h\" id=\"nx-deeper-therisk-global-nexus-reports-editions-xt-04-full-h\">Go deeper<\/h2><ul><li><a href=\"https:\/\/docs.therisk.global\/organization\/model\/scenarios\/urban-flood\" data-ext><span class=\"nx-deeper-k\">Documentation:<\/span> Urban flood<span class=\"nx-deeper-x\" aria-hidden=\"true\">\u2197<\/span><span class=\"nx-deeper-sr\"> (opens another site)<\/span><\/a><\/li><li><a href=\"https:\/\/risksacademy.com\/risk-science\/risk-information-standards\/\" data-ext><span class=\"nx-deeper-k\">Academy:<\/span> Risk information standards and interoperability<span class=\"nx-deeper-x\" aria-hidden=\"true\">\u2197<\/span><span class=\"nx-deeper-sr\"> (opens another site)<\/span><\/a><\/li><li><a href=\"https:\/\/nexustandards.com\/data\/identification-standards\/\" data-ext><span class=\"nx-deeper-k\">Standards:<\/span> Identification (the UNI)<span class=\"nx-deeper-x\" aria-hidden=\"true\">\u2197<\/span><span class=\"nx-deeper-sr\"> (opens another site)<\/span><\/a><\/li><\/ul><\/nav><\/div><\/section><\/div><\/div><script class=\"_iub_cs_skip\">window.__nxMount ? window.__nxMount(document.currentScript) : null;<\/script><style>@media print { @page { margin: 20mm 17mm 20mm 17mm; @top-left { content: \"Nexus Reports\"; font: 500 7.5pt \"IBM Plex Mono\", monospace; color: #4a4a4a; } @top-right { content: \"Exponential Technology Report 2026: Synthetic Biology and Bioengineering \\0000b7  Baseline Edition 2026\"; font: 400 7.5pt \"IBM Plex Sans\", sans-serif; color: #4a4a4a; } @bottom-left { content: \"NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE \\0000b7  Draft, not released\"; font: 400 7pt \"IBM Plex Mono\", monospace; color: #4a4a4a; } @bottom-center { content: \"CC BY 4.0. Free to read. Authors keep copyright.\"; font: 400 6.5pt \"IBM Plex Sans\", sans-serif; color: #4a4a4a; } @bottom-right { content: counter(page) \" \/ \" counter(pages); font: 500 7.5pt \"IBM Plex Mono\", monospace; color: #000000; } } @page :first { @top-left { content: none; } @top-right { content: none; } } html, body { background: #ffffff; } nexus-header, nexus-footer, #wpadminbar, .site-header, .site-footer, #masthead, #colophon, .sidebar, .widget-area, .comments-area, .post-navigation, .entry-meta, .page-header, .elementor-location-header, .elementor-location-footer, body > header, body > footer { display: none; } .nxe-host { margin: 0; padding: 0; } }<\/style><script>(function () { var D = document; function hosts(f) { var h = D.querySelectorAll(\".nxe-host\"); for (var i = 0; i < h.length; i++) { f(h[i].shadowRoot ? h[i].shadowRoot : h[i]); } } function reveal() { hosts(function (r) { var b = r.querySelectorAll(\"[data-nrp-act][hidden]\"); for (var i = 0; i < b.length; i++) { b[i].hidden = false; } }); } function say(el, t) { var p = el; while (p) { var l = p.querySelector ? p.querySelector(\".nrp-live\") : null; if (l) { l.textContent = t; return; } p = p.parentElement; } } D.addEventListener(\"click\", function (e) { var path = e.composedPath ? e.composedPath() : [e.target]; for (var i = 0; i < path.length; i++) { var el = path[i]; var act = el.getAttribute ? el.getAttribute(\"data-nrp-act\") : null; if (act === \"print\") { window.print(); return; } if (act === \"copy\") { var t = el.getAttribute(\"data-nrp-text\"); if (navigator.clipboard) { navigator.clipboard.writeText(t).then(function () { say(el, \"Copied.\"); }, function () { say(el, \"CLIPBOARD_UNAVAILABLE: select the text and copy it.\"); }); } else { say(el, \"CLIPBOARD_UNAVAILABLE: select the text and copy it.\"); } return; } } }); if (D.readyState === \"loading\") { D.addEventListener(\"DOMContentLoaded\", reveal); } else { reveal(); } addEventListener(\"load\", reveal); setTimeout(reveal, 1500); })();<\/script>\n\n\n<script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Report\",\"@id\":\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/full\/#report\",\"name\":\"Synthetic Biology and Bioengineering 2026: complete edition\",\"headline\":\"Synthetic Biology and Bioengineering 2026: complete edition\",\"description\":\"The complete Exponential Technology Report 2026: Synthetic Biology and Bioengineering at one address: cover, imprint, contents.\",\"inLanguage\":\"en\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/full\/#webpage\"},\"author\":{\"@id\":\"https:\/\/therisk.global\/#organization\",\"@type\":\"Organization\",\"name\":\"The Global Centre for Risk and Innovation\",\"url\":\"https:\/\/therisk.global\/\",\"alternateName\":\"GCRI\"},\"publisher\":{\"@id\":\"https:\/\/therisk.global\/#organization\"},\"license\":\"https:\/\/creativecommons.org\/licenses\/by\/4.0\/\",\"isAccessibleForFree\":true,\"creativeWorkStatus\":\"Draft\"}]}<\/script>\n\n<!-- nx-rev:18a40bb0d6e24a69 -->\n<!-- nx-shared:7c12e3ef17fc -->\n<!-- nx-path:\/editions\/xt-04\/full\/ -->","protected":false},"excerpt":{"rendered":"<p>The complete Exponential Technology Report 2026: Synthetic Biology and Bioengineering at one address: cover, imprint, contents.<\/p>\n","protected":false},"author":0,"featured_media":0,"parent":702,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_buddyx_sub_header_visibility":"","_buddyx_sub_header_title_visibility":"","_hide_show_side_panel":"","_buddyxpro_page_sidebar":"","_buddyxpro_page_disable_header":"","_buddyxpro_page_disable_footer":"","_buddyxpro_page_content_width":"","_buddyxpro_page_header_style":"","_buddyxpro_page_color_mode":"","_buddyxpro_page_loader":"","_nx_seo_description":"The complete Exponential Technology Report 2026: Synthetic Biology and Bioengineering at one address: cover, imprint, contents.","_nx_seo_title":"Synthetic Biology and Bioengineering 2026 | Reports GCRI","_nx_seo_image":"","_nx_seo_jsonld":"{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/full\/#webpage\",\"url\":\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/full\/\",\"name\":\"Synthetic Biology and Bioengineering 2026: complete edition\",\"creativeWorkStatus\":\"Draft\",\"description\":\"The complete Exponential Technology Report 2026: Synthetic Biology and Bioengineering at one address: cover, imprint, contents.\",\"inLanguage\":\"en\",\"isPartOf\":{\"@id\":\"https:\/\/therisk.global\/nexus-reports\/#website\"},\"license\":\"https:\/\/creativecommons.org\/licenses\/by\/4.0\/\",\"publisher\":{\"@id\":\"https:\/\/therisk.global\/#organization\"},\"breadcrumb\":{\"@id\":\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/full\/#breadcrumbs\"}},{\"@type\":\"Report\",\"@id\":\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/full\/#complete\",\"name\":\"Synthetic Biology and Bioengineering 2026\",\"url\":\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/full\/\",\"identifier\":[{\"@type\":\"PropertyValue\",\"propertyID\":\"NR\",\"value\":\"NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE-v1.0.0\"},{\"@type\":\"PropertyValue\",\"propertyID\":\"NR-alias\",\"value\":\"NR-XTC-XT-04-2026-BL\"}],\"reportNumber\":\"NR-XTECH-SYNBIO-GLOBAL-2026-BASELINE\",\"version\":\"1.0.0\",\"inLanguage\":\"en\",\"license\":\"https:\/\/creativecommons.org\/licenses\/by\/4.0\/\",\"creativeWorkStatus\":\"Draft\",\"publisher\":{\"@id\":\"https:\/\/therisk.global\/#organization\"},\"editor\":{\"@type\":\"Person\",\"name\":\"Saeed Valadbaygi\",\"jobTitle\":\"Chief Steward and Managing Editor\",\"affiliation\":{\"@id\":\"https:\/\/therisk.global\/#organization\"}},\"author\":{\"@id\":\"https:\/\/therisk.global\/#organization\"},\"isPartOf\":{\"@id\":\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/#report\"}},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/therisk.global\/nexus-reports\/#website\",\"url\":\"https:\/\/therisk.global\/nexus-reports\/\",\"name\":\"Reports \u00b7 GCRI\",\"publisher\":{\"@id\":\"https:\/\/therisk.global\/#organization\"}},{\"@type\":\"Organization\",\"@id\":\"https:\/\/therisk.global\/#organization\",\"name\":\"The Global Centre for Risk and Innovation\",\"alternateName\":\"GCRI\",\"url\":\"https:\/\/therisk.global\/\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/full\/#breadcrumbs\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Reports\",\"item\":\"https:\/\/therisk.global\/nexus-reports\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Editions: the Reports catalogue\",\"item\":\"https:\/\/therisk.global\/nexus-reports\/editions\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Exponential Technology Report 2026: Synthetic Biology and Bioengineering\",\"item\":\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Synthetic Biology and Bioengineering 2026: complete edition\",\"item\":\"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/full\/\"}]}]}","_nx_i18n_locale":"","_nx_i18n_group":"","nexus_page_kind":"","footnotes":"","_nrp_robots":"noindex","_nrp_edition":"702","_nx_seo_image_alt":"","_nx_seo_canonical":"https:\/\/therisk.global\/nexus-reports\/editions\/xt-04\/full\/","_nx_seo_robots":"noindex,follow","_nx_seo_schema_type":"Report"},"class_list":["post-1612","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/therisk.global\/nexus-reports\/wp-json\/wp\/v2\/pages\/1612","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/therisk.global\/nexus-reports\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/therisk.global\/nexus-reports\/wp-json\/wp\/v2\/types\/page"}],"replies":[{"embeddable":true,"href":"https:\/\/therisk.global\/nexus-reports\/wp-json\/wp\/v2\/comments?post=1612"}],"version-history":[{"count":0,"href":"https:\/\/therisk.global\/nexus-reports\/wp-json\/wp\/v2\/pages\/1612\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/therisk.global\/nexus-reports\/wp-json\/wp\/v2\/pages\/702"}],"wp:attachment":[{"href":"https:\/\/therisk.global\/nexus-reports\/wp-json\/wp\/v2\/media?parent=1612"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}